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ABSTRACT 
Bulimia nervosa (BN) and binge eating disorder (BED) are psychiatric disorders 
characterised by recurrent loss-of-control binge eating behaviour, which is associated 
with the consumption of an objectively large quantity of food for the circumstances. BN 
is additionally characterised by recurrent inappropriate compensatory weight control 
behaviours. Both BN and BED cause significant distress and detract from quality of life 
in affected individuals. To date, however, current treatments do not support full recovery 
in a considerable portion of individuals with BN or BED, thus highlighting the need for 
novel treatment approaches which target critical maintenance factors. 
The current thesis synthesises current evidence for the maintenance of recurrent binge 
eating behaviour through neural processes related to reward dysregulation and addiction. 
Based on previous and original evidence, I will go on to propose a new maintenance 
model of BN and BED and apply this model to a multi-modal investigation of 
exogenously-administered intranasal oxytocin in adult women with BN and BED. 
Paper 1 presents a narrative review of empirical literature relating to the dysregulation of 
reward processes in bulimia nervosa and binge eating disorder. Within this paper, I 
propose a new theoretical maintenance model of recurrent binge eating behaviour: the 
“addictive appetite” model. Paper 2 presents an additional narrative review of evidence 
for the novel elements of the addictive appetite model, including evidence for tolerance 
and withdrawal effects in BN and a central insulin- and dopamine-mediated mechanism 
underpinning heightened craving. Paper 3 tests hypotheses stemming from the addictive 
appetite model, which predicts that craving and reward-motivated eating are central to 
the maintenance of BN and BED. Paper 3 presents a cluster analysis demonstrating that 
food craving, reward-motivated eating, and eating for coping purposes significantly 
distinguish women with BN and BED from age- and weight-matched comparison women.  
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Oxytocin, a neuropeptide and hormone, has previously been found to modulate anxiety 
and reward processes, which are central components of the addictive appetite model. 
Paper 4 presents a systematic review and quantitative meta-analysis of the effects of 
oxytocin on feeding behaviour in both animal and human samples. This meta-analysis 
demonstrates that a single dose of central or peripheral oxytocin significantly attenuates 
subsequent feeding in animals, while the effects of oxytocin decrease with chronic 
administration. The evidence for the effects of oxytocin on feeding in humans is mixed, 
and moderated by factors including eating disorder status, sex, and food type. 
Paper 5 tests the functional significance of exogenous oxytocin in altering palatable food 
intake, subjective stress, and salivary cortisol in women with BN or BED and healthy 
comparison women without history of an eating disorder. Contrary to our hypotheses, 
oxytocin did not significantly affect palatable eating behaviour, 24-hour calorie intake, 
subjective, stress, or salivary cortisol. 
Paper 6 investigates the influence of oxytocin on attentional bias to palatable food images. 
Contrary to our hypothesis, we found that oxytocin increased vigilance towards palatable, 
versus neutral, food images. Paper 7 tested the influence of oxytocin on risk-taking 
behaviours in a computerised task. Contrary to our hypotheses, women with BN and BED 
did not demonstrate significantly different risk-taking behaviour on the task in the placebo 
condition. We detected a significant interaction such that oxytocin decreased risk-taking 
behaviour to a greater degree in women with BN and BED. Paper 8 presents the 
preliminary outcomes of a study investigating the effect of 40IU intranasal oxytocin on 
the neural processing of visual and gustatory food stimuli. We did not observe significant 
differences in neural activation between women with BN or BED, versus healthy control 
women, in response to the anticipation or receipt of chocolate taste, versus water taste in 
the brain regions analysed. We did not find a significant effect of 40IU intranasal 
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oxytocin, versus placebo, on BOLD response to the anticipation or receipt of chocolate 
milk, versus water. 
The results of these original experiments testing the influence of oxytocin indicate that a 
divided 64IU dose of oxytocin was not effective in reducing calorie consumption in 
women with BN and BED, although there is preliminary evidence that oxytocin may 
reduce risk-taking and attentional bias to food in women with BN and BED. Future dose-
response studies in women would be helpful in ascertaining whether a different regime 
of oxytocin treatment may be more effective in treating the symptoms and sequelae of 
BN and BED. Future research targeting the maintenance factors of BN and BED 
identified by the addictive appetite model via different treatment methods would be useful 
to advance treatment for affected individuals and further refine this theoretical model of 
recurrent binge eating. 
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OUTLINE OF THESIS 
Chapter 1 presents background information about the two disorders which will be the focus of 
the current thesis: bulimia nervosa and binge eating disorder. More specifically, this thesis 
chapter will present current evidence regarding the diagnostic criteria, incidence and 
prevalence, and  disorder trajectories of bulimia nervosa and binge eating disorder. This chapter 
will then go on to discuss the secondary medical complications, common comorbidities, and 
risk factors for each disorder, followed by a discussion of influential maintenance models for 
bulimia nervosa and binge eating disorder. 
Chapter 2 includes three papers which propose and subsequently defend a novel maintenance 
model of recurrent binge eating in the context of bulimia nervosa and binge eating disorder. 
Chapter 3 discusses the rationale for investigating the influence of oxytocin in curbing binge 
eating behaviours, through a pathway informed by the addictive appetite model. This chapter 
subsequently presents a systematic review and meta-analysis of the effects of oxytocin on 
eating.  
Chapter 4 presents the findings of a double-blind, placebo controlled proof-of-concept study 
with a crossover design. This study investigated the effects of a divided dose of 64IU intranasal 
oxytocin on eating behaviours and stress in women with and without bulimia nervosa and binge 
eating disorder. 
Chapter 5 presents two papers which tested the influence of intranasal oxytocin on attentional 
bias to foods images and risk-taking behaviours in women with and without bulimia nervosa 
and binge eating disorder. 
Chapter 6 presents the results of a functional magnetic resonance imaging investigating the 
effects of oxytocin on the neural processing of taste in women with and without BN and BED. 
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Chapter 7 presents an overview of key findings, a synthesis of these findings with existing 
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1.1 Introduction to Feeding and Eating Disorders 
 
Feeding and eating disorders are defined within the Diagnostic and Statistical Manual of 
Mental Disorders – 5th edition (DSM-5) as psychiatric disorders which “are characterized 
by a persistent disturbance of eating or eating-related behaviour that results in the altered 
consumption or absorption of food and that significantly impairs physical health or 
psychosocial functioning” (American Psychiatric Association, 2013, p. 329). Feeding 
and eating disorders specified with the DSM-5 include pica, rumination disorder, 
avoidant/restrictive food intake disorder, anorexia nervosa, bulimia nervosa, and binge-
eating disorder. Additionally, a diagnosis of Other Specified Feeding or Eating Disorder 
(OSFED) can be administered within the DSM-5 framework for individuals who do not 
meet full criteria for any of the above-listed disorders but do exhibit a disturbance of 
feeding or absorption of food that is associated with significant distress or functional 
impairment. Symptom presentations which may warrant a diagnosis of OSFED include 
atypical anorexia nervosa, bulimia nervosa (of low frequency and/or limited duration), 
binge-eating disorder (of low frequency and/or limited duration), purging disorder, and 
night eating syndrome. 
1.2 Bulimia Nervosa 
1.2.1 Bulimia Nervosa: Diagnostic Criteria 
The DSM-5 specifies that the following five criteria must be met for a diagnosis of 
bulimia nervosa (BN): A) The individual must exhibit recurrent loss-of-control binge 
eating behaviour, which is associated with an objectively large amount of food for the 
circumstances consumed within a two-hour period; B) The individual must engage in 
recurrent inappropriate compensatory behaviours intended to prevent weight gain (e.g., 
self-induced vomiting, laxative abuse, fasting, use of diet pills or diuretics, or excessive 
exercise); C) Both the binge eating and compensatory behaviour must occur, on average, 
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with a frequency of at least once per week over a period of three months; D) The 
individual’s self-evaluation is unduly impacted by body shape and weight; E) These 
disturbances must occur in the absence of anorexia nervosa. 
Previously, DSM-IV criteria imposed a greater frequency requirement of binge eating 
and purging for a diagnosis of BN to be met (American Psychiatric Association, 2000). 
That is, at least two episodes of binge eating and purging per week needed to be present 
over a period of at least three months for a diagnosis of DSM-IV BN. Furthermore, DSM-
IV criteria specified two types of BN: Purging type, characterised by self-induced 
vomiting, laxative abuse, diuretics or enemas, and Nonpurging type, characterised by 
fasting or excessive exercise, but not compensatory behaviours associated with the 
Purging type of BN. The impact of the expansion of frequency criteria in the DSM-5 on 
prevalence and incidence rates will be discussed further in section 1.2.2.  
1.2.2 Bulimia Nervosa: Incidence and Prevalence 
Point prevalence of a disorder refers to the proportion of a given population who meet 
diagnostic criteria for the specified disorder at a single point in time. Point prevalence 
estimates for BN differ slightly across Western cohorts, with the most notable 
demographic difference being a greater prevalence of BN among women, as compared to 
men (Jaite, Hoffmann, Glaeske, & Bachmann, 2013; Smink, van Hoeken, Oldehinkel, & 
Hoek, 2014). 
Machado, Gonçalves, and Hoek (2013) combined data from two epidemiological studies, 
including a total of 3,048 female Portuguese high school and university students, 
estimating the point prevalence of DSM-5 BN to be 0.59%. This point prevalence was 
approximately replicated by Smink et al. (2014) in a Dutch cohort study including 861 
19-year-old women, in which the point prevalence of DSM-5 BN was found to be 0.6%. 
This point prevalence of 0.59-0.6% represents an increase from previous estimates using 
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DSM-IV criteria. For example, when Machado et al. (2013) applied DSM-IV diagnostic 
criteria to the same Portuguese sample of young women, point prevalence of BN was 
found to be 0.46%. Additionally, when using the International Classification of Diseases 
system – 10th edition (ICD-10), the prevalence of BN has been recorded to be as low as 
0.2% in German girls and young women between the ages of 10 and 21 (Jaite et al., 2013). 
It should be noted that point prevalence of BN also varies by age, therefore, cohort studies 
including multiple ages groups can mask significant differences in point prevalence 
across different development periods. In a prospective longitudinal study of 9,031 
American girls and women, Glazer et al. (2018) found that that across the 18-year 
assessment period prevalence was highest between the ages of 19 and 23 years of age. 
When classifying BN using DSM-5 criteria, baseline prevalence among girls aged 9 to 
15 years old was found to be 0.10%, increasing to a maximum of 1.1% between the ages 
of 19 and 22 years old (Glazer et al., 2018). 
As previously stated, the point prevalence of BN is lower among men than women. The 
point prevalence of DSM-5 BN has been found to be 0.1% in 19-year-old Dutch men, 
compared to 0.6% amongst Dutch women in the same study (Smink et al., 2014). 
Although raw estimates differed in a separate study using ICD-10 criteria and including 
participants with a broader range in ages, a similar discrepancy has also been found 
amongst a sample of German men between the ages of 10 and 21 years old, where point 
prevalence was 0.02%, as opposed to the 0.20% point prevalence amongst young German 
women in the same study (Jaite et al., 2013). 
Therefore, when men and women are considered together, the prevalence of DSM-5 BN 
is intermediate between that of the two genders, with overall 12-month prevalence being 
estimated at 0.14% in a sample of 36,209 American adults (Udo & Grilo, 2018), and 3-
month prevalence being estimated at 0.66% in Australian adults (Hay, Girosi, & Mond, 
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2015). Amongst German adolescents and young adults, baseline 12-month prevalence of 
ICD-10 BN was found to be 0.11% in 2009 (Jaite et al., 2013). While reasons for the 
difference in point prevalence estimated in American versus Australian adults are not 
entirely clear, the relatively lower point prevalence found in the German sample likely 
reflects differences in the diagnostic classification used to define cases as well as the 
youth of the sample, which some participants being as young at 10 years old. There 
appears to be limited evidence for differences in prevalence amongst different race and 
ethnic groups (Udo & Grilo, 2018), with the exception that white US Latino men have a 
higher 12-month prevalence of BN when compared to white US non-Latino men 
(Marques et al., 2011). 
In epidemiological terms, incidence refers to the onset of new cases of a disease or 
disorder within a given time period. There is mixed evidence for changes in the incidence 
of BN during the course of the 21st century. For example, a Danish study tracking the 
diagnosis of new cases  of BN across all public health services found that, after adjusting 
for an overall increase in all psychiatric diagnoses, the incidence of BN decreased from 
6.3 to 4.2 cases per 100,000 person-years from 1995 to 2010 (Steinhausen & Jensen, 
2015). Similarly, a decrease in raw incidence rates of BN has been reported in the 
Norwegian health service from 2010 to 2016 (Reas & Rø, 2018) and in Dutch primary 
care service between an initial assessment period from 1985-1989 to the final assessment 
period in 2005-2009 (Smink et al., 2016). 
However, this pattern for decreasing incidence rates was not replicated in a study drawing 
from data in the United Kingdom (UK) General Practice Research Database, which found 
that the incidence of BN remained stable for both men and women from 2000 to 2009 
(Micali, Hagberg, Petersen, & Treasure, 2013). It should be noted, however, that the UK 
General Practice Research Database including records of approximately 5% of the UK 
population, in contrast to the Danish and Norwegian registers recording close to 100% of 
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new psychiatric diagnoses nationwide (Munk-Jørgensen & Dinesen Østergaard, 2011; 
Reas & Rø, 2018). While the data included in the UK study is generally representative of 
the age and gender make-up and geographic distribution of the UK, the possibility that 
the selection of General Practice surgeries contributing to the database is biased in other 
ways cannot be excluded.  
However, evidence of lifetime risk across the 20th century suggests that the lifetime 
prevalence of BN may have, in fact, increased from 1944 until 1985, with the pattern for 
decreasing incidence being a newer phenomenon (Hudson, Hiripi, Pope Jr, & Kessler, 
2007). Hudson et al. (2007) administered diagnostic interviews to a sample of 9,282 US 
adults gauging endorsement for lifetime history of any psychiatric disorder. The authors 
found significant inter-cohort differences in the sample, with lifetime risk of DSM-IV BN 
tending to increase from each cohort to the next, such that the relative odds of participants 
born in 1972-1985 endorsing lifetime history of BN were 16.8, as compared to 
participants born before 1944. It should be noted that these cohort effects are necessarily 
confounded by the age of participants, which may detract from recall ability in older 
adults. However, the fact that cohort effects remain significant from each cohort to the 
next, where each cohort overlaps over a period of a year (cohorts were determined by age 
at interview), suggests a true pattern of increasing incidence over the course of the 20th 
century, despite the potential over-estimation of the magnitude of this cohort effect. 
Current lifetime prevalence of DSM-5 BN has been estimated to be 0.08% in men and 
0.46% in women, with an overall lifetime prevalence of 0.28% (Udo & Grilo, 2018). 
1.2.3 Bulimia Nervosa: Disorder Trajectories 
The average age of onset of BN has historically been estimated to be between 15 and 20 
years old (Micali et al., 2013; Steinhausen & Weber, 2009; Stice, Marti, Shaw, & Jaconis, 
2009), with the most recent estimate being 19.6 to 20 years of age (Favaro, Busetto, 
Collantoni, & Santonastaso, 2019; Udo & Grilo, 2018). However, onset of BN has been 
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reported in children as young as 11 years old (Schmidt, Hodes, & Treasure, 1992) and as 
late as 58 years old (Beck, Casper, & Andersen, 1996). Just over a quarter of individuals 
with BN have a prior history of anorexia nervosa, with a German study finding that 27.6% 
of the 196 sampled inpatients with BN had a history of anorexia nervosa (Fichter, 
Quadflieg, & Hedlund, 2008) and an American study finding that 26.8% of women with 
BN recruited from outpatient clinics and the community had a history of anorexia nervosa 
(Bardone-Cone et al., 2008). 
Estimates of the long-term outcome of BN are complicated by different definitions of 
“recovery” and various degrees of recovery across studies. A meta-analysis in 2009, 
including three outcome classifications (recovered, improved, and chronicity), found that 
across 27 longitudinal studies, 45% of people had achieved recovery by follow-up, 27% 
achieved improvement, and 23% of people with BN exhibited a protracted chronic course 
of illness (Steinhausen & Weber, 2009). However, this meta-analysis included studies 
with follow-up periods as short as 6 months in duration, therefore limiting the insights 
these findings offer regarding rates of true long-term recovery from BN. Rates of recovery 
stratified by duration of follow-up period range from 33% recovery at 3-year follow-up 
(Zeeck, Weber, Sandholz, Joos, & Hartmann, 2011), to 55% at 5-year follow-up (Keski-
Rahkonen et al., 2009), and with most recent estimates indicating a 68.2% recovery rate 
a both 9- and 22-year follow-up (Eddy et al., 2017). 
Individuals who do not meet recovery criteria at follow-up tend to fall into one of the 
following categories: continued demonstration of some, but not all, diagnostic criteria for 
BN, continued demonstration of all diagnostic criteria for BN, crossover to another eating 
disorder diagnosis, or natural or premature death. Additionally, it should be noted that 
there is little correlation between remission at one follow-up time point to another, 
therefore, it can be argued that an additional category best fits some individuals with a 
cyclical pattern of remission and relapse over time (Zeeck et al., 2011). An Italian study 
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of 137 patients with BN found that over a 5-year period 8.4% of patients crossed over to 
a diagnosis of DSM-5 anorexia nervosa and 8.4% crossed over to a DSM-5 diagnosis of 
binge eating disorder. 
Although the mortality rate associated with BN is lower than that of anorexia nervosa 
(Arcelus, Mitchell, Wales, & Nielsen, 2011), premature death remains more likely for 
affected individuals than for the general population. A systematic review of twelve studies 
measuring the mortality rate of BN found a standardised mortality ratio of 1.93 (Arcelus 
et al., 2011), and a more recent study recorded an even higher standardised mortality ratio 
of 2.33 (Franko et al., 2013). Additionally, a systematic review focusing specifically on 
rates of completed suicide in BN found that, of the 1,768 patients identified amongst 
eligible studies, there was a suicide rate of 0.030 per 100 person-years, as opposed to the 
general population suicide rate of .004 per 100 person-years (Preti, Rocchi, Sisti, 
Camboni, & Miotto, 2011). Standardised mortality ratio for death by suicide was 
therefore 7.5 for people with BN versus the general population (95% CI [ 1.6-11.6]). 
1.2.4 Secondary medical complications of bulimia nervosa 
BN is associated with a wide range of secondary medical complications, largely due to 
the deleterious effects of compensatory behaviours such as self-induced vomiting, 
laxative abuse, and insulin omission. Recurrent self-induced vomiting exposes the oral 
cavity to highly acidic stomach contents, which is commonly associated with the 
development of oral complications, including tooth erosion (Dynesen, Bardow, 
Petersson, Nielsen, & Nauntofte, 2008), dental sensitivity (Christensen, 2002), 
inflammation of oral mucosa (Ximenes, Couto, & Sougey, 2010), enlargement of the 
parotid glands (Mignogna, Fedele, & Lo Russo, 2004), and a reduced salivary flow rate 
resulting in oral dryness (Dynesen et al., 2008). Repeated self-induced vomiting can also 
place undue strain on the larynx, sometimes resulting in a hoarse voice, chronic cough, 
sore throat, and difficulty swallowing (Ferreira, Gama, Santos, & Maia, 2010). 
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The trauma of self-induced vomiting has been known to cause tearing of the lining of the 
oesophagus, known as a Mallory-Weiss tear, which sometimes resulting in bleeding 
(Cuellar, Kaye, Hsu, & Van Thiel, 1988). However, there is currently limited evidence 
that Mallory-Weiss tears occur at disproportionate rates in people with BN (Cuellar et al., 
1988). More concerningly, however, rare cases of Boerhaave syndrome have been 
reported in BN (Brauer, Liebermann-Meffert, Stein, Bartels, & Siewert, 1997), in which 
there is full intramural rupture of the oesophagus causing death in approximately 29% of 
cases where treatment is not immediately administered (De Schipper, Ter Gunne, 
Oostvogel, & Van Laarhoven, 2009). 
Syrup of ipecac is an emetic containing the alkaloids emetine and cephaeline, which was 
abused by people with BN with increasing frequency from the late 1980s to early 1990s 
(Greenfeld, Mickley, Quinlan, & Roloff, 1993). Ipecac was commonly kept in households 
in the mid-20th century for the purpose of causing rapid vomiting in cases of inadvertent 
poison ingestion, such as by young children (Manno & Manno, 1977). However, the 
American Academy of Clinical Toxicology and the European Association of Poisons 
Centres and Clinical Toxicologists have since recommended against the routine use of 
ipecac in cases of poisoning, both due to low efficacy in preventing poison expulsion, as 
well as the cardiotoxic and neurotoxic effects of ipecac (Krenzelok, McGuigan, & Lheur, 
1997). The cardiotoxic effects of ipecac increase risk of tachycardia and cardiac 
arrhythmias, while the neuromuscular effects have been known to cause muscle weakness 
(Manno & Manno, 1977). Given the relatively long 56-hour half-life of ipecac, these toxic 
effects can therefore cumulate in individuals abusing it on a regular basis (P. C. Ho, 
Dweik, & Cohen, 1998). Indeed, ipecac has been known to cause death in people with 
BN (Schiff et al., 1986). 
Cardiac complications can also arise in BN due to electrolyte imbalances induced either 
by self-induced vomiting or laxative abuse. For example, a recent study of 1,026 adults 
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consecutively admitted to an eating disorders clinic in the US found that, of the 251 
patients with BN, 26.6% presented with hypokalaemia on admission (Mehler et al., 2018). 
Such electrolyte imbalances commonly occur due to the repeated fluid loss caused by 
self-induced vomiting and laxative abuse, which stimulates activation of the renin-
angiotensin system, thus increasing metabolic alkalosis and hypokalaemia (Brown & 
Mehler, 2012). Severe hypokalaemia can cause cardiac arrhythmias, including fatal 
ventricular rhythms in some cases (Buchanan, Ngwira, & Amsha, 2011; Piotrowicz et al., 
2015). 
In additional to self-induced vomiting and laxative abuse, the DSM-5 also includes 
insulin omission in people with insulin-dependent diabetes as another compensatory 
behaviour contributing to a diagnosis of BN (American Psychiatric Association, 2013). 
Insulin omission in the context of BN, sometimes referred to as “diabulimia” (Martin, 
Darbar, & Mokha, 2008), is associated with health risks including retinopathy, potentially 
leading to vision impairment, and nephropathy, which can result in kidney failure in 
severe cases (Takii et al., 2008). A prospective longitudinal study of 234 women with 
type 1 diabetes mellitus has found evidence for heightened mortality among women 
exhibiting greater levels of insulin restriction behaviour (Goebel-Fabbri et al., 2008). 
1.2.5 Common psychiatric comorbidities of bulimia nervosa 
Estimates of the prevalence rates of psychiatric comorbidity with BN vary slightly 
between samples, likely reflecting differing characteristics of inpatient and outpatient 
samples versus community samples, as well as country differences. However, research 
has consistently indicated heightened prevalence of unipolar depression, alcohol and 
substance abuse, and anxiety disorders among people with BN (Farstad, McGeown, & 
von Ranson, 2016; Hudson et al., 2007; Patel, Olten, Patel, Shah, & Mansuri, 2018; 
Ulfvebrand, Birgegård, Norring, Högdahl, & von Hausswolff-Juhlin, 2015). 
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Amongst a large community sample from the United States, including interviews with 
2,980 English-speaking adults, 94.5% of people with BN met DSM-IV criteria for at least 
one psychiatric comorbidity (Hudson et al., 2007). However, a lower estimate (64.1% 
comorbidity with BN) has been found more recently amongst a German sample of female 
children and adolescents (Jaite et al., 2013). This difference in estimates is likely a product 
of a combination of the differing ages and gender make-up between the two samples, and 
also possibly reflective of country differences. Indeed, there is evidence to suggest that 
rates of psychiatric comorbidity with BN differ between men and women. For example, 
a Swedish study of treatment-seeking people with BN found that 74.4% of women with 
BN presented with at least one comorbid Axis I psychiatric disorder at initial presentation, 
compared to 84.5% of men (Ulfvebrand et al., 2015). Taken together, however, these data 
suggest that the majority of people with BN across countries, ages, and genders have at 
least one comorbid psychiatric disorder, thus adding to the complexity of appropriate 
psychiatric formulation for each individual case. 
Amongst the previously cited US community sample (Hudson et al., 2007), the odds ratio 
for a participant with BN having any anxiety disorder was 8.6 (95% CI [3.4-21.6]), as 
compared to the general population. People with BN had significantly greater odds of 
having the following specific anxiety disorders: panic disorder (OR 2.9, 95% CI [1.1-
7.9]), agoraphobia without panic (OR 8.9, 95% CI [3.0-26.2]), specific phobia (OR 5.4, 
95% CI [2.6-11.4]), social phobia (OR 4.7, 95% CI [2.7-8.3]), post-traumatic stress 
disorder (OR 10.2, 95% CI [5.2-20.0), obsessive-compulsive disorder (OR 7.5, 95% CI 
[1.7-37.5]), and separation anxiety disorder (OR 3.5, 95% CI [1.4-9.0]). Amongst 
treatment-seeking Swedish people with BN, raw prevalence of comorbid anxiety 
disorders has been estimated at 54.4% in women and 56.9% in men (Ulfvebrand et al., 
2015). 
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The odds ratio for a person with BN having any mood disorder, compared to the general 
population, has been estimated at 7.8 in a community sample (95% CI [3.6-16.8]) 
(Hudson et al., 2007). Within this sample, the breakdown regarding the odds ratio of 
specific mood disorders is as follows: major depressive disorder (OR 4.3, 95% CI [1.7-
10.8]), dysthymia (OR 4.4, 95% CI [1.5-12.6]), and bipolar disorder (OR 4.7, 95% CI 
[2.1-10.8]). Amongst a sample of 3,319 inpatients identified with BN in the US, 23.5% 
had comorbid depression. This estimate is numerically lower than the raw prevalence 
estimate of comorbid major depressive disorder in treatment-seeking Swedish women 
with BN (35.8% comorbidity) and marginally higher than the comorbidity estimate for 
major depressive disorder among Swedish men with BN (22.4%) (Ulfvebrand et al., 
2015). This evidence therefore does not support the existence of overall greater 
comorbidity for comorbid major depressive disorder in inpatient populations with BN 
compared to those not receiving residential treatment, although the potential for country 
differences prohibits firm conclusions to this extent. 
There is extensive evidence for deficits in global emotional regulation abilities in BN 
(Brockmeyer et al., 2014; Gilboa‐Schechtman, Avnon, Zubery, & Jeczmien, 2006; 
Harrison, Sullivan, Tchanturia, & Treasure, 2010; Svaldi, Griepenstroh, Tuschen-Caffier, 
& Ehring, 2012), with several studies finding that these deficits confer a general risk for 
psychopathology, rather than a specific risk for BN (Aldao, Nolen-Hoeksema, & 
Schweizer, 2010; Svaldi et al., 2012). In addition to the fact that emotional dysregulation 
acts as a common risk factor for BN, mood disorders, and anxiety disorders, the affect 
regulation model of BN also posits that strong negative emotions, which characterise 
mood disorders and anxiety disorders, directly contribute to subsequent incidents of binge 
eating (Polivy & Herman, 1993). Binge eating is then posited to result in temporary relief 
from negative affect and is thus maintained over time through a mechanism of negative 
reinforcement (Polivy & Herman, 1993). A meta-analysis of studies administering 
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ecological momentary assessment to people with recurrent binge eating has provided 
partial support for this model, finding lower mood immediately prior to binge eating 
episodes versus non-binge eating, and lower mood on binge versus non-binge days 
(Haedt-Matt & Keel, 2011). However, it is unclear to what extent clinically low levels of 
affect, such as that seen in mood disorders and anxiety disorders, confer additional risk 
for BN beyond low affect as experienced by people without comorbid mood or affective 
disorders. 
There is evidence for heightened prevalence of impulse-control disorders and substance 
abuse disorders amongst people with BN versus with general population, as well, with 
odds ratios calculated at 6.7 (95% CI [3.0-15.2]) and 4.6 (95% CI [2.0-10.8]), respectively 
(Hudson et al., 2007). The trans diagnostic traits predicting comorbidity with both 
disorders will be discussed in greater depth in Chapter 2 of the current thesis. 
Finally, BN is also associated with borderline personality disorder (now commonly 
referred to as emotionally unstable personality disorder), avoidant personality disorder, 
and obsessive-compulsive personality disorder (Farstad et al., 2016). Specifically, a meta-
analysis of studies examining personality disorders in adults with eating disorders found 
a raw prevalence of 26% (95% CI [15-40%]) comorbidity with borderline personality 
disorder, 14% comorbidity with avoidant personality disorder (95% CI [5-25%]), and 
16% comorbidity with obsessive-compulsive personality disorder (95% CI [7-28%]) 
among adults with BN. Of clinical significance, individuals with BN and a comorbid 
cluster B personality disorder, such as borderline personality disorder, present a greater 
likelihood of suicide attempt (Favaro et al., 2008).  
Some authors have proposed an aetiological pathway in which borderline personality 
characteristics, including emotional instability, self-harm behaviour, and impulsivity, 
emerge early in development and contribute to subsequent risk for impulsive binge-purge 
Monica Leslie   41 
behaviour observed in BN (Sansone & Sansone, 2010). However, there is little evidence 
supporting the progression from borderline personality disorder to BN. A latent profile 
analysis, however, has provided supporting evidence that people with BN comorbid with 
borderline personality disorder report greater incidence of childhood trauma compared to 
BN without borderline personality disorder (Utzinger et al., 2016). Thus, one can 
speculate that exposure to childhood trauma may predispose the development of 
transdiagnostic traits underpinning both BN and borderline personality disorder, such as 
impulsivity, mood instability, and identity disturbance. However, further research is 
needed to clarify the nature of the relationship between BN and borderline personality 
disorder. 
1.2.6 Risk factors for bulimia nervosa 
The following thesis section will provide a summary of psychological factors, 
environmental and social factors, and genetic factors which have been linked to 
heightened risk for BN. Each category of risk factor has been discussed in a separate 
subsection for clarity; however, it should be noted that cognitive, environmental, and 
genetic factors do not act independently to confer heightened risk for BN. Rather, each 
factor interacts at the nexus of the individual in a variety of ways, including cases in which 
environmental factors alter genetic expression via epigenetic means, cases were passive 
genetic effects influence the environment because parents, with shared genetic material, 
shape that environment, and cases were both genetic and environmental factors act upon 
an individual to shape temperament, personality, and specific risk-related traits. The 
following discussion of risk factors serves to provide a brief introduction to individual 
risk factors for BN which have been identified in the empirical literature. Key 
developmental and maintenance models of BN linking these factors to the progression 
and perpetuation of BN will be discussed in further detail in Section 1.4 of the current 
thesis. For the purpose of the current thesis, I will use terminology definitions proposed 
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by Stice (2002) such that risk factor refers to “a variable that has been shown to 
prospectively predict some subsequent pathological outcome”, as opposed to a causal risk 
factor, which refers more specifically to a variable for which “an experimental increase 
or decrease results in elevated or reduced symptoms, respectively”. Given the logistic and 
ethical difficulty in ascertaining a variable’s status as a causal risk factor, the vast majority 
of the variables discussed in the following thesis section rather refer to risk factors with 
uncertain causal relation to the disorder, with pure genetic effects, outside of the influence 
of epigenetics, being a notable exception. 
1.2.6.1 Psychological risk factors for bulimia nervosa 
There are a number of personality traits and cognitive styles which have been found to 
confer heightened risk for the subsequent onset of BN or worsening of the symptoms of 
BN. A meta-analysis of experimental studies and prospective longitudinal studies found 
that thin-ideal internalisation and body dissatisfaction predict both the subsequent onset 
of BN and increasing severity of the symptoms of BN (Stice, 2002). Additionally, 
negative affectivity was found to predict subsequent increasing severity in the symptoms 
of BN (Stice, 2002). The meta-analysis did not find an overall effect for perfectionism or 
impulsivity in predicting the subsequent worsening of the symptoms of BN (Stice, 2002). 
In a conflicting set of findings, an individual case-control study of 102 participants with 
DSM-IV BN and 204 control participants, as well as a more recent survey study, have 
found heightened retrospective reporting of premorbid perfectionism (Fairburn, Welch, 
Doll, Davies, & O'connor, 1997; Hilbert et al., 2014). Nonetheless, it should be noted that 
these studies are susceptible retrospective report bias, thus the role of perfectionism in 
predisposing individuals to BN is still unclear. 
Other psychological factors which confer risk for the subsequent onset of BN include 
heightened levels of weight and shape concerns (Field et al., 2008; Killen et al., 1996) 
and body dissatisfaction (C. M. Anderson, Petrie, & Neumann, 2011; Kluck, 2010; A. R. 
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Smith, Hames, & Joiner Jr, 2013; Stice, 2002). Retrospective surveys have also indicated 
that childhood attention-deficit/hyperactivity disorder (ADHD)  and premorbid conduct 
problems are disproportionately present in women with BN versus comparison women 
without history of an eating disorder, thus providing tentative evidence that impulse 
control difficulties may predate BN in some women (Hilbert et al., 2014; Seitz et al., 
2013). As described in Section 1.2.5, emotion regulation difficulties are also common in 
BN and likely contribute to the maintenance of the disorder (Haedt-Matt & Keel, 2011). 
This emotion dysregulation pathway will be described in more detail in the context of the 
emotion regulation model of eating disorders in Section 1.4 of the current thesis. 
1.2.6.2 Environmental risk factors for bulimia nervosa 
The majority of research into environmental risk factors for BN has focused on family 
and societal factors and the effects of bullying and abuse. Thus, while there are likely to 
be additional factors predisposing individuals to the onset of BN, the current state of the 
evidence has not systematically supported the influence of other environmental factors. 
One commonly cited risk factor for BN is exposure to, and societal pressure to conform 
to, an image of the “thin ideal”. Stice, Spangler, and Agras (2001), for example, found 
that random assignment to receive a subscription to a fashion magazine, which contained 
images endorsing a thin-ideal body image, was associated with significantly greater 
increases in the symptoms of BN in a subgroup of adolescent girls with low social 
support, as compared to random assignment to receive a generic gift card or book 
subscription. The experimental nature of the study thus provides evidence of a role for 
exposure to thin-ideal images as a causal risk factor for BN. Additionally, in a 7-year 
longitudinal study of 6,916 US girls and 5,618 US boys, self-reported attempts to look 
like same-sex people depicted in media was associated with the subsequent onset of 
weekly binge eating and weekly purging behaviour in girls (Field et al., 2008). Given the 
self-report nature of the latter set of data and widespread access to media promoting thin 
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body image, it is unlikely that such media led to the development of disordered eating in 
all young people. However, as supported by the Stice et al. (2001) study, such messages 
promoting the thin ideal likely interact with existing vulnerabilities to further increase the 
likelihood of the onset of BN symptomology. 
Given the societal emphasis on the thin-ideal body shape in Western culture, some authors 
have argued that BN may be specific to, or a result of exposure to Western culture (Keel 
& Klump, 2003). A 2003 review of the literature, for example, did not find any previous 
studies reporting a case of BN in the absence of exposure to Western culture (Keel & 
Klump, 2003). Indeed, as previously mentioned, there is reason to believe that some 
combination of factors characterising modern, as opposed to pre-modern, Western culture 
further enhances risk for BN, as evidenced by increasing risk of BN with successive birth 
cohorts throughout the 20th century (Hudson et al., 2007). A more recent systematic 
review has also found that increasing exposure to Western culture among immigrants is 
associated with heightened BN symptomology (Doris et al., 2015). However, it is 
important to note that the findings of this latter study are confounded by the stress induced 
by cultural assimilation and should thus be interpreted with caution. While an absence of 
evidence should not be equated with evidence of absence, and thus the possibility of cases 
of BN arising outside of Western culture should not be discounted, evidence on the whole 
suggests that risk for BN is, to a large degree, associated with exposure to Western 
culture. 
 In addition to the societal pressures to conform to the thin-ideal as manifest in media at 
large, pressures for weight control can also be transmitted more proximally through both 
behaviour modelling and critical comments from family members and peers (Hilbert et 
al., 2014; Stice, 2002). While social modelling of disordered eating by family members 
has been found to be associated with heightened risk for the onset of BN and worsening 
of the symptoms of BN, this effect is confounded by shared genetic material between 
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family members (Stice, 2002). It is thus compelling to note that the modelling of 
disordered eating by unrelated peers is also associated with heightened risk for BN (Stice, 
1998). Additionally, risk for BN is associated with childhood bullying (Fairburn et al., 
1997; Hilbert et al., 2014) and critical comments about body weight and shape from 
family members (Fairburn et al., 1997; Kluck, 2010). The effect that family emphasis on 
weight and shape has on risk for BN is statistically mediated by body dissatisfaction in 
the individual (Kluck, 2010). However, given that this mediation was found in a survey 
taken at a single time point, it is unclear whether critical comments, body dissatisfaction, 
and BN symptomology progress in sequential temporal order. 
As might be expected, individuals with BN report a greater likelihood of general 
psychiatric risk factors in childhood, including parental mental health disorders and 
abuse, as compared to participants without history of a psychiatric disorder (Fairburn et 
al., 1997; Hilbert et al., 2014). Additionally, parental alcoholism is specifically associated 
with a greater likelihood of BN, as compared to other psychiatric disorders (Fairburn et 
al., 1997). Furthermore, Steiger, Bruce, et al. (2011) have found evidence of a gene X 
environment interaction such that the risk of BN is heightened further when abuse occurs 
to individuals carrying a C allele on the BCl1 glucocorticoid receptor polymorphism. 
Micali, Crous-Bou, Treasure, and Lawson (2017) have also found evidence of heightened 
binge-purge behaviours in women when poor maternal care occurs in conjunction with 
the AG/GA variant of the rs2254298 oxytocin receptor gene polymorphism. The 
implications of oxytocin in BN and BED will be discussed in further detail in Chapter 3 
of the current thesis. 
1.2.6.3 Genetic risk factors for bulimia nervosa 
Heritability estimates for BN vary widely: from 18% (Baker et al., 2009) to 62% (Bulik 
et al., 2010; Yilmaz, Hardaway, & Bulik, 2015) in women, and at approximately 28% in 
men (Baker et al., 2009). The stability of heritability estimates is likely adversely affected 
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by relatively low sample sizes in studies so far. The power of previous genome-wide 
association studies in BN has been limited by low sample size, such that neither a 
European study of 821 people with BN and 1,968 healthy controls (Boraska et al., 2012) 
nor an Australian study of 2,564 female twins (Wade et al., 2013) found a significant 
association at the requisite p < 10-8 level. 
Nevertheless, it may be the case that some polymorphisms numerically associated with 
BN would reach significance if investigated with larger sample sizes. For example, the A 
allele on the rs7624327 polymorphism, which is located in a genetic region associated 
with birth weight (Freathy et al., 2010) and insulin release (Andersson et al., 2011), has 
previously been found to reach significance at the p < 10-5 level (Boraska et al., 2012). 
Additionally, the AG genotype on the rs1445130 polymorphism has been found to reach 
significance at the  p < 5*10-7 level (Wade et al., 2013). The rs1445130 locus is closest to 
the NT5B1B gene, which regulates production of adenosine, thus indirectly regulating 
cellular metabolism (Gass et al., 2010). Therefore, taken together, the genetic 
polymorphisms so far found to trend towards an association with BN contribute to 
regulation of insulin metabolism and likely to cellular metabolism as well. 
Variants on the fat mass and obesity associated (FTO) gene have been a target of 
candidate gene studies for eating disorders given previous evidence that variants of the 
FTO gene are associated with appetite and weight (Cecil, Tavendale, Watt, Hetherington, 
& Palmer, 2008; Frayling et al., 2007; Hotta et al., 2008; Scuteri et al., 2007; Wardle, 
Llewellyn, Sanderson, & Plomin, 2009). Indeed, one European study including 477 
people with BN and 984 controls found that the A allele on the rs9939609 polymorphism 
of the FTO gene is indeed associated with greater risk of BN compared to control 
participants (Müller et al., 2012). However, this finding requires replication before firm 
conclusions about the role of the FTO gene in predisposing individuals to BN can be 
drawn. 
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Early evidence highlighted differences in the serotonin transporter region polymorphisms 
(5-HTTLPR) in people with BN, as compared to control participants (Di Bella, Catalano, 
Cavallini, Riboldi, & Bellodi, 2000). However, more recent meta-analyses have not 
supported an association between 5-HTTLPR polymorphisms and BN across studies (Lee 
& Lin, 2010; Polsinelli, Levitan, & De Luca, 2012). Nonetheless, the short variant of the 
5-HTTLPR polymorphism has been found to be associated with heightened impulsivity 
and novelty seeking in BN (Steiger, Fichter, et al., 2011; Thaler et al., 2013). Future 
research would be helpful in clarifying whether 5-HTTLPR polymorphisms play a role 
in predisposing impulsive eating behaviour in women with BN. 
Finally, there is also preliminary evidence to support differences in genetic 
polymorphisms related to hormone receptors: specifically oestrogen and oxytocin 
receptors. Nilsson et al. (2004), for example, found greater prevalence of the A allele on 
the oestrogen receptor beta cx polymorphism and greater prevalence of the A allele on 
the oestrogen receptor 1730 polymorphism in people with BN versus controls. 
Additionally, Y.-R. Kim, J.-H. Kim, C.-H. Kim, J.-G. Shin, and J. Treasure (2015) have 
found heightened risk for BN in people carrying a G allele on the rs53576 oxytocin 
receptor gene polymorphism, and Micali, Crous-Bou, et al. (2017) similarly found that 
the GG genotype on the same locus was associated with greater binge-purge behaviour in 
women. As previously mentioned, Micali, Crous-Bou, et al. (2017) also found a gene X 
environment interaction where the AG/GA variant of the rs2254298 oxytocin receptor 
gene polymorphism is associated with greater binging and purging behaviour when the 
individual had experienced poor maternal care. The association between BN and variation 
in the oestrogen receptor polymorphism is interesting in light of evidence that early 
menarche, associated with increasing levels of oestrogen, acts as a risk factor BN 
(Kaltiala-Heino, Rimpel, Rissanen, & Rantanen, 2001), although further evidence is 
needed to establish the functional effects of the oestrogen  receptor beta cx polymorphism 
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in BN. The implication of oxytocin functioning in BN will be explored in detail from 
Chapter 3 through Chapter 6 of the current thesis. 
1.3 Binge Eating Disorder 
1.3.1 Binge Eating Disorder: Diagnostic Criteria 
DSM-5 diagnostic criteria for binge eating disorder (BED) are as follows: A) Recurrent 
loss-of-control binge eating characterised by the consumption of an objectively large 
amount of food for the circumstances within a two-hour period; B) Binge eating episodes 
are characterised by at least three of the following features: eating much more rapidly 
than normal, eating until uncomfortably full, eating large amounts of food when not 
physically hungry, eating alone due to feelings of embarrassment about how much the 
individual is eating, and feeling disgusted within oneself, depressed, or very guilty 
afterward; C) Marked distress as a result of the binge eating behaviour; D) The binge 
eating occurs with a frequency of at least once a week over a period of at least three 
months; E) The binge eating is not associated with recurrent use of inappropriate 
compensatory behaviour (such as behaviours that characterise BN) and does not occur 
exclusively during the course of BN or anorexia nervosa. 
The severity of BED is coded depending of the number of binge-eating episodes per week, 
with mild BED characterised by 1-3 binge-eating episodes per week, moderate BED 
characterised by 4-7 binge-eating episodes per week, severe BED characterised by 8-13 
episodes per week, and extreme BED characterised by 14 or more binge-eating episodes 
per week. 
DSM-IV criteria listed BED as an example of an eating disorder not otherwise specified, 
rather than a diagnostic class of eating disorder (American Psychiatric Association, 
2000). The proposed research criteria for BED proposed within the DSM-IV text revision 
are the same as the current DSM-5 criteria, with the exception that DSM-IV research 
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criteria specify a minimum frequency of binge eating on 2 days per week over a 6-month 
period.  
1.3.2 Binge Eating Disorder: Incidence and Prevalence 
Given the recent inclusion of BED as a diagnostic class of eating disorder, there is a 
relative paucity of research investigating the prevalence and incidence of BED, as 
compared to BN. Furthermore, given that the DSM-IV imposed more stringent frequency 
and duration criteria for a diagnosis of BED, as compared to DSM-5 criteria, estimates of 
the prevalence of BED have correspondingly  increased with the instatement of DSM-5 
diagnostic criteria (Hay et al., 2015; Trace et al., 2012).  
Point prevalence of DSM-IV BED has been estimated at 0.8% in an international World 
Health Organisation study of 24,124 participants and at 1.2%-1.5% in American samples 
(Hudson et al., 2007; R. C. Kessler et al., 2013; D. E. Smith, Marcus, Lewis, Fitzgibbon, 
& Schreiner, 1998). The odds ratio of women to men with BED is lower than that of BN, 
and has been estimated at 2.3 (R. C. Kessler et al., 2013). An Australian study found that 
applying DSM-5, as opposed to DSM-IV, diagnostic criteria approximately doubled the 
reported point prevalence of BED from 2.24% to 5.58% in an Australian sample of 6,041 
adults (Hay et al., 2015). However, Udo and Grilo (2018) found a much lower point 
prevalence of 0.44% using DSM-5 BED criteria in a sample of 36,306 American adults. 
One can speculate that this difference may be due in part to cultural differences and 
differences in the food environment between Australia and the US. However, further 
evidence is required to consolidate these divergent prevalence estimates. To our 
knowledge, only one study has investigated the incidence of DSM-5 BED, finding an 
incidence rate of 35 per 100,000 person-years in Finnish women between the ages of 10 
and 24 (Mustelin, Raevuori, Hoek, Kaprio, & Keski‐Rahkonen, 2015). 
Lifetime prevalence of DSM-IV BED has been estimated at 1.9% in the above-described 
World Health Organisation study (R. C. Kessler et al., 2013) and at 2.8% in an American 
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sample of 9,282 adults (Hudson et al., 2007). Similarly to BN, the prevalence of DSM-
IV BED increased throughout the 20th century, with increased odds of lifetime BED being 
found with successive birth cohorts from 1944 to 1985 (Hudson et al., 2007). However, 
cohort effects observed in adults are distinct from differences observed between adults 
and adolescents at a given time point, as lifetime prevalence rates are somewhat lower in 
American adolescents as compared to American adults: estimated at 2.3% in girls and 
0.8% in boys (Swanson, Crow, Le Grange, Swendsen, & Merikangas, 2011).  
In a similar pattern to point prevalence estimates, DSM-5 criteria are associated with 
roughly double lifetime prevalence rates compared to DSM-IV lifetime prevalence rates. 
A Swedish study of 13,295 female twins, for example, found a lifetime prevalence of 
0.17% using DSM-IV criteria, compared to a 0.35% lifetime prevalence using DSM-5 
criteria (Trace et al., 2012). In an American sample of men and women, lifetime 
prevalence of BED was estimated at 0.85% (0.42% in men and 1.25% in women) (Udo 
& Grilo, 2018). Lifetime prevalence of BED was significantly lower in non-Hispanic 
black (0.62%), as opposed to non-Hispanic white (0.94%) participants (Udo & Grilo, 
2018). 
1.3.3 Binge Eating Disorder: Disorder Trajectories 
World Health Organisation data and American-based community samples demonstrate 
later age of onset for BED versus BN, with mean age of onset estimated between 23.3 
and 25.4 years old, and median age of onset estimated at 19.3 and 21.1 years old, 
respectively (Hudson et al., 2007; R. C. Kessler et al., 2013; Udo & Grilo, 2018). Both 
personality and family factors have been found to influence the developmental trajectory 
of BED. Interpersonal difficulties and an excessively affiliative interpersonal style are 
predictive of an earlier age of onset of BED (Blomquist, Ansell, White, Masheb, & Grilo, 
2012). Furthermore, a quadratic function has been reported such that both extremely high 
and extremely low levels of dominance predict earlier onset of BED (Blomquist et al., 
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2012). Distinct developmental trajectories have also been reported in overweight people 
with BED whose parents had a substance use disorder during the individual’s childhood, 
versus overweight people with BED whose parents did not have a substance use disorder 
(Blomquist, Masheb, White, & Grilo, 2011). In a retrospective interview study, 
Blomquist et al. (2011) found that having a parent with substance use disorder was 
associated with earlier onset of BED, greater likelihood of binging behaviour before 
dieting behaviour, and a quicker escalation from binge eating to full spectrum BED. 
A longitudinal study of 1,383 Australian adolescents recruited pre-birth as part of the 
Raine study also found differing patterns in the development of binge eating between 
male and female participants (Allen, Crosby, Oddy, & Byrne, 2013). For female 
participants, binge eating behaviour remained stable between the ages of 14 and 17, 
before subsequently increasing to age 20. Additionally, amongst the female participants, 
having depression at age 14 significantly predicted greater binge eating across the 6-year 
measurement period from age 14 to age 20. The study identified differential trajectories 
such that girls without depression at age 14 exhibited a gradual increase in binge eating 
to age 20, while girls with depression exhibit a gradual decrease in binge eating over the 
same period. Nonetheless, girls with depression at age 14 maintained higher levels of 
binge eating compared to girls without depression at age 14 over the entire duration of 
the study period. By contrast, for male participants in the study, binge eating decreased 
from age 14 to age 17 and then remained stable to age 20. Having depression at age 14 
also predicted greater binge eating across the 6-year measurement period in boys, 
although no time X depression interaction effect was observed. 
Studies consistently find an association between BED and heightened depressive 
symptoms, although the order of the development of binge eating behaviour versus 
depressive symptoms is yet unclear. A longitudinal study of 8,594 American girls from 
ages 9 to 15 found that BED was associated with the subsequent risk of heightened 
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depressive symptoms (Field et al., 2012), while the Raine study rather found that 
depression at age 14 predicted greater levels of binge eating compared to girls without 
depression at age 14 (Allen et al., 2013). Depressive symptoms and BED are therefore 
likely to be closely intertwined, as will be discussed further in Section 1.4 of the current 
thesis in the context of the emotion regulation model of binge eating. 
Although not all people with BED are overweight, overweight and obesity commonly co-
occur with BED. Field et al. (2012) found that girls with BED were more likely to be 
overweight or obese compared to girls with BN at age 9 to 15. Girls with BED who were 
not overweight or obese at baseline were also more likely to become overweight or obese 
over the following year of the study (Field et al., 2012). A separate Finnish study of 2,825 
female twins found that two-thirds of adult women with BED were in the highest weight 
quartile at age 16 (Mustelin et al., 2015). Evidence suggests that weight gain is an 
influential factor in motivating treatment-seeking, as weight tends to increase 
substantially in the year prior to treatment-seeking in obese people with BED (Masheb, 
White, & Grilo, 2013).  
Current estimates regarding the average duration of BED vary widely, from a median of 
4.3 years for DSM-IV BED (R. C. Kessler et al., 2013) to a mean of 15.9 years in 
Americans with DSM-5 BED (Udo & Grilo, 2018).  Future international studies will help 
to clarify whether this greater average duration with DSM-5 diagnostic criteria applies 
across industrialised countries. However, recovery rates are similar when measured either 
using DSM-IV research criteria or DSM-5 criteria. A study of women recruited from a 
hospital in Germany found a 78.3% recovery rate for BED at 6-year follow-up using 
DSM-IV research criteria (Fichter & Quadflieg, 2007), and an Italian clinic has found a 
63.8% recovery rate for DSM-5 BED at 6-year follow-up (Castellini et al., 2011). There 
is evidence to suggest that persistence of BED is shorter in duration for adolescents, with 
an American study finding that 93% of adolescent girls reached remission within one year 
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of baseline, although approximately 33% of participants experience recurrence of the 
disorder within 8 years (Stice, Marti, & Rohde, 2013).  
It is relatively common for people with BED to later crossover into an other specified 
feeding or eating disorder (Fichter & Quadflieg, 2007; Stice, Marti, et al., 2013), such as 
subthreshold BN and BED, and a 7.1-8.3% crossover rate to BN has been documented at 
6-year follow-up (Castellini et al., 2011; Fichter & Quadflieg, 2007). Cases of diagnostic 
crossover between BED and anorexia nervosa are rare (Castellini et al., 2011; Utzinger 
et al., 2015; E. Welch et al., 2016); however, a history of anorexia nervosa or BN is 
associated with greater persistence of eating disorder psychopathology and objective 
binge eating episodes after treatment (Utzinger et al., 2015). BED is not associated with 
heightened mortality, with a standardised mortality ratio of 1.50 (95% CI 0.87 – 2.40) 
(Fichter & Quadflieg, 2016) and an all-cause hazard ratio of 1.77 (95% CI 0.60 – 5.27) 
(Suokas et al., 2013) compared to the general population. BED is associated with a suicide 
rate of 0.082 per 100 person-years (Suokas et al., 2013) as opposed to the general 
population suicide rate of .004 per 100 person-years (Preti et al., 2011). 
1.3.4 Secondary medical complications of binge eating disorder 
A 2017 systematic review has recently summarised medical conditions found to be 
associated with BED in both cross-sectional and longitudinal paradigms (Olguin et al., 
2017). The majority of studies included in the review adopted a cross-sectional design. 
Among these cross-sectional studies, BED was found to associated with heightened risk 
of diabetes mellitus, hypertension, arthritis, chronic back or neck pain, gastrointestinal 
problems (including stomach ulcers and irritable bowel syndrome), sleep problems, 
asthma, and other pain disorders. Additionally, after controlling for overweight and 
obesity, associations with fibromyalgia, pain conditions, irritable bowel syndrome, 
gastrointestinal symptoms, and sleep problems remained, thus suggesting that these 
medical complications cannot be attributed to high weight alone. Additionally, after 
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controlling for psychiatric comorbidity with BED, associations with diabetes, 
hypertension, chronic back and neck pain, chronic headaches, other pain conditions, and 
asthma remained significant. In women, BED was also found to be associated with 
menstrual dysregulation and early menarche.  
The latest cross-sectional data, from an epidemiological sample of 36,306 American 
adults, continues to support the existence of elevated odds of diabetes, hypertension, high 
cholesterol, and high triglycerides in BED after controlling for demographic factors and 
other psychiatric comorbidities (Udo & Grilo, 2019). This latest study also reported 
evidence of greater odds for stomach ulcers, arthritis, sleep problems, anaemia, 
fibromyalgia, bowel problems, osteoporosis, lung problems, liver disease, nerve 
problems, and heart conditions other than heart attacks in BED, although these 
associations did not survive adjustment for other psychiatric comorbidities (Udo & Grilo, 
2019). 
In terms of the metabolic profile of adults with BED, Succurro et al. (2015) found higher 
fasting insulin levels, lower HDL levels, and greater concentrations of inflammatory 
markers in people with obesity and BED, versus adults with obesity alone. However, 
obese children with binge-eating behaviour exhibit similar glucose and lipid profiles 
compared to obese children without binge-eating behaviour (Lourenço et al., 2008). Thus, 
it may be the case that differences in metabolic profiles emerge later in the developmental 
trajectory of BED. Nonetheless, current evidence does not support different odds of 
metabolic syndrome in overweight and obese people with and without binge eating 
disorder (Barber, Schumann, Foran-Tuller, Islam, & Barnes, 2015). 
It should be noted that these associations with medical complications observed in cross-
sectional studies do not necessarily indicate the direction of effect between BED and 
associated medical complications. It is therefore of interest to note that a retrospective 
Monica Leslie   55 
World Health Organisation study with 24,000 participants found that BED predicted the 
later onset of arthritis, chronic back and neck pain, chronic headaches, other chronic pain 
conditions, diabetes, adult-onset asthma, hypertension, and ulcers (Alonso et al., 2014; R. 
C. Kessler et al., 2013; D. J. Stein et al., 2014). Primary physical conditions did not 
significantly predict the subsequent onset of BED (R. C. Kessler et al., 2013). The 
strongest evidence for the influence of binge-eating behaviour on the development of 
secondary medical complications, however, comes from longitudinal prospective data. In 
line with some of the most common associations reported in cross-sectional studies, 
having BED at baseline has been found to be associated with the subsequent onset of 
dyslipidaemia, hypertension, and diabetes over the following five years of measurement 
(Hudson et al., 2010). 
1.3.5 Common comorbidities of binge eating disorder 
The majority of research studies investigating the prevalence of psychiatric comorbidities 
among populations with BED has been carried out using DSM-IV research criteria for 
BED, rather than current DSM-5 diagnostic criteria. However, across both sets of 
diagnostic criteria, studies consistently indicate elevated rates of unipolar depressive 
disorders, bipolar disorder, anxiety disorders, and ADHD in people with BED, as 
compared to participants without history of an eating disorder (Cossrow et al., 2016; 
Hudson et al., 2007; R. C. Kessler et al., 2013; E. Welch et al., 2016).  Indeed, rates of 
current psychiatric comorbidity in DSM-IV BED tend to vary from 36.6% to 42.8% 
(Grilo, White, Barnes, & Masheb, 2013; Grilo, White, & Masheb, 2009). One Swedish 
study found that 75% of participants with BED had a comorbid psychiatric disorder, 
although this estimate should be treated with caution given the relatively small sample of 
participants with BED (n = 28) (Ulfvebrand et al., 2015). Rates of lifetime psychiatric 
comorbidity vary from 66.9% to 73.8% (Grilo et al., 2013; Grilo et al., 2009). 
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 Exact odds ratio estimates vary widely for specific psychiatric disorders across samples 
and differing diagnostic criteria applied. For example, odds ratios comparing the 
prevalence of major depressive disorder among people with DSM-IV BED versus people 
without an eating disorder vary from 2.2 (95% CI [1.3,3.7]) in a large American sample 
to 7.6 (95% CI [6.2, 9.3]) in a sample of treatment-seeking Swedish people with BED. 
The odds ratio for having major depressive disorder in people with DSM-5 BED, as 
compared to healthy controls, has been estimated at 3.82 (95% CI [3.06-4.78]) in a large 
survey study of 22,397 American adults (Cossrow et al., 2016), which falls within the 
range of existing estimates for comorbidity with DSM-IV BED. 
Odds ratio estimates for the co-occurrence of an anxiety disorder in people with DSM-IV 
BED, as compared to control participants, vary from 3.4 to 5.2 (Hudson et al., 2007; R. 
C. Kessler et al., 2013; E. Welch et al., 2016). The odds ratio for the comorbidity of 
anxiety disorders with DSM-5 BED has been estimated to be slightly lower than this 
range (OR 3.17, 95% CI [2.53-3.97]). One can speculate that people with a shorter 
frequency and duration of binge eating, as captured by DSM-5 criteria, may exhibit lower 
levels of overall psychopathology compared to those meeting the strict criteria imposed 
by DSM-IV research criteria, thus accounting for this difference in comorbidity. Indeed, 
a positive correlation has previously been observed to exist between binge eating 
frequency and social anxiety (Sawaoka, Barnes, Blomquist, Masheb, & Grilo, 2012), 
although future research is needed to clarify the generalisation of this link to other specific 
forms of anxiety. There is a relative paucity of research investigating the incidence of 
specific anxiety disorders in DSM-5 BED; however, DSM-IV BED is associated with 
generalised anxiety disorder, panic disorder, agoraphobia, social phobia, specific phobia, 
post-traumatic stress disorder, separation anxiety disorder, and obsessive-compulsive 
disorder (Hudson et al., 2007; R. C. Kessler et al., 2013). 
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Odds ratios for lifetime impulse-control disorders in people with DSM-IV BED, versus 
control participants, have been estimated at 2.5 (95% CI [1.4,4.6]) in an American sample 
and 3.0 (95% CI [2.1-4.4]) in a large international sample (R. C. Kessler et al., 2013). 
While data in DSM-5 BED is lacking, DSM-IV BED is associated with elevated odds of 
the following specific impulse-control disorders: ADHD, conduct disorder, oppositional 
defiant disorder, and intermittent explosive disorder (Hudson et al., 2007; R. C. Kessler 
et al., 2013). DSM-IV BED is also associated with relatively high rates of personality 
disorders, with 29% of affected individuals estimated to have a personality disorder 
(Friborg et al., 2014). The most common type of personality disorder detected in people 
with DSM-IV BED is avoidant personality disorder, followed by borderline personality 
disorder and obsessive-compulsive personality disorder (Friborg et al., 2014). However, 
future studies recruiting control participants are required to more conclusively assess 
whether the odds of personality disorders are significantly elevated in BED. 
1.3.6 Risk Factors for Binge Eating Disorder 
The following thesis section will provide a summary of risk factors contributing to the 
likelihood of the onset of BED. This thesis section will proceed in a similar fashion to 
section 1.2.6 of the current thesis, in that psychological, environmental, and genetic risk 
factors will each be discussed in turn. As previously described in section 1.2.6, each 
category of risk factor has been discussed separately for clarity. Nonetheless, it should be 
noted than, just as in BN, these factors do not influence risk for BED in isolation, but 
rather interact in myriad ways within the lives of affected individuals. Further discussion 
of these interactions and hypothesised pathways to the development of BED will be 
discussed further in the context of maintenance models for BED, presented in Section 1.4. 
1.3.6.1 Psychological risk factors for binge eating disorder 
While BED, by definition, often entails intense feelings of depressed mood following 
binge eating episodes (American Psychiatric Association, 2013), numerous lines of 
evidence suggest that low affect also increases the likelihood of subsequent binge eating 
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episodes (Cardi, Leppanen, & Treasure, 2015; Haedt-Matt & Keel, 2011). In addition to 
bidirectional influences of binge eating and depressed mood within the context of the 
maintenance of BED, prospective longitudinal studies also indicate that childhood 
unhappiness predicts the future onset of BED (Micali, Martini, et al., 2017) and 
depressive symptoms predict the future onset of BED in adolescence and young 
adulthood (Goldschmidt, Wall, Zhang, Loth, & Neumark-Sztainer, 2016; Stice, Gau, 
Rohde, & Shaw, 2017; Stice, Presnell, & Spangler, 2002; Zaider, Johnson, & Cockell, 
2002). Additionally, depressive symptoms predict quantitative increases in binge eating 
behaviour in adolescents (Allen et al., 2013) and young adults (Spoor et al., 2006). 
Both generalised anxiety and eating- and body-specific anxieties have also been found to 
predict the future onset of BED. For example, in a prospective longitudinal study 
including 45 women with a lifetime history of BN/BED and 1,515 control women, greater 
levels of perceived stress were found to predate the onset of binge eating across BN and 
BED (Striegel-Moore et al., 2007). A longitudinal study of 201 American adolescents 
similarly found that greater anxiety was associated with the subsequent onset of BED 
(Zaider et al., 2002). Additionally, both prospective longitudinal and retrospective studies 
indicate that appearance pressure, thin-ideal internalisation, and body dissatisfaction 
independently predict the later onset of binge eating (Racine et al., 2017; Stice et al., 
2017; Stice et al., 2002), and have even greater predictive value in conjunction with high 
levels of negative urgency (Racine et al., 2017). 
Specific forms of impulsivity have also been implicated in the development and 
psychological profile of people with BED. In particular, negative urgency, which refers 
to the tendency to act without deliberation when experiencing strong negative emotion, 
predicts increases in subsequent eating behaviour (Pearson, Combs, Zapolski, & Smith, 
2012). This effect has been found to be mediated by the expectation that eating will help 
to ameliorate low mood (Pearson et al., 2012). Cross-sectional and longitudinal studies 
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have also found that attentional and motor impulsivity predict binge eating (Meule & 
Platte, 2015; Sonneville et al., 2015). Moreover, longitudinal evidence suggests that the 
effect of hyperactivity and inattention in late childhood impacts binge eating in mid-
adolescence via an indirect effect acting via an increase in late-childhood overeating and 
early-adolescent desire for food (Sonneville et al., 2015). 
In light of evidence that emotion dysregulation predicts greater levels of disordered eating 
in people with BED (Gianini, White, & Masheb, 2013), one can speculate that high levels 
of anxiety and depression interact with poor coping skills to predict increased likelihood 
of coping-focused binge eating. Furthermore, evidence suggests that impulsivity interacts 
with body dissatisfaction, thin-ideal internalisation, and appearance pressure to influence 
binge eating (Racine et al., 2017). Taken together, this pattern of findings raises the 
hypothesis that high levels of anxiety and depression combined with poor coping skills 
additionally act in conjunction with tendencies for impulsivity to increase the risk for 
binge eating behaviour. This hypothesis will be explored further in both Section 1.4 and 
Chapter 2 of the current thesis. 
Finally, both cross-sectional and longitudinal studies also indicate an association between 
personality psychopathology and BED. Cross-sectional studies, for example, have found 
a pattern of high novelty seeking, high harm avoidance, high reward sensitivity, and low-
self-directedness compared to normal-weight control participants (Davis et al., 2008; 
Fassino et al., 2002; Grucza, Przybeck, & Cloninger, 2007; Peterson et al., 2010). 
However, empirical evidence suggests that the personality profile of overweight and 
obese people with BED differs little from weight-matched control participants; with only 
self-directedness being lower in overweight and obese people with BED (Fassino et al., 
2002). Of functional significance, however, greater levels of personality psychopathology 
are associated with frequency of binge eating episodes in people with DSM-IV BED 
(Picot & Lilenfeld, 2003). Additionally, in a longitudinal study, antisocial and schizotypal 
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symptoms at age 22 were found to be associated with recurrent binge eating behaviour at 
age 33 (J. G. Johnson, Cohen, Kasen, & Brook, 2006). While the precise nature of the 
relationship of specific personality traits and binge eating remains unclear, one can 
speculate that low levels of self-directedness and high reward sensitivity contribute to 
reward approach behaviour in BED and that disordered personality traits detract from 
social functioning, thus further increasing the risk of the anxious and depressive 
symptoms that contribute to recurrent binge eating behaviour. 
1.3.6.2 Environmental risk factors for binge eating disorder 
Environmental factors related to poor family functioning, weight and body shape-based 
teasing, and childhood trauma have all been found to increase risk of BED later in life. 
For example, a longitudinal study of 1,043 UK women found that low maternal warmth 
and an oppressive parental relationship significantly predicted the future onset of BED 
(Micali, Martini, et al., 2017). Additionally, a previous retrospective case-control study 
found that parental depression significantly predicted BED in adulthood, as compared to 
healthy control status (Fairburn et al., 1998). 
The same case-control study also found that exposure to negative comments around body 
weight, shape, and eating predicted BED (Fairburn et al., 1998). A similar finding has 
been replicated with reference to the predictive value of weight stigmatisation to risk for 
BED (Almeida, Savoy, & Boxer, 2011). Furthermore, non-weight and shape-based 
bullying in childhood has also been found to confer risk for subsequent binge eating in 
both longitudinal and retrospective interview studies (Copeland et al., 2015; Striegel-
Moore, Dohm, Pike, Wilfley, & Fairburn, 2002).  
A meta-analysis investigating the effect of abuse on eating disorder risk, which included 
a total of 14,169 participants, found significant associations between childhood sexual 
abuse, childhood emotional abuse, and childhood physical abuse on later onset of BED 
(Caslini et al., 2016). Abuse appears to be even more prevalent amongst women with 
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BED with a comorbid personality disorder (Grilo & Masheb, 2002). There is some 
indication that sexual abuse may confer different risk for BED depending on ethnicity, as 
greater levels of sexual abuse have been found to differentiate black women with BED 
from a psychiatric comparison group, while this effect was not found for white women 
with BED (Striegel-Moore et al., 2002). Nonetheless, it should be noted that almost all 
findings linking childhood abuse to BED have been found in retrospective studies, and 
should thus be treated with caution given the possibility of recall bias (Caslini et al., 
2016). Future prospective longitudinal studies will help to clarify aetiological pathways 
from abuse to BED, as well as influential protective factors. 
Mixed findings have been reported with regards to the effect of socioeconomic status on 
BED and binge eating behaviour; however, in sum, existing evidence tends not to support 
an overall effect of income levels on risk for BED. While one cross-sectional study of 
475 people in the Detroit metropolitan area found that lower income was associated with 
increased frequency of binge eating in women, but not men (Reagan & Hersch, 2005), 
larger Australian studies of 4,200 and 6,041 people, respectively, found no association 
between household income and binge eating (Hay, 1998; Mulders-Jones, Mitchison, 
Girosi, & Hay, 2017). Additionally, a recent study of 35,306 American adults also failed 
to find an association between income level and risk for BED (Udo & Grilo, 2018). This 
pattern of findings in BED is therefore in contrast to the increased prevalence of obesity 
amongst low income groups (Ogden, Lamb, Carroll, & Flegal, 2010), and highlights 
dissociations between aetiology and risk factors for binge eating versus a more general 
positive energy balance leading to obesity in the absence of eating psychopathology.  
BED is not culturally specific to the West and has rather been observed in approximately 
10% of women in an indigenous Fijian community (Becker, Burwell, Navara, & Gilman, 
2003). Nevertheless, binge eating behaviour was found to be associated with holding a 
Westernised view of the body (Becker et al., 2003), which reflects findings in the West 
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linking body dissatisfaction and thin-ideal internalisation to BED (Racine et al., 2017). 
This pattern of findings therefore suggests the existence of some sociocultural influence 
in the development of BED, without going so far as to support the specificity of BED to 
Western, industrialised societies. 
1.3.6.3 Genetic risk factors for binge eating disorder 
The heritability of current BED has been estimated between 41% and 57%, with 
somewhat lower estimates of heritability found in twin studies (Bulik, Sullivan, & 
Kendler, 2003; K. Mitchell et al., 2010) versus a case-control study (Javaras et al., 2008). 
Heritability of binge eating behaviour is similar when assessed in terms of frequency of 
loss-of-control binge eating, versus the binary criterion of BED or non-BED, although 
the heritability of lifetime binge eating versus no lifetime binge eating of any frequency 
has been found to be as high as 70% to 74% (Root et al., 2010). 
While at least a subset of genetic factors conferring risk to BED are distinct from genetic 
factors conferring risk for obesity in the absence of BED (Hudson et al., 2006), there is 
some evidence to suggest that allelic variants associated with polymorphisms on the FTO 
gene do enhance risk for BED. In a genetic study of 4,916 adolescents enrolled in a UK-
based longitudinal study, Micali, Field, Treasure, and Evans (2015) found that binge 
eating was associated with the AT genotype on the rs1558902 SNP of the FTO gene at 
the p = 8 x 10-3 alpha level. Furthermore, a weighted allelic score including 32 SNPs 
across the FTO gene was associated with binge eating at the p = 8 x 10-4 alpha level. A 
separate study has also found that the AA or AT genotype on the rs9939609 SNP of the 
FTO gene confers significantly greater risk for BED than the TT genotype, and that 
AA/AT carriers consumed a significantly greater percentage of energy from fat in a 
laboratory-based test meal (Tanofsky-Kraff et al., 2009). Associations between BED and 
allelic variants on the rs9939609 SNP were not replicated by a later study in adults, 
although this latter study was limited by low sample size (N = 178) (Cameron et al., 2018). 
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Nevertheless, Cameron et al. (2018) did find evidence of an interaction such that a CC or 
TC genotype on the rs1421085 SNP of the FTO gene, in combination with a high avoidant 
attachment style, conferred risk for greater frequency of binge eating, whilst the CC/TC 
variants were not associated with binge eating among those low in avoidant attachment 
style. On the whole, current evidence therefore suggests that some SNPs on the FTO gene 
may be related to binge eating, although the influence of specific SNPs has not been 
consistently supported across studies. Future genome-wide association studies in larger 
samples will help to clarify the extent to which the FTO gene is related to the development 
of BED. 
Extensive evidence supporting a role for activation of the melanocortin 4 receptor 
(MC4R) in inhibiting subsequent food intake has also highlighted the MC4R gene as a 
putative candidate in which genetic variation may lead to disinhibited eating (Garfield et 
al., 2015). Indeed, two studies have found that a significantly greater proportion of 
mutation carriers on the MC4R gene present with binge eating, compared with non-
carriers (Branson et al., 2003; Potoczna et al., 2004). However, this finding was not 
replicated by a separate research group (Hebebrand et al., 2004). Associations with BED 
have also been found on SNPs related to the dopamine D2 receptor (Davis et al., 2012), 
the serotonin transporter gene (Monteleone, Tortorella, Castaldo, & Maj, 2006), the 
ghrelin gene (Monteleone, Tortorella, Castaldo, Di Filippo, & Maj, 2007), and the brain-
derived neurotrophic factor-related gene (Monteleone, Zanardini, et al., 2006). 
Nevertheless, a lack of replication in findings supporting an association between these 
genes, SNPs of the FTO gene, and MC4R genetic variants precludes the possibility of 
drawing firm conclusions regarding the genetic basis of BED. Future genome-wide 
association studies with larger sample sizes will be helpful in clarifying allelic variants 
which pose genetic risk for BED, as well as relevant gene X environment interactions. 
Monica Leslie   64 
1.4 Maintenance models of bulimia nervosa and binge eating disorder 
Several theoretical models have been proposed linking the risk factors described above 
to form coherent explanations of the development and maintenance of BN and BED. The 
current thesis section will describe four key influential theoretical models which bear 
relevance to the maintenance of binge eating behaviours in BN and BED: the emotion 
regulation model (Leehr et al., 2015), the dual-pathway model (Stice, 1994), the 
interpersonal theory of eating disorders (Rieger et al., 2010), and the trans diagnostic 
model (Fairburn, Cooper, & Cooper, 1986; Fairburn, Cooper, & Shafran, 2003). The 
current thesis section will also briefly describe key strengths and limitations of each 
theoretical model before going on to outline a rationale for a new maintenance model of 
BN and BED. 
1.4.1 The emotion regulation model of bulimia nervosa and binge eating disorder 
The emotion regulation model of binge eating, proposed by Leehr et al. (2015) stems 
from prior specific emotional regulation theories including escape theory (Heatherton & 
Baumeister, 1991), affect regulation theory (Polivy & Herman, 1993), and the emotional 
arousal theory of binge eating (Pine, 1985). Each specific emotional regulation theory 
differs slightly. For example, both escape theory and affect regulation theory purport that 
heightened negative emotion triggers subsequent binge eating for the purposes of relief. 
However, escape theory proposes that the improvement in mood occurs during the course 
of a binge eating episode, while affect regulation theory hypothesises that relief occurs 
following the conclusion of the binge eating episode. Emotional arousal theory places 
greater emphasis on the arousal, rather than valence, component of emotion, proposing 
that overeating is triggered to reduce excessively heightened arousal, regardless of 
valence. Leehr et al. (2015), in their broader emotion regulation model, however, subsume 
both escape theory and affect regulation theory by placing less emphasis on the timing of 
relief, and instead focus on the three components of the emotion regulation process: 1) 
negative emotion, which is followed by 2) the down-regulation of negative emotion 
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through binge eating, and finally 3) some relief component from negative emotion, which 
negatively reinforces binge eating behaviour.  
In a systematic review of experimental studies testing the effect of negative mood on 
binge eating and subsequent improvements in mood in people with BED, Leehr et al. 
(2015) found that the evidence generally supported the emotion regulation model of binge 
eating. That is, nine out of fifteen included studies found that experimentally induced 
negative emotion acted as a trigger for binge eating or overeating in people with BED. 
More limited evidence was available to support the relief component of the emotion 
regulation model. Nevertheless, both of the two experimental studies testing changes in 
mood following overeating or binge eating behaviour indeed found that negative 
emotions decreased after food intake. 
This set of findings differs slightly from those reported in a previous systematic review 
of naturalistic studies testing the relationship between emotion and binge eating through 
the use of ecological momentary assessments (Haedt-Matt & Keel, 2011). Haedt-Matt 
and Keel (2011) indeed found overall greater levels of negative emotion on days in which 
binge eating episodes occurred, and that greater levels of negative emotion preceded 
binge eating versus regular meals and snacks. Nevertheless, overall, ecological 
momentary assessment data did not support an improvement in mood following binge 
eating. Methodological reasons for this finding will be discussed in more detail in Paper 
3 of the current thesis. On the whole, however, both experimental and naturalistic 
evidence provide strong support for the role of negative emotions in triggering binge 
eating episodes. This “trigger” component of the emotion regulation model therefore 
forms an important component of our proposed comprehensive maintenance model of 
binge eating, which I will expound in Chapter 2. 
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1.4.2 The dual-pathway model of bulimia nervosa 
The dual-pathway model of BN, as the name suggests, proposes that two distinct 
aetiological pathways act in concert to increase risk for, and maintenance of, BN (Stice, 
1994). One pathway entails the transmission of sociocultural pressures for thinness via 
messages from peers, family, and the media, which is then internalised, leading to body 
dissatisfaction and dietary restraint. Sustained periods of dietary restraint subsequently 
increase the likelihood of binge eating episodes. In addition to this sociocultural pathway, 
the second pathway relates strongly to the emotion regulation model of BN, such that 
negative affect combines with poor coping skills to increase the likelihood that the 
individual will engage in binge eating and purging in the pursuit of relief from negative 
mood. 
The dual-pathway model of BN is supported by longitudinal evidence finding that thin-
ideal internalisation and perceived pressures to be thin precede subsequent increases in 
body dissatisfaction, which predicts subsequent increases in dieting and low mood, which 
predicts subsequent worsening of binge eating and purging behaviour (Allen, Byrne, & 
McLean, 2012; Stice, 2001). Structural equation modelling of binge eating progression 
over time has indicated an adequate, but not excellent, fit to the dual-pathway model of 
BN (Allen et al., 2012). 
One significant limitation of the dual-pathway model, however, includes the significant 
focus on the role of thin-ideal internalisation specifically in women. The original model 
paper, for example, organised supporting evidence in terms of increasing emphasis on the 
thin-ideal body type for women throughout the 20th century, the importance of appearance 
within the female gender-role, and the important of appearance, and particularly of 
women’s appearance, for societal success (Stice, 1994). The dual-pathway model 
therefore fails to account for the incidence of BN in men, for whom social standards have 
tended to favour a muscular body ideal (Labre, 2002).  
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Additionally, while the affective pathway is supported by a wide array of evidence, as 
discussed above within the context of the emotion regulation model of binge eating, the 
sociocultural pathway fails to account for cases of BN and BED in which binge eating 
precedes dieting behaviour. Indeed, in retrospective studies conducted in participants with 
BED, 35-81% of participants reported that the onset of binge eating occurred prior to the 
onset of any dieting (Grilo & Masheb, 2000; Manwaring et al., 2006). Therefore, while 
the dual-pathway model may indeed encapsulate the aetiology of binge eating well among 
many women with BN, the model fails to account for significant subgroups with recurrent 
binge eating, including men and people with BED. 
1.4.3 The interpersonal theory of eating disorders 
The interpersonal theory of eating disorders postulates first that disturbances in the 
individual’s sense of self, including low self-esteem and negative affect, lead to 
disordered eating behaviours across the eating disorder spectrum (Rieger et al., 2010). 
These disturbances in the individual’s sense of self are postulated to arise from 
interpersonal difficulties. Rieger and colleagues’ model proposes that the key 
interpersonal factor maintaining identity disturbances is negative social evaluation, which 
is exacerbated by specific interpersonal processes including role disputes, role transitions, 
grief, and interpersonal deficits. Furthermore, insufficient positive social evaluation can 
also contribute to an overriding perception of negative social evaluation when it is also 
perceived to communicate a lack of social value. 
Where the individual is unable to engage in positive social interactions and achieve a 
sense of social worth through conventional interpersonal means, the individual is 
hypothesised to engage in disordered eating behaviours in an attempt to achieve a sense 
of self-worth and improved affect via alternative means (Rieger et al., 2010). Disordered 
eating behaviours are then hypothesised to further exacerbate interpersonal difficulties, 
thus initiating a vicious cycle. Indeed, a previous empirical study has found that 
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experimental provision of negative social evaluation is associated with the greater 
consumption of high-caloric foods in a subsequent taste test (Baumeister, DeWall, 
Ciarocco, & Twenge, 2005). Furthermore, structural equation modelling of 118 students 
also found that social appearance anxiety and fear of negative social evaluation were 
significant risk factors for greater eating disorder pathology (Levinson & Rodebaugh, 
2012). Nevertheless, these studies fail to establish the primacy of social evaluation 
concerns in maintaining eating disorder symptoms, as both studies are confounded by 
general negative affect induced by negative social evaluation and fears. Therefore, one 
can argue that the emotion regulation model more comprehensively and parsimoniously 
accounts for binge eating behaviour in BN and BED, where negative social evaluation 
acts as one of a variety of factors which contributes to the low affect maintaining the 
eating disorder. 
1.4.4 The trans diagnostic model of eating disorders 
The trans diagnostic model of eating disorders, originally proposed by Fairburn and 
colleagues in 1993, proposed that anorexia nervosa and BN were maintained by same 
core psychological factors, with the most important maintenance factor being the 
overvaluation of body shape and weight and their control. The model was later revised to 
suggest that this core maintenance factor can then interact with one or more of four 
additional factors to influence the course of the eating disorder (Fairburn et al., 2003). 
These additional four maintenance factors include 1) Clinical perfectionism, defined as 
“overvaluation of the striving for, and achievement of, personally demanding standards, 
despite adverse consequences” (Fairburn et al., 2003, p. 515); 2) Core low self-esteem, 
defined as “having an unconditional and pervasive negative view of oneself which is seen 
as part of one’s permanent identity” (Fairburn et al., 2003, p. 516); 3) Mood intolerance, 
defined as “the inability to cope appropriately with certain emotional states” (Fairburn et 
al., 2003, p. 517); and 4) Interpersonal difficulties, which occur when difficulties with 
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others, and especially close others, drive a fight for control, heighten stress, and 
potentially undermine self-esteem in the long-term. A schematic depicting the interaction 
of these factors in perpetuating disordered eating behaviour is presented in Figure 1. 
 
Figure 1. A schematic representation of the trans diagnostic model of eating disorders. 
Adapted from Fairburn, Cooper, & Shafran, 2003. 
In light of the inclusion of BED as a criterial eating disorder, more recent evidence has 
also provided evidence that at least moderate levels of overvaluation of weight and body 
shape distinguish a more severe phenotype of BED (Goldschmidt et al., 2010) and that 
Monica Leslie   70 
overvaluation of weight and shape mediates the relationship between low self-esteem and 
weight bias internalisation in BED (Pearl, White, & Grilo, 2014). 
The transdiagnostic model of eating disorders forms the basis for enhanced cognitive 
behavioural therapy (CBT-E) for BN and BED, which remains the gold-standard 
treatment for both disorders (National Institute for Health and Clinical Excellence, 
2017). The success of CBT-E in treating BN and BED thus provides indirect evidence for 
the importance of maintenance factors proposed within the trans diagnostic model, as 
CBT-E is formulated to primarily target these factors. Nonetheless, it is possible that 
CBT-E achieves therapeutic success via incidental improvement in maintenance factors 
not proposed within the transdiagnostic model, and that other maintenance factors 
therefore exert greater influence in perpetuating BN and BED. 
Studies testing changes in self-esteem, interpersonal difficulties, perfectionism, and mood 
intolerance over the course of CBT-E have produced mixed findings regarding the 
influence of each factor on treatment outcome. For example, one clinical trial found no 
significant difference in perfectionism and mood intolerance over the course of CBT-E 
(Byrne, Fursland, Allen, & Watson, 2011), although one later trial did find an 
improvement in emotion regulation (Wonderlich et al., 2014). However, studies directly 
testing the mediating effect of changes in each postulated interacting factor on treatment 
outcome are limited. A recent systematic review found that only two mediators of clinical 
improvement in BN hypothesised within transdiagnostic model formulation have been 
directly tested in empirical studies: dietary restraint and body-related concerns (Linardon, 
de la Piedad Garcia, & Brennan, 2017). Reductions in dietary restraint were found to be 
associated with better outcome across studies. However, change in body-related concerns, 
which is arguably more closely related to the transdiagnostic core maintenance factor 
“overvaluation of weight and shape”, was not found to be related to treatment outcome. 
The systematic review did not find evidence of any clinical trials of CBT-E for BED 
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which tested maintenance factors specific to the transdiagnostic model of eating 
disorders. Thus, while the primary treatment stemming from the transdiagnostic model of 
eating disorders is indeed effective for many people with BN and BED (Hay, 2013; Peat 
et al., 2017), evidence supporting its purported mechanism of action is lacking. 
Additionally, approximately 50% of people with BN do not achieve remission by the end 
of treatment with CBT-E, thus highlighting the possibility that different maintenance 
factors from those targeted by CBT-E may perpetuate the BN and BED in a large 
subgroup of individuals, who may be better served by a different treatment programme. 
1.4.5 Rationale for a new maintenance model of BN and BED 
Each of the above-described maintenance models of BN and BED serves to elucidate 
pathways connecting the disparate risk factors described in Sections 1.2.6 and 1.3.6 to 
produce a coherent formulation of BN and BED, as supported by a range of cross-
sectional and longitudinal evidence. Nevertheless, each maintenance model is associated 
with specific limitations, including: the failure of the dual-pathway model to account for 
BN and BED amongst significant subgroups of affected individuals, the lack of 
parsimony associated with the interpersonal theory of eating disorders, and the lack of 
supporting clinical evidence for the interacting proposed maintenance factors within the 
transdiagnostic model. Additionally, each of these three maintenance models, as well as 
the emotion regulation model, also fail to account for the widely different behavioural 
phenotypes observed across the eating disorder spectrum from anorexia nervosa to BED. 
That is, while each model predicts how disordered eating behaviour comes to occur, the 
models have little predictive validity in explaining why this would manifest as weight 
control behaviour in isolation, weight control behaviour in combination with binge eating 
behaviour, or binge eating behaviour in isolation. In Chapter 2 of the current thesis, I will 
further elaborate on the need for a new comprehensive maintenance model of BN and 
BED, and present both a summary of existing evidence as well as original evidence for a 
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novel maintenance model of BN and BED: The Addictive Appetite Model of Bulimia 
Nervosa and Binge Eating Disorder. 
1.5 Aims and hypotheses of the current thesis 
 The overall aim of the current thesis is to propose and investigate a novel maintenance 
model of BN and BED: The Addictive Appetite Model of Bulimia Nervosa and Binge 
Eating Disorder. I will first present this novel illness formulation alongside a review of 
existing evidence for the maintenance model. Subsequently, I aimed to investigate the 
maintenance model via analysis of motivations for eating behaviour. Furthermore, the 
model predicts that treatments for substance abuse disorders warrant investigation in 
individuals with BN and BED. I therefore go on to present the results of an original study 
investigating the effects of exogenous oxytocin administration in women with BN and 
BED, based on a burgeoning field of work establishing the relevance of oxytocin in 
curbing substance addictions and relapse to substance use. The thesis is structured as a 
series of papers which are each associated with separate but related aims and hypotheses. 
The aims and hypotheses of each paper are presented in Table 1.
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Table 1 
Aims and hypotheses of the papers in this thesis 
Paper Title Aims and Hypotheses 
Paper 1 Are trans diagnostic models of eating disorders fit for 
purpose? A consideration of the evidence for food 
addiction 
This paper aimed to formulate a novel comprehensive maintenance 
model of bulimia nervosa and binge eating disorder: The Addictive 
Appetite Model. 
Paper 2 Towards a translational approach to food addiction: 
Implications for bulimia nervosa 
The aim of this narrative review was to summarise existing evidence in 
support of the most novel elements proposed within The Addictive 
Appetite Model: the existence of tolerance and withdrawal affects in 
bulimia nervosa and the impact of foods with a high glycaemic index in 
maintaining elevated food craving. 
Paper 3 Testing the addictive appetite model: The importance 
of craving, reward, and reward enhancement 
This original study aimed to test two maintenance processes proposed 
within The Addictive Appetite Model of binge eating: eating due to 
enhanced incentive salience and eating for emotion regulation. Our 
hypotheses were 1) People with BN and BED would show higher levels 
of craving for food than weight-matched controls; 2) People with BN and 
BED would endorse eating palatable food as a method of coping with 
distress and as a means of enhancing mood; and 3) Food craving, eating 
for emotional coping, and eating for reward enhancement would 
distinguish individuals with binge-type eating disorders from weight-
matched controls.  
Paper 4 A Systematic Review and Quantitative Meta-Analysis 
of the Effects of Oxytocin on Feeding 
This paper aimed to conduct a systematic review synthesising the effects 
of oxytocin on feeding. We used PRISMA guidelines to identify all 
original published and unpublished experiments testing the effects of 
exogenous oxytocin on energy intake in wild-type animals and in humans, 
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where oxytocin was administered in the absence of other active drugs or 
surgeries. We also aimed to identify relevant moderators of oxytocin’s 
effects on feeding in order to clarify the conditions under which these 
anorexigenic effects hold. We hypothesised that exogenous oxytocin 
administration, as compared to placebo administration, would reduce 
feeding in both humans and animals. 
Paper 5 The influence of oxytocin on eating behaviours and 
stress in women with bulimia nervosa and binge eating 
disorder 
The aim of the current study was to explore the impact of the 
administration of oxytocin on both reward and anxiety-related processes. 
We hypothesised that a divided dose of 64IU intranasal oxytocin 
administration would reduce subjective hunger, the immediate 
consumption of palatable food, 24-hour calorie consumption, and the 
incidence of binge eating when compared to placebo. We also 
hypothesised that oxytocin administration would be associated with lower 
levels of stress, and that participants would report lower levels of “feeling 
fat”. Finally, we predicted that participants would have lower salivary 
cortisol concentrations in the oxytocin, versus placebo, condition. We 
hypothesised that each of these effects would be moderated by eating 
disorder status, such that participants with BN or BED would experience 
greater reductions in food consumption and stress-related variables than 
participants with no history of an eating disorder. 
Paper 6 A Pilot Study Investigating the Influence of Oxytocin 
on Attentional Bias to Food Images in Women with 
Bulimia Nervosa and Binge Eating Disorder 
This study aimed to test the effect of a divided dose of 64IU intranasal 
oxytocin on attentional bias to palatable food in women with and without 
bulimia nervosa and binge eating disorder. Our hypotheses were: 1) 
Women with BN or BED would demonstrate greater attentional biases 
towards food images than women without history of an eating disorder; 2) 
There would be an interaction between time point and participant group, 
such that the difference in attentional bias to food in the BN/BED, versus 
healthy control group, would be even greater following food consumption; 
3) Oxytocin administration would reduce vigilance towards food images 
Monica Leslie   75 
in both groups of women, based on previous work suggesting that oxytocin 
reduces the incentive salience of palatable food in healthy participants (Ott 
et al., 2013); 4) Oxytocin would reduce vigilance towards food images to 
a greater degree in women with BN or BED, versus healthy comparison 
women, due to potential flooring effects in the healthy comparison group. 
Paper 7 The Influence of Oxytocin on Risk-Taking in the 
Balloon Analogue Risk Task Among Women with 
Bulimia Nervosa and Binge Eating Disorder 
This study aimed to compare the performance of women with clinical 
levels of recurrent binge eating on the BART to that of control women 
without previous history of an eating disorder. Furthermore, we also aimed 
to investigate the differential effect of intranasal oxytocin on risk-taking 
in the BART in women with BN and BED compared to healthy controls. 
We hypothesised that women with BN and BED would demonstrate 
greater baseline risk-taking behaviour on the BART in the placebo 
condition, relative to women without previous history of an eating 
disorder. Given previous research indicating that oxytocin induces a 
down-regulation of reward seeking in men, we hypothesised that a divided 
dose of 64IU intranasal oxytocin, versus placebo, would be associated with 
reduced risk-taking behaviour in the BART in women, and that this effect 
would be stronger in women with bulimia nervosa and binge eating 
disorder due to higher trait levels of risk-taking behaviour.  
Paper 8 The effect of oxytocin on the neural processing of taste 
reward in women with and without binge-type eating 
disorders 
This study aimed to investigate differences in neural activation in response 
to the anticipation and receipt of chocolate milk, versus water, in women 
with BN and BED versus healthy comparison women. We also aimed to 
investigate the influence of 40IU intranasal oxytocin on the neural 
processing of the anticipation and receipt of chocolate milk, versus water.  
We conducted whole-brain exploratory analyses to identify regions in 
which women with BN and BED exhibited different patterns of BOLD 
response to palatable taste anticipation and receipt, and regions where 
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40IU intranasal oxytocin moderated neural activation to palatable taste 
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Abstract 
Explanatory models for eating disorders have changed over time to account for changing 
clinical presentations. The transdiagnostic model evolved from the maintenance model, 
which provided the framework for cognitive behavioural therapy for bulimia nervosa.  
However, for many individuals (especially those at the extreme ends of the weight 
spectrum), this account does not fully fit. New evidence generated from research framed 
within the food addiction hypothesis is synthesised here into a model that can explain 
recurrent binge eating behaviour.  New interventions that target core maintenance 
elements identified within the model may be useful additions to a complex model of 
treatment for eating disorders.   
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Introduction 
Current treatments for bulimia nervosa and binge eating disorder are only moderately 
effective, with 30-50% of individuals achieving complete abstinence from binge eating 
at the end of treatment (Hay, 2013) and a 68% remission rate at 9-year follow-up (Eddy 
et al., 2017).  This suggests that the transdiagnostic model that underpins cognitive 
behavioural therapy may require modification in order to accommodate the diverse eating 
patterns and weight across the eating disorder spectrum. Eating behaviour has been 
relatively neglected (Treasure, Cardi, & Kan, 2012) but the concept of food addiction has 
brought it into the foreground (Gearhardt, Boswell, & White, 2014; Gearhardt et al., 2012; 
Granero et al., 2014; Meule & Gearhardt, 2014b; Schulte & Gearhardt, 2017). 
Nonetheless, the concept of food addiction is controversial (Finlayson, 2017; Hebebrand 
et al., 2014; Long, Blundell, & Finlayson, 2015; Schulte, Potenza, & Gearhardt, 2017), 
in part due to the different levels of description being used. For example, the Yale Food 
Addiction Scale (Gearhardt, Corbin, & Brownell, 2009b) examines behaviours and 
subjective reports, while the focus of other studies has been on underpinning mechanisms 
(Colantuoni et al., 2002; Colantuoni et al., 2001). Some of the controversy may stem from 
semantics: does addiction imply a set of behaviours, or a form of neuroadaptation within 
hedonic circuits, or an underlying disease process (Lewis, 2017)? If we step aside from 
the linguistic term “addiction”, with all the stigma and social implications it may carry, 
and instead focus on the function that related processes serve, this conceptualisation may 
prove a useful frame for work within the field. Targeting the maintenance factors 
underpinned by addiction-related neural processes may enhance our ability to prevent and 
treat these disorders, which lead to misery and disability in many domains (Gramaglia, 
Brytek-Matera, Rogoza, & Zeppegno, 2017; Simpson & Mazzeo, 2017).  In the following 
account, we suggest an update to the model of binge eating disorder and bulimia nervosa, 
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which incorporates some of the new evidence that is emerging. First, we consider the 
profound changes in the epidemiology of eating disorders over the last 50 years. 
Epidemiology 
An increasing number of people received a diagnosis for bulimia nervosa in the UK in 
the eighties (Currin, Schmidt, Treasure, & Jick, 2005; Turnbull, Ward, Treasure, Jick, & 
Derby, 1996) and binge eating disorder in the new millennium (Micali et al., 2013).  
Possible new forms of eating disorders such as orthorexia nervosa (Gramaglia et al., 2017; 
Simpson & Mazzeo, 2017) and diabulimia (Wilson, 2012) have been described more 
recently. This increase in eating disorders parallels the worldwide increase in the 
prevalence of obesity (Ng et al., 2014).  There are several explanations for this rapid 
increase in eating and weight problems, including changes to the food environment and 
associated novel interactions with individual vulnerabilities. 
In the West, in particular, the evolving food environment has changed what and how we 
eat (Lewis, 2017). Foods have been modified to become more accessible, cheap, and 
palatable, while nutrients have been ultra-processed and /or purified (Gramaglia et al., 
2017). Food now requires little effort to procure and prepare and is therefore less bound 
within social processes.  At the same time, the relevance of food and eating to health and 
body image has become a dominant discourse. Fatness is stigmatised (de la Haye, 
Dijkstra, Lubbers, van Rijsewijk, & Stolk, 2017; Di Pasquale & Celsi, 2017), “fat talk” 
is associated with body dissatisfaction (Mills & Fuller-Tyszkiewicz, 2017) and abnormal 
eating practices (Arroyo, Segrin, Harwood, & Bonito, 2017), while thinness and 
muscularity are valued as the ideal body form (Karazsia, Murnen, & Tylka, 2017).  What 
is the evidence that these changes in the food environment could lead to changes in eating 
behaviours?  
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Proof of Concept Animal Models: Changes in the Food environment as Risk 
Factors for Binge Eating Disorder 
Animal studies have demonstrated proof of the concept that manipulations of the food 
environment can produce “binge eating”. Putative risk factors including a period of 
undernutrition, followed by the intermittent addition of palatable food (high sugar and fat 
combinations) and stress (particularly social stress), have been shown to lead to “binge 
eating” (Murray, Tulloch, Chen, & Avena, 2015; Razzoli, Pearson, Crow, & 
Bartolomucci, 2017; Wiss, Criscitelli, Gold, & Avena, 2017). Interestingly, animals 
exposed to this food schedule exhibit signs of food addiction, such as physical withdrawal 
symptoms, when intermittent palatable sucrose intake is followed by administration of an 
opioid antagonist (Colantuoni et al., 2002). These animals are also more vulnerable to 
developing other addictive behaviours (Avena, 2010; Avena, Bocarsly, & Hoebel, 2012). 
Moreover, deeper examination of the hedonic circuits involved has shown neuroadaptive 
changes in dopamine and opiate neurons (Avena, Rada, & Hoebel, 2009; Rada, Avena, 
& Hoebel, 2005). This is of interest as the mechanisms underpinning substance abuse are 
also thought to involve “hijacking” of normal hedonic processes (Lewis, 2017). 
 One theory of addiction processes is that aspects of the pharmacology (more potent 
agents) or the pharmacokinetics (e.g. rapid rate of change in levels of a psychoactive 
chemical) leads to greater activation and sensitisation in the “wanting” component of the 
hedonic system (Volkow, Fowler, Wang, & Swanson, 2004). In turn, this leads to 
secondary neuroadaptive changes (Sweatt, 2016), including the down-regulation of 
dopamine and opioid receptors. As tolerance develops along with persistent and 
increasing craving for the substance, individuals engage in particular behaviours to 
restore hedonic balance. “Addictive behaviours” are considered out of control and 
shameful activities and are therefore often carried out in solitude. The repeated occurrence 
of these behaviours therefore results in a shift in the overall balance between positive and 
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negative affect, thereby increasing the desire for further activation of the hedonic system 
(Lewis, 2017; Probst & van Eimeren, 2013).  This can lead to the development of a 
vicious circle of behaviour, where susceptibility is potentially moderated by gender 
(Jiménez-Murcia et al., 2017).  
The Concept of Food Addiction 
It follows from this model that certain foods may have an addictive potential because of 
a similar change in the “pharmacokinetics” of glucose and possibly fat metabolism. For 
example, foods with a high glycaemic load have the potential to cause greater fluxes in 
blood glucose. A survey examining the addictive potential of different foods found 
technologically-processed foods with added refined carbohydrate and fat, and /or with a 
higher glycaemic load were most implicated (Schulte, Avena, & Gearhardt, 2015). 
Support for this concept comes from an experimental study in men which found that foods 
with a high glycaemic load led to greater post meal changes in hunger and activation of 
reward circuits (Lennerz et al., 2013).   Previous evidence has demonstrated individual 
variation in susceptibility to this effect (Zeevi et al., 2015). For example, insulin resistance 
or insulin omission (a key behaviour in “diabulimia”) might enhance an individual’s 
potential to develop a cycle of addictive food consumption because of the wider swings 
in blood sugar.  The same explanation may explain the similar effects of self-induced 
vomiting. These physiological processes may account for the higher risk of developing 
an eating disorder in type 1 diabetes (Young et al., 2013),  and may also explain the fact 
that higher levels of binge-purge behaviours in eating disorders worsen prognosis and 
increase treatment drop-out (Custal et al., 2014; Vall & Wade, 2015). 
What is the evidence for similarity in brain circuits between binge eating disorder 
and substance abuse disorders? 
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Recurrent binge eating of foods high in fat and sugar has been associated with 
desensitisation of opioid and dopamine receptors (Colantuoni et al., 2002; Colantuoni et 
al., 2001). This pattern mimics the neural underpinning of tolerance and dependence 
observed in substance use disorders (Christie, 2008). Indeed, Broft and colleagues have 
similarly reported a lower level of dopamine binding in the striatal region for individuals 
with bulimia nervosa (Broft et al., 2012). Furthermore, they found that lower levels of 
dopamine binding were correlated with greater severity of bulimic symptoms (Broft et 
al., 2012). 
It is also notable that common neural substrates appear to be relevant in supporting both 
substance disorders and binge-type eating disorders (Berridge, 2009; R. M. Kessler, 
Hutson, Herman, & Potenza, 2016; Mameli et al., 2009). The ventral tegmental area and 
nucleus accumbens play important roles in the processing of reward and maintenance of 
addictions (Berridge, 2009). Specifically, it has been shown that cocaine use results in the 
initial potentiation of synapses within the ventral tegmental area (Mameli et al., 2009), 
which gradually comes to lead to neuroplastic changes within the dorsal striatum (Everitt 
& Robbins, 2013) (in a path acting via the nucleus accumbens) (Mameli et al., 2009). 
These changes in the dorsal striatum subsequently consolidate the compulsive nature of 
the addiction over time. The ventral tegmental area and nucleus accumbens are also 
highly involved in the processing of taste reward (Berridge, 2009) and, as cited above, 
reduced dopamine binding in the these same regions of the striatum have been noted in 
bulimia nervosa (Broft et al., 2012; Steward, Menchón, Jiménez-Murcia, Soriano-Mas, 
& Fernández-Aranda, 2017) as well as obesity (Wang, Volkow, Thanos, & Fowler, 2004) 
(as is also seen in individuals with drug addictions) (Wang et al., 2004). 
Corresponding with these findings, Gearhardt and colleagues have previously 
investigated individuals high in food addiction and found that the pattern of neural 
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activation in response to food cues bears similarity to that observed in individuals with 
substance disorders in response to drug cues (Gearhardt et al., 2011). 
It is interesting to note that these similarities in neural circuits underpinning reward 
processing are also accompanied by similarities in general neuropsychological traits. 
Voon used a paradigm that measured aspects of risk taking (valence, probability, and 
value) and found similarities between people with binge eating disorders and substance 
abuse, who favoured greater risk taking than healthy controls when anticipating rewards 
(Voon, Morris, et al., 2015). In the loss domain, however, there were some differences, 
indicating that individuals with binge eating disorder may not be quite as prone to risk 
taking when faced with a high probability of loss. Similar findings were obtained when 
obesity, substance-related disorders and behavioural addictions were compared on 
decision making tasks (Mallorquí-Bagué et al., 2016). 
It has been argued that binge eating disorder and addiction are two clusters of one 
disorder, with impulsivity and compulsivity as transdiagnostic traits (Figee et al., 2016; 
Jiménez-Murcia et al., 2015; R. M. Kessler et al., 2016). Compulsive patterns of 
behaviour, generally, are believed to be underpinned by anomalies in circuits relating to 
reward and punishment (particularly among striato-thalamo-cortical circuits (Volkow & 
Fowler, 2000)) .   
Building Models for Understanding Bulimia Nervosa and Binge Eating disorder 
Fairburn developed a maintenance model for bulimia nervosa in 1981, forming the basis 
of cognitive behavioural treatment (CBT) (Fairburn, 1981) This was later adapted into 
the transdiagnostic model, designed to apply to all forms of eating disorder (Fairburn et 
al., 2003). In these earlier models, the biology and behaviour related to eating and appetite 
had been largely ignored (Treasure et al., 2012). However, a simple transdiagnostic 
formulation cannot easily account for the divergent pattern of eating behaviour and 
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weight between restrictive anorexia nervosa and binge eating disorder. Explanatory 
models for restrictive anorexia nervosa (AN) (low appetite, aversion to satiety) and both 
bulimia nervosa (BN) and binge eating disorder (BED) (high appetite, weak satiation) 
need to account for these differences in the domain of appetitive traits.  
The behavioural susceptibility theory has gone some way toward addressing differences 
between restrictive AN and BN/BED, as it suggests that eating behaviours lie on a 
continuum (Carnell & Wardle, 2008; Llewellyn & Fildes, 2017). The behavioural 
susceptibility theory was built upon evidence from precision phenotyping of appetite in 
large longitudinal studies (Carnell & Wardle, 2008; Llewellyn & Fildes, 2017; Llewellyn 
& Wardle, 2015).  These studies have shown that the variation in appetite is measurable 
from birth, is highly heritable, and that ‘food-approach’ traits (greater appetite for food) 
predispose individuals to obesity (Llewellyn & Fildes, 2017). Conversely, ‘food-
avoidance’ traits, including poorer appetite and a stronger predisposition to satiety, 
predispose individuals to being underweight (Llewellyn & Fildes, 2017).  
It is possible that this dissimilarity relates to variants of the FTO gene, which has been 
associated with AN, BN and binge eating (Micali et al., 2015; Müller et al., 2012). This 
hypothesis is supported by genome-wide association studies and case-control studies 
indicating that single nucleotide polymorphisms in the FTO gene (including at rs9930506 
and rs9939609) are associated with increased body mass index (BMI) in both European 
American, Hispanic American, British, and Japanese populations (Frayling et al., 2007; 
Hotta et al., 2008; Scuteri et al., 2007). Furthermore, lab studies have indicated that the 
A allele at rs9939609 within the FTO gene is associated with significantly greater food 
intake in test meals (Cecil et al., 2008; Wardle et al., 2009). Thus, there may be biological 
factors that predispose to the various forms of eating disorders, with the greatest contrasts 
between binge eating disorders and restricting anorexia nervosa.  
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New findings from genetic studies suggest that both psychological and somatic aspects 
may need to feature in our models of eating disorders (Duncan et al., 2017). One example 
of this is the disordered eating food addiction nutrition guide (DEFANG) (Wiss & 
Brewerton, 2016), which uses two dimensions, weight and predisposition, as a means of 
categorising the different forms of eating disorders.  
We have developed a maintenance model for binge eating disorder and bulimia nervosa 
(Figure 2), which translates findings from animal studies and builds upon evidence for 
the theories described above. This differs from the earlier models by including differences 
in appetitive traits (i.e., the balance between reward and punishment sensitivity) and 
aspects of executive function (such as impulsivity), while also considering neuroadaptive 
changes. The five primary maintenance factors proposed within this model are as follows: 
(1) The salience of food reward is increased as a result of a predisposing susceptibility. 
This susceptibility to food addiction reaches the full phenotype following strict dieting 
behaviour, which further increases the incentive salience of food cues (Berridge & 
Robinson, 1998). (2) The likelihood of food addiction is further increased within the 
context of chronic stress and problems with interpersonal relationships, which result in a 
paucity of other sources of reward. (3) The Western food environment fosters the 
intermittent consumption of palatable foods with a high glycaemic index in large 
quantities. Traits of impulsivity and difficulties in delaying action towards rewards can 
exaggerate susceptibilities to these triggers. (4) Processed foods with added fat and 
refined carbohydrates produce wide fluxes in blood glucose. These swings in blood sugar 
can be accentuated by purging behaviours and a lack of, or resistance to, the effects of 
insulin. (5) In turn, these gradients in blood glucose alter the pattern of dopamine firing 
(Lennerz et al., 2013). It is thought that these changes in dopamine activity lead to 
neuroadaptation and the formation of a habitual pattern of behaviour, whereby the drive 
to eat is no longer dependent on the goal to reduce hunger and is rather triggered by food 
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cues in the environment.  Eating behaviour becomes compulsive (Robbins, Gillan, Smith, 
de Wit, & Ersche, 2012; Voon, Derbyshire, et al., 2015) and a vicious circle is set in 
motion. This model can be used as a framework for treatment (Figure 2). 
Implications for Treatment 
This updated model for binge eating suggests there is potential for adaptations to the 
traditional treatment approaches. Specifically, we identify five potential maintaining 
mechanisms within the updated model that provide potential targets for treatment within 
the domains of psychotherapy and nutrition guidance (presented in Figure 3). These 
treatment targets are as follows: 
• Target 1: An important maintenance factor within the model is the large amount 
of glucose flux induced by the intermittent consumption of foods with a high 
glycaemic index. A major difference in the updated model would be the 
recommendation to avoid and abstain from technologically-modified foods that 
trigger over-eating, or to manage them in a way that reduces harm (Wiss & 
Brewerton, 2016) rather than encouraging an absolute “no dieting approach”.  
• Target 2: Another mechanism that promotes the maladaptive neuroadaptation is 
the limitation and restriction of all forms of food. While individuals would be 
recommended to avoid highly-processed foods, treatment based on this new 
model would continue to discourage individuals from restricting healthy foods, to 
prevent them from reaching a state of semi-starvation. 
• Target 3: In order to counteract habit formation that entrenches stimulus-
responses association between food cues and eating, another addition may be to 
add treatments which target impulsivity and habitual patterns of responding. Pilot 
studies for computerised approaches such as stop signal and go/no-go training 
have potential  (Adams, Lawrence, Verbruggen, & Chambers, 2017; Lawrence, 
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Verbruggen, Morrison, Adams, & Chambers, 2015; Preuss, Pinnow, Schnicker, 
& Legenbauer, 2017; Schag, Schönleber, Teufel, Zipfel, & Giel, 2013), but also 
virtual reality cue exposure (Ferrer-García et al., 2017) and emotional regulation 
video game training (Fernandez-Aranda et al., 2015) and modification to make 
these training programmes accessible, more rewarding, and personalised are in 
progress (Forman et al., 2017).  The updated model also opens up the possibility 
for new pharmacological treatments targeting the sensitisation to food cues, while 
preventing receptor tolerance triggered by binge eating. For example, 
Lisdexamphetamine, which targets dopamine systems in binge eating disorder, is 
already available in the US (Ágh, Pawaskar, Nagy, Lachaine, & Vokó, 2016; 
McElroy et al., 2016). Work is in progress to further examine drugs which act on 
the opiate system (Cambridge et al., 2013)  and the impact of oxytocin (Y.-R. 
Kim, J.-S. Eom, J.-W. Yang, J.-W. Kang, & J. Treasure, 2015; Leppanen, Cardi, 
et al., 2017a; Russell et al., 2018) (which is known to interact with the opiate 
system) (Flanagan, Verbalis, & Stricker, 1988).  
• Target 4: Binge eating is partially maintained, following a negative reinforcement 
model, by high levels of stress and reward seeking that is not satisfied in other 
domains of life. The model therefore highlights the importance of developing 
positive anxiety management and coping mechanisms. It is also beneficial to 
support positive social connections and identify sources of meaning in other areas 
of life. 
• Target 5: Maladaptive compensatory behaviours, such as vomiting and insulin 
omission, further contribute to the large swings in blood glucose that maintain the 
disorder. Psychoeducation and supporting the development of coping mechanisms 
to deter these behaviours is therefore also recommended.   
Suggestions for Future Research 
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While the body of evidence described above currently provides a sound basis for this 
updated model of binge eating behaviour, our understanding of and ability to effectively 
treat bulimia nervosa and binge eating disorder would benefit from further research in a 
number of areas. These suggestions are summarised in Table 2. 
We recommend future research continue to refine our understanding of the ‘food 
approach’ phenotype. Future work specifically identifying the profiles of traits that are 
most closely linked to the development of recurring binge eating behaviour would be 
particularly beneficial in elaborating upon the currently proposed model, in order to 
further clarify links between traits, environmental cues, thoughts, and disordered eating 
behaviour. Clarifying which food avoidance traits are most relevant to the onset and 
maintenance of anorexia nervosa would be similarly useful for the field. 
Based on the recognition of neural similarities between substance addiction and binge 
eating in the proposed model, we would further encourage future research to draw 
inspiration from interventions previously developed within the addiction sciences and 
investigate their relevance and effectiveness for curbing binge eating behaviour. 
Finally, further research into pharmacological and hormonal treatments that prevent the 
sensitisation to binge cues and/or reduce receptor tolerance to the ‘liking’ of food stimuli 
is warranted based on the current model. Relevant research into the potential therapeutic 
effects of oxytocin and opioid antagonists for binge eating is currently underway; 
however, research into pharmacological treatments for eating disorders is still nascent 
and would benefit from further investigation.  
Conclusion 
We have argued from the impressive evidence from clinical and preclinical science that 
it is time to put eating behaviour into a central place in models of eating disorders.  
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Changes in the food environment interacting with individual vulnerability are recognised 
to be key predisposing risk factors. However, neuroadaptive changes in reward circuits 
are thought to maintain these disorders. The next step is to develop the evidence for 
interventions targeting these risk and maintenance factors, with the hope of reversing the 
increasing prevalence of these problems.  
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Table 2 
Outstanding Questions for Future Research: 
• What are the most relevant ‘food approach traits’ determining susceptibility to 
bulimia nervosa or binge eating disorder? 
• What are the most relevant ‘food avoidance traits’ determining risk for anorexia 
nervosa? 
• What programmes of behavioural intervention would be most effective for breaking 
automatic stimulus-response associations in bulimia nervosa and binge eating 
disorder? 




Figure 2. A food addiction model of binge eating behaviour. GI = glycaemic index. 
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Figure 3. The targets for treatment within a food addiction model of binge eating behaviour. GI 
= glycaemic index. 
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2.2 Paper 2: Towards a translational model of food addiction: Implications for bulimia 
nervosa 
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Abstract 
 
Purpose of review: In recent years, the food addiction hypothesis of loss-of-control eating 
has gained traction in the field of eating disorders. In particular, the neural process of food 
addiction plays a dominant role in the recently formulated “addictive appetite” model of 
bulimia nervosa and binge eating disorder. Nonetheless, several components of the food 
addiction hypothesis, including the presence of withdrawal and tolerance effects, as well 
as the proposition that some foods possess “addicting” properties, remain highly 
controversial. In response, the current review synthesises existing evidence for 
withdrawal and tolerance effects in people with bulimia nervosa.  
Recent findings: The recent development of a validated tool to measure withdrawal from 
highly processed foods will aid in measuring withdrawal symptoms and testing 
hypotheses related to withdrawal in the context of food addiction. We subsequently 
describe preclinical and human evidence for a central insulin- and dopamine-mediated 
pathway by which recurrent loss-of-control binge eating is maintained in bulimia nervosa.  
Summary: Evidence in populations with bulimia nervosa and loss-of-control eating 
provides preliminary support for the role of food addiction in the maintenance of bulimia 
nervosa. Future longitudinal research is needed to develop a clearer profile of illness 
progression and to clarify the extent to which dysregulation in glucose metabolism 
contributes to food craving and symptom maintenance in bulimia nervosa.  
Keywords: Food addiction; bulimia nervosa; eating disorders; sugar; dopamine  
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Background 
The concept of “food addiction” has received increasing attention in the scientific 
literature of recent years. While cogent arguments have been made against the 
establishment of food addiction as a psychiatric diagnosis in its own right (Finlayson, 
2017), there is substantial evidence to suggest that processes similar to those observed in 
substance abuse disorders play a significant role in the maintenance of eating disorders in 
which loss of control of  eating is a feature (e.g., anorexia nervosa -binge purge type, 
bulimia nervosa and binge eating disorder) (Treasure, Leslie, Chami, & Fernández-
Aranda, 2018). In this article, we will use bulimia nervosa (BN) as the exemplar. The 
“Addictive Appetite Model” proposes that three primary processes maintain 
psychopathology in BN: 1) The high salience of palatable foods (Berridge & Robinson, 
1998), which is moderated by a genetic susceptibility to food approach tendencies, 
reduced efficiency in satiation processes (Carnell & Wardle, 2008), and/or episodes of 
food restriction; 2) Chronic stress and interpersonal difficulties resulting  in a deficiency 
of alternative  rewards and a primed stress system (Turton, Chami, & Treasure, 2017); 
and 3) Large swings in blood glucose, caused  by the consumption of foods with a high 
glycaemic index, self-induced vomiting or insulin resistance (and insulin omission in 
diabetes mellitus). These pathways may contribute to compulsive binge eating behaviour 
through aberrations in dopaminergic function in a similar way to substance addictions.  
The current review presents a synthesis of the literature investigating some of the 
controversial aspects of applying the food addiction paradigm to eating disorders.  For 
instance, there is uncertainty as to whether tolerance and withdrawal criteria for an 
addictive disorder, as specified within the DSM-5, are met. We also present a synthesis 
of molecular, preclinical, and clinical evidence illustrating how fluxes in glucose and 
insulin moderate central dopaminergic functioning. 
Does Bulimia Nervosa Meet DSM-5 Criteria for an Addictive Disorder? 
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The DSM-5 criteria for an addictive disorder are presented in Table 3. The extent 
to which BN meets these criteria has been reviewed extensively elsewhere (Brewerton, 
2014). In his 2014 review, Brewerton acknowledges significant phenotypic overlap 
between disorders of substance dependence and BN but highlights a paucity of systematic 
clinical evidence for tolerance and withdrawal in the latter, a point frequently cited as a 
major weakness of the food addiction hypothesis (Ziauddeen, Farooqi, & Fletcher, 2012). 
Much research on tolerance and withdrawal symptoms in humans to date has been largely 
anecdotal (Gearhardt et al., 2009b). However, herein we synthesise the evidence from 
new assessment methods.   
Tolerance 
The most compelling evidence for food tolerance is demonstrated in animal 
models, as previously reviewed by Murray, Gordillo, and Avena (2014). Rats who 
voluntarily overeat highly palatable food exhibit evidence of a neural reward deficit due 
to downregulated dopamine D2 receptors, which worsens as weight is gained (Colantuoni 
et al., 2001; P. M. Johnson & Kenny, 2010; M. J. Robinson et al., 2015). This decreased 
sensitivity to reward is directly linked to the onset of compulsive food seeking in rats (P. 
M. Johnson & Kenny, 2010). Repetitive bingeing on sucrose interspersed with periods of 
dietary restriction causes rats to triple their overall daily sugar consumption (Rada et al., 
2005), a finding which may be of particular importance to BN, as it is characterised by 
intermittent fasting and binge episodes (American Psychiatric Association, 2013). A 
similar downregulation of dopamine D2 receptors is found in humans addicted to drugs 
of abuse (Koob & Volkow, 2016) and is thought to be a key driver of compensatory 
overconsumption in the Reward Hyposensitivity Theory (Blum et al., 2000; P. J. Rogers, 
2017). Behavioural observations in people with substance use disorders mirror these 
findings.  
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Individuals with BN endorse higher levels of  tolerance-like symptoms measured 
using the Yale Food Addiction Scale (YFAS) (Gearhardt et al., 2009b), compared with 
healthy controls (de Vries & Meule, 2016; Meule & Gearhardt, 2014a). There are clinical 
reports of subthreshold BN patients initiating larger and more frequent binge episodes 
over time (Stice et al., 2009). Consistent with these accounts is cross-sectional evidence 
of the correlation between higher body weight and frequency and severity of binge eating 
episodes (Picot & Lilenfeld, 2003). Individuals with binge-type eating disorders endorse 
significantly greater levels of eating for purposes of reward enhancement compared with 
weight-matched controls (Leslie, Turton, Burgess, Nazar, & Treasure, 2018). Such 
evidence, although compelling, remains indirect and is insufficient to prove the existence 
of tolerance in humans.  
A preference for intensely sweet food and larger quantities of sweeteners in 
individuals with BN is a characteristic often presented as an indicator of tolerance 
(Berridge & Robinson, 1998; Drewnowski, Bellisle, Aimez, & Remy, 1987; 
Drewnowski, Shrager, Lipsky, Stellar, & Greenwood, 1989; Franko, Wolfe, & Jimerson, 
1994). Furthermore this  preference remains after ingesting a glucose load (Rodin, 
Bartoshuk, Peterson, & Schank, 1990). Magnetic resonance imaging (MRI) studies 
indicate hypofunctioning of gustatory and limbic circuitry in BN patients when tasting 
palatable food compared with controls (Bohon & Stice, 2011; Frank, Reynolds, Shott, & 
O'Reilly, 2011) and compared with individuals recovered from BN (Oberndorfer et al., 
2013; Radeloff et al., 2014). This evidence is consistent with the idea that individuals 
with BN ingest more food over time because of a decreased sensitivity to sweet taste 
resulting from repeated binging on hyperpalatable foods (Bohon & Stice, 2011).  
The development of impaired satiety mechanisms may be an indirect indicator of 
tolerance (Brewerton, 2014; Haedt-Matt & Keel, 2011; Halmi, Sunday, Puglisi, & 
Marchi, 1989). For example, a recent functional MRI (fMRI) study found that women in 
Monica Leslie   99 
remission from BN exhibited the same response to taste stimuli in brain regions 
implicated in translating sensory information about taste into motivated behaviour, 
regardless of whether the individuals were hungry or sated, whilst healthy controls 
showed an increased response to taste stimuli when hungry versus when fed (Ely et al., 
2017). The authors also found an increased amygdala response in their remitted BN 
sample when fed compared to healthy controls, which they propose might project to the 
hypothalamus and motivate eating in the absence of hunger (Ely et al., 2017; Sun et al., 
2015). It is possible that brain circuitry in BN fails to de-value food reward when in a fed 
state, leading to eating beyond metabolic need. 
Five years on from Brewerton’s 2014 review, there remains a paucity of direct 
evidence of tolerance in humans in relation to food intake and prospective, longitudinal 
studies are needed.  
Withdrawal Syndromes 
Preliminary evidence for a withdrawal syndrome in relationship to palatable food 
comes from animal models. There are consistent observations of strong physical (e.g., 
forepaw tremor, teeth chattering) and psychological (e.g., aggression, anxiety) 
withdrawal responses in rats during periods of withdrawal from sucrose (Avena, Rada, & 
Hoebel, 2008; Iemolo et al., 2012; Wideman, Nadzam, & Murphy, 2005). The same 
observations, however, are not found with removal of high-fat foods (Bocarsly, Berner, 
Hoebel, & Avena, 2011) and have not yet been studied with removal of highly processed 
foods (Schulte, Smeal, Lewis, & Gearhardt, 2018). Neuroimaging studies show patterns 
consistent with this behavioural data. Sugar-dependent rats show a significant increase in 
extracellular acetylcholine and a decrease in dopamine release in the nucleus accumbens 
shell, as compared to control groups, during a 36-hour period of food deprivation (Avena 
et al., 2008), effects which are similar to withdrawal from morphine, nicotine, and 
alcohol. 
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Traditionally withdrawal symptoms have not been clearly defined in the context of 
addictive-like eating, prompting criticism of the food addiction framework (Ziauddeen & 
Fletcher, 2013). To date, the food addiction field has largely relied on observational and 
anecdotal clinical reports based on small cohorts or single case studies (Davis & Carter, 
2009; Gearhardt, Corbin, & Brownell, 2016; Hansen, 2016; Ifland et al., 2009; 
Lingswiler, Crowther, & Stephens, 1989; Thornley & McRobbie, 2009) and on self-
reported endorsement of withdrawal symptoms on the YFAS (Meule & Gearhardt, 2014a) 
and other withdrawal scales (Gilbert, Gilbert, & Schultz, 1998). Cross-sectional self-
report accounts are consistent in describing physiological symptoms of withdrawal 
similar to those experienced during opiate withdrawal (Farrell, 1994; Gearhardt et al., 
2009b). Headaches, irritability and flu-like symptoms are reported by individuals 
abstaining from sugar (Davis & Carter, 2009), stomach pains, muscle spasms and 
shakiness by individuals abstaining or reducing intake of carbohydrates (Ifland et al., 
2009; Thornley & McRobbie, 2009), and nausea by individuals abstaining from salted 
food (Tekol, 2006). Furthermore, tiredness and irritability have been cited as motivating 
factors for eating (Ifland et al., 2009), providing some suggestion of food being used as a 
“pick-me-up”, or to avoid an experience of negative feelings of withdrawal.  
Symptoms of psychological withdrawal are also widely reported. Cross-sectional self-
report accounts from patients with BN reveal that most feel tension, loneliness, and 
physical symptoms of anxiety before a binge, and the majority feel that their negative 
psychological states are alleviated whilst engaged in a binge (Schulte et al., 2018). 
Longitudinal studies using Ecological Momentary Assessment technology also report that 
binge eating and subsequent purging are usually preceded by dysphoric mood states 
(Anestis et al., 2010; Selby et al., 2012; Smyth et al., 2007). However, there is high 
prevalence of depression and emotion dysregulation in BN populations (Braun, Sunday, 
& Halmi, 1994), so it is not clear whether such presentations of low mood represent 
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psychological withdrawal from food. Future research should aim to elucidate whether 
dysphoric mood states before bingeing are distinct from more permanent mood-related 
comorbidities, perhaps by comparing depressed versus non-depressed individuals with 
BN.  
The first and only tool to evaluate withdrawal in the context of addictive-like 
eating has been developed recently: The Highly Processed Food Withdrawal Scale – 
ProWS (Schulte et al., 2018). This, in part, is derived from the premise that specific 
nutritional ingredients are capable of triggering addictive-like responses (Pursey, Davis, 
& Burrows, 2017). In a pilot study, the ProWS was found to be positively associated with 
elevated YFAS symptoms, BMI and weight cycling in a community sample, and 
responses on the ProWS explained an additional 11.2% of the variance in self-reported 
dieting success (Schulte et al., 2018). This tool may help differentiate between the 
withdrawal effects from different types of palatable food  (Curtis & Davis, 2014; Schulte 
et al., 2015) . 
 
The Impact of Glucose Metabolism on Hedonic Eating Behaviour 
Preclinical Evidence 
Sweet, palatable foods act as an unconditioned rewarding stimulus in humans and 
rodent models, with evidence suggesting that merely tasting sucrose without digestion 
produces activation of dopaminergic circuits within the striatum (Avena, Rada, Moise, & 
Hoebel, 2006). However, there is evidence to suggest that palatable foods with a high 
glycaemic index further contribute to the development of compulsive binge eating 
behaviour through changes in dopaminergic functioning triggered by wide swings in 
blood glucose. One candidate mechanism for this effect relates to the interaction between 
insulin and dopaminergic functioning. 
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The role of mesolimbic dopaminergic functioning in food approach behaviours 
has been reviewed extensively elsewhere (Berridge, Ho, Richard, & DiFeliceantonio, 
2010). Dopamine-deficient mouse models exhibit severe aphagia leading to weight loss 
and death (Q.-Y. Zhou & Palmiter, 1995). Conversely the stimulation of dopaminergic 
activity within the striatum triggers food consumption in rats without enhancing “liking” 
responses (e.g., lip-licking and paw licking). Thus, dopaminergic functioning is thought 
to hold a role  in food approach behaviours (wanting) that is discrete from the hedonic 
response to food receipt (Berridge & Valenstein, 1991). In contrast, central insulin 
suppresses feeding (Woods, Lotter, McKay, & Porte Jr, 1979). It is thought that the effects 
of central insulin and dopamine on food intake, are not independent, but rather interact to 
regulate hedonic eating behaviour. 
Dopaminergic neurons within the ventral tegmental area (VTA) express insulin 
receptors (Figlewicz, Evans, Murphy, Hoen, & Baskin, 2003; Pardini et al., 2006), 
presenting a possible mechanism by which insulin might influence the dopaminergic 
induction of feeding behaviour. Furthermore, central insulin enhances the expression of 
dopamine transporter protein within the VTA via a protein kinase B (Akt) signalling 
system (Figlewicz, Szot, Chavez, Woods, & Veith, 1994; Williams et al., 2007). The 
enhanced expression of dopamine transporters on the cell surface induced by insulin 
exposure is associated with greater dopamine uptake (Carvelli et al., 2002), thus reducing 
levels of synaptic dopamine. 
            With regards to the effects of insulin on postsynaptic dopaminergic signalling, in 
vitro studies have found that insulin exposure invokes long-term depression of excitatory 
signalling within VTA dopamine neurons extracted from male C57BL/6J mice (Labouèbe 
et al., 2013). This effect appears to be long-lasting as, once induced, the long-term 
depression of VTA dopamine cells is not reversed by application of the insulin receptor 
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antagonist S961 or through a tyrosine kinase inhibitor, which suppresses insulin receptor 
functioning (Labouèbe et al., 2013). 
            The effects of central insulin on dopaminergic functioning within the VTA likely 
have downstream effects in suppressing feeding, and particularly hedonic feeding. For 
example, Bruijnzeel, Corrie, Rogers, and Yamada (2011) found that injecting insulin 
directly into the VTA of female rats decreased 24-hour food intake. Mebel, Wong, Dong, 
and Borgland (2012) have similarly found that injecting insulin directly into the VTA 
suppresses subsequent feeding in male C57BL/6J mice; however, this effect was 
dependent on the hunger status of the animals. That is, insulin in the VTA suppressed the 
quantity of sweetened high fat food consumed by sated mice but did not affect normal 
chow intake in hungry mice. This pattern of effects therefore suggests that insulin activity 
in the VTA acts selectively to suppress subsequent hedonic feeding, with weaker evidence 
for effects on homeostatic feeding behaviour.  
            Central insulin functioning may play a role in blocking the memory of palatable 
food reward or attenuating the incentive salience of cues associated with palatable food. 
Evidence for this hypothesis comes from studies demonstrating that injecting insulin 
either into the cerebral ventricles (Figlewicz et al., 2004) or VTA (Labouèbe et al., 2013) 
of rats at the time of memory retrieval reduces conditioned place preference for palatable 
food. Furthermore, Bruijnzeel et al. (2011) found that injecting insulin at a dose of 
.005mU/side into the VTA elevated the reward threshold for intracranial self-stimulation, 
thus indicating a reduction of reward functioning.  
 Evidence in Humans 
   
Insulin resistance impacts on central dopaminergic systems in humans. For 
example, Dunn et al. (2012) conducted a positron emission tomography (PET) study 
using the dopamine D2/D3 receptor radioligand [18F]fallypride, and found that insulin 
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sensitivity is negatively correlated with dopamine type 2 receptor availability in the 
ventral striatum in a heterogeneous sample of lean and obese women. In men, Anthony 
et al. (2006) found that exogenously administered insulin increases metabolism in the 
ventral striatum and prefrontal cortex, while decreasing metabolism in the right 
amygdala, hippocampus, and cerebellar vermis. Furthermore, the effect of insulin in 
increasing metabolism in the ventral striatum and PFC was lower in insulin-resistant, 
versus insulin-sensitive participants (Anthony et al., 2006). This pattern of findings is 
thus indicative of trait-level differences in the effects of central insulin on dopaminergic 
mesolimbic regions, known to be critical for food craving and food approach behaviour 
(Volkow et al., 2002; Q.-Y. Zhou & Palmiter, 1995). 
 Interactions between insulin resistance and central dopaminergic functioning may 
have functional significance for food craving in humans. Chechlacz et al. (2009), in an 
fMRI study, found that people with Type II diabetes mellitus (characterised by insulin 
resistance) exhibit greater blood oxygenated level dependent (BOLD) response to food 
versus non-food images in the insula, orbitofrontal cortex (OFC), and basal ganglia, when 
compared to people without diabetes mellitus. Moreover, this increased activation within 
the insula and OFC is positively correlated with self-reported external eating. These 
findings, taken together, thus provide evidence that insulin resistance, commonly 
observed following repeated excess consumption of fructose in combination with an 
overall excessive energy intake (MacDonald, 2016), is positively correlated with a pattern 
of neural response to food stimuli which is associated with greater external cue-driven 
eating. However, it should be noted that the correlational nature of these findings limits 
the ability to draw firm causal inferences. Although there is relatively less evidence 
regarding food craving in Type I diabetes, an fMRI study has found that insulin detemir, 
which more readily enters the brain compared to standard forms of insulin, is associated 
with reduced BOLD response to food images in the bilateral insula, a brain region 
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associated with the regulation of appetite (van Golen et al., 2014). The authors have 
speculated that insulin detemir may therefore induce a more effective satiety reaction, 
thus explaining the reduced levels of weight gain observed in people with Type I diabetes 
mellitus taking insulin detemir (Hermansen et al., 2004). 
 In a related study, Jastreboff et al. (2013) recruited 25 men and women in the 
obese weight range and 25 lean controls. Fasting insulin and glucose were taken to 
measure insulin resistance. During a subsequent fMRI task, audio scripts designed to 
provoke relaxing imagery or favourite food imagery were played. Food craving was 
assessed before and after each imagery trial. The degree of food craving following food 
imagery trials was positively associated with insulin resistance in the obese, but not lean, 
participant group. Furthermore, the relationship between insulin resistance and food 
craving within the obese participant group was mediated by BOLD responses in 
dopaminergic regions including the ventral tegmental area (VTA) and substantia nigra. 
These studies suggest that insulin resistance moderates craving and associated neural 
circuits in response to food related imagery.  
 Thus, the above studies illustrate that interactions between central insulin and 
dopaminergic systems, known to impact on feeding behaviour in animals, also regulate 
food craving in humans. While this evidence therefore supports a potential mechanism 
linking the short- and long-term physiological effects of sugar consumption to food 
craving in humans, it is also of interest to disentangle the effects of sweet taste on 
dopaminergic incentive sensitisation from the physiological effects of sugar in food 
approach behaviour in humans. In support of the physiological effects of glucose 
consumption on central dopaminergic functioning, regardless of sweet taste, Haltia et al. 
(2007) found that the intravenous administration of glucose, versus placebo, was 
associated with increased D2 receptor binding potential in the right caudate nucleus and 
bilateral putamen in both lean and overweight women. However, intravenous glucose 
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administration was rather associated with reductions in D2 receptor binding potential in 
the bilateral caudate nucleus, left putamen, and right thalamus in men. It should be noted 
that the intravenous method of administration employed in this study bypassed the 
gastrointestinal system, thus failing to stimulate the production of gastrointestinal 
hormones, such as glucagon-like peptide 1, which also impact on appetitive functioning 
(Flint, Raben, Astrup, & Holst, 1998; Vilsbøll, Krarup, Madsbad, & Holst, 2003). This 
study is therefore limited in the extent to which it directly bears upon the oral consumption 
of glucose versus calorie-free sweet taste. Nonetheless, these findings provide evidence 
for the impact of glucose on mesolimbic dopaminergic functioning in the absence of 
sweet taste. The functional significance of the sexual dimorphism in brain response is not 
yet clear and would be an interesting avenue for future research. 
In another PET study conducted in nineteen participants with BMIs ranging from 
the lean to obese weight range, dopamine functioning was measured following the 
consumption of a 75g oral glucose drink versus a calorie-free sucralose drink of equal 
volume and sweetness. Within the lean participant group, consuming the glucose drink, 
versus the calorie-free sucralose drink, was associated with increased dopaminergic 
binding potential within the ventral striatum, while the opposite was observed in the obese 
participant group (Wang et al., 2014). Thus, there is evidence that glucose impacts upon 
dopaminergic functioning separately from the effects of sweet taste alone, with BMI 
modulating the direction of that effect. The reduced activation stimulated by sugar 
consumption in obese participants is in line with previous evidence of down-regulated 
striatal response to the receipt of sugar solutions, including chocolate milk and 
milkshakes (Burger & Stice, 2014; Stice, Yokum, Blum, & Bohon, 2010). 
There is a relative paucity of research investigating the effects of glucose 
metabolism on dopamine-mediated feeding in BN and binge eating disorder without 
obesity. A recent meta-analysis of studies analysing insulin sensitivity in BN and binge 
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eating disorders has found significantly reduced insulin sensitivity in both disorders (Ilyas 
et al., 2018). Such insulin resistance therefore leads to greater flux in blood glucose 
following the consumption of foods with a high glycaemic index, thus potentially 
contributing to food craving in a similar manner to that described above for populations 
with obesity (Jastreboff et al., 2013). The effect of insulin resistance on glucose flux is 
further exacerbated by the wide swings in blood glucose induced by intermittent fasting 
followed by objectively large binge eating episodes in people with BN (Monteleone et 
al., 2000). Frank et al. (2006) found evidence of some trait differences in brain response 
to glucose, with participants recovered from BN exhibiting suppressed BOLD response 
to a glucose, versus artificial saliva solution, in the anterior cingulate cortex and left 
cuneus in comparison to the control group. However, this study is confounded by the 
difference in sweet taste as well as nutritional content (glucose versus calorie-free liquid). 
It will therefore be critical to carry out similar research to that described above for obesity 
in populations with bulimia-spectrum disorders in order to clarify the functional role of a 
glucose metabolism pathway in loss-of-control binge eating versus the chronic overeating 
which commonly characterises overweight and obesity.  
Conclusion 
The current literature review has thus far served to illustrate the existing state of 
the evidence with regards to food tolerance and withdrawal effects in BN. Additionally, 
preclinical and preliminary evidence in human studies has elucidated an insulin-
dependent mechanism whereby foods with a high glycaemic index interact with 
mesolimbic dopamine systems and heighten food craving in cases of insulin 
dysregulation. Nonetheless, there are several lines of evidence that should be explored 
further before definite conclusions can be drawn with regards to withdrawal and tolerance 
in BN and the physiological mechanisms which maintain addictive responses to palatable 
food.   
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Table 3 




Criteria 1. The substance is often taken in larger amounts or over a longer period 
than was intended  
Criteria 2. There is a persistent desire or unsuccessful efforts to cut down or 
control use of the substance 
Criteria 3. A great deal of time is spent in activities necessary to obtain the 
substance, use the substance, or recover from its effects 
Criteria 4. Craving, or a strong desire or urge to use the substance 
Criteria 5. Recurrent use of the substance despite having persistent or recurrent 
social or interpersonal problems caused or exacerbated by the effects 
of its use 
Criteria 6. Continued use of the substance despite having persistent or recurrent 
social or interpersonal problems caused or exacerbated by the effects 
of its use 
Criteria 7. Important social, occupational, or recreational activities are given up or 
reduced because of use of the substance 
Criteria 8. Recurrent use of the substance in situations in which it is physically 
hazardous 
Criteria 9. Tolerance, as defined by either of the following:  
 
(a) A need for markedly increased amounts of the substance to 
achieve intoxication or desired effect  
(b) A markedly diminished effect with continued use of the same 
amount of the substance  
Criteria 10. Withdrawal, as manifested by either of the following: 
 
(a) The characteristic withdrawal syndrome for other substance 
(b) The substance (or a closely related substance) is taken to relieve 
or avoid withdrawal symptoms  
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2.3 Rationale for testing the addictive appetite model 
Sections 2.1 and 2.2 of the current thesis have presented a novel maintenance model for 
bulimia nervosa and binge eating disorder and presented evidence for some of the more 
controversial components of this theoretical model, respectively. However, as highlighted 
in Paper 2, the state of evidence supporting some elements of the model remains 
preliminary. The following paper therefore aimed to test psychological, versus metabolic, 
aspects of the maintenance model, with a specific focus on the importance of food 
craving, emotional coping, and reward enhancement in bulimia nervosa and binge eating 
disorder. 
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2.4 Paper 3: Testing the addictive appetite model: The importance of craving, coping, 
and reward enhancement 
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Abstract 
In the current study, we examine components of the “addictive appetite” model of 
recurrent binge eating. Specifically, we tested the influence of addictive processes and 
the influence of emotional regulation processes on recurrent binge eating behaviour. We 
recruited 79 women in total for the current study; 22 with bulimia nervosa, 26 weight-
matched lean comparison women, 15 women with binge eating disorder, and 16 weight-
matched overweight/obese comparison women. Participants completed questionnaire 
assessments of food craving and motivations for eating. Compared to weight-matched 
comparison women, women with binge-type eating disorders endorse significantly 
greater levels of food craving, eating for purposes of coping, and eating for purposes of 
reward enhancement. A cluster analysis revealed that these three traits distinguish women 
with binge-type eating disorders from weight-matched comparison women. These 
findings provide support for the addictive appetite model of binge eating behaviour and 
highlight addictive and emotional regulation processes as potential targets for treatment. 
 
Key Words: Bulimia Nervosa; Binge Eating Disorder; Food Addiction; Research 
Domain Criteria 
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The trans diagnostic model of eating disorders has played a dominant role in 
informing psychological treatment for adults with bulimia nervosa and binge eating 
disorder over the last several decades (Fairburn et al., 2003). However, treatment 
informed by the trans diagnostic approach is not effective for many individuals with 
bulimia nervosa, with only 30-50% achieving abstinence from binge-purge behaviours 
by the end of treatment (Hay, 2013; National Institute for Health and Clinical Excellence, 
2017), and 68% achieving remission at 9-year follow-up (Eddy et al., 2017). 
An updated model of recurrent binge eating behaviour has therefore recently been 
proposed (Treasure et al., 2018), which addresses the dysregulation of appetite in bulimia 
nervosa and binge eating disorder not previously highlighted within the trans diagnostic 
model. One of the key factors proposed by this updated “addictive appetite” model of 
recurrent binge eating behaviour is the increased incentive salience of food cues and 
habitual response patterns to palatable food cues, which heighten desire and craving for 
these foods (Berridge, 2007). At a neural level, this pattern of heightened response to food 
cues and subdued responding to the receipt of pleasant tastes bears resemblance to 
substance use disorders, in which a similar pattern of neural responding has been observed 
in relation to drug cues (Gearhardt et al., 2011). For the purposes of the current paper, we 
define food craving as being characterised by intense desire or urge to eat a particular 
type of food, where that desire corresponds to a specific flavour and texture (Pelchat, 
2002). “Craving”, in its current usage, can therefore be contrasted to both generalised 
hunger that does not necessarily drive behaviour towards a specific type of food, and to 
mild preferences for one type of food over another. 
  There is also thought to be a down-regulation of the response to other rewards in 
bulimia nervosa and binge eating disorder, such that basal levels of low affect are 
common in this population (Volkow, Wise, & Baler, 2017). This low affect thus 
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contributes to heightened likelihood of compensatory reward-seeking, specifically in the 
form of palatable tastes (Treasure et al., 2018). This model of binge eating behaviour has 
previously received support from ecological momentary assessment studies, which found 
that participants reported greater levels of low affect immediately prior to binge eating 
episodes (Haedt-Matt & Keel, 2011). However, relatively little previous research has 
explored the relationship between individuals’ motivations for eating and eating disorder 
pathology (Burgess, Turan, Lokken, Morse, & Boggiano, 2014).  
The aim of this study was to test two maintenance processes proposed within the 
addictive appetite model of binge eating: eating due to enhanced incentive salience and 
eating for emotion regulation. Our hypotheses were as follows:   
1. People with BN and BED would show higher levels of craving for food than 
weight-matched controls. 
2. People with BN and BED would endorse eating palatable food as a method of 
coping with distress and as a means of enhancing mood. 
3. Food craving, eating for emotional coping, and eating for reward enhancement 
would distinguish individuals with binge-type eating disorders from weight-
matched controls.  
Methods 
Participants 
Seventy-nine women were recruited through flyers and e-mail circulars at King’s 
College London, as well as through eating disorder clinics in London. Twenty-six women 
met criteria for the lean control group, 22 women met DSM-5 criteria for bulimia nervosa, 
15 women met DSM-5 criteria for binge eating disorder, and 16 women were included in 
the overweight/obese control group. Of the women with bulimia nervosa or binge eating 
disorder, 25 had received treatment for their eating disorder within six months prior to 
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the study. Further details regarding the type of treatment participants received are 
presented in Supplementary Table 1. Of the participants with BN or BED, 15 
participants had a comorbid diagnosis of a depressive disorder, 8 participants had 
comorbid generalised anxiety, 1 participant had a comorbid diagnosis of social anxiety 
disorder, two participants had borderline personality disorder, two participants had post-
traumatic stress disorder, and 1 participant had obsessive-compulsive disorder.  
The non-eating disorder comparison groups were age- and weight-matched with 
the groups with eating disorders as far as possible. Ethical approval for the study was 
granted by the Hampstead Research Ethics Committee (reference number: 14/LO/2166). 
All participants voluntarily consented to take part in the study. 
 Inclusion criteria for the study required participations’ age to be between 18 and 
65 years old. Participants in the eating disorder sample were required to meet DSM-5 
diagnostic criteria for BN or BED (American Psychiatric Association, 2013). Healthy 
control participants were required to have a body mass index (BMI) of at least 18.5 and 
have no history of an eating disorder. Exclusion criteria included: current substance 
abuse, history of an abnormal neurological condition, acute suicidality, and severe co-
morbidity (e.g., active psychosis). Participants were screened using the Structured 
Clinical Interview for DSM-5 (SCID) (American Psychiatric Association, 2013). 
Screening was conducted either by a psychiatrist or graduate-level psychology student 
who had received specific training in correct use of the SCID. Demographic descriptive 
statistics for each sample of participants are reported in Table 4. 
Experimental Design 
 After signing informed consent and undergoing screening for eligibility, 
participants were invited to complete an online survey containing the following battery 
of measures: the Eating Disorder Examination – Questionnaire version (EDE-Q) 
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(Fairburn & Beglin, 1994b), the Depression and Anxiety Stress Scales (DASS) (Lovibond 
& Lovibond, 1995), Food Craving Questionnaire – Trait subscale (FCQ) (Cepeda-Benito, 
Gleaves, Williams, & Erath, 2000), and the Palatable Eating Motives Scale (PEMS) 
(Burgess et al., 2014). These online questionnaires were conducted prior to a subsequent 
battery of tests conducted in the lab, the results of which are reported in a previously 
published paper (Turton et al., 2018). The PEMS has been described in detail below and 
all other measures are described within the Supplementary Material. Participants were 
also asked to confirm their current binge eating frequency and answer demographic 
questions, including their age and education level (measured as the total number of years 
spent in education). 
Palatable Eating Motives Scale (PEMS). The Palatable Eating Motives Scale 
(PEMS) (Burgess et al., 2014) yields a measure of the extent to which individuals tend to 
eat food for reasons other than maintaining metabolic homeostasis (i.e., in response to 
hunger). The PEMS consists of 19 items answered in the form of a 5-point Likert scale 
from 1 (Almost Never/Never) to 5 (Almost Always/Always). The PEMS contains four 
subscales corresponding to different reasons people consume palatable food (Social, 
Coping, Conformity, and Reward Enhancement). The social subscale measures 
motivation to eat for social reasons (e.g., when going out for a meal or to a party with 
friends), the coping subscale measures motivation to eat in order to regulate negative 
affect (e.g., to distract oneself and/or improve mood after a bad day),  the conformity 
subscale measures motivation to eat due to social pressures (e.g., to fit in with others, or 
to be liked), while the reward enhancement subscale measures motivation to eat in order 
to enhance positive experiences or the intrinsic reward of palatable foods. Within the 
current sample, the total PEMS scale was associated with excellent internal consistency 
(a = 0.92). All subscales of the PEMS were associated with good internal consistency: 
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Social (a = 0.88), Coping (a = 0.95), Enhancement (a = 0.85), and Conformity (a = 
0.89). 
Statistical Analysis 
In order to account for the potential effect of BMI, the sample with bulimia 
nervosa was compared against a weight-matched lean comparison group in the following 
analyses, and the sample with binge eating disorder was likewise compared against an 
overweight/obese comparison group. Each of the above-mentioned variables were 
compared across groups using a Student’s t-test. Multiple comparisons were controlled 
for by setting the False Discovery Rate at 0.05 (Benjamini & Hochberg, 1995). 
Exploratory correlation analyses were then conducted to examine relationships between 
subscales of the EDE-Q, the subscales of the PEMS, BMI, and the FCQ. 
A k-means cluster analysis was then used to determine whether food craving, 
eating for emotional coping, and eating for reward enhancement would distinguish 
individuals with binge-type eating disorders from weight-matched controls. This cluster 
analysis was conducted using a single-linkage cluster method. Squared Euclidean 
distance was the chosen distance measure for the cluster analysis. All analyses were 
performed in SPSS version 23.0. 
The data were first analysed for outliers and assumptions of normality.  Three 
outliers (Z > |3.0|) were observed in the BMI variable, one in the age variable, two in the 
social subscale of the PEMS, three in the conformity subscale of the PEMS, and one in 
the binge frequency variable. These values were excluded case-wise from all relevant 
analyses. 
Results 
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 Demographics. There were no significant differences in age between each sample 
and its weight-matched comparison group. There were no significant differences in BMI 
or education between the bulimia nervosa sample and lean control group, although the 
binge eating disorder group had a significantly higher BMI than the overweight/obese 
control group (Z = -2.02, p = .044) and spent significantly fewer years in education 
(t(28.30) = 3.04, p = .005). The descriptive statistics and effect size comparisons for these 
variables are presented in Table 4.  
 Eating disorder symptomatology, food craving, depression, anxiety, and eating 
motivations for each diagnostic group. The descriptive statistics and effect size 
comparisons for EDE-Q subscales (Eating Concern, Restraint, Weight Concern, Shape 
Concern, Binge Frequency), FCQ, the PEMS subscales (Social, Conformity, Coping, and 
Reward Enhancement), and the DASS for each diagnostic group are reported in Table 5. 
The results of the t-tests comparing lean controls with the bulimia nervosa sample on the 
EDE-Q subscales, FCQ, the PEMS subscales, and the DASS are presented in Table 6. 
Due to excessive skew in the binge eating frequency variable for the lean control sample, 
this variable was compared to the bulimia nervosa sample using a Mann-Whitney U test. 
The Mann-Whitney U test for binge frequency revealed that the sample with bulimia 
nervosa reported a significantly higher binge frequency than the lean control sample (U 
= 0.50, Z = -6.20, p < .001). There were no significant differences regarding the extent to 
which individuals ate for social reasons measured between these two samples. The sample 
with bulimia nervosa had significantly higher levels of depression, anxiety, and stress (as 
measured by the DASS), significantly higher scores on all EDE-Q subscales (restraint, 
eating concern, weight concern, and shape concern), greater levels of food craving, and 
reported significantly greater tendencies to eat for purposes of coping, reward 
enhancement, and conformity than the lean control group.  
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The results of the t-tests comparing the overweight/obese control sample with the 
binge eating disorder sample on the EDE-Q subscales FCQ, the PEMS subscales, and the 
DASS are presented in Table 7. There were no significant differences between the two 
groups in eating for purposes of socialising or conformity. However, the binge eating 
disorder group had significantly higher levels of depression, anxiety, and stress (as 
measured by the DASS), significantly higher scores on all EDE-Q subscales (restraint, 
eating concern, weight concern, and shape concern), a significantly greater frequency of 
binge eating, greater levels of food craving, and reported significantly greater tendencies 
to eat for purposes of coping and reward enhancement. 
The results of the t-tests comparing the BN sample with the BED sample on the 
EDE-Q subscales FCQ, the PEMS subscales, and the DASS are reported in Table 8. No 
significant differences in restraint, shape concern, binge frequency, food craving, eating 
for social purposes, eating for purposes of coping, eating for purposes of reward 
enhancement, or depression were observed between participants with binge eating 
disorder versus participants with bulimia nervosa. Although initial comparisons 
suggested that participants with binge eating disorder had significantly greater levels of 
eating concern and weight concern in comparison to participants with bulimia nervosa, 
these differences did not survive after controlling for multiple comparison. Likewise, 
while initial the initial t-test suggested that people with bulimia nervosa had significantly 
greater levels of eating for purposes of conformity in comparison to participants with 
binge eating disorder, this analysis did not hold following correction for multiple 
comparisons. 
Components of food craving for each diagnostic group. The descriptive statistics 
and effect size comparisons for the FCQ subscales are reported for each diagnostic group 
in Table 9.  
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The results of the t-tests comparing lean controls with the bulimia nervosa sample 
on the FCQ subscales are presented in Table 10. There were significant differences 
between the two samples for all subscales. The BN sample had significantly greater scores 
than the lean control sample on all FCQ subscales. 
The results of the t-tests comparing the obese/overweight comparison group with 
the BED sample on the FCQ subscales are presented in Table 11. (The subscale FCQ – 
Preoccupation was excluded from the t-tests as the data was skewed in the 
overweight/obese group.) The BED sample had significantly greater scores than the 
overweight/obese control sample on all FCQ subscales.  
Correlations between eating concern, craving, eating motivations, and binge 
eating. Correlations between eating concern, food craving, binge eating frequency, and 
each subscale of the PEMS for individuals with bulimia nervosa are presented in 
Supplementary Table 2. Trait levels of food craving were strongly positively correlated 
with eating for reasons of coping and reward enhancement. The different subscales of the 
EDE-Q were strongly and positively correlated with each other (with the exception of 
eating concern and restraint, which were not significantly correlated). 
Correlations between eating concern, food craving, binge frequency, and each 
subscale of the PEMS for individuals with binge eating disorder are presented in 
Supplementary Table 3. As in bulimia nervosa, most subscales of the EDE-Q were 
strongly and positively correlated with each other (with the exception of restraint and 
weight concern). Trait levels of food craving were strongly and positively correlated with 
eating for emotional coping, reward enhancement, and conformity. 
Cluster analysis. We next conducted a k-means cluster analysis for all participants 
including the variables FCQ, PEMS-Coping, and PEMS-Enhancement, where the number 
of clusters to be identified was set to two. Between-subjects ANOVAs subsequently 
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revealed significant differences between the two clusters on the FCQ (F = 371.24, df = 
99, p < .001), PEMS-Coping (F = 193.07, df = 99, p < .001), and PEMS-Enhancement (F 
= 48.38, df = 99, p < .001). 
 We then conducted a chi-square test to determine if each of these two clusters 
contained a significantly different proportion of individuals with and without eating 
disorders. Cluster 1 contained 42 individuals without an eating disorder, and two with BN 
or BED. Cluster 2 contained 39 individuals with BN or BED, and 6 without an eating 
disorder. These proportions were significantly different (c2 = 60.39, df = 1, p < .001), thus 
indicating that food craving, eating for emotional coping, and eating for reward 
enhancement significantly distinguished the sample with BN or BED from the lean and 
overweight/obese comparison samples. 
Discussion 
The current study aimed to test maintenance processes proposed within the 
addictive appetite model through an assessment of craving and motivations for eating. 
Our hypotheses were that women with BN and BED would endorse significantly greater 
levels of food craving, and tendencies to eat for purposes of coping and reward 
enhancement, when compared to weight-matched healthy control participants. Our data 
supported these hypotheses with strong effect sizes for each comparison. A cluster 
analysis subsequently supported our hypothesis that food craving, eating for purposes of 
coping, and eating for purposes of reward enhancement would significantly distinguish 
women with BN or BED from the lean and overweight/obese comparison samples of 
women without an eating disorder. 
 These findings, drawn from a clinical population of individuals with eating 
disorders, corroborate results previously reported by (Boggiano et al., 2014), amongst 
students: such that eating for purposes of coping and reward enhancement was associated 
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with exhibiting recurrent binge eating behaviour, and eating for social purposes was not. 
Differences in the extent to which individuals reported eating for reasons of conformity 
was significantly different only between individuals with BN versus lean controls and did 
not differ significantly between the BED group and the overweight/obese control sample. 
It is not completely clear why this is the case, although one hypothesis may be that in the 
absence of a visual difference of appearance or weight, the BN group is more highly 
motivated to mask their disorder by conforming to the eating behaviours exhibited by 
others in a social setting. This hypothesis requires further research to corroborate. 
Our findings provide support for the addictive appetite model of bulimia nervosa 
and binge eating disorder (Leslie, Turton, et al., 2018) by providing evidence for 
heightened levels of craving for palatable foods, and the tendency for these individuals to 
use eating as an emotion regulation strategy. These findings also contribute to the existing 
field of research testing the affect regulation model of binge eating (Haedt-Matt & Keel, 
2011; Leehr et al., 2015). A meta-analysis of ecological momentary assessment studies 
by Haedt-Matt and Keel (2011) supported the hypothesis that increased negative mood 
immediately precipitates binge eating episodes, when compared to both average affect 
and affect preceding non-binge eating. The findings of the present study similarly 
highlight that eating for purposes of coping is characteristic of individuals with recurrent 
loss-of-control binge eating behaviour. Furthermore, a meta-analysis of studies inducing 
negative affect has also supported a causal link between negative affect and binge eating 
(Leehr et al., 2015) 
 The effect of binge eating on mood itself is, however, less clear. Haedt-Matt and 
Keel (2011), in their meta-analysis found that mood worsened following a binge in a 
heterogeneous population of binge eaters (including those diagnosed with BN, BED, and 
self-identified binge eaters). On the contrary, Leehr et al. (2015) reported improved mood 
following binge eating in people with binge eating disorder. These contradictory findings 
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may be explained by the addictive appetite model of binge eating, which posits that 
neuroadaptation promotes tolerance for the “liking” hedonic component of tasty foods, 
which develops over time (Berridge, 2009; Volkow et al., 2004). This process co-occurs 
with progressive increases in “wanting” (incentive salience) of binge foods (Berridge, 
2009; Treasure et al., 2018; Volkow et al., 2004). It may therefore be the case that studies 
using ecological momentary assessment included in the Haedt-Matt and colleagues’ 
meta-analysis fail to capture an immediate reduction in negative urgency occurring during 
the course of a binge eating episode, while succeeding in the capture of guilt and shame 
following the binge eating episode. This hypothesis receives support from studies 
demonstrating the influence of negative urgency on binge eating, independent of other 
facets of negative affect (Anestis, Smith, Fink, & Joiner, 2009; Racine et al., 2013). 
Within the addictive appetite model of binge eating, this emotional process is posited to 
be intrinsically underpinned by the large, repeated incidence of addictive appetite. This 
repeated addictive appetite over time results in the heightened “wanting” of binge foods 
and directly contributes to the experience of negative urgency. 
 The addictive appetite model also highlights the relevance of drawing from 
theoretical models and effective treatments currently employed within the addictions 
science literature. Heilig et al. (2010), for example, have proposed that alcohol 
dependency proceeds from “reward craving” in the early phase of the addiction, to “relief 
craving” as the addiction proceeds. These constructs are conceptually identical to the 
motivations for Reward Enhancement and Coping, respectively, proposed in relation to 
eating within the PEMS. It would therefore be interesting to stratify by duration of illness 
in future research, to determine whether individuals with bulimia nervosa and binge 
eating disorder demonstrates a similar progression in eating motivation, from Reward 
Enhancement to Coping. 
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The prevalence of emotion-triggered eating within this population further 
highlights the importance of supporting effective emotional regulation strategies among 
this population. Indeed, it has previously been found that emotion regulation abilities 
improve throughout the course of treatment for bulimia nervosa, and especially amongst 
individuals with a better treatment outcome (Mallorquí-Bagué et al., 2018). It can 
therefore be hypothesised that improvement in emotional regulation strategies is one of 
the mediating factors in achieving remission from bulimia nervosa, although further 
studies measuring the time-course of changes are required to determine whether short-
term improvements in emotion regulation strategy precede improvements in symptom 
remission.  
It was interesting to note that, after controlling for multiple comparison, there 
were no significant differences between women with bulimia nervosa versus women with 
binge eating disorder on measure of food craving, eating disorder psychopathology, or 
eating motivations. Within the framework of the addictive appetite model of binge eating, 
this finding can be explained by the fact that the same neural process is hypothesised to 
underpin binge eating behaviour in populations with eating disorders, and therefore 
operates identically on a functional level in both bulimia nervosa and binge eating 
disorder (Treasure et al., 2018). These findings therefore highlight commonalities in the 
psychological profile and maintenance factors of bulimia nervosa and binge eating 
disorder, suggesting that similar treatment approaches may be useful in treatment both 
disorders. 
Within the current study, the fact that levels of food craving and eating for mood 
regulation alone can be used to differentiate individuals with BN/BED from weigh-
matched controls provides further evidence for the significance of these processes to 
recurrent binge eating behaviour, even after controlling for overall energy balance, and 
highlights the importance of targeting emotion regulation in treatment. Individuals with 
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BN and BED may need guidance with managing food-related cues in the environment in 
the early stages of treatment, given their high levels of craving. The continued 
development of treatment approaches that weaken automatic stimulus-response 
associations to palatable food would similarly be useful in supporting recovery (Turton 
et al., 2018).  
Limitations of the current study include the small sample size for each diagnostic 
group, and the use of self-report measures (which are subject to social desirability bias), 
and the limitations of the participants’ memory and understanding of their motivations 
for eating. Furthermore, as the current study only included women, the current findings 
are not generalizable to men with bulimia nervosa or binge eating disorder. The subjective 
perception of the close link between high emotion and eating, however, provides an 
important indication of the purpose that binge eating serves for women with BN and BED.  
We recommend that future studies continue to test other aspects of the addictive 
appetite model, including the contribution of insulin resistance/sensitivity to the onset of 
binge eating behaviour. We would also recommend future research to continue to 
examine the genetic factors accounting for variation in individual risk for binge-eating 
behaviour. We propose that continued research into the intersection between genetic risk 
for recurrent binge eating, metabolic dysregulation, and the psychological trait profile of 
each individual will continue to aid the development of more efficacious and personalised 
treatment approaches, in line with the burgeoning movement towards ‘precision 
psychiatry’ (Fernandes et al., 2017). 
In conclusion, the current study identified significantly higher levels of food 
craving, eating for purposes of emotional coping, and eating for purposes of reward 
enhancement among women with BN and BED versus weight-controlled women without 
an eating disorder. A cluster analysis subsequently identified that these three traits 
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significantly distinguished women with recurrent binge eating behaviour from the general 
population. These findings provide further support for the food addiction model of 
recurrent binge eating behaviour and highlight the importance of targeting addictive and 
emotional regulation processes within treatment. 
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Table 4 
Descriptive Statistics Associated with the Demographic Variables for the BN and BED 
samples, and Respective Weight Matched Control Groups  
 Lean Control 
N = 26 
Bulimia 
Nervosa 
N = 22 
Overweight/Obese 
N = 15 
Binge Eating 
Disorder 









 M SD M SD M SD M SD   
Age (years) 27.85 7.330 25.41 5.963 30.00 6.831 32.26 8.034 -0.37 0.30 
BMI (kg/m2) 21.70 1.698 22.21 2.582 28.06 4.711 31.60 7.278 0.23 0.58 
Education 
(years) 
16.83 3.696 15.36 4.262 19.11 2.213 14.53 5.729 -0.37 -1.05 
Note. BMI = Body Mass Index 
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Table 5 
Descriptive Statistics and Effect Size Comparisons for Each Diagnostic Group 
 Lean 
Control 
N = 26 
Bulimia 
Nervosa 






N = 16 
Cohen




























































































































































Note. BN = bulimia nervosa; LC = lean controls; BED = binge eating disorder; OC = 
overweight/obese controls; DASS = Depression Anxiety Stress Scale; EDE-Q = Eating Disorder 
Examination Questionnaire; PEMS = Palatable Eating Motives Scale; FCQ = Food Craving 
Questionnaire. 
** p < .01. *** p < .001. 
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Table 6 
Results of t-tests comparing the lean control sample with the bulimia nervosa sample 
 t df p Q Cohen’s 
d 
Age 1.33 51 .189 .223 -0.37 
BMI -0.84 51 .403 .411 0.23 
Education 1.35 52 .183 .223 -0.37 
DASS -6.87*** 30.30 a < 
.001 
< .001 1.84 
Eating Concern -9.89*** 32.12 a < 
.001 
< .001 2.65 
Restraint -6.61*** 52 < 
.001 
< .001 1.80 
Weight Concern -7.49*** 52 < 
.001 
< .001 2.05 
Shape Concern -9.08*** 52 < 
.001 
< .001 2.47 
PEMS - Social -0.83 50 .411 .411 0.23 
PEMS – Conformity -4.20*** 30.17 a < 
.001 
< .001 1.19 
PEMS – Coping -7.76*** 31.90 a < 
.001 
< .001 2.11 
PEMS - Enhancement -3.29** 51 .002 .003 0.90 
FCQ -9.53*** 51 < 
.001 
< .001 2.63 
Note. BMI = Body Mass Index; DASS = Depression Anxiety Stress Scale; EDE-Q = 
Eating Disorder Examination Questionnaire; PEMS = Palatable Eating Motives Scale; 
FCQ = Food Craving Questionnaire. 
a Degrees of freedom adjusted for unequal variances between samples. 
** p < .01. *** p < .001. 
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Table 7 
Results of t-tests comparing the overweight/obese sample with the binge eating disorder 
sample 
 t df p Q Cohen’s 
d 
Age -0.94 36 .356 .356 0.30 
Education 3.04** 28.30 a .005 .007 -1.05 
DASS -6.25*** 30.37 a < .001 < .001 2.03 
Eating Concern -10.49*** 36 < .001 < .001 3.40 
Restraint -5.21*** 36 < .001 < .001 1.68 
Weight Concern -9.42*** 31.56 a < .001 < .001 3.05 
Shape Concern -7.99*** 28.23 a < .001 < .001 2.61 
PEMS - Social 1.37 34 .180 .213 -0.46 
PEMS – Conformity 1.20 34 .241 .261 -0.40 
PEMS – Coping -7.32*** 34 < .001 < .001 2.44 
PEMS - Enhancement -3.53** 28.77 a .001 .001 1.17 
FCQ -8.84*** 34 < .001 < .001 2.94 
Binge Frequency -6.76*** 18.22 a < .001 < .001 2.20 
Note. DASS = Depression Anxiety Stress Scale; EDE-Q = Eating Disorder Examination 
Questionnaire; PEMS = Palatable Eating Motives Scale; FCQ = Food Craving 
Questionnaire. 
a Degrees of freedom adjusted for unequal variances between samples. 
* p < .05. ** p < .01. *** p < .001. 
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Table 8 
Differences in Eating Disorder Pathology, Food Craving, Eating Motivations, and 
Depression Between Participants with Bulimia Nervosa and Participants with Binge 
Eating Disorder 
 
 t df p Q Cohen’s 
d 
Eating Concern -2.28 45 .027 .099 0.69 
Restraint -0.07 45 .944 .944 0.02 
Weight Concern -2.50 42.76 a .016 .088 0.70 
Shape Concern -1.30 44.23 a .202 .444 0.37 
Binge Frequency 0.55 42 .588 .847 -0.17 
FCQ -0.14 43 .892 .944 0.04 
PEMS – Social -0.33 42 .745 .911 0.10 
PEMS – Conformity 2.96 40.19 a .005 .055 -0.88 
PEMS – Coping -0.51 29 .616 .847 0.41 
PEMS - Enhancement -1.49 29 .147 .404 0.26 
DASS -0.56 35 .577 .847 0.06 
Note. DASS = Depression Anxiety Stress Scale; EDE-Q = Eating Disorder Examination 
Questionnaire; PEMS = Palatable Eating Motives Scale; FCQ = Food Craving 
Questionnaire. 
a Degrees of freedom adjusted for unequal variances between samples. 
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Table 9 
Descriptive Statistics and Effect Size Comparisons for Each Diagnostic Group on the FCQ 
Subscales 
 Lean Control 
N = 26 
Bulimia 
Nervosa 












 (BED vs 
OC) 












5.115 2.046 11.15 5.005 9.61 3.600 5.56 2.975 0.42*** 1.23*** 
FCQ – Lack 
of Control 
9.654 4.335 27.89 7.371 27.89 6.342 9.89 4.028 0.92*** 3.39*** 
FCQ – 
Preoccupation 




9.692 3.642 14.48 5.177 14.44 3.761 8.94 3.796 -0.45*** 1.46*** 
FCQ – 
Emotions 
7.692 3.541 18.67 6.051 20.28 3.691 8.67 4.201 -0.05*** 2.94*** 
FCQ – Cue 
Triggered 
9.538 4.207 17.44 4.209 18.22 3.797 11.06 4.917 -0.21*** 1.63*** 
FCQ – Guilt 6.077 3.224 15.15 3.393 15.44 2.572 7.22 4.138 0.23*** 2.39*** 
Note. BN = bulimia nervosa; LC = lean controls; BED = binge eating disorder; OC = overweight/obese 
controls; DASS = Depression Anxiety Stress Scale; EDE-Q = Eating Disorder Examination 
Questionnaire; PEMS = Palatable Eating Motives Scale; FCQ = Food Craving Questionnaire. 
*** p < .001. 
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Table 10 
Results of t-tests comparing lean control sample with the bulimia nervosa sample on the 
FCQ Subscales 
 t df p Q Cohen’s 
d 
FCQ – Intention to Eat -8.10*** 51 < .001 < .001 -0.25 
FCQ – Positive Reinforcement -4.53*** 51 < .001 < .001 -0.62 
FCQ – Negative Reinforcement -5.78***  34.72 
a 
< .001 < .001 
0.42 




< .001 < .001 
0.92 
FCQ – Preoccupation -9.15***  34.40 
a 
< .001 < .001 
0.64 
FCQ – Physiological Craving -3.91*** 46.75 
a 
< .001 < .001 
-0.45 
FCQ – Emotions -8.09***  42.23 
a 
< .001 < .001 
-0.05 
FCQ – Cue Triggered -6.84*** 51 < .001 < .001 -0.21 
FCQ – Guilt -9.97*** 51 < .001 < .001 0.23 
Note. FCQ = Food Craving Questionnaire. 
a Degrees of freedom adjusted for unequal variances between samples. 
*** p < .001. 
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Table 11 
Results of t-tests comparing the overweight/obese sample with the binge eating disorder 
sample on the FCQ Subscales 
 t df p Q Cohen’s 
d 
FCQ – Intention to Eat -6.26*** 34 < .001 < .001 2.09 
FCQ – Positive Reinforcement -5.08*** 34 < .001 < .001 1.69 
FCQ – Negative Reinforcement -3.68*** 34 < .001 < .001 1.23 
FCQ – Lack of Control -
10.16*** 
34 < .001 < .001 
3.39 
FCQ – Physiological Craving -4.37*** 34 < .001 < .001 1.46 
FCQ – Emotions -8.81*** 34 < .001 < .001 2.94 
FCQ – Cue Triggered -4.89*** 34 < .001 < .001 1.63 
FCQ – Guilt -7.16*** 34 < .001 < .001 2.39 
Note. FCQ = Food Craving Questionnaire. 
*** p < .001. 
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Supplementary Materials 
Treatment 
 Twenty-five women with bulimia nervosa or binge eating disorder had received 
treatment within six months prior to taking part in the study. The type of treatment 
received by these women is reported in Supplementary Table 1. 
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Supplementary Table 1 
Treatment Received by the Sample of Women with Bulimia Nervosa or Binge Eating 
Disorder 
Type of Treatment 
Number of Women Receiving 
Treatment 
Psychiatrist Support 3 
Outpatient Support 4 
Psychologist Support 7 
Counselling 8 
Eating Disorder-Specific Group Therapy 2 
Non-Eating Disorder-Specific Group 
Therapy 
3 
Individual Psychotherapy 3 
Family Therapy 2 
Community Psychiatric Nurse Support 1 
Self-help Support Group 3 
Community Nurse 2 
Dietician 6 
Online Cognitive Behavioural Therapy 1 
Measures 
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Eating Disorder Examination Questionnaire (EDE-Q). The Eating Disorder 
Examination – Questionnaire version (EDE-Q) (Fairburn & Beglin, 1994a) is a self-report 
questionnaire. Twelve items are presented as a 7-point scale assessing the number of days 
within the past month that the participant exhibited a certain eating disorder symptom. 
Each item scale is anchored from 0 (no days) to 6 (every day). Participants also respond 
to several open-ended questions regarding the frequency with which they exhibited 
particular eating disorder-related behaviours within the past month (e.g., binge eating 
episodes and purging episodes). A greater score on the EDE-Q corresponds with a more 
severe level of eating disorder psychopathology. The EDE-Q comprises four difference 
subscales for: Eating Concern, Restraint, Weight Concern, and Shape Concern. The total 
EDE-Q scale was associated with excellent internal consistency (a = 0.97). 
 Depression and Anxiety Stress Scales (DASS). The Depression and Anxiety Stress 
Scale (DASS) (Lovibond & Lovibond, 1995) includes a total of 42 self-report items, 
which are answered in the form of a 4-point Likert scale. The items are anchored from 0 
(Did Not Apply To Me At All) to 3 (Applied To Me Very Much). These items gauge the 
individual’s current symptoms of depression, anxiety, and stress. The total DASS was 
associated with excellent internal consistency (a = 0.95). 
 Food Craving Questionnaire – Trait subscale (FCQ). The trait subscale of the 
Food Craving Questionnaire (FCQ) (Cepeda-Benito et al., 2000) consists of 39 items 
answered in the form of a 6-point Likert scale ranging from 1 (Never or Not Applicable) 
to 6 (Always). This scale assesses the extent to which individuals experience food craving 
in general, as opposed to the state subscale which measured the amount of food craving 
experienced in the present moment. The total FCQ scale was associated with excellent 
internal consistency in this sample (a = 0.98).  
Monica Leslie   137 
 The FCQ contains 9 subscales, each associated with good internal consistency in 
the current study: Having Intentions and Plans to Consume Food (a = 0.88), Anticipation 
of Positive Reinforcement That May Result From Eating (a = 0.87), Anticipation of 
Relief From Negative States and Feelings as a Result of Eating (a = 0.88), Lack of 
Control Over Eating (a = 0.97), Thoughts or Preoccupation With Food (a = 0.97), 
Craving as a Physiological State (a = 0.77), Emotions That May Be experienced Before 
or During Food Cravings or Eating (a = 0.96), Cues That May Trigger Food Craving (a 
= 0.85), Guilt From Cravings and/or for Giving Into Them (a = 0.94). 
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Supplementary Table 2 
Correlation Matrix for Eating Concern, Food Craving, Binge Frequency, and PEMS Subscales in Bulimia Nervosa Sample 















Eating Concern .33 .59** .60** .52* .12 .30 .11 .35 .37 .32 
Restraint  .50* .48* .17 -.43 .04 .03 .16 -.12 -.02 
Weight Concern   .86*** .55* -.10 .45* .29 .45* .09 .51* 
Shape Concern    .59** -.10 .34 .19 .58** .16 .52* 
FCQ     .30 .15 .09 .77*** .68** .24 
Binge Frequency      -.16 -.42 .03 .42 .03 
PEMS- Conformity       .79*** .12 .17 .37 
PEMS- Social        -.004 .02 .31 
PEMS- Coping         .60** .29 
PEMS-
Enhancement 
         .13 
Note. FCQ = Food Craving Questionnaire; PEMS = Palatable Eating Motives Scale; BMI = body mass index. 
 
N = 21. 
*p < .05. **p < .01. ***p < .001. 
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Supplementary Table 3 
 
Correlation Matrix for Eating Concern, Food Craving, Binge Frequency, and PEMS Subscales in Binge Eating Disorder Sample 















Eating Concern .57* .58* .66** .26 .45 .40 .25 .15 .37 .31 
Restraint  .41 .54* .13 .13 .27 -.08 .34 .02 .37 
Weight Concern   .75** .31 .22 .38 .22 .31 .38 .21 
Shape Concern    .07 .57* .31 .16 .20 .42 .32 
FCQ     .20 .52* .15 .51* .46* .23 
Binge Frequency      -.05 .12 .21 .45 .28 
PEMS- 
Conformity 
      .54* -.13 .57* -.07 
PEMS- Social        -.25 .59 -.11 
PEMS- Coping         .02 .28 
PEMS-
Enhancement 
         -.16 
Note. FCQ = Food Craving Questionnaire; PEMS = Palatable Eating Motives Scale; BMI = body mass index. 
N = 16. 
*p < .05. ** p < .01.
Chapter 3 
 
3 The implication of oxytocin within the addictive appetite model 
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3.1 Oxytocin 
Oxytocin is a nanopeptide hormone and neuromodulator that is primarily produced within 
the paraventricular nucleus and supraoptic nucleus of the hypothalamus (Swaab, Nijveldt, 
& Pool, 1975). The structure of oxytocin is depicted in Figure 4. As a hormone, oxytocin 
is synthesised within the hypothalamus and subsequently stored within neurosecretory 
vessels in the posterior pituitary gland before being released into the bloodstream to reach 
peripheral targets (Poulain & Wakerley, 1982).  
In rats, oxytocin neurons have been found to project to most forebrain regions,  including 
the olfactory system, orbital regions, the insula, the cingulate cortex, basal ganglia, and 
limbic regions (Knobloch et al., 2012). Parvocellular neurons in the paraventricular 
nucleus of the hypothalamus of rats also project to as hindbrain regions including the 
brainstem and the spinal cord (Althammer & Grinevich, 2018). Axonal projections have 
not been as well-described in humans; however, oxytocin projections to the midbrain, 
brainstem, and spinal cord are found across basal vertebrates (Althammer & Grinevich, 
2018).  Oxytocin is also released centrally within the hypothalamus via dendritic emission 
and somata, which results in non-targeted, dispersed release of oxytocin acting in both a 
paracrine fashion on proximal sites of actions, as well as on distant sites of action  
(Ludwig & Leng, 2006).  
The oxytocin receptor is a rhodopsin-type G-protein coupled receptor (Gimpl & 
Fahrenholz, 2001). Depending on the extracellular concentration of oxytocin, oxytocin 
can act on different G proteins, including Gq, Gi1, Gi2, Gi3, Goa, and GoB proteins 
(Chini, Verhage, & Grinevich, 2017). Binding at the oxytocin receptor triggers a 
cascading secondary messenger system to subsequently alter gene transcription within 
the cell.  Oxytocin also has partial binding affinity for the V1a and V1b vasopressin 
receptor, which are also expressed within the central nervous system (Chini et al., 2017). 
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Figure 4. The chemical structure of oxytocin. 
 
Oxytocin receptors are expressed in many peripheral tissues including the kidney, the 
heart, adipocytes, the thymus, the pancreas, adrenal glands, and sex-specific tissues such 
as the uterus, ovaries, and myoepithelial cells of mammary glands in women and the 
prostate and testes in men (Gimpl & Fahrenholz, 2001). Post mortem immunohistological 
work in humans has identified oxytocin receptors within the cell bodies of neurons in the 
cingulate cortex, piriform cortex, post-orbital gyrus, subcallosal area, the spinal 
trigeminal nucleus, the nucleus prepositus, the olfactory nucleus, incus, ventrolateral 
septal nucleus, basolateral amygdala, central amygdala, posterior cortical nucleus 
amygdala, medial preoptic area, paraventricular nucleus, ventromedial nucleus, 
tuberomamillary nucleus, and solitary nucleus (Boccia, Petrusz, Suzuki, Marson, & 
Pedersen, 2013; Freeman, Smith, Goodman, & Bales, 2017). Oxytocin receptors are also 
expressed on the nerve fibres of the hippocampus, the subiculum, the supraoptic nucleus 
and all previously-mentioned brain regions where neuron cell bodies express oxytocin 
receptors, except for the post-orbital gyrus (Boccia et al., 2013). Autoradiographic studies 
have identified oxytocin receptors in mesolimbic regions of the human brain including 
the globus pallidus and ventral pallidum (Loup, Tribollet, Dubois-Dauphin, & Dreifuss, 
1991). 
Monica Leslie   143 
In terms of peripherally-mediated effects, oxytocin has long been known for its role in 
stimulating uterine contractions during parturition and stimulating milk let-down during 
breast-feeding in mammals (Fuchs, Fuchs, Husslein, Soloff, & Fernstrom, 1982; Soloff, 
Alexandrova, & Fernstrom, 1979). However, in humans, oxytocin has recently gained 
greater attention for centrally-mediated effects, such as the processing of social 
information (Bartz, Zaki, Bolger, & Ochsner, 2011; Kosfeld, Heinrichs, Zak, 
Fischbacher, & Fehr, 2005), modulating stress responses mediated by the hypothalamic-
pituitary-adrenal axis (Ochedalski, Subburaju, Wynn, & Aguilera, 2007), deterring 
relapse to substance abuse (Zanos et al., 2018), and the regulation of feeding (Olszewski, 
Klockars, & Levine, 2016). The following thesis section will discuss current animal and 
human evidence clarifying the role of oxytocin in reward processing and substance 
addictions, before going on to outline a hypothesised role for oxytocin in food addiction. 
3.2 The Role of Oxytocin in Substance Addiction 
Oxytocin has been found to directly alter dopamine turnover and neuron firing in reward-
related mesolimbic brain regions. For example, in male mice, chronic oxytocin 
administration has been found to reduce utilisation of dopamine in the basal forebrain in 
resting conditions (Kovács, Faludi, Falkay, & Telegdy, 1986) and to specifically reduce 
cocaine-induced dopamine utilisation in the nucleus accumbens, which is associated with 
the antagonism of cocaine-induced hyperactivity (Kovacs, Sarnyai, Babarczi, Szabo, & 
Telegdy, 1990). Oxytocin has also been found to increase the firing rate of neurons within 
the nucleus accumbens shell of both opiate-naïve and opiate-experienced rats (Moaddab, 
Hyland, & Brown, 2015) and to increase extracellular dopamine levels in in the nucleus 
accumbens in male rats (Succu et al., 2007). This mixed pattern of effects of oxytocin in 
alternately increasing or decreasing dopamine release and dopaminergic effects in 
mesolimbic regions indicates that the effects of oxytocin are likely dependent on dose, 
particularly given that oxytocin acts on different G proteins depending on the extracellular 
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concentration of oxytocin (Chini et al., 2017). The effects of oxytocin on central 
dopaminergic activity may also be dependent on prior experience of opioidergic and 
dopaminergic drugs and species of the animal under investigation (Zanos et al., 2018). 
In terms of behavioural effects, the bulk of the evidence supports a role for oxytocin in 
attenuating opioid seeking. Three studies have found that pre-treatment with oxytocin 
reduces subsequent heroin self-administration in heroin-tolerant rats when oxytocin is 
injected into the nucleus accumbens or ventral tegmental area, the lateral septum, or 
subcutaneously (Ibragimov & Kovacs, 1987; Ibragimov, Kovács, Szabó, & Telegdy, 
1987; Kovács, Borthaiser, & Telegdy, 1985). Furthermore, intraperitoneal oxytocin 
administration has also been found to prevent stress-induced morphine-seeking and 
priming-induced reinstatement of a morphine conditioned place preference after a period 
of abstinence (Georgiou et al., 2015; Zanos et al., 2014). 
This pattern of effects, whereby oxytocin prevents reinstatement of opiate self-
administration, may be explained by the effect of oxytocin on opioid tolerance. Central 
injections of oxytocin directly to the dorsal hippocampus and nucleus accumbens have 
been found to reduce heroin tolerance in mice (Kovacs, Horváth, Sarnyai, Faludi, & 
Telegdy, 1985; Kovács, Faludi, & Telegdy, 1985; Kovács, Izbéki, Horváth, & Telegdy, 
1984; Kovács & Telegdy, 1987). Thus, greater sensitivity to the euphoric and withdrawal-
alleviating effects of opioids may explain the reduced opioid-seeking behaviour in opioid-
tolerant mice and rats. 
However, it should be noted that not all studies have supported a role for oxytocin in 
deterring opioid-seeking behaviour. For example, a study by Moaddab et al. (2015) found 
that 0.2 micrograms of oxytocin injected into the cerebral ventricles actually enhanced 
the expression of morphine-induced place preference after acquisition, and Van Ree and 
de Wied (1976) found that oxytocin facilitated morphine dependence. However, these 
findings may be explained by the 0.2 microgram dose of centrally-injected oxytocin in 
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the Moaddab et al. (2015), which is substantially larger than the 0.2 nanogram dose of 
centrally-injected oxytocin which was found to reduce heroin self-administration in the 
earlier Ibragimov et al. (1987) study. As mentioned above, the difference dose of oxytocin 
may exert differing effects by acting via different G-protein-coupled secondary 
messenger systems, or by paradoxical effects induced by binding to V1a or V1b receptors 
at high doses (Chini et al., 2017).  The difference in findings may also be due to the 
different region of administration: the cerebral ventricles in the Moaddab et al. (2015) 
study versus the nucleus accumbens and ventral tegmental area in the Ibragimov et al. 
(1987) study. Furthermore, Van Ree and de Wied (1976) found that oxytocin facilitated 
morphine dependence in female rats, in contrast to the male rats who exhibited reductions 
in opioid seeking in other studies. Therefore, this pattern of findings suggests that both 
dose and sex moderate the effect of oxytocin on opioid seeking. 
To date, there are few studies examining the effects of oxytocin on substance addictions 
in humans. One study has found that a single dose of 40IU oxytocin, in comparison to 
placebo, had no effect on cue-induced drug craving in opioid-dependent participants 
undergoing an opioid replacement programme (Woolley et al., 2016). However, it may 
be the case that longer time frames are needed to observe an effect, as a separate double-
blind placebo-controlled crossover trial found that twice-daily doses of 40IU oxytocin 
significantly reduced cocaine craving at day 15 compared to baseline, although the 
authors failed to find an effect of oxytocin on heroin craving (Stauffer et al., 2016). Thus, 
there is some evidence that oxytocin can alleviate cravings in people with cocaine use 
disorder. 
3.3 The Role of Oxytocin in Food Addiction 
The evidence described above has provided an overview of some of the neurological 
pathways by which oxytocin interacts with dopamine and opioid systems to influence 
reward-seeking behaviour. However, it should be noted that many of the same hedonic 
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systems implicated in substance use disorders, including neural pathways between the 
nucleus accumbens and ventral tegmental area, are also relevant to food cravings 
(Berridge, 2009). Indeed, if food-related appetitive processes interact with oxytocin 
functioning in a similar manner to drug-related appetitive processes, the evidence 
described in Section 3.2 would suggest that oxytocin may inhibit palatable food-seeking 
behaviour just as it has also been found to inhibit opioid-seeking behaviour.  For example, 
recent work has concisely reviewed neural mechanisms by which repeated sucrose 
consumption ultimately leads to disinhibition of hedonic eating, which include 
antagonism of the effects of oxytocin in terminating feeding via a sucrose-induced 
increase in opioid tone (Olszewski, Wood, Klockars, & Levine, 2019). 
However, it is possible that any effect of oxytocin on eating may also be mediated via 
mechanisms other than the modulation of reward, such as through the down-regulation of 
the stress response and alteration of attentional bias to eating disorder-related stimuli. The 
following thesis sections will therefore serve to provide an overview of the existing 
evidence for altered oxytocin functioning, and the effects of exogenously-administered 
oxytocin, in populations with eating disorders. 
3.4 The implication of oxytocin in eating disorders: Genetic and epigenetic evidence 
As alluded to in sections 3.1 and 3.3, oxytocin functioning is strongly implicated in the 
regulation of eating behaviour. Indeed, disruptions in endogenous oxytocin systems have 
been found to be associated with pronounced, compulsive overeating. For example, mice 
with mutations on the SIM1 gene, which regulates the development of the paraventricular 
nucleus of the hypothalamus, exhibit reduced oxytocin synthesis and a pattern of 
overeating and obesity (Michaud et al., 2001). Similarly, humans with Prader-Willi 
syndrome present with a reduction in oxytocin-synthesising neurons in the 
paraventricular nucleus of the hypothalamus, and also present with compulsive 
overeating behaviour from early in childhood (Swaab, Purba, & Hofman, 1995). 
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Some differences in genetic and epigenetic oxytocin-related factors have also been 
observed across the eating disorders spectrum. Women with anorexia nervosa have been 
observed to exhibit greater levels of methylation at five polymorphisms of the oxytocin 
receptor gene (OXTR) (Y.-R. Kim, J.-H. Kim, et al., 2015). As DNA methylation can 
alter transcription of a gene (Zilberman, Gehring, Tran, Ballinger, & Henikoff, 2007), it 
is possible that altered regulation of the oxytocin receptor gene has functional effects 
pertaining to cognition and behaviour in anorexia nervosa. Furthermore, women with a 
history of anorexia nervosa who carry an A allele on the rs53576 and rs2254298 OXTR 
polymorphisms have been found to exhibit greater eating disorder psychopathology, 
compared to women with the GG genotype at both loci (Acevedo, Valencia, Lutter, & 
McAdams, 2015). 
However, rather than the G allele being protective from anorexia nervosa, it may be that 
the G allele is associated with greater food approach behaviour more generally. This 
hypothesis comes from a study indicating that the G allele on the rs53576 polymorphism 
confers greater risk for BN (Y.-R. Kim, J.-H. Kim, et al., 2015), and a separate study 
indicating that the GG genotype on the rs53576 polymorphism is associated with greater 
binging and purging behaviour in women (Micali, Crous-Bou, et al., 2017). Furthermore, 
a gene X environment interaction has been found in bulimia nervosa such that carrying 
the AG/GA variant of the rs2254298 polymorphism of the OXTR gene, in combination 
with poor maternal care, predicts greater binging and purging behaviour (Micali, Crous-
Bou, et al., 2017). 
No direct genetic links have been found between the OXTR gene and populations 
diagnosed with binge eating disorder. However, at a trait level, the TT genotype on the 
rs2268493 OXTR polymorphism has been found to be associated with greater overeating 
behaviour, and the A allele of the rs2268494 OXTR polymorphism has been found to be 
associated with greater preference for sweet and fat-rich foods (Davis, Patte, Zai, & 
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Kennedy, 2017). However, the implication of these OXTR polymorphisms in clinical 
levels of binge eating has not yet been established. 
3.5 The implication of oxytocin in eating disorders: Alterations in central and peripheral 
concentrations of oxytocin 
With regards to differences in oxytocin synthesis and secretion, lower night-time serum 
oxytocin levels have been found in women with current anorexia nervosa, compared to 
healthy comparison women (Lawson et al., 2011). Furthermore, in women partially 
recovered from anorexia nervosa, lower fasting serum levels of oxytocin are associated 
with greater levels of depression, anxiety, and eating disorder psychopathology 
(Afinogenova et al., 2016). Conversely, serum oxytocin levels were higher in women 
with anorexia nervosa 60 and 120 minutes after eating compared to healthy control 
women, and but lower in women weight-recovered from anorexia nervosa 0, 30, and 120 
minutes after eating (Lawson et al., 2012). Thus, on the whole, the evidence suggests that 
women with anorexia nervosa and partially-recovered from anorexia nervosa tend to 
exhibit lower levels of serum oxytocin, with the exception of women with current 
anorexia nervosa following food consumption. Nonetheless, while the association with 
clinical variables might seem to suggest a causal effect on psychopathology, evidence has 
generally shown that plasma levels of oxytocin are an unreliable indicator of endogenous 
central oxytocin concentrations (Valstad et al., 2017). Thus, the implication of serum 
oxytocin for centrally-mediated cognitions related to eating disorder psychopathology is 
unclear from a biological standpoint. 
Cerebrospinal fluid levels of oxytocin have not been found to differ significantly between 
people with or recovered from bulimia nervosa, as compared to the general population 
(Demitrack et al., 1990; Frank, Kaye, Altemus, & Greeno, 2000). However, cerebrospinal 
fluid levels of oxytocin do not necessarily reflect the bioavailability of oxytocin to brain 
regions involved in the regulation of eating and appetitive processes. Furthermore, even 
in the presence of similar levels of centrally available oxytocin, differential expression 
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and functioning of the oxytocin receptor gene can still result in functional differences 
across the oxytocinergic system between people with and without BN. Thus, the extent 
to which levels of central levels of biologically-available oxytocin, and oxytocinergic 
functioning, may differ between people with eating disorder versus the general population 
remains an open question. 
3.6 The implication of oxytocin in eating disorders: Social and Emotional Effects 
Given the role of oxytocin in modulating the processing of social information, oxytocin 
treatment has received substantial attention in the context of its potential efficacy in 
treating social deficits in autism spectrum disorders (Preti et al., 2014). Anorexia nervosa 
shares several features in common with autism spectrum disorders, including a detail-
focused, inflexible cognitive processing style (Lopez, Tchanturia, Stahl, & Treasure, 
2008; Westwood, Stahl, Mandy, & Tchanturia, 2016) and deficits in cognitive empathy, 
which refers to the ability to recognise and understand another person’s mental state 
(Kerr-Gaffney, Harrison, & Tchanturia, 2019). Recent basic psychology and clinical 
studies have therefore begun to investigate the potential therapeutic effects of oxytocin 
for social and emotional functioning across the eating disorders spectrum. This literature 
will be reviewed in the current thesis section. 
With regards to anorexia nervosa, one study has found that 40IU intranasal oxytocin 
attenuated baseline avoidance of images of angry faces in the placebo condition (Kim, 
Kim, Park, Pyo, & Treasure, 2014). However, later studies have found that exogenous 
oxytocin had no effect on emotion recognition sensitivity, interpretation of emotion, or 
expression of emotion in people with anorexia nervosa (Y.-R. Kim, J.-S. Eom, et al., 
2015; Leppanen, Cardi, et al., 2017b). Indeed, a 2017 meta-analysis failed to find an effect 
of oxytocin on emotion interpretation or expression across all studies to have investigated 
these effects in clinical populations (Leppanen, Ng, Tchanturia, & Treasure, 2017). Thus, 
while intranasal oxytocin may affect attentional processing of emotional stimuli, the 
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existing evidence does not support a functional role for exogenous oxytocin in altering 
higher-level interpretation or emotional behaviour in anorexia nervosa. 
A mixed pattern of results has been found in the two studies investigating the effect of 
intranasal oxytocin on attentional bias to eating and body-related stimuli in anorexia 
nervosa. Kim, Kim, Cardi, et al. (2014) found that 40IU intranasal oxytocin, versus 
placebo administration, reduced bias towards both negative body shape images and 
eating-related images amongst participants with anorexia nervosa. By contrast, Leppanen, 
Cardi, et al. (2017a) found that participants with anorexia nervosa displayed attentional 
avoidance of eating-related stimuli at baseline, and that 40IU intranasal oxytocin rather 
increased vigilance to eating stimuli, compared to the placebo condition, after smoothie 
consumption. It is therefore possible that the discrepancy between the two sets of findings 
may be explained by the moderating effect of calorie consumption on the effect of 
oxytocin on attentional processing of disorder-related stimuli, although future research is 
required to corroborate this hypothesis. 
Oxytocin has been found to reduce the salivary cortisol response to the presentation of 
food stimuli among people with anorexia nervosa, both when administered as a single 
dose (Leppanen, Cardi, et al., 2017a) and in the context of a four-to-six-week clinical trial 
(Russell et al., 2018). Furthermore, after four to six weeks of daily treatment of 36IU 
intranasal oxytocin, overall eating concern among participants with anorexia nervosa was 
found to decrease to a significantly greater extent compared to a placebo group (Russell 
et al., 2018). While oxytocin was not found to affect weight recovery amongst the 
participants with anorexia nervosa in the latter clinical trial (Russell et al., 2018), overall, 
the evidence suggests that oxytocin is efficacious in reducing the stress response of people 
with anorexia nervosa in some circumstances. 
Compared to anorexia nervosa, relatively less research has so far been carried out 
investigating the social and emotional effects of oxytocin for people with BN. A single 
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dose of oxytocin has been found to improve emotion recognition specifically for sad faces 
(Y.-R. Kim, J.-S. Eom, et al., 2015), and to reduce attentional bias to angry, versus 
neutral, faces in participants with BN (Kim, Eom, Leppanen, Leslie, & Treasure, 2018). 
Further research is needed to elucidate the clinical significance of these findings. 
One clinical trial has investigated the effects of chronic oxytocin treatment in obese 
people with BED (Agabio et al., 2016). Within this clinical trial, participant received 
either four doses of 24IU oxytocin daily over a period of eight weeks, or an equal volume 
of placebo treatment. Oxytocin did not have a significant effect on anxiety, depression, 
or number of binge eating episodes per week by the end of the study. However, the clinical 
trial was severely underpowered, with only seventeen participants in total. Thus, the null 
findings reported in this study should be interpreted with caution. 
3.7 Current gaps in knowledge regarding the effect of oxytocin on eating in animals and 
humans 
The preceding thesis section has provided an overview of previous literature investigating 
the effects of oxytocin on social and emotional functioning in eating disorders. However, 
it is of great clinical interest to determine if oxytocin can indeed alleviate core symptoms 
of disordered eating across the eating disorder spectrum. Since the 1970s, a large body of 
research has documented the effect of exogenous oxytocin on feeding in animals (Blevins 
& Baskin, 2015). Additionally, in recent years, these findings have gradually been 
translated to investigations of the effects of oxytocin on eating in both healthy and clinical 
human populations (Blevins & Baskin, 2015). However, this research has not yet been 
compiled systematically. The following systematic review and meta-analysis therefore 
aims to fill this gap in the literature in order to develop a complete picture of the role of 
exogenous central and peripherally-administered oxytocin in modulating subsequent 
eating behaviour.  
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3.8 Paper 4: A Systematic Review and Quantitative Meta-Analysis of the Effects of 
Oxytocin on Feeding 
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Abstract 
Purpose: Oxytocin’s anorexigenic effects have been widely documented and accepted; 
however, no paper has yet used the Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis (PRISMA) guidelines to compile previous findings in a single 
systematic review and quantitative meta-analysis. The current paper aimed to identify 
published and unpublished studies examining the effects of oxytocin on energy intake in 
animals and humans, and the factors that moderate this effect. 
Methods: Web of Science, Pub Med, and Ovid were searched for published and 
unpublished studies reporting the effects of oxytocin on energy intake in wild-type 
animals and in humans, when administered in the absence of other active drugs or surgery.  
Results: 2049 articles were identified through the original systematic literature search, 
from which 54 articles were identified as relevant for inclusion in this review. An 
additional 3 relevant articles were identified in a later update of the literature search. 
Overall, a single dose of oxytocin was found to reduce feeding in animals. Despite several 
individual studies which found that this effect persists to the end of the third week of 
chronic administration in rodent models, overall, this anorexigenic effect did not hold in 
the meta-analyses testing the effects of chronic administration. There was no overall 
effect of oxytocin on energy intake in humans, although a trend was identified for 
oxytocin to reduce consumption of solid foods. 
Conclusions: Oxytocin reduces energy intake when administered as a single dose. 
Oxytocin can inhibit feeding over two- to three-week periods in rodent models. These 
effects typically do not persist beyond the third week of treatment. The anorexigenic 
effect of oxytocin is moderated by pregnant status, dose, method of administration, and 
diet composition. 
KEYWORDS: OXYTOCIN; ENERGY INTAKE; FEEDING; ANIMALS; HUMANS   
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Introduction 
 Verbalis, McCann, McHale, and Stricker (1986) and Kirchgessner, Sclafani, and 
Nilaver (1988) first proposed a link between oxytocin and the control of food intake 
almost 30 years ago; which was subsequently corroborated by the Arletti lab (Arletti, 
Benelli, & Bertolini, 1989). Today, oxytocin has a well-established and well-accepted 
role in reducing food intake in rodents, although these effects have been found to be 
conditional on several factors (Olszewski, Klockars, & Levine, 2016).  
 The reported inhibitory effect of oxytocin on feeding has taken on new relevance 
in the face of the high prevalence of obesity in developed countries (Arroyo-Johnson & 
Mincey, 2016) and recognition of the psychological and functional difficulties faced by 
individuals with binge-type eating disorders, including bulimia nervosa and binge eating 
disorder (American Psychiatric Association, 2013; Pawaskar, Witt, Supina, Herman, & 
Wadden, 2017). It has, accordingly, been proposed that oxytocin may be a useful 
supplement to administer to counter overeating and obesity (Roberts et al., 2017; Spetter 
& Hallschmid, 2017). 
 In recent years, several narrative reviews have examined the role of oxytocin in a 
variety of functions related to the homeostasis of energy status: including its effects on 
feeding, energy expenditure, lipolysis, glucose homeostasis, and macronutrient 
preference (Lawson, 2017; Leng & Sabatier, 2017; Sabatier, Leng, & Menzies, 2013; 
Spetter & Hallschmid, 2017), as well as its potential to regulate disordered eating in 
humans (Giel, Zipfel, & Hallschmid, 2017). However, systematic reviews and meta-
analyses in the style of the Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) guidelines are not commonly used in neurobiology and have not 
been previously used to estimate the size of the effect of oxytocin on feeding, and its 
possible moderators. This systematic method offers benefits such as the reproducibility, 
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accountability of the search methods used, and quantitative precision in the measurement 
of effect size across different samples (Moher, Liberati, Tetzlaff, & Altman, 2009). De 
Vries and colleagues have therefore adapted similar guidelines for systematic reviews of 
animal intervention studies in order to bring these same benefits in methodical rigor to 
animal research (Vries et al., 2015). 
The current paper therefore aimed to use this rigorous methodology to synthesize 
oxytocin’s effects on feeding. We used PRISMA guidelines to identify all original 
published and unpublished experiments testing the effects of exogenous oxytocin on 
energy intake in wild-type animals and in humans, where oxytocin was administered in 
the absence of other active drugs or surgeries. Following this, we then identified subsets 
of experimental designs conducive to synthesis by quantitative meta-analysis. We also 
aimed to identify relevant moderators of oxytocin’s effects on feeding in order to clarify 
the conditions under which these anorexigenic effects hold. 
Methods 
Search Strategy and Eligibility Criteria 
Two of the authors conducted a systematic literature search to identify original 
studies which had administered exogenous oxytocin to either animals or humans and 
compared its effects on energy intake with a placebo condition. This search was 
conducted following PRISMA guidelines (Moher et al., 2009). We followed reporting 
guidelines suggested by de Vries and colleagues for pre-clinical intervention studies in 
the data extraction and reporting methods described below (Vries et al., 2015). 
 The search terms included in the literature search were: “oxytocin” AND (“feed*” 
OR “food” OR “eat” OR “consum*” OR “intake” OR “hunger” OR “satiety” OR 
“appetite” OR “meal”). The eligibility criteria for studies included in the systematic 
review are as follows: 
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Inclusion criteria: 
• Original experiment 
• Independent variable: Administration of exogenous oxytocin compared to 
placebo 
• Dependent variable: Quantity of food or nutritive substance consumed 
• Oxytocin administered in isolation from any other drug or neural stimulation 
• Article available in English 
• Neurologically typical participants (e.g., participants with Prader-Willi Syndrome 
were excluded) 
Exclusion criteria: 
• Studies testing consumption of alcohol/ethanol or methamphetamines 
• Studies testing consumption of plain water, saccharin, or sodium solutions 
• Studies of breastfeeding neonates 
• Studies measuring oxytocin’s effect on conditioned taste aversion 
In March 2016, these terms were included in a title or topic search in the Web of 
Science (Core Collection) and in a text word search in PubMed. In November 2016, these 
same search terms were entered into a literature search using the following Ovid 
resources: International Pharmaceutical Abstracts, Ovid MEDLINE(R) I-Process & 
Other Non-Indexed Citations, Ovid MEDLINE R, PsycArticles Full Text, PsycInfo, Ovid 
MEDLINE(R) Epub Ahead of Print. The PubMed and Web of Science searches were then 
updated by the first author in December 2016. 
 The first author then proceeded to screen the reference lists of relevant reviews in 
order to identify articles not included in the main search results, and independently 
contacted authors known to have unpublished eligible studies (identified through 
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individual correspondence, conference attendance, and reference to unpublished data 
within a published paper). In March 2017, the second author repeated the literature search 
among the same databases. The first and second authors discussed discrepancies among 
the identified search results until a consensus regarding each article’s eligibility was 
reached. The literature search was once again updated using the same databases in July 
2017. Basic study characteristics (including sample information, dose of oxytocin 
administration, and duration of feeding measurement) and a qualitative summary of each 
experiment’s findings were extracted by a single author. 
Meta-Regression 
 Given the wide variety of studies identified by the systematic literature search, we 
opted to conduct five separate meta-regressions in order to maximize the homogeneity 
within each analysis. The five meta-regressions were then conducted amongst each of the 
following sets of experiment: 1) single-dose animal studies measuring feeding over one 
hour after a central injection of oxytocin; 2) single-dose animal studies measuring feeding 
over one hour after systemic administration of oxytocin; 3) chronic-dosing animal studies 
administering central injections of oxytocin; 4) chronic-dosing animal studies 
administering systemic injections of oxytocin; 5) human studies. Effect size data 
(including raw means and standard deviation or standard error) and sample sizes for each 
study were necessary for each eligible study to be included in a meta-regression. These 
data were extracted by a single author directly from tables or text within the paper in cases 
where they were reported. For papers in which these data were not reported, the authors 
of the paper were contacted with a request for this information via e-mail, or via Research 
Gate where a current valid e-mail address was unavailable. Where these data were 
unavailable, the eligible paper has been described in the results of the systematic review 
but omitted from the meta-regression by necessity. 
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As not all of the studies identified in original systematic review were eligible for 
inclusion in one of these meta-regressions, the full findings of each study included in the 
systematic review have been reported in separate tables. The moderating and mediating 
factors influencing oxytocin’s effects on energy intake have been summarized in a 
qualitative synthesis, which follows the quantitative results reported below. 
 Each meta-regression was conducted as a random-effects multi-level analysis 
with autoregressive structure, where the second-level corresponded to a specific sample 
of test subjects. The meta-regressions’ results are reported in terms of the standardized 
mean difference between placebo and oxytocin conditions. The meta-regressions were 
conducted using the escalc and rma.mv commands in the metafor package for R 
(Viechtbauer, 2010). The forest plots and bias plots were generated using the 
Comprehensive Meta-Analysis software. In four experiments within the meta-analysis for 
human studies, the within-subject correlation was not available. The average within-
subject correlation for human studies (0.61) was therefore imputed for these experiments. 
Results 
Systematic Review 
The quantity of papers identified and screened at each step of the PRISMA process 
during the original systematic literature search is presented in Figure 5. Two additional 
unique papers were identified through the updated literature search, and one additional 
paper was identified through author correspondence. The original and updated literature 
searches together identified a total of 57 relevant papers.  
Forty-seven papers included at least one experiment that measured the effects of 
a single dose of oxytocin on feeding. The 114 experiments measuring the effects of a 
single dose of oxytocin are summarized in Supplementary Table 4. Eighteen papers 
included at least one experiment that administered chronic dosing of oxytocin. The 56 
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experiments measuring the effects of chronic oxytocin dosing on feeding are summarized 
in Supplementary Table 5. 
Meta-Regression 
 Acute central animal studies. We first conducted the meta-regression for the 
studies that administered oxytocin centrally, entering moderators for Dose and Body 
Mass. As all animals were male and housed individually, we did not include moderators 
for gender or socialization. The Cook’s plot generated by this analysis revealed that one 
study ((Arletti et al., 1989), Experiment 2a) yielded undue influence on the results. This 
study was therefore excluded from the final analysis, resulting in a total of nine 
experiments with a pooled sample size of 150 observations. (Note: as several studies 
incorporated a within-subjects design and/or repeated experiments using the same 
animals, the number of total observations does not equal the total number of subjects.) 
The final analysis found a significant main effect of oxytocin, showing that a single dose 
of centrally-administered oxytocin reduced feeding with a large effect size (d = -1.26, SE 
= 0.451, p = 0.005, 95% CI [-2.149, -0.380]). The forest plot for this meta-regression is 
shown in Figure 6. Neither of the included moderators was significant: Dose (estimate = 
-0.003, SE = 0.017, p = 0.857, 95% CI [-0.036, 0.030]); Body Mass (estimate = 0.000, SE 
= 0.000, p = .315, 95% CI [-0.000, 0.000]). There was significant residual heterogeneity: 
Q(8) = 22.94, p = 0.003. There was significant residual heterogeneity after controlling for 
Dose (QE(7) = 22.94, p = 0.002 and Body Mass QE(7) = 20.49, p = 0.005. 
 Acute systemic animal studies. We next repeated the analysis for studies 
administering a single dose of systemic oxytocin including moderation analyses for 
Gender, Dose, and Body Mass. This meta-regression included findings from 26 
experiments and 510 observations. All animals were individually housed; therefore, 
socialization was not entered as a moderator. Visual inspection of the Cook’s plot did not 
Monica Leslie   160 
reveal undue influence of any study (all values < 0.12). This analysis for single-dose 
studies administering oxytocin systemically also found that oxytocin significantly 
reduced feeding with a large effect size (d = -1.17, SE = 0.307, p < .001, 95% CI [-1.776, 
-0.574]). There was significant heterogeneity in the results: Q(25) = 188.38, p < .001. The 
moderation analyses revealed a small dose-response effect (estimate = -0.002, SE = 
0.0005, p < .0001, 95% CI [-0.003, -0.001]). The forest plot for this meta-regression is 
shown in Figure 7. Neither of the other included moderators were significant: Gender 
(estimate = 0.48, SE = 1.220, p = .694, 95% CI [-1.912, 2.872]); Body Mass (estimate = 
0.008, SE = 0.005, p = .091, 95% CI [-0.001, 0.017]). There was significant residual 
heterogeneity after controlling for each moderator: Dose (QE(d24) = 104.31, p < .001); 
Gender (QE(24) = 187.81, p < .001); Body Mass (QE(24) = 131.74, p < .001). 
 Chronic central animal studies. For the meta-regression of animal studies 
administering repeated central injections of oxytocin we entered the following 
moderators: Gender, Dose, Body Mass, and Duration of Oxytocin Administration. The 
quantity of energy intake on the final day of feeding measurement was compared between 
oxytocin and placebo conditions. Data were drawn from 20 experiments with a total of 
349 observations. As all animals were housed alone, socialization was not included as a 
potential moderator. Visual inspection of the Cook’s plot did not reveal undue influence 
of any study (all values < 0.30). This analysis did not find a significant main effect of 
oxytocin on feeding when administered centrally in chronic infusions (d = 0.15, SE = 
0.171, p = .379, 95% CI [-0.185, 0.485]). The forest plot for this meta-regression is shown 
in Figure 8. There was significant heterogeneity: Q(19) = 43.08, p = 0.001. None of the 
included moderators were significant, and there was significant residual heterogeneity 
after controlling for each moderator. The results of all moderation analyses are presented 
in Table 12. 
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 Chronic systemic animal studies. The same analysis was then repeated for animal 
studies that administered chronic infusions of oxytocin systemically. The quantity of 
energy intake on the final day of feeding measurement was compared between oxytocin 
and placebo conditions. Seventeen experiments with a total of 255 observations were 
included in this meta-regression. We entered the following moderators: Gender, Dose, 
Body Mass, Duration of Administration, and Social Condition. Visual inspection of the 
Cook’s plot did not reveal undue influence of any study (all values < 0.90). Again, we 
did not find a significant main effect of oxytocin on feeding (d = -1.52, SE = 0.963, p = 
.115, 95% CI [-3.407, 0.369]). The forest plot for this meta-regression is shown in Figure 
9. The moderators Gender, Dose, and Duration of Administration were significant. 
Oxytocin had a significantly greater anorexigenic effect in males, and the inhibitory effect 
of oxytocin on feeding decreased in magnitude over time. The results for dose indicated 
a reverse dose-response effect, such that greater dose was associated with less inhibition 
of oxytocin on feeding; however, the effect size was close to zero (estimate = 0.0002, SE 
= 0.0001, p = 0.039, 95% CI [0.0000, 0.0003]. There was significant heterogeneity in 
study results (Q(22) = 206.88, p < .001) and significant residual heterogeneity after 
controlling for each moderator. The results of all other moderator analyses are reported 
in Table 13. 
Human studies. The meta-regression for human studies included 21 experiments 
with a total of 1020 observations. We entered the following moderators: Liquid-versus-
Solid Food, Gender, Dosage, Fasted-versus-Full condition, Duration of Feeding, and 
Diagnosis. Visual inspection of the Cook’s plot did not reveal undue influence of any 
study (all values < 0.8). This analysis did not find a significant main effect of oxytocin 
on feeding (estimate = -0.10, SE = 0.075, p = 0.194, 95% CI [-0.245, 0.050]). The forest 
plot for this analysis is shown in Figure 10. 
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There was significant heterogeneity between studies: Q(df = 20) = 55.82, p < .001. 
All moderators except for Dose and Diagnosis were found to be significant (results shown 
in Table 14). Oxytocin reduced feeding to a greater degree for solid, rather than liquid 
foods (e.g., nutrient drinks, juice and smoothies). There was a greater inhibitory effect of 
oxytocin on feeding for males than females, when participants were full, rather than 
fasted, and when food was presented for a longer period of time (although the effect size 
was close to zero). There was a marginally significant effect such that oxytocin reduced 
feeding to a greater degree in obese participants. A greater dose of oxytocin was not 
associated with quantity of food consumption. There was significant residual 
heterogeneity after taking each moderator into account. Residual heterogeneity for each 
moderator is reported in Table 14. 
Based on the difficulty of interpreting the results given such a range of significant 
moderators, we then proceeded to repeat the analysis including only studies that had 
measured the consumption of solid foods. As all but one of the studies in the meta-
regression for solid foods included only female participants, the gender moderator was 
not included in this analysis.  
Ten experiments with a total of 486 observations were included in the meta-
regression for human studies measuring consumption of solid foods. Visual inspection of 
the Cook’s plot did not reveal undue influence of any study (all values < 0.7). The meta-
regression for human studies isolated into the solid food condition found a marginally 
significant main effect of oxytocin on food consumption with a small effect size (d = -
0.25, SE = 0.132, p = 0.055, 95% CI [-0.510, 0.006]). The forest plot for this meta-
regression is shown in Figure 11. None of the included moderators were significant 
(results shown in Table 15). There was significant residual heterogeneity after controlling 
for Gender, Fasted or Full condition, Duration of Administration, and Dose. Although the 
diagnosis moderator was not significant (Qm(3) = 3.01, p = 0.391), there was no longer 
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significant residual heterogeneity after controlling for diagnosis (QE(6) = 12.18, p = 
.058). 
Publication Bias. The funnel plots associated with each meta-regression are 
shown in Supplementary Figures 1-5. The funnel plots indicated that most studies had 
a moderate degree of precision, with a broad range of effect sizes reported. These findings 
do not suggest systematic publication bias towards papers with either strong or weak 
effect sizes. 
Mediators and Moderators of Oxytocin’s Anorexigenic Effects 
 Among the systematic review, there were many factors that were found to 
moderate the effect of oxytocin on feeding in some studies, including: sex of the animal, 
pregnancy, dose, method of administration, setting, and dietary factors. As not all studies 
met criteria for inclusion in one of the meta-regressions, the following reported results 
will focus on a sample of other identified studies that examined a moderating or mediating 
factor in a controlled experimental design. 
 Sex differences. Several studies investigated sex differences in oxytocin’s effects 
on feeding. Bjorkstrand and Uvnas-Moberg (1996) found that a 5µg 
intracerebroventricular injection of oxytocin increased feeding in female, but not male 
rats. Conversely, L. Zhou, Ghee, See, and Reichel (2015) found that oxytocin induced a 
greater reduction in feeding in female rats, with anorexigenic effects observed at 0.3, 1, 
and 3mg/kg doses of oxytocin, while only the 3mg/kg dose was effective at reducing 
feeding in males. To further add to these mixed findings, Benelli, Bertolini, and Arletti 
(1991) failed to find any differences in male versus female rats’ response to oxytocin’s 
effects on feeding. Previous studies have demonstrated that feeding varies across differing 
stages of the oestrous cycle in rodents, non-human primates, and humans (Buffenstein, 
Poppitt, McDevitt, & Prentice, 1995; Dye & Blundell, 1997; Reddy & Kulkarni, 1999). 
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The feeding response to hunger-related hormones (including ghrelin) and neurosteroids 
also varies throughout different stages of the oestrous cycle in female rats (Sakurazawa, 
Mano-Otagiri, Nemoto, & Shibasaki, 2013). It is recommended that future studies 
continue to investigate the extent to which estrous cycle phase and fluctuations in ovarian 
hormones may influence the satiety response to oxytocin in female animal models. 
 Pregnancy. Only one study (Douglas, Johnstone, & Leng, 2007) tested the effect 
of pregnancy as a moderator for oxytocin’s effect on feeding. This study identified that 
1µg intracerebroventricular injection decreased feeding in virgin female rats over one 
hour of measurement, while having no continued effect on feeding over 12 hours. 
However, a different pattern of effects was observed in pregnant rats, with the same dose 
of oxytocin exerting no effect on feeding over one hour, while increasing feeding over 12 
hours. The authors have proposed that this may be due to changes in the expression and 
binding affinity of central oxytocin receptors during pregnancy (Douglas et al., 2007).  
 Dose and method of administration. Most studies testing a dose-response effect 
of oxytocin found that greater doses of oxytocin were associated with correspondingly 
lower levels of subsequent feeding. The minimum effective dose required to observe 
anorexigenic effects of oxytocin depended on the method of administration, with central 
injections of oxytocin requiring much lower doses than peripheral injections.  
Findings of note include that of Ong, Alhadeff, and Grill (2015), who reported 
that a 1µg/1µL dose of oxytocin injected into the fourth ventricle reduces feeding over 30 
minutes only when a dietary preload had been provided, and did not continue to affect 
feeding over 1.5 hours. By contrast, a 0.3µg dose of oxytocin injected into the nucleus of 
the solitary tract (NTS) was found to significantly reduce feeding over 30 minutes 
regardless of whether a dietary preload had been provided. This inhibitory effect on 
feeding persisted over 1.5 hours in the dietary preload condition. These findings seem to 
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point to greater sensitivity to oxytocin’s effects on feeding within the NTS than within 
hindbrain receptors accessed via fourth cerebral ventricle, suggesting that the NTS may 
represent a more proximal site mediating oxytocin’s effects on feeding. However, these 
results contradict those found by J. M. Ho et al. (2014), who reported that oxytocin 
injection into the fourth ventricle was effective at reducing feeding in the absence of a 
preload at a dose of 1µg. The differential sensitivity of the NTS and fourth ventricle to 
oxytocin’s anorexigenic effects is therefore a question that would be interesting for future 
research to explore.    
 In another study examining the impact of injecting oxytocin into different regions 
of the central nervous system, Herisson et al. (2016) demonstrated that 1µg and 3µg doses 
of oxytocin injected directly into the nucleus accumbens core reduces both chow intake 
and the consumption of a 10% sucrose solution in male rats, while these inhibitory effects 
are not observed when the same dose is injected into the nucleus accumbens shell. The 
administration of oxytocin into the nucleus accumbens core was associated with increased 
Fos-immunoreactivity in both the nucleus accumbens core itself, as well as the 
paraventricular nucleus and supraoptic nucleus of the hypothalamus: two regions dense 
in oxytocin neurons and receptors which are involved in feeding regulation (Johnstone, 
Fong, & Leng, 2006). These findings therefore support a potential role of the nucleus 
accumbens core in mediating oxytocin’s anorexigenic effects, which does not extend to 
the nucleus accumbens shell. 
 One point to note, however, are that most studies administered high 
supraphysiologic doses of oxytocin. While these doses may be required in the case of 
peripheral administration to increase the chances that some oxytocin will cross the blood-
brain barrier, it ought to be noted that these findings may reflect partial oxytocin binding 
with vasopressin receptors at high doses that would not occur at physiological levels. 
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 Social setting. The social conditions in which animals were housed was also found 
to impact the effect of oxytocin on feeding. Grippo, Trahanas, Zimmerman, Porges, and 
Carter (2009) found that isolating female prairie voles from littermates resulted in a 
decrease in sucrose intake over a period of two weeks in a placebo condition, but that this 
effect was prevented by oxytocin. In the co-housed group of prairie voles, however, there 
were no changes in sucrose intake over time, or any differences between the oxytocin and 
placebo conditions. Additionally, Herisson et al. (2016) found that central oxytocin 
administration reduced food and sucrose intake in individually-housed male rats, while 
neither of these effects were observed in male rats allowed some social contact with a 
conspecific. Both of these studies point to the potential for social housing to prevent 
oxytocinergic reductions in feeding that would otherwise occur in isolated social settings.  
Dietary factors. Finally, diet-induced obesity was also identified as an important 
moderating factor for oxytocin’s effects on feeding in both animals and humans (Blevins 
et al., 2016; Deblon et al., 2011; Maejima et al., 2011; Morton et al., 2012; Roberts et al., 
2017; Thienel et al., 2016). On the whole, direct comparisons of lean animals consuming 
standard chow with diet-induced obese animals consuming high-fat diets found that 
oxytocin had more consistent inhibitory effects on feeding in the dietary-induced obese 
animals (Blevins et al., 2016; Roberts et al., 2017). Blevins and colleagues have shown 
that this moderating effect persists in high fat diet-fed rats, even when matched for body 
mass and adiposity with chow-fed controls (Blevins et al., 2016), thus indicating that this 
moderating effect may be more attributable to the fat-content of the animal’s diet than 
body composition. 
Discussion 
This review aimed to identify published and unpublished studies testing the 
effects of exogenous oxytocin on energy intake in wild-type animals and humans, where 
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oxytocin was administered in isolation from other active drugs and surgery. The 
systematic review and meta-analysis revealed a robust inhibitory effect of oxytocin on 
energy intake when administered as a single dose in animals, regardless of whether it was 
administered via a central or peripheral route. Additionally, while several individual 
experiments did show a continued inhibitory effect of oxytocin for periods of two or more 
weeks in rats and mice (Altirriba et al., 2014; Balazova et al., 2016; Beranger et al., 2014; 
Blevins et al., 2015; Blevins et al., 2016; Roberts et al., 2017; G. Zhang & Cai, 2011), 
when final-day energy intake was compared between placebo and oxytocin conditions in 
the quantitative meta-analysis this inhibitory effect did not hold, despite a trend towards 
inhibition in studies administering oxytocin systemically.  
The human studies did not find a main effect of oxytocin on energy intake; 
however, there was found to be a trend towards a decrease in the consumption of solid 
foods induced by oxytocin. Additionally, oxytocin had a stronger inhibitory effect on 
energy intake in male participants, in obese participants, and when participants completed 
the experiment in the full condition (rather than fasted condition). The specific finding 
that oxytocin reduced feeding to a greater degree in obese humans (Thienel et al., 2016) 
is consistent with findings from animal studies, which have also indicated a greater 
anorexigenic effect in diet-induced obese mice and rats (Roberts et al., 2017). 
The moderating effect of liquid versus solid foods was unexpected amongst 
human studies, particularly given previous animal research demonstrating the inhibitory 
effect of oxytocin on the consumption of palatable liquid solutions  (Herisson et al., 2016; 
Lokrantz, Uvnas-Moberg, & Kaplan, 1997; Mullis, Kay, & Williams, 2013). The 
mechanism driving the difference between oxytocin’s effect on liquid and solid foods is 
unclear. One hypothesis is that oxytocin may reduce gastric motility, thus contributing to 
the sensation of satiety as solid food remains in the gut for a longer period of time. This 
hypothesis is supported by research demonstrating that oxytocin can reduce gastric 
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motility in rats (Flanagan, Olson, Sved, Verbalis, & Stricker, 1992; R. C. Rogers & 
Hermann, 1987; C. L. Wu et al., 2002; C. L. Wu, Hung, Chang, Pau, & Wang, 2003) and 
mice (M. G. Welch, Margolis, Li, & Gershon, 2014). However, Borg and colleagues have 
found evidence to the contrary, indicating that oxytocin does not affect gastric emptying 
rate in humans following consumption of a liquid meal (Borg, Simren, & Ohlsson, 2011). 
Further research would be useful to test this hypothesis as it pertains to solid foods, and 
to further investigate the reasons for oxytocin’s greater inhibitory effect for solid, versus 
liquid, consumption in humans.  
The pattern for the inhibitory effect of oxytocin on feeding to decrease over time 
was reflected in a significant moderator analysis carried out for the meta-regression of 
studies that administered systemic oxytocin to animals chronically over time. This meta-
regression, as well as the meta-regression for human studies, were also significantly 
moderated by sex, such that the effects of oxytocin on reducing feeding were significantly 
greater for male animals. This overall moderating effect of sex across studies included in 
the meta-regression is interesting to observe given the highly mixed findings regarding 
sex differences reported in individual studies (Benelli et al., 1991; Bjorkstrand & Uvnas-
Moberg, 1996; L. Zhou et al., 2015). A greater density of oxytocin receptors has 
previously been reported within the spinal cord and ventromedial hypothalamus of male 
rats (Uhl-Bronner, Waltisperger, Martinez-Lorenzana, Lara, & Freund-Mercier, 2005), 
which may potentially explain the greater sensitivity to oxytocin’s anorexigenic effects 
in males. However, the activity of oxytocin and oxytocin receptors also varies across 
stages of the follicular cycle in female prairie voles (Witt, Carter, & Lnsel, 1991). 
Furthermore, it is known that levels of endogenous plasma oxytocin vary across stages of 
the menstrual cycle in humans (Salonia et al., 2005). One can hypothesize that this natural 
variation may moderate the effects of exogenously-administered oxytocin. Variation in 
the follicular stage at which oxytocin was administered to female animals may therefore 
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partially account for mixed findings reported for feeding effects in previous studies. It 
would therefore be useful to specifically investigate variation in oxytocin’s effect on 
feeding across different phases of the follicular cycle, and associated variation in plasma 
levels of other hormones (e.g., oestrogen).  
In terms of the mechanisms explaining oxytocin’s greater effect in obese animals 
and humans, it is known that oxytocin receptors exhibit a higher-affinity binding state in 
the presence of cholesterol (Gimpl, 2016). Therefore, it may be that a greater fat- and 
cholesterol-rich diet at least partially explains the greater anorexigenic effects of oxytocin 
observed in obese animals and humans. 
The mechanisms and neural circuits explaining the overall anorexigenic effects of 
oxytocin are still somewhat uncertain. Oxytocin is known to mediate the anorexigenic 
effects of cholecystokinin (CCK), which acts on oxytocin neurons via vagal afferents 
from the gut (Verbalis et al., 1986). This finding has received further support from 
research demonstrating that injections of oxytocin into the third cerebral ventricle 
enhance the anorexigenic effects of low doses of CCK-8 (Blevins et al., 2016) while, 
conversely, pre-treatment of an oxytocin receptor antagonist into the fourth ventricle 
suppresses the anorexigenic effects of CCK (Blevins, Eakin, Murphy, Schwartz, & 
Baskin, 2003; Olson, Drutarosky, Stricker, & Verbalis, 1991) . In addition to this role 
mediating the effects of CCK, oxytocin has also been implicated in mediating leptin’s 
(Blevins, Schwartz, & Baskin, 2004; Z. Wu et al., 2012) and nesfatin-1’s (Saito et al., 
2017) inhibitory effects on food intake. The downstream mechanisms by which oxytocin 
impacts on feeding; however, are less certain.  
It is likely that central and peripheral oxytocin exert effects of feeding via different 
mechanisms. Previous research has identified that only approximately 0.002% of 
peripheral oxytocin crosses the blood-brain barrier where it might access central receptors 
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(Mens, Witter, & Greidanus, 1983). However, the extent to which peripheral oxytocin 
exerts its effects via central versus peripheral receptors, such as those in the gut (Ohlsson, 
Truedsson, Djerf, & Sundler, 2006), may be species-dependent. In mice, the literature 
supports a role for vagal afferent nerves in mediating the anorexigenic effect of peripheral 
oxytocin (Iwasaki et al., 2015; M. G. Welch et al., 2009). This interpretation draws 
support from research finding that oxytocin receptors are expressed in the nodose 
ganglion of the vagus nerve (M. G. Welch et al., 2009), as well as further research that 
has gone on to demonstrate that vagotomy results in an attenuation of the anorexigenic 
effect of peripherally-administered oxytocin in mice (Iwasaki et al., 2015). In rats, 
however, Ho and colleagues (2014) have demonstrated that hindbrain receptors accessed 
via the fourth ventricle are predominantly responsible for mediating the inhibitory effects 
of peripheral oxytocin on feeding. Further research clarifying which pathway/s 
predominate this mediating effect in primates and humans has not yet been conducted and 
would be useful to investigate in future studies. 
Brain nuclei including the paraventricular nucleus, NTS, and arcuate nucleus have 
been implicated as potentially relevant in mediating oxytocin’s effects on feeding 
(Fenselau et al., 2016; Iwasaki et al., 2015; Maejima et al., 2014; Olszewski et al., 2010; 
Ong et al., 2015). This evidence comes from studies indicating that direct injections of 
oxytocin into these areas suppresses food intake (Maejima et al., 2014; Ong et al., 2015), 
as well as immunohistological studies demonstrating that the Fos activation of oxytocin 
neurons in these regions co-occurs with the termination of feeding (Fenselau et al., 2016; 
Iwasaki et al., 2015; Maejima et al., 2014; Olszewski et al., 2010). Furthermore, studies 
have demonstrated that injections of oxytocin directly into the ventral tegmental area, 
nucleus accumbens core, and ventromedial hypothalamus are effective in inhibiting 
feeding; thereby indicating that these regions may mediate the anorexigenic effects of 
oxytocin as well (Herisson et al., 2016; Mullis et al., 2013; Noble, Billington, Kotz, & 
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Wang, 2014). Given that oxytocin is effective in reducing energy intake when 
administered both centrally and peripherally, it may be the case that oxytocin acts as a 
central messenger integrating central and peripheral signals. This hypothesis, however, 
requires further evidence to corroborate. 
It has also been proposed that oxytocin may exert inhibitory effects on energy 
intake via a physiological pathway mediated by reward-based mechanisms (Klockars, 
Brunton, Li, Levine, & Olszewski, 2017). This hypothesis is lent support by the high 
density of oxytocin receptors along the pathways connecting the nucleus accumbens and 
ventral tegmental area (Mitre et al., 2016; Peris et al., 2017; Shahrokh, Zhang, Diorio, 
Gratton, & Meaney, 2010), two regions known to be highly involved with processing 
food reward (Berridge, 2009). Additionally, oxytocin injected directly into the nucleus 
accumbens has been found to reduce methamphetamine-induced place preference 
(Baracz et al., 2012) and prevent relapse to methamphetamine-seeking behavior after 
extinction (Baracz, Everett, McGregor, & Cornish, 2016). Together, these findings point 
to an ability for oxytocin to disrupt reward-related processing in these regions, which may 
additionally extend to suppressing reward-based feeding behaviour. This hypothesis, if 
true, may also explain the stronger effects of oxytocin in reducing hedonic, as opposed to 
hunger-driven, feeding in human studies (Burmester, 2017; Ott et al., 2013; Thienel et 
al., 2016). Further research in animals and humans would be useful to test this hypothesis 
further and elucidate the precise mechanisms of oxytocin’s acute action on energy intake. 
The confirmation of oxytocin’s anorexigenic effects when administered as a 
single dose echoes conventional understanding in the literature, while highlighting the 
limits of this effect: such as the reverse (orexigenic) effect observed in pregnancy 
(Douglas et al., 2007) and when socially-housed animals subsequently undergo separation 
from litter-mates (Grippo et al., 2009). The null findings revealed in the meta-analysis 
testing the chronic effects of oxytocin on feeding are disappointing in the context of 
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potential hopes for developing oxytocin supplementation as a new treatment for binge-
type eating disorders in humans, and conflict with individual studies which have reported 
the persistence of oxytocin’s anorexigenic effects over two to three weeks of 
measurement in rats and mice (Balazova et al., 2016; Beranger et al., 2014; Blevins & 
Baskin, 2015; Blevins et al., 2016; Roberts et al., 2017; Guo Zhang et al., 2011), and for 
two weeks post-treatment in rhesus monkeys (Blevins et al., 2015). It may be the case 
that a regime of intermittent oxytocin administration would result in the same 
anorexigenic effects observed within the course of a single experimental administration, 
without resulting in the same degree of receptor adaptations. Future research testing 
different temporal regimes of oxytocin administration is recommended to test this 
hypothesis.  
The diminishing effects of oxytocin are in keeping with the results arising from 
individual studies making use of the repeated administration of oxytocin (Altirriba et al., 
2014; Beranger et al., 2014; Blevins et al., 2016; Maejima et al., 2011; Roberts et al., 
2017) or an oxytocin agonist (Olson, Drutarosky, Chow, et al., 1991).  These findings 
also concord with social experiments which have found that the anxiolytic effects of 
oxytocin disappear or reverse over time (Peters, Slattery, Uschold-Schmidt, Reber, & 
Neumann, 2014). Peters et al. found that the reversal of acute anxiolytic effects over 
chronic dosing was associated with a concurrent reduction in oxytocin receptor binding. 
Indeed, previous work has shown that oxytocin receptor binding can reduce by as much 
as 50% over 10 days of chronic administration, driven largely by down-regulation of the 
oxytocin receptor (Insel, Winslow, & Witt, 1992). It is therefore likely that this reduced 
binding potential may explain the dampening of oxytocin’s effects on feeding.  
The null findings generated from the meta-regressions of chronically-
administered oxytocin studies should be interpreted with some degree of caution. 
Although the final-day analyses used for the meta-regressions maximized the number of 
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commensurable studies eligible for inclusion, it may be that noise in the data on the final 
day data masked smaller effects identified by studies that compared average consumption 
across several days. It should also be noted that the scope of the current review is limited 
to oxytocin’s effects on energy intake alone, and that oxytocin’s effects on other 
metabolic parameters deterring obesity (e.g., lipolysis, brown adipose tissue 
thermogenesis, and energy expenditure) may persist with chronic administration (Blevins 
& Baskin, 2015).  
Limitations of the current review include some inherent drawbacks of the 
methodology chosen for the meta-regressions. We aimed to reach a compromise between 
maximizing homogeneity of studies included in the meta-regression, while also including 
the maximum number of experiments. The choice to therefore include only single-dose 
studies that measured the effects of oxytocin over one hour of feeding therefore 
constrained these meta-regressions to a reasonable scope and similar effect size. 
Differences in the exact location of administration and animals included in each 
experiment, however, may have added to the heterogeneity of effect size observed across 
studies. Furthermore, the current systematic review did not include findings from non-
wild-type animals (e.g., Sim-haploinsufficient rats and mice) or animals whose nervous 
systems were altered by surgery or direct stimulation. Therefore, although the current 
findings reveal the effects of exogenous oxytocin in wild-type animals, it should be noted 
that there are further findings reflecting the implication of oxytocin on feeding that were 
not included within the scope of the present review. 
Regarding the clinical implications of these findings, it is particularly encouraging 
to have observed that the anorexigenic effects of oxytocin were stronger for populations 
that suffer from over-eating and binge-eating. These findings suggest that, in the short 
term, oxytocin may reduce the likelihood of binge-eating and overeating for populations 
with obesity, bulimia nervosa, and binge eating disorder. However, the null findings from 
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the meta-regressions of chronic animal studies cast doubt on the persistence of oxytocin’s 
acute effects. Testing different dosing schedules of oxytocin would be useful for 
identifying a potential frequency and dose of administration that maintains oxytocin’s 
beneficial effects over time, without resulting in the reduction of receptor binding. 
In conclusion, the current systematic review has confirmed the anorexigenic effect 
of a single dose of oxytocin in animals first documented by the Arletti lab (Arletti et al., 
1989), while demonstrating that this anorexigenic effect does not persist throughout 
chronic dosing. There was a trend for intranasal oxytocin to reduce feeding in humans, 
and this effect was stronger for individuals with obesity, bulimia nervosa, and binge 
eating disorder. Future research is needed to further elucidate the mechanisms of these 
effects, and whether differing dosing schedules might prevent their attenuation with 
chronic administration. 
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Table 12 
Results of Moderator Analyses for Chronic Central Studies 
 










Gender -0.16 0.580 .787 -1.293 0.980 42.80 < .001 
Dose -0.004 0.025 .881 -0.054 0.046 42.61 < .001 
Body Mass -0.001 0.001 .437 -0.002 0.001 40.52 .002 
Duration of 
Administration 
-0.01 0.022 .494 -0.057 0.028 41.56 .001 
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Table 13 
Results of Moderator Analyses for Chronic Systemic Studies 
 










Gender -0.71* 0.292 .015 -1.281 -0.136 200.99 < .001 
Socialization -0.28 0.275 .306 -0.821 0.258 205.83 < .001 
Body Mass 0.000 0.000 .456 -0.000 0.000 101.78 < .001 
Duration of 
Administration 
0.02* 0.009 .021 0.003 0.038 201.53 < .001 
* p < .05. 
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Table 14 
Results of Moderator Analyses for All Human Studies 
 












-0.30*** 0.077 < 
.001 
-0.456 -0.153 40.46 .003 
Gender -0.39** 0.134 .004 -0.650 -0.123 47.70 < .001 
Fasted or full 
condition 
-0.14** 0.047 .003 -0.230 -0.047 48.57 < .001 




0.0001 .002 -0.0003 -0.0001 50.62 < .001 
Diagnosis 
(Obesity vs AN) 
-0.570 0.316 .071 -1.189 0.048 49.08 < .001 
Dose 0.01 0.006 .141 -0.003 0.020 53.24 < .001 
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Table 15 
Results of Moderator Analyses for Human Studies in Solid Food Condition 
 










Gender -0.28 0.264 0.300 -0.791 0.241 19.36 .013 
Fasted or Full 
Condition 
-0.06 0.057 .266 -0.174 0.048 22.01 .005 
Duration of 
Administration 
0.0002 0.0002 .281 -0.0002 0.0006 19.32 .013 
Dose 0.02 0.017 .297 -0.015 0.050 19.36 .013 
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Figure 5. PRISMA flow diagram for the original systematic literature search 
 
Figure 6.  Forest plot of studies measuring the effect of a single-dose of central oxytocin on 
energy intake over a one-hour measurement duration in animals. RLCV = right lateral cerebral 
ventricle; 4V = fourth cerebral ventricle; VMH = ventromedial hypothalamus; ICV = 
intracerebroventricular.  
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Figure 7. Forest plot of studies measuring the effect of a single-dose of systemic oxytocin on 
energy intake over a one-hour measurement duration in animals. 
 
 
Figure 8. Forest plot of studies measuring the effect of chronic dosing of central oxytocin on 
energy intake in animals. ICV = intracerebroventricular; 3V = third cerebral ventricle; 4V = 
fourth cerebral ventricle. 
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Figure 9. Forest plot of studies measuring the effect of chronic dosing of systemic oxytocin on 
energy intake in animals. 
 
 
Figure 10. Forest plot of studies measuring the effect of a single dose of intranasal oxytocin on 
energy intake in humans. AN = anorexia nervosa; BN = bulimia nervosa. 
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Figure 11. Forest plot of studies measuring the effect of a single dose of intranasal oxytocin on 
solid food intake in humans. AN = anorexia nervosa; BN = bulimia nervosa.
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Arletti et al. 
(1989) 
Influence of oxytocin 
on feeding behavior in 
the rat; Experiment 1 
OT 1µg (n = 
27) 
OT 2µg (n = 
27) 
OT 10µg (n 
= 27) 









Rats Male Chow 
Doses of 1µg, 
2µg, and 10µg 
significantly 
reduced 













at hours 2 and 
3. 
Arletti et al. 
(1989) 
Influence of oxytocin 
on feeding behavior in 
the rat; Experiment 2 
OT 1µg (n = 
11) 
OT 10µg (n 
= 11) 




1µg; 10µg 1 hour 
Intracerebroventricul
ar injection 
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Arletti et al. 
(1989) 
Influence of oxytocin 
on feeding behavior in 
the rat; Experiment 3 
OT (n = 7) 




10µg 1 hour 
Intracerebroventricul
ar injection 






Arletti et al. 
(1989) 
Influence of oxytocin 
on feeding behavior in 
the rat; Experiment 4 
OT 375µg 
/kg (n = 6) 
OT 750 µg 
/kg (n = 8) 
OT 1500 µg 
/kg (n = 19) 
OT 3000 µg 
/kg (n = 12) 
OT 6000 µg 
/kg (n = 8) 




























Oxytocin inhibits food 
and fluid intake in rats; 
Experiment 1, fed 
condition 
OT 1µg (n = 
10) 
OT 10µg (n 
= 10) 




1µg; 10µg 1 hour 
Right lateral cerebral 
ventricle injection 





to vehicle at a 
dose of 1µg, 
and 
completely 
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inhibited food 
intake at a 
dose of 10µg. 
Arletti et al. 
(1990) 
Oxytocin inhibits food 
and fluid intake in rats; 
Experiment 2, fasted 
condition 
OT 375µg 
/kg (n = 6) 
OT 750µg 
/kg (n = 8) 
OT 1500µg 
/kg (n = 19) 























Arletti et al. 
(1993) 
The effect of oxytocin 
on feeding, drinking, 
and male copulatory 
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and male copulatory 
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both 1ng and 
10ng doses. 
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Benelli et al. 
(1991) 
Oxytocin-induced 
inhibition of feeding 
and drinking: no 
sexual dimorphism in 






1µg; 10µg 1 hour 
Intracerebroventricul
ar injection 










both 1µg and 
10µg doses. 
Benelli et al. 
(1991) 
Oxytocin-induced 
inhibition of feeding 
and drinking: no 








1µg; 10µg 1 hour 
Intracerebroventricul
ar injection 










both 1µg and 
10µg doses. 
Benelli et al. 
(1991) 
Oxytocin-induced 
inhibition of feeding 
and drinking: no 
sexual dimorphism in 
rats; Experiment 3 
OT 187µg 
/kg (n not 
reported) 
OT 375µg 
/kg (n = 12) 
OT 750µg 
/kg (n = 12) 
OT 1500µg 
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Benelli et al. 
(1991) 
Oxytocin-induced 
inhibition of feeding 
and drinking: no 
sexual dimorphism in 







(n = 12) 
OT 
750µg/kg 
(n = 12) 
OT 
1500µg/kg 





























1, freely-fed condition 
OT (n = 8) 




22µg 9 days 
Subcutaneously 
injected 




feeding at any 
day following 
a single dose 
of oxytocin. 
Bernal et al. 
(2013) 
Differential lasting 








OT (n = 8) 




22µg 9 days 
Subcutaneously 
injected 




feeding at any 
day following 
a single dose 
of oxytocin. 
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Bernal et al. 
(2013) 
Differential lasting 







OT (n = 7) 




44µg 6 hours 
Subcutaneously 
injected 




feeding at any 
day following 
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and daily weight gain 
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increases food intake 
and daily weight gain 
in rats; fasted 
condition 
OT (n = 5) 
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ar injection 
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in rats; effects of three 
doses 
OT 1µg (n = 
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OT 5µg (n = 
11) 
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increases food intake 
and daily weight gain 
in rats; Effects of IP 
injections of oxytocin 
OT (n = 6) 




5µg 24 hours 
Intraperitoneal 
injection 









increases food intake 
and daily weight gain 
in rats; Experiment 6, 
fed condition 
OT (n = 12) 


















Oxytocin prolongs the 
gastric emptying time 
in patients with 
diabetes mellitus and 
gastroparesis, but 
does not affect satiety 
or volume intake in 
patients with 
functional dyspepsia 
OT (n = 12) 




















Borg et al. 
(2011) 
Oxytocin reduces 
satiety scores without 
affecting the volume 
of nutrient intake or 
gastric emptying rate 
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(n = 10) 
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OT (n = 20) 


















eating in satiated 
males; snack 
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OT (n = 20) 





















and Fuxe (2000)  
Oxytocin/alpha(2)-
Adrenoceptor 
interactions in feeding 
responses 
OT (n = 8) 




1nmol 1320 minutes 
Right lateral cerebral 
ventricle injection 




feeding at 30, 
90, 240 or 
1320 minutes. 
Douglas et al. 
(2007) 
Neuroendocrine 
mechanisms of change 
in food intake during 
pregnancy: A potential 
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ar injection 
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Douglas et al. 
(2007) 
Neuroendocrine 
mechanisms of change 
in food intake during 
pregnancy: A potential 







1µg 12 hours 
Intracerebroventricul
ar injection 





one hour of 
measurement
. There was 
no effect of 
oxytocin on 
feeding over 
12 hours.  








food intake in rats; 
Table 1 
OT (n = 6) 












feeding at 0-6 
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hour time 
points. 








food intake in rats; 
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OT (n = 7) 




0.1µg 24 hours 
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injection 
Rats Male Chow 
No effect of 
oxytocin on 
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Ray, and Sharma 
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Effects of acute and 
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10µg /kg 24 hours 
Subcutaneous 
injection 




feeding at any 
time point. 
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K. Gulati, Ray, 
and Sharma 
(1992) 
Effects of acute and 
chronic 
ketocyclazocine and its 
modulation by 
oxytocin or 
vasopressin on food 






10µg /kg 18 hours 
Subcutaneous 
injection 




feeding at any 
time point. 
Herisson et al. 
(2016) 
Oxytocin acting in the 
nucleus accumbens 
core decreases food 
intake; Deprivation-
induced chow intake, 
AcbC injection 
OT 0.3µg 
(n = 8-9) 
OT 1µg (n = 
8-9) 
OT 3µg (n = 
8-9) 







Injected into nucleus 
accumbens core 
Rats Male Chow 
The 1µg and 









no effect on 
feeding at 2 
or 4 hours. 
Herisson et al. 
(2016) 
Oxytocin acting in the 
nucleus accumbens 




(n = 12) 
OT 1µg (n = 
12) 
OT 3µg (n = 
12) 












The 1µg and 






The 0.1µg and 
0.3µg doses 
of oxytocin 
had no effect 
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on sucrose 
consumption.  
Herisson et al. 
(2016) 
Oxytocin acting in the 
nucleus accumbens 
core decreases food 
intake; Deprivation-
induced chow intake, 
AcbSh injection 
OT .3µg (n 
= 8) 
OT 1µg (n = 
8) 
OT 3µg (n = 
8) 







Injected into nucleus 
accumbens shell 




feeding at any 
dose. 
Herisson et al. 
(2016) 
Oxytocin acting in the 
nucleus accumbens 
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OT 1µg (n = 
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AcbC injection (Figure 
2) 
OT (n = 7) 
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solution, AcbC 
injection (Figure 2) 
compared to 
vehicle. 
Herisson et al. 
(2016) 
Oxytocin acting in the 
nucleus accumbens 
core decreases food 
intake; incomplete 
socialising condition 
OT 1µg (n = 
8 or 9 or 
10) 
OT 3µg (n = 
8) 
PL (n = 8 or 
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rats; Figure 1 
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Intraperitoneal 
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OT (n = 7) 
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food intake in male 
rats; Figure 2A 
compared to 
vehicle. 




to the effects of 
circulating oxytocin on 
food intake in male 
rats; Figure 2B 
OT (n = 9) 




5mg/kg 30 minutes 
Intraperitoneal 
injection 











to the effects of 
circulating oxytocin on 
food intake in male 
rats; Figure 2C 
OT (n = 12) 




5mg/kg 30 minutes 
Intraperitoneal 
injection 











to the effects of 
circulating oxytocin on 
food intake in male 
rats; Figure 2D 
OT (n = 9) 




5mg/kg 30 minutes 
Intraperitoneal 
injection 
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hypophagia 
OT (n = 8) 
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rats; Figure 6B 
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food intake in male 
rats; Figure 7A 
OT (n = 6) 




0.5mg/kg 30 minutes 
Intraperitoneal 
injection 











to the effects of 
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food intake in male 
rats; Figure 7B 
OT (n = 8) 




0.5mg/kg 30 minutes 
Intraperitoneal 
injection 
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OT 
1200mU/k
g (n =10) 
PL (n = 10) 
 




afferent neurons to 
suppress feeding in 
normal and leptin-
resistant mice: a route 
for ameliorating 
hyperphagia and 
obesity; Figure 1A 
OT 
200µg/kg 
(n = 8) 
OT 
400µg/kg 
(n = 8) 













feeding at 30 
minutes, 1hr, 
3hr, and 6hr 
compared to 
vehicle. This 
was true for 
both doses. 




afferent neurons to 
suppress feeding in 
normal and leptin-
resistant mice: a route 
for ameliorating 
hyperphagia and 
obesity; Figure 1C 
OT (n = 6) 




200µg/kg 6 hours 
Intraperitoneal 
injection 




diet intake at 
30 minutes 
and 1hr, but 
not 3hr or 6hr 
time points. 




afferent neurons to 
suppress feeding in 
normal and leptin-
resistant mice: a route 
for ameliorating 
OT (n = 6) 





200µg/kg 6 hours 
Intraperitoneal 
injection 




feeding at 30 
minutes, 1hr, 
and 3hr, but 
not 6hr time 
points. 
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hyperphagia and 
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blind single dose 
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over design; Juice 
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OT (n = 33) 
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over design; Juice 
experiment 
Y.-R. Kim, J.-S. 
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OT (n = 34) 
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blind single dose 
within- subject cross-
over design; Food 
diary experiment 
caloric intake 
over 24 hours. 
Kim, Kim, Cardi, 
et al. (2014) 
Intranasal oxytocin 
attenuates attentional 
bias for eating and fat 
shape stimuli in 
patients with anorexia 
nervosa 
OT (n = 33) 
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oxytocin in rats 
acutely decreases 
deprivation-induced 
chow intake, but it 
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OT 0.1µg 
/kg (n = 8-
9) 
OT 0.3µg 
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1 and 2 hours 
of 
measurement
. There was 
no significant 
effect for the 
0.03µg /kg 
dose. or for 
any dose 
There was not 
a significant 
effect of 
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oxytocin at 
any dose after 
24 hours of 
measurement
. 
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Lokrantz et al. 
(1997) 
Effects of central 
oxytocin 
administration on 
intraoral intake of 
glucose in deprived 
and nondeprived rats; 
Experiment 2 
(deprived condition), 
first intake test 
OT 5nmol 
(n = 8) 
OT 10nmol 
(n = 8) 
OT 20nmol 
(n = 8) 




























Lokrantz et al. 
(1997) 
Effects of central 
oxytocin 
administration on 
intraoral intake of 
glucose in deprived 
and nondeprived rats; 
Experiment 3 
(deprived condition) 
OT (n = 8) 






















obesity by reducing 
food intake and 
visceral fat mass; 
Figure 1A 
OT 200µg 
/kg (n = 5) 
OT 400µg 
/kg (n = 5) 













feeding at 30 
minutes, 1hr, 
2hr, 3hr, and 
6hr at both 
doses. This 
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obesity by reducing 
food intake and 
visceral fat mass; 
Figure 2A 
OT (n = 5) 




1600µg/kg 24 hours 
Subcutaneous 
injection 




feeding at 30 
minutes, 1hr, 
2hr, 3hr, and 
6hr. This 
effect was no 
longer 
significant 
after 24 hours 




obesity by reducing 
food intake and 
visceral fat mass; 
Figure 2B 
OT (n = 5) 




1600µg/kg 24 hours 
Subcutaneous 
injection 




feeding at 30 
minutes, 1hr, 
2hr, 3hr, 6hr, 
and 24hr. 




reduces food intake 
without affecting 
locomotor activity and 
glycemia with c-Fos 
induction in limited 
brain areas; Figure 1a-
c 
OT 0.1µg 
(n = 8 or 9) 
OT 1µg (n = 
8-9) 
OT 10µg (n 
= 12-13) 














feeding at the 
6hr and 24hr 
time points at 
the 1µg dose, 
and at the 30 
minute, 1hr, 
2hr, 6hr, and 
24hr time 
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feeding at the 
0.1µg dose. 




reduces food intake 
without affecting 
locomotor activity and 
glycemia with c-Fos 
induction in limited 
brain areas; Figure 1d-
e 
OT 40µg 
/kg (n = 4) 
OT 400µg 
/kg (n = 4) 














1hr, 2hr, and 
6hr (but not 






feeding at the 
40µg /kg 
dose.  




and supraoptic nuclei 
to arcuate POMC 
neurons in 
hypothalamus 
OT (n = 10) 




4nmol 6 hours 
Lateral ventricle 
injection 





1hr, 3hr, and 
6hr. 




and supraoptic nuclei 
to arcuate POMC 
neurons in 
hypothalamus 
OT (n = 8) 




0.4nmol 24 hours 
Arcuate nucleus 
injection 




intake at 1hr 
and 12hr time 
points, but 
not 2hr, 3hr, 
and 24hr time 
points. 
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in the paraventricular 
nucleus causes 
anorexia through a 
leptin-independent 
melanocortin pathway 
OT (n = 7-
9) 








intake over 6 
hours. 




in the paraventricular 
nucleus causes 
anorexia through a 
leptin-independent 
melanocortin pathway 
OT (n = 9-
10) 









intake over 1 
hour. 
Morton et al. 
(2012) 
Peripheral oxytocin 
suppresses food intake 
and causes weight loss 
in diet-induced obese 
rats; Low-fat diet 
condition 
OT (n = 13) 









4hr and 18hr 
time points. 
Morton et al. 
(2012) 
Peripheral oxytocin 
suppresses food intake 
and causes weight loss 
in diet-induced obese 
rats 
OT (n = 5-
8) 









4hr and 18hr 
time points. 
Mullis et al. 
(2013) 
Oxytocin action in the 
ventral tegmental area 
affects sucrose intake; 
Figure 1A 
OT 0.3µg 
(n = 10) 
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OT 3µg (n = 
10) 








Mullis et al. 
(2013) 
Oxytocin action in the 
ventral tegmental area 
affects sucrose intake; 
Figure 3A 
OT (n = 7) 




1µg 30 minutes 










Noble et al. 
(2014) 
Oxytocin in the 
ventromedial 
hypothalamic nucleus 





(n = 11) 
OT 0.5nmol 
(n = 11) 
OT 1nmol 
(n = 11) 















feeding at all 
doses at the 












Noble et al. 
(2014) 
Oxytocin in the 
ventromedial 
hypothalamic nucleus 
reduces feeding and 
acutely increases 
OT 0.1nmol 
(n = 10) 
OT 1nmol 














both doses at 
the 1hr and 
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energy expenditure; 
Experiment 2 






Noble et al. 
(2014) 
Oxytocin in the 
ventromedial 
hypothalamic nucleus 




OT (n = 8) 















Chow, et al. 
(1991) 
Oxytocin and an 
oxytocin agonist 
administered centrally 
decrease food intake 
in rats 
OT 0.5nmol 
(n = 4-12) 
OT 1nmol 
(n = 4-12) 
OT 2nmol 
(n = 4-12) 
OT 4nmol 
(n = 4-12) 

























orexigenic effects of 
butorphanol tartrate; 
Experiment 2, lateral 
ventricle injection 
OT 0.1µg 
(n = 7-9) 
OT 0.3µg 









Rats Male Chow 





1hr, but not 2 
or 4hr of 
measurement
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OT 1µg (n = 
7-9) 
PL (n = 7-9) 
. The 0.1µg 
and 0.3µg 










orexigenic effects of 
butorphanol tartrate; 
Experiment 2, 4V 
injection 
OT 0.1µg 
(n = 7-9) 
OT 0.3µg 
(n = 7-9) 
OT 1µg (n = 
7-9) 






2 hours 4V injection Rats Male Chow 





1hr, but not 2 
or 4hr of 
measurement
. The 0.1µg 
and 0.3µg 
doses had no 
effect on 
feeding. 
Ong et al. (2015) 
Medial nucleus tractus 
solitarius oxytocin 
receptor signaling and 
food intake control: 





OT 1µg (n = 
12) 
OT 3µg (n = 
12) 
OT 6µg (n = 
12) 
OT 12µg (n 
= 12) 











30 minutes at 
the 1µg, 3µg, 






1hr. The 1µg 
dose of 
oxytocin had 
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no effect on 
feeding. 
Ong et al. (2015) 
Medial nucleus tractus 
solitarius oxytocin 
receptor signaling and 
food intake control: 






(n = 12) 
OT 1µg (n = 
12) 




0.3µg; 1µg 24 hours Injected into NTS Rats Male Chow 





This effect did 
not continue 
to 1hr or 2hr 
of 
measurement
. The 0.3µg 
dose of 
oxytocin had 
no effect on 
feeding. 
Ong et al. (2015) 
Medial nucleus tractus 
solitarius oxytocin 
receptor signaling and 
food intake control: 





OT (n = 13) 










and 1hr, but 
not 2hr. 
Ong et al. (2015) 
Medial nucleus tractus 
solitarius oxytocin 
receptor signaling and 
food intake control: 
the role of 
gastrointestinal 
satiation signal 
OT (n = 14) 
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processing; 
Experiment 4 
effect did not 
continue to 
1hr or 1.5hr 
time points. 
Ong et al. (2015) 
Medial nucleus tractus 
solitarius oxytocin 
receptor signaling and 
food intake control: 





OT (n = 14) 




















Ott et al. (2013) 
Oxytocin reduces 
reward-driven food 
intake in humans; 
Fasted condition 
OT (n = 20) 











Ott et al. (2013) 
Oxytocin reduces 
reward-driven food 
intake in humans; Fed 
condition 
OT (n = 20) 



















OT (n = 7-
8) 




10µg 4 hours 
Intracerebroventricul
ar injection 




intake for 1hr, 
but not at the 
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factor but not for 
oxytocin 
2 and 4hr 
time points. 
Saito et al. 
(2017) 
Involvement of central 
nesfatin-1 neurons on 
oxytocin-induced 
feeding suppression in 
rats 
OT (n = 6) 




500µg /kg 24 hours 
Intraperitoneal 
injection 






Thienel et al. 
(2016) 
Oxytocin's inhibitory 
effect on food intake is 
stronger in obese than 
normal-weight men; 
Fasted condition 
OT (n = 18) 













Thienel et al. 
(2016) 
Oxytocin's inhibitory 
effect on food intake is 
stronger in obese than 
normal-weight men; 
Fed condition 
OT (n = 18) 













van Miert and 
van Duin (1991) 
Feed intake and 
rumen motility in 







OT (n = 8) 

























Evidence for an 
interaction between 
CB1 cannabinoid and 
oxytocin receptors in 
food and water intake 










Rats Male Chow 
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 OT 1IU (n = 
8) 
OT 10IU (n 
= 8) 
PL (n = 8) 
60 minutes 
and 2 hours. 
The 0.1IU 




Warren et al. 
(2015) 
Effects on intranasal 
oxytocin on satiety 
signaling in people 
with schizophrenia 
 
OT (n = 16) 










no effect on 
consumption 
of the test 
meal. 
Yayou, Kitagawa, 
Ito, Kasuya, and 
Sutoh (2011) 




hormone on feeding 
behavior in steers 
OT 5µg (n = 
6) 
OT 50µg (n 
= 6) 




5µg; 50µg 1 hour 
Intracerebroventricul
ar injection 












programming of body 
weight and energy 
balance 
 
OT (n = 11) 














L. Zhou et al. 
(2015) 
Oxytocin differentially 
affects sucrose taking 
and seeking in male 
and female rats 
OT 
0.3mg/kg 
(n = 9-10) 
OT 1mg/kg 
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OT 3mg/kg 
(n = 9-10) 
 
PL (n = 9-
10) 
in females, 





in males.  
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Summary of Findings 
Altirriba et 
al., 2014  
Divergent effects of 
oxytocin treatment of 
obese diabetic mice on 
adiposity; Figure 1 
OT (n = 14) 




50nmol/day Subcutaneous injection Mice Male 14 days Chow 
Oxytocin significantly 
reduced food 
consumption each day 
during Week 1; and 
3/7 days during Week 
2. 
Altirriba et 
al., 2014  
Divergent effects of 
oxytocin treatment of 
obese diabetic mice on 
adiposity; Figure 1 
OT (n = 12) 




50nmol/day Subcutaneous injection Mice Male 14 days Chow 
Oxytocin decreased 
food intake only 
during the first day. 
Altirriba et 
al., 2014  
Divergent effects of 
oxytocin treatment of 
obese diabetic mice on 
adiposity; Figure 2E 
OT (n= 5) 




50nmol/day Subcutaneous injection Mice Male 14 days Chow 
No significant effect of 
oxytocin on feeding. 
Balazova et 
al., 2016   
Metabolic effects of 
subchronic peripheral 
oxytocin 
administration in lean 
and obese Zucker rats 
OT (n= 7) 







Subcutaneous injection Rats Male 14 days Chow 
Oxytocin significantly 
reduced cumulative 2-
week food intake and 
daily food intake. 
Balazova et 
al., 2016  
Metabolic effects of 
subchronic peripheral 
oxytocin 
administration in lean 
and obese Zucker rats 
OT (n= 7) 







Subcutaneous injection Rats Male 14 days Chow 
Oxytocin significantly 
reduced cumulative 2-
week food intake and 
daily food intake. 
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Beranger et 
al., 2014   
Oxytocin reverses 
ovariectomy-induced 
osteopenia and body 
fat gain 
OT (n = 12) 







Mice Female 10 weeks Chow 
Oxytocin significantly 
reduced food intake 
by the 3rd week of 
measurement. There 
were no significant 
differences at the end 





Experiment 2  
Central oxytocin 
increases food intake 
and daily weight gain in 
rats 
OT (n = 8) 







Rats Female 3 days Chow 
Oxytocin significantly 
increased cumulative 
3-day food intake. 




food intake, increases 
energy expenditure, 
and produces weight 
loss in fructose-fed 
obese rhesus monkeys; 
Low-dose chow 
experiment 
OT (n = 5) 




0.2mg/kg/day Subcutaneous injection 
Rhesus 
Monkey 
Male 1 week Chow 
Oxytocin significantly 
reduced 12-hour food 
intake after 1 week 
chronic 
administration. 




food intake, increases 
energy expenditure, 
and produces weight 
loss in fructose-fed 
obese rhesus monkeys; 
Low-dose Kool-Aid 
experiment 
OT (n = 5) 




0.2mg/kg/day Subcutaneous injection 
Rhesus 
Monkey 
Male 2 weeks Kool-Aid® 
No significant effect of 
oxytocin on Kool-Aid® 
intake. 




food intake, increases 
energy expenditure, 
OT (n = 5) 




0.4mg/kg/day Subcutaneous injection 
Rhesus 
Monkey 
Male 1 week Chow 
Oxytocin significantly 
reduced 8-hour and 
12-hour food intake 
Monica Leslie   220 
and produces weight 
loss in fructose-fed 
obese rhesus monkeys; 
High-dose chow 
experiment 
after 1 week chronic 
administration. 




food intake, increases 
energy expenditure, 
and produces weight 
loss in fructose-fed 
obese rhesus monkeys; 
High-dose Kool-Aid® 
experiment 
OT (n = 5) 




0.4mg/kg/day Subcutaneous injection 
Rhesus 
Monkey 
Male 2 weeks Kool-Aid® 
Oxytocin reduced 8-
hour and 12-hour 
Kool-Aid® intake after 
2 weeks of chronic 
administration. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-




utilization; Study 1 
OT (n = 9) 




16nmol/day 3V injection Rats Male 26 days Chow 
No significant effect of 
oxytocin on feeding. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-




utilization; Study 1 
OT (n = 5) 








daily food intake on 
10/26 days. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-
fat diet-fed rats by 
OT (n = 8) 









intake over 26-day 
period; and was 




utilization; Study 3 
maintained during last 
week of study. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-




utilization; Study 3 
OT (n = 9) 




16nmol/day 3V injection Rats Male 26 days Chow 
No significant effect of 
oxytocin on feeding. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-




utilization; Study 4 
OT (n = 7) 




16nmol/day 3V injection Rats Male 21 days 
High-Fat 
Chow 
Oxytocin reduced food 
intake on days 1-5, 
and again on days 9-
12. These effects were 
no longer significant 
by the end of the 21-
day administration 
period. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-




utilization; Study 4 
OT (n = 7) 




16nmol/day 3V injection Rats Male 21 days Chow 
No significant effect of 
oxytocin on feeding. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-
fat diet-fed rats by 
enhancing satiety 
responses and 
OT (n = 10) 











food intake. This 
effect was maintained 
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increasing lipid 
utilization; Study 7 
until the third week of 
administration. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-




utilization; Study 9, 
1µg 
OT (n = 6) 




1µg /day Subcutaneous injection Rats Male 3 days Chow 
 
No significant effect of 
oxytocin on feeding. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-




utilization; Study 9, 
5µg 
OT (n = 6) 




5µg/day Subcutaneous injection Rats Male 3 days Chow 
No significant effect of 
oxytocin on feeding. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-




utilization; Study 9, 
20µg 
OT (n = 6) 




20µg/day Subcutaneous injection Rats Male 3 days Chow 
No significant effect of 
oxytocin on feeding. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-
fat diet-fed rats by 
OT (n = 8) 




50µg/day Subcutaneous injection Rats Male 3 days Chow 
No significant effect of 
oxytocin on feeding. 




utilization; Study 9, 
50µg 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-




utilization; Study 9, 
100µg 
OT (n = 9) 




100µg/day Subcutaneous injection Rats Male 3 days Chow 
No significant effect of 
oxytocin on feeding. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-




utilization; Study 9, 
200µg 
OT (n = 7) 




200µg/day Subcutaneous injection Rats Male 3 days Chow 
No significant effect of 
oxytocin on feeding. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-




utilization; Study 10, 
HFD Sep2013 
OT (n = 3) 








for oxytocin group to 
consume less high-fat 
chow. 
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Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-




utilization; Study 10, 
HFD Oct2013 
OT (n = 3) 




50µg/day Subcutaneous injection Rats Male 13 days 
High-Fat 
Chow 
No significant effect of 
oxytocin on feeding. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-




utilization; Study 10, 
Chow Dec2013 
OT (n = 3) 




50µg/day Subcutaneous injection Rats Male 13 days Chow 
No significant effect of 
oxytocin on feeding. 
Blevins et al., 
2016  
Chronic CNS oxytocin 
signaling preferentially 
induces fat loss in high-




utilization; Study 10, 
Chow Jan2014 
OT (n = 3) 




50µg/day Subcutaneous injection Rats Male 13 days Chow 
No significant effect of 
oxytocin on feeding. 










OT (n = 6-7) 







Rats Male 14 days 
High-Fat 
Chow 
No significant effect of 
oxytocin on feeding. 
Monica Leslie   225 
 











OT (n = 6-7) 












intake over the two-
week measurement 
period. 












OT (n = 6-7) 









intake over the two-
week measurement 
period. 
Deblon et al., 
2011 
Mechanisms of the 
anti-obesity effects of 
oxytocin in diet-




OT (n = 7-8) 









intake over the two-
week measurement 
period. 







term social isolation; 
Pair-fed experiment 
OT (n = 8) 




20µg/day Subcutaneous injection 
Prairie 
Voles 
Female 14 days 
Sucrose 
Solution 
No significant effect of 
oxytocin on sucrose 
consumption. 
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term social isolation; 
Individually-housed 
experiment 
OT (n = 8) 




20µg/day Subcutaneous injection 
Prairie 
Voles 
Female 14 days 
Sucrose 
Solution 
The vehicle group 
decreased food intake 
over time in 
comparison to 
baseline levels. This 
reduction was not 
observed in the 
oxytocin treatment 
group. 








food intake in rats 
OT (n = 7) 







Rats Male 7 days Chow 
No significant effect of 
oxytocin on feeding. 








food intake in rats 
OT (n = 6) 







Rats Male 7 days Chow 
No significant effect of 
oxytocin on feeding. 
Gulati et al., 
1991  
Effects of acute and 
chronic morphine on 




OT (n = 7) 




10µg/kg/day Subcutaneous injection Rats Male 7 days Chow 
Chronic oxytocin 
treatment associated 
with greater food 






during dark phase. 
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Iwasaki et 
al., 2015  
Peripheral oxytocin 
activates vagal afferent 
neurons to suppress 
feeding in normal and 
leptin-resistant mice: a 
route for ameliorating 
hyperphagia and 
obesity 
OT (n = 10) 








Mice Male 12 days Chow 
Oxytocin significantly 
reduced food intake 
between days 2 and 
12, compared to 
vehicle treatment. 
Kublaoui et 
al., 2008  
Oxytocin deficiency 
mediates hyperphagic 
obesity of Sim1 
haploinsufficient mice 
OT (n = 7) 







Mice Female 12 days Chow 
No significant effect of 
oxytocin on food 
intake in wild-type 
mice. 
Ludri & 




crossbred cows milked 
with and without 
oxytocin 
OT (n = 6) 




30 IU/day Intramuscular injection Cows Female 10 days Lean feed 
No significant effect of 
oxytocin on feeding. 
Maejima et 
al., 2011  
Peripheral oxytocin 
treatment ameliorates 
obesity by reducing 
food intake and 
visceral fat mass 
OT (n = 5) 




1600µg/kg/day Subcutaneous injection Mice Male 17 days 
High-Fat 
Chow 
Oxytocin reduced food 
intake up to day 6, but 
not beyond. 
Maejima et 
al., 2011  
Peripheral oxytocin 
treatment ameliorates 
obesity by reducing 
food intake and 
visceral fat mass 
OT (n = 14) 








reduced food intake 
on days 3 and 4 of 
administration, but 
not before or after. 
Morton et 
al., 2012  
Peripheral oxytocin 
suppresses food intake 
and causes weight loss 
OT (n = 8) 








reduced food intake 
on days 2, 3, 4, 6, and 
7 of treatment, 
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in diet-induced obese 
rats 
compare to vehicle 
treatment. 
Roberts et 
al., 2017  
Chronic hindbrain 
administration of 
oxytocin is sufficient to 
elicit weight loss in 
diet-induced obese 
rats; Study 1A, obese 
OT (n = 18) 











al., 2017  
Chronic hindbrain 
administration of 
oxytocin is sufficient to 
elicit weight loss in 
diet-induced obese 
rats; Study 1A, lean 
OT (n = 6) 




16nmol/day 3V injection Rats Male 28 days Chow 
No significant effect of 
oxytocin on feeding. 
Roberts et 
al., 2017  
Chronic hindbrain 
administration of 
oxytocin is sufficient to 
elicit weight loss in 
diet-induced obese 
rats; Study 2A, obese 
OT (n = 12) 










over the first two 
weeks, but not 
beyond. 
Roberts et 
al., 2017  
Chronic hindbrain 
administration of 
oxytocin is sufficient to 
elicit weight loss in 
diet-induced obese 
rats; Study 2A, lean 
OT (n = 9) 




16nmol/day 3V injection Mice Male 28 days Chow 
No significant effect of 
oxytocin on feeding. 
Roberts et 
al., 2017  
Chronic hindbrain 
administration of 
oxytocin is sufficient to 
elicit weight loss in 
diet-induced obese 
rats; Study 3A, obese 
OT (n= 12) 
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Roberts et 
al., 2017  
Chronic hindbrain 
administration of 
oxytocin is sufficient to 
elicit weight loss in 
diet-induced obese 
rats; Study 3A, lean 
OT (n = 7) 




16nmol/day 4V injection Rats Male 28 days Chow 
No significant effect of 
oxytocin on feeding. 
Roberts et 
al., 2017  
Chronic hindbrain 
administration of 
oxytocin is sufficient to 
elicit weight loss in 
diet-induced obese 
rats; Study 4A 
PL (n = 11) 











al., 2017  
Chronic hindbrain 
administration of 
oxytocin is sufficient to 







(n = 5) 
OT 
16nmol/day 
n = 9) 






3V injection Rats Male 26 days 
High-fat 
chow 
No significant effect of 
oxytocin on feeding. 
Uvnas-
Moberg et 
al., 1996  
Dissociation of 
Oxytocin Effects on 
Body Weight in Two 
Variants of Female 
Sprague-Dawley Rats 
OT (n = 5) 




1.5mg/kg/day Subcutaneous injection Rats Female 5 days Chow 
No significant effect of 
oxytocin on feeding. 
Uvnas-
Moberg et 
al., 1996  
Dissociation of 
Oxytocin Effects on 
Body Weight in Two 
Variants of Female 
Sprague-Dawley Rats 
OT (n = 18) 





1.0mg/kg/day Subcutaneous injection Rats Female 4 days Chow 
Oxytocin significantly 
reduced food intake 
over four days, 
compared to vehicle 
treatment. 
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OT (n = 5 or 
6) 









reduced food intake 
over 7 days compared 
to vehicle treatment. 









OT (n = 5 or 
6) 









reduced food intake 
over 7 days compared 
to vehicle treatment. 








OT (n = 5 or 
6 or7) 
PL (n = 5 or 











reduced food intake in 
weeks 4, 5, and 6. 
There were no 
significant differences 
in earlier weeks. 
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Supplementary Figure 1. Funnel bias plot for animal studies administering a single dose of 
central oxytocin. 
 
Supplementary Figure 2. Funnel bias plot for animal studies administering a single dose of 
systemic oxytocin. 
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Supplementary Figure 3. Funnel bias plot for animal studies administering chronic central 
oxytocin. 
 
Supplementary Figure 4. Funnel bias plot for animal studies administering chronic systemic 
oxytocin. 
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Supplementary Figure 5. Funnel bias plot for human studies measuring the effect of intranasal 




4 The Functional Significance of Oxytocin Supplementation in Women with 
Bulimia Nervosa, Binge Eating Disorder, and Healthy Comparison Women 
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4.1 Rationale for investigating the effect of oxytocin on eating behaviours and stress in 
bulimia nervosa and binge eating disorder 
The systematic review presented in Section 3.7 has synthesised evidence demonstrating 
an overall inhibitory effect of a single dose of oxytocin on feeding in animals. While the 
effects of oxytocin on feeding in humans are highly mixed, there is preliminary evidence 
to suggest that oxytocin may specifically reduce hedonic eating in healthy men and 
overall caloric intake in women with BN. However, the inhibitory effect of oxytocin on 
feeding in women with BN has not yet been replicated, nor is the mechanism mediating 
such an effect clear.  
Given the well-established role of oxytocin in supporting abstinence from substance 
addictions (Zanos et al., 2018), there is reason to believe that oxytocin administration may 
modulate the very hedonic systems proposed to underpin recurrent binge eating behaviour 
in BN and BED. Therefore, one hypothesis stemming from the addictive appetite model 
is that treatments targeting addiction-related neural circuits, potentially including 
oxytocin administration, should be efficacious in reducing binge eating tendencies in BN. 
Furthermore, while initial evidence has found that oxytocin reduces eating-related stress 
responses in women with anorexia nervosa (Leppanen, Cardi, et al., 2017a; Russell et al., 
2018), the effect of oxytocin on stress in women with BN and BED has not yet been 
investigated. The following study therefore aimed to fill this gap in the literature. Further 
details regarding the study’s rationale and methods are included within the following 
paper.  
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4.2 Paper 5: The influence of oxytocin on eating behaviours and stress in women 
with bulimia nervosa and binge eating disorder 
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Abstract 
 The current study aimed to test the influence of oxytocin on palatable food intake, 
24-hour caloric consumption, and stress in women with bulimia nervosa and binge eating 
disorder. We recruited 25 women with DSM-5 bulimia nervosa or binge eating disorder, 
and 27 weight-matched comparison women without history of an eating disorder. We 
employed a double-blind, placebo-controlled crossover design in which each participant 
attended the lab for two experimental sessions, receiving a divided dose of 64IU 
intranasal oxytocin in one session and equivalent volume of placebo nasal spray in the 
opposite session. The order of administration was pseudo-randomised across participants. 
We hypothesised that a divided dose of 64IU intranasal oxytocin administration would 
reduce subjective hunger, the immediate consumption of palatable food, 24-hour calorie 
consumption, and the incidence of binge eating when compared to placebo. We also 
hypothesised that oxytocin administration would be associated with lower levels of stress 
and salivary cortisol, and that there would be an interaction with participant group such 
that oxytocin would reduce eating behaviour and stress to a greater degree in women with 
bulimia nervosa or binge eating disorder, compared to women without history of an eating 
disorder. We did not find a significant effect of oxytocin on any of the measurements of 
eating behaviour, subjective stress, or salivary cortisol. We recommend that future studies 
test the dose-response effect of oxytocin on eating behaviours and stress in human 
populations with eating disorders to further clarify the moderating factors for oxytocin’s 
effect on eating. 
KEYWORDS: OXYTOCIN; BULIMIA NERVOSA; BINGE EATING DISORDER; 
EATING; STRESS  
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Bulimia nervosa and binge eating disorder are DSM-5 eating disorders 
characterised by recurrent loss-of-control binge eating episodes 
(American Psychiatric Association, 2013). This recurrent binge eating is a source of 
significant distress for individuals with bulimia nervosa and binge eating disorder 
(American Psychiatric Association, 2013; Mitchison et al., 2018), and the disorders are 
associated with functional impairment and lower health-related quality of life (Ágh, 
Kovács, et al., 2016; Pawaskar et al., 2017). 
 Currently, cognitive behavioural therapy (CBT) and enhanced CBT (CBT-E) are 
the recommended gold-standard treatments for binge eating disorder and bulimia nervosa, 
respectively (National Institute for Health and Clinical Excellence, 2017; Peat et al., 
2017). However, only 30-50% of people with bulimia nervosa experience full remission 
from symptoms at the end of treatment with therapist-led CBT-E (Hay, 2013), with a 68% 
recovery rate at 9-year follow-up (Eddy et al., 2017). The remission rates for binge eating 
disorder are somewhat better following therapist-led CBT, with a recent meta-analysis 
finding that 58.8% of people with binge eating disorder achieve remission by the end of 
treatment (Brownley et al., 2016). Nevertheless, there is additional scope to explore new 
treatment methods and supplementation in order to better support the significant portion 
of people who do not respond to treatment. 
 One promising new avenue of research is the possibility for oxytocin 
supplementation in binge-type eating disorders (Y.-R. Kim, J.-S. Eom, et al., 2015). 
Anomalies in oxytocin function have been implicated as risk factors for the development 
of bulimia nervosa and binge eating. For example, the GG variant of the rs53576 oxytocin 
receptor gene polymorphism is associated with greater binging and purging behaviour in 
women (Micali, Crous-Bou, et al., 2017). Additionally, the AG/GA variant of the 
rs2254298 oxytocin receptor gene polymorphism is also associated with greater binging 
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and purging behaviour in the context of poor maternal care (Micali, Crous-Bou, et al., 
2017). 
Oxytocin is a neuropeptide and hormone, commonly associated with its role in 
social functioning (Meyer-Lindenberg, Domes, Kirsch, & Heinrichs, 2011). However, 
oxytocin has recently received further attention for its roles in down-regulating anxiety 
and palatable food intake (Neumann & Slattery, 2016; Ott et al., 2013), both of which are 
strongly implicated in the pathology of bulimia nervosa and binge eating disorder 
(Treasure et al., 2018). 
 A recent systematic review and meta-analysis has shown that acute 
administration of oxytocin in animals has a strong, inhibitory effect on subsequent food 
consumption (Leslie, Silva, Paloyelis, Blevins, & Treasure, 2018). In humans, the 
evidence suggests that the inhibitory effect of oxytocin on feeding may be specific to 
reward-driven eating, as opposed to hunger-driven eating (Ott et al., 2013), and that this 
inhibitory effect is stronger in overweight and obese populations (Leslie, Silva, et al., 
2018; Thienel et al., 2016). In a sample of South Korean women with bulimia nervosa, a 
single dose of 40IU intranasal oxytocin reduced caloric intake over the following 24 hours 
in a sample of South Korean women with bulimia nervosa (Y.-R. Kim, J.-S. Eom, et al., 
2015). However, this study did not measure the immediate impact of oxytocin on binge-
type foods. 
The mechanism for the effect of oxytocin on eating may be explained by the 
down-regulation of neural circuits related to the processing of hedonic food motivation, 
including circuits involving the caudate nucleus (Spetter & Hallschmid, 2017). It has 
recently been proposed that the cycle of binge eating behaviour in bulimia nervosa and 
binge eating disorder may be primarily maintained by addictive processes, underpinned 
by reward-related neural circuits (Treasure et al., 2018). Given the implication of oxytocin 
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in regulating reward-driven eating, it may therefore be the case that oxytocin 
supplementation directly modulates the eating processes most relevant to binge eating 
behaviour.  
 An alternative explanation for the effect of oxytocin on feeding posits that this 
effect may be mediated by the anxiolytic properties of oxytocin (Anestis et al., 2009; 
Culbert, Racine, & Klump, 2016). In anorexia nervosa, oxytocin has been found to reduce 
eating concern (Russell et al., 2018) and cortisol reactivity in response to viewing or 
consuming food (Leppanen, Cardi, et al., 2017a). Previous research has also found that 
intranasal oxytocin administration reduces salivary cortisol in response to interpersonal 
rejection and conflict with an intimate partner in healthy men and women (Ditzen et al., 
2009; Linnen, Ellenbogen, Cardoso, & Joober, 2012). In terms of a physiological 
mechanism, there is evidence to suggest that oxytocin may affect stress reactivity by 
modulating the hypothalamic-pituitary-adrenal axis via modulation of neural activity 
within the amygdala (Viviani et al., 2011).  
Subjective stress and cortisol levels are known to be highly related to eating 
behaviour in healthy women (Epel, Lapidus, McEwen, & Brownell, 2001), and play an 
even more dominant role in the motivation of eating behaviour in women with bulimia 
nervosa and binge eating disorder (Leslie, Turton, et al., 2018). The implication of 
oxytocin in both reward and anxiety-related processes may therefore explain previous 
findings implicating abnormal oxytocin functioning in bulimia nervosa. 
The aim of the current study was to explore the impact of the administration of 
oxytocin on both reward and anxiety-related processes. Therefore, we tested the impact 
of intranasal oxytocin supplementation on subjective hunger, immediate consumption of 
palatable food, and the 24-hour pattern of eating in women with  binge eating disorder 
and bulimia nervosa and healthy controls. In order to assess the implication of anxiety in 
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this effect, we also measured the effect of oxytocin on subjective stress, the extent to 
which participants reported “feeling fat” (as a disorder-specific indication of anxiety), 
and on salivary cortisol levels. 
 We hypothesised that a divided dose of 64IU intranasal oxytocin administration 
would reduce subjective hunger, the immediate consumption of palatable food, 24-hour 
calorie consumption, and the incidence of binge eating when compared to placebo. We 
also hypothesised that oxytocin administration would be associated with lower levels of 
stress, and that participants would report lower levels of “feeling fat”. Finally, we 
predicted that participants would have lower salivary cortisol concentrations in the 
oxytocin, versus placebo, condition. We hypothesised that each of these effects would be 
moderated by eating disorder status, such that participants with BN or BED would 
experience greater reductions in food consumption and stress-related variables than 
participants with no history of an eating disorder. 
Methods 
 Participants 
 We recruited a total of 52 women for the current study: 25 women met DSM-5 
criteria for either bulimia nervosa or binge eating disorder and 27 women had no current 
or prior history of an eating disorder. Participants were identified via an e-mail circular 
at King’s College London and through posters placed throughout King’s College London 
and local community noticeboards. Participants were required to be female, between 18 
and 40 years old, proficient in English, and righthanded (due to an MRI scan conducted 
within the current battery of tasks). Exclusion criteria included pregnancy, severe 
comorbidity (e.g., substance abuse, drug addiction, psychosis, diabetes), history of drug 
dependence, history of a neurological condition (e.g., epilepsy), a significant visual 
impairment, which is not corrected by eyewear, currently suffering from a cold or flu, 
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currently smoking > 5 cigarettes per day (past 6 months), consuming > 21 units of alcohol 
per week, contraindication to MRI scans (due to an MRI conducted as part of the current 
battery of tasks), and current intake of medication that might potentially interact with 
oxytocin (e.g., Prostaglandins).  
Participants with bulimia nervosa and binge eating disorder reported an average 
binge eating frequency of 14.14 episodes over the past 28 days (SD = 9.88).  The women 
with bulimia nervosa endorsed an average frequency of self-induced vomiting equal to 
10.40 occasions over the past 28 days (SD = 13.61), an average laxative abuse frequency 
of 5.13 occasions over the past 28 days (SD =  8.35), an average frequency of “hard 
exercise intended to control weight or shape” equal to 7.31 occasions over the past 28 
days (SD = 8.57), and one participant reported using diuretic pills on 4 occasions over the 
past 28 days.  
Of the 25 women with bulimia nervosa and binge eating disorder, 7 women had a 
comorbid psychiatric disorder. Specifically, 5 women had comorbid depression, 4 women 
had comorbid generalised anxiety disorder, 4 women had borderline personality disorder, 
1 woman had social anxiety, 1 woman had obsessive-compulsive disorder, and 1 woman 
had an autism spectrum disorder. At the time of the study, 7 women were taking an 
antidepressant, 1 woman was taking a mood stabiliser, and one woman was taking an 
antipsychotic drug.  
 Ethical approval for the study was granted by the London – Camberwell St Giles 
Research Ethics Committee (Reference: 14/LO/2115). 
 Study Design 
 This proof-of-concept study was double-blind and placebo-controlled with a 
crossover design. Each participant was invited to come to the laboratory on three 
occasions. The first occasion was a preliminary screening visit in which each participant 
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signed informed consent and was screened for eligibility for the study. The height and 
weight of each participant was also measured in this initial screening visit. Each 
participant was then given a link to an online survey in which they could provide basic 
demographic data (including age and education level) before the first experimental visit. 
 Following this screening visit, each participant came to the laboratory for two 
experimental visits, held two days apart in order to ensure that each participant completed 
each of the experimental study sessions whilst in the same phase of the oestrous cycle. 
Each participant was also asked to report the first day of their last menstrual period and 
any hormonal contraception they were currently taking. Participants were asked to eat 2.5 
hours prior to each experimental visit, and both sessions occurred at the same time of day 
to control for random variance in baseline hunger.  
 The order of activities for each experimental visit is depicted in Figure 12. On 
arrival at the laboratory for the first experimental session, each participant completed a 
visual analogue scale indicating their state level of stress, hunger, and the extent to which 
they “felt fat” on a scale anchored from 0 to 10. At this time participants also provided a 
1ml saliva sample, which was used to test for salivary cortisol concentration.  
Fifty minutes following this baseline measurement, each participant self-
administered 40IU of intranasal oxytocin or identical volume of placebo spray. One hour 
and twenty minutes after the initial administration of the visit’s allocated nasal spray, each 
participant self-administered an additional 24IU of intranasal oxytocin or identical 
volume of placebo spray, completed a second visual analogue scale, and provided a 
second 1ml saliva sample1. The need for a second dose of oxytocin at this time point was 
based on previous neuroimaging research indicating that the central action of a 40IU dose 
                                                             
1 An MRI scan was conducted in the hour following the initial nasal spray administration for each visit 
(40IU oxytocin or placebo), and the second nasal spray administration (24IU oxytocin or placebo). This 
scan is not reported within the scope of the current paper. 
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of intranasal oxytocin peaks between 39 and 51 minutes following administration 
(Paloyelis et al., 2016). Thirty minutes after the second administration of the allocated 
nasal spray, each participant was presented with a bogus taste test (described in further 
detail below) concurrently with a third visual analogue scale to complete. At the 
conclusion of each experimental session (180 minutes after first drug administration), 
each participant provided a third 1ml saliva sample and guessed which spray (oxytocin 
or placebo) they believed they had been provided with on that day. Participants were then 
provided with a paper log on which they were requested to record everything they ate or 
drank, other than water, over the 24 hours following the experimental session. Each 
participant was then sent a link to an online survey, in which they could input their food 
and drink intake at the conclusion of the 24-hour period. 
 The second experimental session followed the same protocol except with the 
opposite spray to that allocated for the first experimental session (i.e., if a participant 
received oxytocin intranasal spray on the first experimental visit, the placebo spray was 
allocated for the second visit and vice versa). The order in which each participant received 
oxytocin or placebo nasal spray was pseudo-randomised, such that an equal number of 
participants in both the BN/BED and healthy control samples received the oxytocin spray 
during the first visit as received the placebo spray during the first visit. Both the 
experimenter and participant were blind to the order of spray allocation. 
Bogus Taste Test 
The bogus taste test is a validated task commonly used to measure the effect of 
factors hypothesised to contribute to palatable food consumption (E. Robinson et al., 
2017). In the current study, participants were presented with three bowls of food in 
standardised white bowls. One bowl contained 250g grapes, one contained 50g crisps, 
and the last contained 220g chocolate. These quantities were chosen in order to 
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standardise the degree to which each food appeared to fill the bowl. The bowls were 
presented in a standardised order from left to right (first grapes, then crisps, then 
chocolate). Participants were presented with a visual analogue scale for each of the three 
types of food, and asked to rate each food for tastiness, sweetness, saltiness, richness, and 
pleasantness on a scale from 0 to 10. Each participant was instructed to taste each food 
so that they could complete the visual analogue scales. The participant was left alone in 
a private room for 15 minutes to complete the task. As the experimenter exited the room, 
the participant was told as an “afterthought” to eat as much as they would like as the 
remaining food would be thrown out. 
Upon completion of the taste test, the bowls (with the remaining food) were 
brought to another room, where an assistant weighed the remaining food of each type 
whilst out of sight of the participant. The remaining weight was subtracted from the exact 
initial weight to calculate the quantity of each food eaten by the participant. This quantity 
was then later converted into calories.  
Biochemical Analysis 
Saliva samples were stored at -20.0C prior to the immunoassay for cortisol levels. 
The enzyme immunoassay to determine cortisol concentration was conducted using the 
Salimetrics® Expanded Range High Sensitivity immunoassay kit. This assay method is 
sensitive to distinguish concentrations of 0.007µg/dl cortisol from 0. 
Statistical Analysis 
Demographic data. Age and BMI for the BN/BED and healthy control samples 
were compared using Mann-Whitney U tests due to excessive skew in the Age and BMI 
variables. Education level was converted to a standardised scale based on the United 
Kingdom’s Regulated Qualifications Framework (RQF). RQF Education level was 
compared between groups using an independent-samples median test. 
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Preliminary analyses of the moderating effect of follicular phase. Due to 
restrictions associated with availability of the MRI scanner, it was not possible to test all 
participants during the same menstrual phase. We therefore conducted preliminary 
analyses testing the moderating influence of menstrual phase on the effect of oxytocin on 
each of the following dependent variables. Menstrual phase did not have a significant 
moderating effect for any variable. The full results of these preliminary analyses are 
reported in the Supplementary Material. 
Eating behaviour data. The food diary data reported by participants was converted 
into calories using the nutrition label for packaged foods, where possible. For items of 
produce and where no brand of food was reported by the participant, calorie reference 
values were drawn from MyNetDiary.com. The incidence of binge eating was defined by 
the consumption of at least 1000 calories at a single time point reported in the food diary, 
when this consumption was not part of a main meal. Due to the great variability in calorie 
consumption observed in both the taste test and food diary data, we therefore proceeded 
to conduct negative binomial regressions with exchangeable correlation matrix in order 
to validly retain all possible data points in the analyses for caloric consumption in the 
taste test, and the 24-hour food diaries (Gardner, Mulvey, & Shaw, 1995). Exact binomial 
tests were conducted to investigate the association between drug allocation and the 
incidence of binge eating over the following 24 hours.  
Cortisol data. The cortisol data were analysed with a linear mixed effects analysis 
using the lmerTest package for R (Kuznetsova, Brockhoff, & Christensen, 2017). 
Salivary cortisol concentration was the planned dependent variable. We tested a full 
factorial model of the fixed effects for eating disorder status, drug condition, time point, 
and all associated two- and three-way interaction effects. Individual participant was 
entered as a random effect. 
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Visual analogue scale data. The visual analogue scale data for hunger, stress, and 
feelings of fatness were analysed with linear mixed effects analyses using the lmerTest 
package for R (Kuznetsova et al., 2017). We included a full factorial model including 
fixed effects for the within-subject variables Drug Condition (oxytocin or placebo) and 
Time Point (measured at time point 1, 2, or 3), and the between-subject variable Eating 
Disorder Status (healthy control or BN/BED).  
Results 
 Demographic Data 
Demographic data for the BN/BED sample and healthy control sample are 
presented in Table 16. There were no significant differences between the healthy control 
and BN/BED samples in Age (U = 302.00, p = .772) or BMI (U = 336.00, p = .202). 
There were no significant differences in education between groups (test statistic = 1.78, 
p = .317). Participants in the BN/BED group reported having an eating disorder for an 
average of 10.30 years (SD = 5.87 years), with an average age of onset of 15.74 years (SD 
= 4.76 years).  
Drug Blinding 
Participants guessed drug condition correctly on 57 out of the total 104 visits 
(54.8% of visits), which was not found to be significantly greater than chance (p = .377). 
Data for Calorie Consumption 
Within the taste test data, one outlier (Z > |3.0|) was found in the quantity of 
chocolate consumed in the oxytocin condition, and another outlier was identified for a 
separate participant in the quantity of chocolate consumed in the placebo condition. There 
was a great deal of variability in the reported calorie consumption in the 24-hour food 
diaries, particularly by participants with BN (see Figure 13). Descriptive statistics for the 
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food consumption data are reported in Table 17. Data plots illustrating the distribution of 
caloric consumption in the taste test are presented in Supplementary Figure 6. 
Analysis of the Effects of Oxytocin on Calorie Consumption, By Eating Disorder 
Status 
24-hour calorie consumption. We conducted a negative binomial regression with 
the predictors Drug Condition and Eating Disorder Status to test the effects of oxytocin 
on 24-hour calorie consumption. Neither Drug Condition, Eating Disorder status, nor the 
Drug Condition*Eating Disorder Status interaction were significant. The full results of 
the negative binomial log linked regression for the food diary data are reported in Table 
18. 
Taste test calorie consumption. We conducted a negative binomial regression with 
the predictors Drug Condition and Eating Disorder Status to test the effects of oxytocin 
on calorie consumption in the taste test. The negative binomial regression did not reveal 
a main effect of Drug Condition or Eating Disorder Status on calorie consumption in the 
taste test, nor was there a significant interaction between Drug Condition and Eating 
Disorder Status. The full results of the negative binomial log linked regression for the 
taste test data are reported in Table 19. 
 Effect of oxytocin on subsequent incidence of binge eating 
 We next conducted an exact binomial test to determine whether oxytocin 
impacted whether participants in the BN/BED group had a binge eating episode in the 24 
hours following oxytocin administration, versus placebo administration. Fifteen 
participants did not have a binge eating episode on either day. No participant had a binge 
eating episode following both respective experimental sessions. Two women experienced 
a binge eating episode in the 24 hours following oxytocin administration, while three 
women had a binge eating episode in the 24 hours following placebo administration. An 
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exact binomial test revealed the frequency of binge eating following oxytocin 
administration versus placebo was not significant (p = .999). 
Salivary Cortisol 
The salivary cortisol data were screened for outliers and violations of the 
assumption of normality. It was found that the cortisol data was highly positively skewed. 
Therefore, the cortisol data was transformed by adding a value of one2, and then log 10 
transforming the cortisol data. Six outliers (Z > |3.0|) were identified in the transformed 
cortisol data. However, as none of the participants’ data had excessive influence on 
overall model parameters (Cook’s distance < 1.0), these outliers were retained in the 
mixed linear effects analysis. Descriptive statistics for the raw cortisol data are presented 
in Table 20. Data plots for the transformed cortisol variable are presented in Figure 14.  
 The linear mixed model testing the effect of oxytocin on salivary cortisol levels 
revealed a significant main effect of experiment time point, such that salivary cortisol 
tended to decrease from time point 1 to time point 3. Neither the main effects for drug 
condition or eating disorder status, nor any two- or three-way interaction, were 
significant. The fixed effects for the linear mixed model testing the moderating effect of 
eating disorder status on the effect of oxytocin on salivary cortisol are presented in Table 
21. 
Visual Analogue Scales 
 The data were first analysed for outliers and assumptions of normality. 
The stress variable in the oxytocin condition at time point 2 was found to be significantly 
skewed in the healthy control sample (skew = 2.08). Due to skew in the data for subjective 
                                                             
2 A value of one was added before log transforming the data in order to retain one case with a cortisol 
concentration of zero. 
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stress, a value of one was added to the stress data3 and the data was Log10 transformed 
before proceeding with the planned analysis. All variables within the data for hunger and 
the perception of feeling fat were approximately normally distributed (skew < |2.0|, 
kurtosis < |9.0|). The descriptive statistics for the Visual Analogue Scale data are 
presented in Tables 22 and 23. 
 None of the data points within the linear mixed model for hunger had undue 
influence on the model (Cook’s distance < 1.0). The linear mixed model for hunger 
revealed a significant main effect of Time Point, such that hunger linearly increased from 
time point 1 to time point 3. Neither the main effects for Drug Condition or Eating 
Disorder Status, nor any of the two- or three-way interactions were significant. Fixed 
effects of the linear mixed model for hunger are reported in Table 24. 
None of the data points within the linear mixed model for feeling fat had undue 
influence on the model (Cook’s distance < 1.0). The linear mixed model for the extent to 
which participants felt fat revealed a main effect of Eating Disorder Status, such that the 
BN/BED group reported significantly greater levels of “feeling fat”, compared to the 
healthy control group. Neither the main effect for Drug Condition, Time Point, nor any 
of the two- or three-way interactions were significant. Fixed effects of the linear mixed 
model for feelings of fatness are reported in the Table 25. 
None of the data points within the linear mixed model for the transformed stress 
variable had undue influence on the model (Cook’s distance < 1.0). The linear mixed 
model for the transformed stress variable revealed a significant main effect of Time Point, 
such that subjective stress tended to decrease from time point 1 to time point 3. There was 
also a significant main effect of Eating Disorder Status, such that the BN/BED group 
                                                             
3 A value of one was added before log transforming the data in order to retain cases where subjective 
stress was reported to be equal to zero. 
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reported significantly greater levels of subjective stress. Fixed effects for the linear mixed 
model for the transformed stress data are reported in the Table 26. 
Discussion 
 The current study aimed to test the influence of a divided dose of 64IU intranasal 
oxytocin on eating behaviour and stress in adult women with bulimia nervosa or binge 
eating disorder. Contrary to our hypotheses, we did not find that oxytocin affected 
subjective hunger, the immediate consumption of palatable food, 24-hour calorie 
consumption, or the incidence of binge eating, and eating disorder status did not modify 
the effect of oxytocin on eating. We also failed to corroborate our hypothesis that oxytocin 
would reduce subjective stress, the extent to which participants “felt fat”, and salivary 
cortisol levels. The effect of oxytocin on these stress-related variables was also not 
moderated by eating disorder status. 
 These findings differ from previous research showing that intranasal oxytocin 
administration reduced reward-driven food intake in healthy and overweight/obese men 
(Ott et al., 2013; Thienel et al., 2016). Visual inspection of the data revealed that there 
were some differences in the distribution of extreme values of caloric intake within the 
sample of women with bulimia nervosa, such that the very high values tended to occur in 
the placebo condition while very low values tended to occur in the oxytocin condition. 
Overall, however, the current findings failed to corroborate a previous study which found 
that oxytocin reduced 24-hour caloric consumption in Korean women with bulimia 
nervosa (Y.-R. Kim, J.-S. Eom, et al., 2015; Micali, Crous-Bou, et al., 2017). 
 There are several possible explanations as to why the current study failed to 
replicate the finding that oxytocin suppresses 24-hour caloric intake in women with 
bulimia nervosa. One possible reason may be related to the different dose of oxytocin 
employed in the current experimental design. Due to previous evidence that the brain 
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response to intranasal oxytocin peaks between 39-51 minutes following administration 
(Paloyelis et al., 2016), we opted to administer a top-up dose of 24IU following an MRI 
scan conducted during the current battery of tasks in addition to the original dose of 40IU 
oxytocin. There is evidence to suggest that the potency of oxytocin may be related to dose 
by an inverse quadratic function. Specifically, it has previously been shown that 
approximately 24IU intranasal oxytocin significantly reduces plasma cortisol levels 
relative to placebo, while this effect is not apparent at a dose of 48IU oxytocin (Cardoso, 
Ellenbogen, Orlando, Bacon, & Joober, 2013). It may therefore be the case that oxytocin 
does indeed reduce 24-hour caloric intake in women with bulimia nervosa at lower doses 
(such as the 40IU dose tested in Korean women) (Y.-R. Kim, J.-S. Eom, et al., 2015), 
while failing to produce an effect at higher doses (such as the 64IU dose employed in the 
current study).  
 The discrepant findings may also be explained by some demographic and clinical 
differences between the current sample and the sample recruited by (Y.-R. Kim, J.-S. 
Eom, et al., 2015). For example, the inhibitory effect of oxytocin on caloric consumption 
in women with bulimia nervosa may be moderated by cultural and/or unexplored genetic 
factors differing between women of Eastern Asian origin and Caucasian women. 
Additionally, it should be noted that there was a longer average duration of illness in the 
current sample (10.3 years as opposed to 4.8 years in the study by Kim and colleagues) 
and a younger average age of onset (15.74 years, as opposed to 18.74 years in the study 
by Kim and colleagues). That being said, given the short-acting effects of a single dose 
of oxytocin, it is unclear what mechanism could explain the continued effect of oxytocin 
on feeding approximately 23 hours following its peak physiological potency (Paloyelis et 
al., 2016). It may, therefore, rather be the case that the previous findings by (Y.-R. Kim, 
J.-S. Eom, et al., 2015) represent a Type I error, which was not replicated in the current 
study. 
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 One notable difference between the current study design to that of previous studies 
demonstrating an inhibitory effect of oxytocin on palatable food intake (Burmester, 
Higgs, & Terry, 2018; Ott et al., 2013; Thienel et al., 2016) was the gender of participants 
included, with the current sample including only female participants, while studies 
conducted by Ott et al. (2013), Thienel et al. (2016), and Burmester et al. (2018) included 
only male participants. Another difference between the current study and these previous 
studies was the lack of a full meal before provision of the snack foods used to test 
palatable food intake. While the current null findings may be partially due to the influence 
of hunger-driven eating in the current paradigm, the current experimental design bears 
closer resemblance to the circumstances in which binge eating often occurs; that is, after 
a period of mild to moderate food restriction (with more severe restriction often observed 
in bulimia nervosa). Therefore, while it may be the case that prior provision of a full meal 
may have elicited stronger results in the taste test, the current null findings have more 
valid implications for the effects of oxytocin on real-world binge eating episodes (as 
reflected in the null effects on subsequent binge eating in the current study). 
 It should be noted that the current study was affected by low power in light of the 
small effect size of oxytocin on the dependent variables of interest. For example, given 
the results of the current cortisol analysis, a sample size of 59 participants across would 
have been necessary for the overall linear mixed model to have a power of 80%, while 
the current study had 52 participants. The small effect sizes associated with the 
association between oxytocin and stress and salivary cortisol in the current study add to 
an increasingly complex picture in the relevant literature. Oxytocin has been shown 
repeatedly to reduce the anxiety response in animals (Neumann & Slattery, 2016) and to 
reduce social anxiety in humans. However, a recent meta-analysis has shown that 
exogenous oxytocin administration, in fact, increases the startle response in healthy 
humans (Leppanen, Ng, Kim, Tchanturia, & Treasure, 2018). Furthermore, research in a 
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clinical population of participants with generalised anxiety disorder has suggested the 
anxiolytic properties of oxytocin may be specific to men (Feifel, MacDonald, McKinney, 
Heisserer, & Serrano, 2011). Further research testing the dose-response effect of oxytocin 
on stress in eating disorders in both men and women with bulimia nervosa and binge 
eating disorder will be useful in clarifying further moderators of oxytocin’s effects on 
anxiety in human populations.  
 Limitations of the current study include the adoption of a single session study 
design. Although commonly used prior to clinical trials in translational science, the 
current design may not be suitable for populations with binge-type eating disorders. 
Given that the current DSM-5 definition for both bulimia nervosa and binge eating 
disorder requires a minimum of one binge eating episode per week, it is perhaps 
unsurprising that few participants (5 out of 25 participants with bulimia nervosa or binge 
eating disorder) experienced a binge eating episode following one experimental session, 
while others exhibited a more restrictive pattern of eating (commonly observed in bulimia 
nervosa). This variable eating pattern contributed to the large standard deviation in 
subsequent caloric consumption over the following 24 hours, thus potentially masking 
any true effect that oxytocin may exert on eating patterns in the sample of participants 
with bulimia nervosa or binge eating disorder. We would therefore recommend that future 
studies measure the influence of oxytocin on eating behaviours over longer periods of 
time in populations with binge-type eating disorders to control for the large degree of 
within-person baseline variability in eating patterns. It would also be helpful to measure 
early sensitive indicators of the effect of oxytocin on approach bias to food, such as 
attentional bias. 
 Additionally, we would also recommend that future studies test populations of 
women with bulimia nervosa and binge eating disorder separately, as the current study 
found numerically divergent patterns of results in some analyses. Finally, it should be 
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noted that the current sample consisted exclusively of women, and the current findings 
should therefore not be generalised to men with BN or BED, especially in light of 
previous literature indicating that the response to other treatments for BN is moderated 
by gender (Agüera et al., 2017). 
 In conclusion, the current study aimed to investigate the effects of intranasal 
oxytocin on eating behaviours and stress in a sample of women with bulimia nervosa and 
binge eating disorder. We did not find that oxytocin significantly affected the 
consumption of palatable food intake, 24-hour caloric consumption, or subjective 
measurements of stress. Further studies testing a dose-response of oxytocin in a chronic 
treatment paradigm will be useful in further clarifying the moderating effects of 
oxytocin’s effects on eating in populations with binge-type eating disorders. 
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Table 16 
Descriptive demographic data 
 Healthy Control (n = 27) BN/BED (n = 25) 
 Median IQR Median IQR 
Age 23.50 5.50 23.50 9.75 
BMI 22.04 1.76 23.09 3.87 
RQF Education 
Level 
6 4 4.5 3 
Note. BN = bulimia nervosa; BED = binge eating disorder; IQR = interquartile range; 
BMI = body mass index; RQF = Regulated Qualifications Framework. 
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Table 17 
Descriptive statistics for calorie consumption data in the bogus taste test and 24-hour food diary 
 Healthy Control (n = 27) BN/BED (n = 25) 
 Placebo Oxytocin Placebo Oxytocin 
 Median IQR Median IQR Median IQR Median IQR 
Grape consumption 94.38 77.88 93.72 80.52 60.06 85.63 57.22 91.41 
Crisp consumption 136.76 147.28 147.28 117.04 68.38 168.06 52.60 148.86 
Chocolate consumption 115.50 264.00 132.00 291.5 98.45 163.35 82.50 192.50 
24-hour consumption 1617.63 650.19 1672.90 1119.29 1951.30 1542.66 1606.00 1086.05 
Note. Data recorded as number of calories consumed. BN = bulimia nervosa; BED = binge eating disorder. 
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Table 18 
Results from the negative binomial regression testing the effect of oxytocin and eating 







Drug Condition 1.11 1 .292 0.780 
Eating Disorder Status 0.93 1 .336 0.770 
Drug Condition*Eating Disorder 
Status 
3.257 1 .071 
1.369 
* p < .05 
 
Table 19 
Results from the negative binomial regression testing the effect of oxytocin and eating 








Drug Condition 0.46 1 .498 1.040 
Eating Disorder Status 1.40 1 .237 1.235 
Drug Condition*Eating Disorder 
Status 
0.04 1 .845 
1.033 
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Table 20 
Descriptive statistics for the raw salivary cortisol data 
 Healthy Control (n = 27) BN/BED (n = 25) 
 Placebo Oxytocin Placebo Oxytocin 
 Median IQR Median IQR Median IQR Median IQR 
Salivary Cortisol (nmol/L) Time 
Point 1 
2.48 1.68-3.03 2.31 1.54-3.13 3.13 1.53-5.72 3.23 2.04-4.89 
Salivary Cortisol (nmol/L) Time 
Point 2 
1.06 0.63-1.76 1.09 0.54-1.66 1.31 0.63-3.00 1.59 0.92-2.10 
Salivary Cortisol (nmol/L) Time 
Point 3 
1.43 0.90-1.79 1.17 0.65-1.65 1.48 0.70-2.56 1.04 0.87-1.74 
Note. BN = bulimia nervosa; BED = binge eating disorder. 
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Table 21 
Results of the linear mixed effects analysis testing a full factorial model with fixed 
effects for eating disorder status, oxytocin, and experiment time point on the 
transformed salivary cortisol variable 
Fixed Effects Estimate SE df t p 
Intercept 0.58*** 0.050 217.14 11.47 2.16E-16 
ED Status 0.12 0.074 226.92 1.67 .097 
Drug Condition -0.01 0.058 247.69 -0.19 .847 
Experiment Time Point -0.08*** 0.019 248.30 -4.41 1.56E-5 
ED Status * Drug Condition 0.06 0.084 247.44 0.77 .442 
ED Status * Experiment Time 
Point 
-0.02 0.028 247.53 -0.88 .379 
Drug Condition * Experiment Time 
Point 
-0.01 0.027 247.03 -0.21 .831 
ED Status * Drug Condition * 
Experiment Time Point 
-0.03 0.039 246.72 -0.66 .511 
Random Effects Variance     
Individual Participant 0.025     
Residuals 0.019     
Note. ED = Eating disorder. 
*** p < .001 
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Table 22 
Descriptive statistics for the visual analogue scale data for hunger and feeling fat 
 Healthy Control (n = 27) BN/BED (n = 25) 
 Placebo Oxytocin Placebo Oxytocin 
 M SD M SD M SD M SD 
Hunger Time 1 2.91 2.127 3.29 2.313 4.04 2.626 2.72 2.313 
Hunger Time 2 4.10 2.671 3.96 2.573 5.10 2.487 4.24 2.374 
Hunger Time 3 4.95 2.312 5.14 2.553 6.11 2.066 5.02 2.652 
Feel Fat Time 1 1.40 1.564 2.04 2.357 7.10 2.295 7.10 1.912 
Feel Fat Time 2 1.39 2.033 1.48 2.219 6.44 2.608 6.19 2.308 
Feel Fat Time 3 1.23 1.944 1.55 2.311 7.11 2.159 6.42 2.556 
Log10 Stress Time 1 0.06 0.406 0.05 0.403 0.57 0.268 0.39 0.554 
Log10 Stress Time 2 -0.10 0.437 -0.12 0.419 0.33 0.472 0.30 0.475 
Log10 Stress Time 3 -0.26 0.369 -0.13 0.452 0.48 0.353 0.30 0.535 
Note. BN = bulimia nervosa; BED = binge eating disorder. 
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Table 23 
Descriptive statistics for the visual analogue scale data for stress 
 Healthy Control (n = 27) BN/BED (n = 25) 
 Placebo Oxytocin Placebo Oxytocin 
 Median IQR Median IQR Median IQR Median IQR 
Stress Time 1 1.05 1.83 1.33 1.29 3.36 4.03 3.32 4.09 
Stress Time 2 0.52 1.22 0.56 1.45 2.53 4.74 1.55 3.71 
Stress Time 3 0.40 0.65 0.40 1.37 3.33 4.42 2.41 3.85 
Note. BN = bulimia nervosa; BED = binge eating disorder; IQR = interquartile range. 
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Table 24 
Results of the linear mixed effects analysis testing a full factorial model with fixed 
effects for eating disorder status, oxytocin, and experiment time point on subjective 
hunger 
Fixed Effects Estimate SE df t p 
Intercept 2.02** 0.636 289.27 3.18 .002 
ED Status 1.25 0.916 289.06 1.37 .172 
Drug Condition 0.26 0.793 256.02 0.33 .742 
Experiment Time Point 1.02*** 0.262 255.62 3.90 < .001 
ED Status * Drug Condition -1.64 1.143 256.00 -1.43 .153 
ED Status * Experiment Time Point -0.13 0.376 255.87 -0.34 .732 
Drug Condition * Experiment Time 
Point 
-0.10 0.367 255.62 -0.27 .790 
ED Status * Drug Condition * 
Experiment Time Point 
0.32 0.528 255.75 0.61 .541 
Random Effects Variance     
Individual Participant 2.262     
Residuals 3.561     
Note. ED = Eating disorder. 
** p < .01. 
*** p < .001. 
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Table 25 
Results of the linear mixed effects analysis testing a full factorial model with fixed 
effects for eating disorder status, oxytocin, and experiment time point on feelings of 
fatness 
Fixed Effects Estimate SE df t p 
Intercept 1.90*** 0.479 101.87 3.98 < .001 
ED Status 5.22*** 0.683 98.386 7.64 < .001 
Drug Condition 0.27 0.373 244.61 0.73 .465 
Experiment Time Point -0.12 0.127 243.90 -0.94 .346 
ED Status * Drug Condition -0.17 0.528 244.11 -0.32 .748 
ED Status * Experiment Time Point -0.004 0.177 243.77 -0.02 .981 
Drug Condition * Experiment Time 
Point 
-0.09 0.175 244.34 -0.53 .598 
ED Status * Drug Condition * 
Experiment Time Point 
-0.11 0.245 243.98 -0.45 .656 
Random Effects Variance     
Individual Participant 4.174     
Residuals 0.731     
Note. ED = Eating disorder. 
*** p < .001. 
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Table 26 
Results of the linear mixed effects analysis testing a full factorial model with fixed 
effects for eating disorder status, oxytocin, and experiment time point on the 
transformed stress variable 
Fixed Effects Estimate SE df t p 
Intercept 0.42 0.061 220.94 6.99 < .001 
ED Status 0.22* 0.087 220.57 2.51 .013 
Drug Condition -0.03 0.068 256.15 -0.51 .612 
Experiment Time Point -0.08*** 0.022 255.91 -3.63 < .001 
ED Status * Drug Condition -0.04 0.098 256.13 -0.41 .681 
ED Status * Experiment Time Point 0.05 0.032 256.04 1.67 .097 
Drug Condition * Experiment Time 
Point 
0.03 0.031 255.91 0.93 .354 
ED Status * Drug Condition * 
Experiment Time Point 
-0.03 0.045 255.98 -0.58 .565 
Random Effects Variance     
Individual Participant 0.036     
Residuals 0.026     
Note. ED = Eating disorder. 
* p < .05. 
*** p < .001. 





Figure 12. Order of activities for each experimental visit.  
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Figure 13.  24-hour caloric consumption by participant diagnosis and drug condition.  
  

















Figure 14. Log transformed salivary cortisol concentration separated by drug condition, time point, and eating disorder status. 
Note. ED = eating disorder participant group; HC = healthy comparison group. 
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Supplementary Material 
Analysis of the Effects of Oxytocin on Calorie Consumption, By Eating Disorder 
Status and Oestrous Phase 
24-hour calorie consumption. Fifteen women completed the study in the follicular 
phase of the oestrous cycle, thirteen women completed the study in the luteal phase, and 
twenty-two women were taking hormonal contraception at the time of the study. In order 
to account for the possible moderating effect of varying oestrous phase on the effect of 
oxytocin on eating, we first conducted a preliminary negative binomial regression with 
the predictors Oestrous Phase and Drug Condition. This analysis revealed a main effect 
of oestrous phase (Wald Chi-Square = 6.88, df = 2, p = .032), such that women consumed 
significantly more calories over a 24-hour period when in the luteal phase, as opposed to 
the follicular phase or when taking hormonal contraception. However, there was not a 
significant interaction between oestrous phase and drug condition on food consumption 
reported in the 24-hour food diary (full results of the negative binomial regression are 
reported in the Supplementary Table 6). We therefore proceeded with the main analysis 
without including oestrous phase as a predictor. 
Taste test calorie consumption. We first conducted a negative binomial regression 
to determine whether oestrous phase and food type interacted with oxytocin to impact 
caloric consumption in the taste test. There was a significant effect of food type, such that 
participants consumed significantly fewer calories in grapes, as opposed to crisps or 
chocolate. This binomial regression did not reveal either a significant main effect of 
oestrous phase, a significant interaction between oestrous phase and drug condition, or a 
significant interaction between food type and drug condition on caloric consumption in 
the taste test. (full results of this negative binomial regression are reported in the 
Supplementary Table 7).  
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Supplementary Table 6 
Results from the preliminary negative binomial regression testing the effect of oestrous 
phase and oxytocin on calorie consumption in the 24-hour food diaries 
 Wald Chi-Square df p 
Drug Condition 0.16 1 .692 
Oestrous Phase 6.88* 2 .032 
Drug Condition*Oestrous Phase 3.65 2 .161 
* p < .05 
 
 
Supplementary Table 7 
Results from the preliminary negative binomial regression testing the effect of oestrous 
phase and oxytocin on calorie consumption in the taste test 
 Wald Chi-Square df p 
Drug Condition 0.58 1 .448 
Oestrous Phase 2.64 2 .267 
Food Type 31.05*** 2 < .001 
Drug Condition*Oestrous Phase 1.30 2 .522 
Drug Condition*Food Type 0.33 2 .847 
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Supplementary Table 8 
Results of the linear mixed effects analysis testing the moderating effect of follicular 
phase on the effects of oxytocin on salivary cortisol 
Fixed Effects Estimate SE df t p 
Intercept 0.48*** 0.05 80.96 8.71 3.03E-
13 
Follicular Phase -0.03 0.02 80.36 -1.11 .272 
Drug Condition 3.63E-5 0.05 235.7 0.001 .999 
Follicular Phase*Drug 
Condition 
-2.69E-3 0.02 235.7 -0.121 .904 
Random Effects Variance     
Individual Participant 0.01     
Residuals 0.03     
*** p < .001 
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Supplementary Figure 6. Grape consumption in the taste test by participant diagnosis and drug condition. Note: BED = binge eating disorder, BN = 
bulimia nervosa; HC = healthy control. 
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Supplementary Figure 7. Crisp consumption in the taste test by participant diagnosis and drug condition. Note: BED = binge eating disorder, BN = 
bulimia nervosa; HC = healthy control. 
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Supplementary Figure 8. Chocolate consumption in the taste test by participant diagnosis and drug condition. Note: BED = binge eating disorder, BN = 




5 The effects of oxytocin on neurocognitive processes in bulimia nervosa and 
binge eating disorder 
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5.1 Rationale for investigating the effects of oxytocin on attentional processing and 
decision-making in bulimia nervosa and binge eating disorder 
One hypothesis proposed within the addictive appetite model is that people with bulimia 
nervosa and binge eating disorder will exhibit disinhibited stimulus-response pathways 
in response to palatable food. Thus, despite ongoing efforts towards recovery, the nature 
of attentional and response patterns in the advanced stage of the disorder continues to 
contribute to the progression of the disorder. It is therefore of clinical interest to disrupt 
such automated patterns of responding to palatable food in order to curb loss-of-control 
binge eating behaviour in both bulimia nervosa and binge eating disorder.  
The rationale for using oxytocin supplementation as a treatment approach for unhelpful 
attentional biases and impulsive decision-making tendencies will be described in further 
detail in the following papers. That is, while the evidence presented in Paper 5 suggests 
that a divided dose of 64IU oxytocin does not immediately impact hedonic eating, it 
remains to be seen as to whether intranasal oxytocin impacts underlying processes which 
contribute to binge eating behaviour in the long-term. 
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5.2 Paper 6: A Pilot Study Investigating the Influence of Oxytocin on Attentional Bias to 
Food Images in Women with Bulimia Nervosa and Binge Eating Disorder 
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Abstract 
Background: Previous research has found that exogenous oxytocin administration has 
the potential to modulate attentional biases in women with anorexia nervosa. Recent work 
has indicated that attentional biases to food may reinforce the recurrent binge eating 
behaviour which characterises bulimia nervosa and binge eating disorder. To date, 
however, no study has yet investigated the effect of oxytocin on attentional biases to 
palatable food in women with bulimia nervosa and binge eating disorder.  
Methods: The current study employed a single-session crossover design to test the 
hypothesis that a divided dose of 64IU intranasal oxytocin, versus placebo administration, 
would reduce attentional biases towards food images in a dot probe task. We further 
hypothesised that oxytocin administration would reduce vigilance towards food to a 
greater degree in women with bulimia nervosa or binge eating disorder, versus healthy 
comparison women, due to potential flooring effects in the healthy comparison group. 
Twenty-five women with bulimia nervosa or binge eating disorder and 27 comparison 
women without history of an eating disorder were recruited to take part in the study.  
Results: Contrary to our hypothesis, there was no main effect of diagnosis on attentional 
bias to food (fixed effect = 5.70, p = .363), nor a significant interaction between diagnosis 
and drug condition (fixed effect = -14.80, p = .645). There was a main effect of drug 
condition, such that oxytocin increased vigilance towards food, versus neutral, images in 
the dot probe task (fixed effect = 10.42, p = .044); however, a sensitivity analysis 
subsequently suggested that this finding was primarily driven by women with binge 
eating disorder.  
Conclusion: The current findings add to a mixed body of literature investigating the 
therapeutic effects of oxytocin in women. Future research would benefit from dose-
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response studies investigating the optimal dose of oxytocin for modulating the attentional 
processing of palatable food in populations with eating disorders. 
Keywords: Bulimia nervosa; binge eating disorder; eating disorders; attentional bias; 
oxytocin 
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Introduction 
Bulimia nervosa (BN) and binge eating disorder (BED) are DSM-5 eating 
disorders characterised by recurrent, loss-of-control binge eating behaviour over a period 
of at least three months (American Psychiatric Association, 2013). Currently, the average 
remission rate for people with BN and BED remains low and treatment presents a 
significant challenge (Hay, 2013). The development of new treatment approaches is 
therefore warranted to address this unmet need.  
A meta-analysis has found that people with BN exhibit greater attentional bias 
towards food words in Stroop tasks when compared to participants without history of an 
eating disorder (Brooks, Prince, Stahl, Campbell, & Treasure, 2011). More recently, 
evidence has supported the hypothesis that attentional bias towards food cues is 
associated with core eating disorder behaviours and psychopathology in BN and BED. 
For example, Albery et al. (2016) used a Stroop task to measure attentional bias to both 
food- and body-related words amongst women with BN. They found that the degree of 
attentional bias towards food-related words was associated with greater frequency of 
binge-purge behaviour. Additionally Svaldi, Naumann, Biehl, and Schmitz (2015) used a 
visual priming task to investigate attentional bias to food images, versus neutral images, 
among obese participants with and without BED. While this priming effect ultimately did 
not differ between the BED and non-BED groups of overweight participants, they did 
find that the degree of priming was positively correlated with overall eating disorder 
psychopathology, as measured using the Eating Disorder Examination – Questionnaire 
(EDE-Q) (Fairburn & Beglin, 1994b). In a spatial cueing task, Schmitz, Naumann, 
Trentowska, and Svaldi (2014) also found the same positive correlation between 
attentional bias to food images and EDE-Q scores in a sample of participants with BED. 
It has been proposed that attentional bias toward palatable food cues is a cognitive 
maintenance factor for BN and BED, as these preconscious biases enhance the salience 
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of external cues for binge eating (Turton, Bruidegom, Cardi, Hirsch, & Treasure, 2016). 
Evidence suggests that the link between attention to food cues and subsequent binge 
eating behaviour may be especially strong in these disorders due to an automatic stimulus-
response association that becomes increasingly reinforced with continued binge eating 
behaviour (Robbins et al., 2012; Treasure et al., 2018). Previous evidence has indicated 
that attentional biases to food are especially strong following actual food consumption in 
populations with obesity, as compared to healthy control participants (Castellanos et al., 
2009). However, the effect of food consumption on behavioural measures of attentional 
bias to food has not been investigated in people with BN and BED (Giel, Teufel, Junne, 
Zipfel, & Schag, 2017). It is therefore of interest to determine whether attentional biases 
to palatable food occur prior to food consumption, thus supporting the incentive salience 
hypothesis (Berridge, 2007), or whether attentional biases only or also occur following 
food consumption, thus potentially highlighting that the onset of food consumption 
triggers subsequent increases in incentive salience. 
Recent research has suggested that the hormone oxytocin may affect the upstream 
cognitive and emotional processes that contribute to the maintenance of disordered eating 
behaviour in anorexia nervosa. For example, chronic administration of oxytocin has been 
found to reduce eating concern (Russell et al., 2018). Additionally, a single dose of 
oxytocin has been found to reduce attentional bias to disgusted faces and correct 
avoidance of angry faces in women with anorexia nervosa. (Kim, Kim, Park, et al., 2014). 
A separate study also found that oxytocin corrected attentional avoidance of food images 
in women with anorexia nervosa (Leppanen, Cardi, et al., 2017a). This finding potentially 
carries clinical significance given evidence that attentional avoidance of food stimuli is 
correlated with disorder severity in anorexia nervosa (Giel et al., 2011), although future 
research is necessary before causal effects of attentional bias can be determined. To our 
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knowledge, no study has yet investigated the effects of oxytocin on attentional bias to 
food images in BN and BED.  
It is not entirely clear by what mechanism oxytocin alters attentional bias 
specifically to food images, although the strength of the effect of oxytocin on attentional 
bias is related to the anxiolytic effects of oxytocin with a medium effect size (Leppanen, 
Cardi, et al., 2017a). It may be the case that anxiety primarily drives baseline attentional 
biases away from food in anorexia nervosa, and the oxytocin-induced reduction in anxiety 
has the downstream effect of normalising this bias. A current lack of evidence does not 
allow for the establishment of firm conclusions regarding the mechanism of the effect 
oxytocin on attentional bias; however, it is reasonable to suspect that oxytocin may exert 
a similar effect in normalising baseline attentional biases towards food in BN and BED if 
oxytocin modulates a common anxiety-based mechanism accounting for baseline 
attentional biases in each disorder, albeit in opposite directions. 
Previous evidence that intranasal oxytocin suppresses hedonic eating in 
overweight men has provided tentative evidence that oxytocin may also suppress the 
reward salience of palatable food (Thienel et al., 2016), which has previously been found 
to affect preconscious attentional bias (B. A. Anderson, Laurent, & Yantis, 2011). 
Furthermore, previous neuroimaging work has found that people recovered from BN 
exhibit similar blood-oxygenated-level-dependent (BOLD) responses within the left 
putamen, a neural region strongly associated with the processing of reward, in response 
to taste stimuli received when either hungry or sated (Ely et al., 2017). This is in contrast 
to healthy control participants, who exhibit a down-regulated BOLD response in the left 
putamen following food consumption (Ely et al., 2017). One potential hypothesis 
stemming from this pattern of effects is that the incentive salience of palatable food, and 
attentional bias to palatable food, will decrease following food consumption to a greater 
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degree amongst healthy control participants, as compared to participants with BN or 
BED.  
 The current pilot used a double-blind, placebo-controlled crossover design to test 
the effect of a divided dose of 64IU intranasal oxytocin on attentional bias to food images 
among women with BN or BED and comparison women without history of an eating 
disorder. Our hypotheses were: 1) Women with BN or BED would demonstrate greater 
attentional bias towards food images than women without history of an eating disorder; 
2) Oxytocin administration would reduce vigilance towards food images in both groups 
of women, based on previous work suggesting that oxytocin reduces the incentive 
salience of palatable food in healthy participants (Ott et al., 2013); 3) Oxytocin would 
reduce vigilance towards food images to a greater degree in women with BN or BED, 
versus healthy comparison women, due to potential flooring effects in the healthy 
comparison group; 4) There would be an interaction between time point and participant 
group, such that the difference in attentional bias to food in the BN/BED, versus healthy 
control group, would be even greater following food consumption. 
Methods 
 Participants 
 Fifty-two women were recruited to take part in the current study. Twenty women 
met DSM-5 diagnostic criteria for BN, five women met DSM-5 diagnostic criteria for 
BED, and twenty-seven women had no prior history of an eating disorder at the time of 
the study. The study was advertised on the website for a major eating disorder charity in 
the United Kingdom (Beat), via e-mail circulars at King’s College London, and on flyers 
displayed on community bulletin boards. The London – Camberwell St Giles NHS 
Research Committee granted ethical approval for the current study (reference: 
14/LO/2115). All participants gave written informed consent in accordance with the 
Monica Leslie   284 
Declaration of Helsinki. Full inclusion and exclusion criteria for the study are presented 
in the Supplementary Material. Eligibility for the current study was established via a 
phone screening, which included the Structured Clinical Interview for DSM-5 
(American Psychiatric Association, 2013). Seven participants who met diagnostic criteria 
for BN or BED had at least one comorbid psychiatric disorder. Specifically, 5 women had 
comorbid depression, 4 women had borderline personality disorder, 4 women had 
comorbid generalised anxiety disorder, 1 woman had obsessive-compulsive disorder, 1 
woman had social anxiety, and 1 woman had an autism spectrum disorder. At the time of 
the study, 7 women were taking an antidepressant, 1 woman was taking an antipsychotic 
drug, and 1 woman was taking a mood stabiliser. Twenty-two of the fifty-two participants 
were taking hormonal contraception at the time of the study. Fifteen women completed 
the study whilst in the follicular phase of the oestrous cycle and thirteen women 
completed the study in the luteal phase of the menstrual cycle. Menstrual phase data were 
missing for two women. Descriptive statistics for the age, body mass index (BMI), and 
education level of the participant sample are presented in Table 27.  
Study Design 
This study used a double-blind placebo-controlled crossover design. Each 
participant came to the laboratory for three study visits: one orientation visit and two 
experimental sessions. During the orientation visit, each participant had the opportunity 
to discuss any queries with the researcher in person before signing informed consent and 
practising self-administration of a placebo nasal spray. The height and weight of each 
participant was also measured during the orientation visit. At the conclusion of the 
orientation visit, each participant was provided with a link to an online survey, in which 
participants provided basic demographic data prior to the second study visit.  
Monica Leslie   285 
 Each participant subsequently came to the laboratory for two experimental study 
visits. Participants received a divided dose of 64IU intranasal oxytocin during one 
experimental study visit, and an equal volume of a placebo nasal spray during the opposite 
visit. The order in which each participant received each nasal spray was pseudo-
randomised, such that an equal number of participants received oxytocin on the first, 
versus the second, experimental study visit. Both the participant and the researcher were 
blind to the order in which each participant was allocated the oxytocin, versus placebo, 
nasal spray. These experimental study visits were held two days apart to ensure that each 
participant would complete both experimental study visits whilst in the same phase of the 
menstrual cycle. Perfusion data analysing the central effects of oxytocin suggest that 
carryover effects from oxytocin administration on the first experimental visit to the 
second experimental visit are highly unlikely (Paloyelis et al., 2016). 
Participants were requested to abstain from consuming alcohol or caffeine from 
8.00pm on the evening prior to each experimental study visit. Participants were also asked 
to eat 2.5 hours prior to the beginning of each experimental study visit, and nothing else 
between this time and the beginning of the experimental study visit. 
 Participants arrived for each study visit at 5.00pm. At 5.50pm, each participant 
self-administered the first dose of the allocated nasal spray for that day: either 40IU 
oxytocin or an equal volume of the placebo nasal spray. Each participant then underwent 
a functional MRI scan, the results of which are not reported in the current paper. The 
functional MRI scan ended at 7.00pm. At 7.10pm, participants self-administered a second 
dose of the allocated nasal spray for that day: either 24IU oxytocin or an equal volume of 
the placebo nasal spray. The dose and timing of drug administration was based on 
previous work finding peak central effects of 40IU oxytocin at 39-51 minutes following 
administration (Paloyelis et al., 2016), thus suggesting the need for an additional dose at 
this time.  At 7.25pm, each participant then completed a visual dot probe task, which is 
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described in further detail below. Immediately following the completion of this task, each 
participant completed a “bogus” taste test, which is also described below. The taste test 
continued for a standard 15-minute duration. Following the taste test, each participant 
repeated the visual dot probe task. Subsequently, each participant reported whether they 
believed they had been allocated the oxytocin or placebo for that study visit. 
Visual Dot Probe Task 
The visual dot probe task is a common test of attentional bias to disorder-relevant 
images, which has been used to measure attentional biases across a range of psychiatric 
disorders (MacLeod, Mathews, & Tata, 1986; Shafran, Lee, Cooper, Palmer, & Fairburn, 
2007). The visual dot probe task used in the current study was adapted from Cardi, 
Lounes, Kan, and Treasure (2013) and presented using E-prime software (Psychology 
Software Tools, Sharpsburg, USA). Each task run consisted of 96 trials. In each trial, the 
participant was first presented with two images side by side, with 115mm between the 
centre of each image. Each image belonged to one of two category types: food images 
(32 different images) or neutral images (48 different images). Food images depicted 
close-up photographs of palatable foods on a plate. Food was depicted in a “ready-to-eat” 
form without any packaging.  
Participants were presented with a total of 32 different food-neutral image pairs, 
and 16 different neutral-neutral image pairs. Each image pair was presented twice (once 
with the food picture on the left, and once with the food picture on the right; the order of 
image pairings was randomly determined for each participant). All food images were 
matched for size and caloric content. Neutral images depicted furniture. Each image had 
a resolution of 72dpi, measured 45 x 70mm on the computer screen, and was matched for 
colour saturation. Each picture pair was presented for 500ms.  
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Immediately following the presentation of each image pair, one of the images was 
replaced by a visual probe. Visual probes consisted of either a pair of horizontally or 
vertically oriented dots. Participants were instructed to press the letter ‘z’ as soon as they 
saw a pair of horizontally oriented dots, or the letter ‘q’ as soon as they saw a pair of 
vertically oriented dots. Stickers depicting the corresponding dot orientation were 
attached to the letters ‘q’ and ‘z’ on the keyboard to prevent confusion for participants. 
The inter-trial interval was 500ms. Reaction time and accuracy was recorded for each 
trial.  
Bogus Taste Test 
The bogus taste test is a validated measure of eating behaviour used to test the 
effect of experimental factors on the consumption of palatable food (E. Robinson et al., 
2017). In the current study, each participant was presented with three types of food, each 
of which was contained in a standardised white ceramic bowl. One bowl contained 250g 
of grapes, one bowl contained 50g Walker’s ready-salted crisps, and the final bowl 
contained 220g Cadbury Bitsa WispaÔ chocolate. The bowls were presented in a 
standard order, with the bowl of grapes on being the leftmost bowl, followed by the bowl 
of crisps, and the bowl of chocolate being the rightmost bowl. Participants were asked to 
rate each type of food for tastiness, sweetness, saltiness, richness, and pleasantness on a 
visual analogue scale anchored from 0 to 10. As the researcher was leaving the room after 
explaining the instructions for the bogus taste test, the researcher told each participant as 
an “afterthought” that the participant was welcome to eat as much as they would like, as 
the remaining food would be thrown away. Participants were then left alone in a room 
with the three bowls of food for 15 minutes to complete the task. 
Following the completion of the bogus taste test, the three bowls of food were 
brought to a separate room, out of sight of the participant, where a research assistant 
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weighed the remaining food in each bowl and subtracted this amount from the initial 
weight of each type of food. The effect of oxytocin on the quantity of food eaten is 
reported elsewhere (Leslie, Leppanen, Paloyelis, & Treasure, 2018). 
Statistical Analysis 
Attentional bias scores for each task run were calculated for the dot probe task by 
subtracting each participant’s mean reaction time to probes that were preceded by a food 
image from those that were preceded by a neutral image. Therefore, positive attentional 
bias scores indicate vigilance to food images, and negative attentional bias scores indicate 
avoidance of food images. Trials that presented matching image pairs (e.g., two neutral 
images) and trials in which the participant responded incorrectly were excluded. All task 
runs for all participants met the minimum requirement of an 80% correct response rate. 
We tested our hypotheses using a 2 x 2 x 2 linear mixed effects model in the 
lmerTest package for R (Kuznetsova et al., 2017). We included experiment time point 
(before or after the taste test), eating disorder status (healthy controls or BN/BED), drug 
condition (placebo or oxytocin), and all associated interactions as fixed effects. The 
intercept for each participant was entered as a random effect. A preliminary linear mixed 
effects analysis was conducted to determine whether hormonal state (follicular phase, 
luteal phase, or current hormonal contraception) moderated the effect of oxytocin on 
attentional bias. The results of this linear mixed effects analysis are reported in 
Supplementary Table 9. The interaction effect between oxytocin and hormonal state 
was not significant, and hormonal state was therefore not included as a covariate in the 
final mixed effects model. 
Results 
 The attentional bias scores were first screened for outliers and violations of the 
assumption of normality. Four outliers (|Z| > 3.0) were found in the attentional bias 
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variable and excluded from subsequent analyses. Three of these outlier data points were 
in the BN/BED participant group and one was in the healthy control participant group. 
Descriptive statistics associated with the attentional bias scores are presented in Table 28 
and visual depictions of the data are presented in Supplementary Figures 9 and 10. 
The linear mixed model showed that none of the interaction effects reached 
significance in the full factorial model. The fixed effects associated with the full factorial 
linear mixed effect analysis are presented in Table 29. We did not identify any cases with 
excessive influence on the model (all Cook’s distances < 1.0). 
As there were not any significant interaction effects in the full factorial model, we 
therefore conducted a follow-up linear mixed effects analysis including only main effects. 
The main effects analysis revealed that neither eating disorder status nor experiment time 
point significantly affected attentional bias. However, there was a significant main effect 
of drug condition, such that oxytocin administration, versus placebo administration, was 
associated with significantly greater vigilance towards food images. The fixed effects 
associated with the linear mixed effects analysis are presented in Table 28. Again, we did 
not identify any cases with excessive influence on the model (all Cook’s distances < 1.0). 
Visual inspection of the data revealed a numerically greater difference in 
attentional bias to food images between the oxytocin and placebo conditions among BED, 
as opposed to healthy control or BN participants groups. We therefore conducted a 
sensitivity analysis excluding BED participants. Given that this exclusion would 
substantially reduce power given the already low sample size, we imputed the mean for 
each drug condition and experiment time point among the BN participant group for an 
additional five simulated BN participants.  After excluding participants with BED, the 
effect of drug condition was no longer significant (p = .084) although there was a trend 
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towards an effect in the same direction. Full results of this sensitivity analysis are reported 
in Supplementary Table 10. 
Discussion 
 The current study aimed to test the effect of a divided dose of 64IU intranasal 
oxytocin on attentional bias to food images in women with and without BN or BED. We 
hypothesised that women with BN or BED would demonstrate greater vigilance towards 
food images and that oxytocin administration would reduce vigilance towards food 
images in both participant groups, but with a stronger effect in the BN/BED versus 
healthy comparison group. 
 Our first hypothesis was not supported by the results, as there was no main effect 
of eating disorder status on attentional bias to food images. Oxytocin was found to have 
a significant effect on attentional bias; however, this was in the opposite direction to our 
hypothesis. That is, oxytocin was found to increase vigilance to food images, rather than 
decreasing vigilance as originally predicted. This finding, however, was primarily driven 
by the five participants with BED, as the significance of this effect did not survive after 
excluding participants with BED. Our third hypothesis was also not supported by the 
results as there was not a significant interaction between oxytocin treatment and eating 
disorder status on attentional bias to palatable food. Finally, we did not find evidence of 
an interaction between participant group and time point (before or after the taste test) on 
attentional bias to food images.   
The lack of difference in baseline attentional bias to food stimuli between women 
with, versus without, BN or BED is in contrast to a previous studies using Stroop tasks 
(Brooks et al., 2011). This contrast in findings may be due, in part, to differences in the 
food-related stimuli presented: food images being used in the current study versus food 
words in the Stroop task. However, previous evidence has suggested that food images are 
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rather associated with a greater difference in attentional bias to food amongst participants 
with eating disorders and healthy controls, when compared to word stimuli (Stormark & 
Torkildsen, 2004). The null effect of eating disorder status in the current study may, 
therefore, rather be due to the stage of attention processing targeted in the current study. 
The target for the task was presented 500ms after each image pair, while the nature of the 
Stroop task necessarily requires that the target be presented simultaneously with the food-
related word. This is potentially relevant given previous eye-tracking evidence finding no 
difference in attention to food images among women with anorexia nervosa at early stages 
of attentional processing but avoidance of food images at later stages of attentional 
processing (Giel et al., 2011). If similar variation in attentional biases also exist in 
populations with BN and BED, it is possible that the current study failed to detect 
differences in attentional bias before or after the target appeared.  
The finding that oxytocin induced greater, rather than less, vigilance towards food 
stimuli in the current study was surprising, and contrasts with previous research finding 
that oxytocin attenuated baseline attentional biases away from food images in women 
with anorexia nervosa, with no effect in healthy comparison women (Leppanen, Cardi, et 
al., 2017a). However, it should be noted that the increased vigilance observed in the 
current study was not robust to the exclusion of the five participants with BED, even after 
imputing the mean for five simulated participants with BN to make up for the loss of 
power.  Although the sample of participants with BED was not large enough to warrant a 
moderation analysis comparing the influence of oxytocin on participants with BN versus 
BED, these preliminary results demonstrating numerical divergence in the effect of 
oxytocin on attentional bias to palatable food among each disorder suggest that attentional 
biases to palatable food should be investigated separately among samples with BN and 
BED in future studies. On the whole, given that baseline attentional biases in women with 
anorexia nervosa were away from food images, rather than towards food images, the 
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evidence to date suggests that oxytocin increases vigilance to food images in women, 
with preliminary evidence suggesting that this effect is greater in women with anorexia 
nervosa and binge eating disorder (Leppanen, Cardi, et al., 2017a). 
The mechanism by which oxytocin increases attentional bias to food images in 
women is yet unclear, but may involve interactions with dopaminergic signalling systems 
in mesolimbic brain regions (Shamay-Tsoory & Abu-Akel, 2016). Specifically, binding 
to oxytocin receptors in the ventral tegmental area and nucleus accumbens, two regions 
strongly related to reward processing, may initiate neural processes ultimately enhancing 
reward salience of signals (including food) in the immediate environment (Bethlehem, 
Baron-Cohen, van Honk, Auyeung, & Bos, 2014). However, it should be noted that this 
hypothesis is still in the speculative stage of proposal and requires additional empirical 
evidence for corroboration. 
This reward salience hypothesis, as well as the finding that oxytocin increases 
vigilance to food stimuli, is difficult to consolidate with previous findings demonstrating 
that oxytocin decreases hedonic food consumption (Burmester et al., 2018; Ott et al., 
2013; Thienel et al., 2016). That is, one might reasonably hypothesise that reduced 
hedonic food consumption would be associated with less attentional and motivational 
orientation to food stimuli. However, previous studies finding a suppression of hedonic 
eating reported this effect in male participant samples (Burmester et al., 2018; Ott et al., 
2013; Thienel et al., 2016), while no effect of oxytocin on feeding was found in the current 
sample of female participants (Leslie, Leppanen, et al., 2018). An accumulating range of 
studies has found mixed effects of oxytocin on eating in women, both with and without 
eating disorders (Kim, Kim, Park, et al., 2014; Leppanen, Cardi, et al., 2017a), therefore 
suggesting that the inhibitory effect of oxytocin on hedonic eating, and orienting to food 
stimuli, may be sex-specific in humans. However, further research is necessary to clarify 
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whether oxytocin may influence reward salience attribution and actual food consumption 
via different mechanisms. 
There is evidence to suggest that the potency of oxytocin on psychosocial 
functioning has an inverse quadratic function with drug dose (Cardoso et al., 2013). Given 
the relatively high dose of oxytocin administered in the current study (a divided dose of 
64IU), it may therefore be the case that oxytocin administration does have different 
effects on attentional bias in this population at lower doses. Previous evidence has 
indicated that the effects of oxytocin on resting neural activation vary over time  (Martins 
et al., Under Review). Therefore, it is possible that the functional effects of oxytocin on 
attentional biases to palatable food may also differ at other time points after 
administration given differing bioavailability of exogenous oxytocin to neural regions 
underpinning the control of attentional bias. 
 Additional limitations of the current study include the low sample size and our 
inability to measure the effects of oxytocin on early and late stages of attentional 
processing due to the nature of the dot probe task. It should be noted that a different 
pattern of effects may be found at different points within the time course of attentional 
processing given that different patterns of attentional vigilance versus avoidance have 
been observed at different stages of attentional processing in other eating disorders (Giel 
et al., 2011). Future studies of attention bias in BN and BED may be improved through 
the use of alternative measures of attentional bias, such as eye-tracking tasks. 
Additionally, as oxytocin has been found to have sex-specific effects in other studies of 
psychopathology (Feifel et al., 2011), the current findings should therefore not be 
generalised to men with BN and BED.   
 In conclusion, this is the first study to our knowledge to investigate the influence 
of oxytocin on attentional bias to food images in women with BN and BED and healthy 
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comparison women. A divided dose of 64IU intranasal oxytocin increased vigilance to 
palatable food images, although a sensitivity analysis suggests that this effect is primarily 
driven by women with BED. Further studies testing the effects of oxytocin on attentional 
biases to palatable food at different doses and time courses of administration in larger 
samples are warranted. 
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Table 27 
 
Descriptive demographic data 
 Healthy Control (n = 27) BN/BED (n = 25) 
 Median IQR Median IQR 
Age 23.50 5.50 23.50 9.75 
BMI 22.04 1.76 23.09 3.87 
RQF Education 
Level 
6 4 4.5 3 
Note. BN = bulimia nervosa; BED = binge eating disorder; IQR = interquartile range; 
BMI = body mass index; RQF = Regulated Qualifications Framework. 
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Table 28 
Results of the linear mixed effects analysis testing the main effects of eating disorder 
status, oxytocin, and food presentation (experiment time point) on attentional bias to 
food images 
 
 HC (n = 27) 
Mean(SD) 








Oxytocin 10.07(37.200) 10.54(39.720) ED Status: Z = 5.70, SE = 
6.206, df = 46.00, p = .363 
Drug Condition: Z = 
10.42*, SE = 5.136, df = 
142.20, p = .044 
Experiment Time Point: Z 
= 1.10, SE = 5.14, df = 
143.76, p = .831 




Oxytocin 2.74(31.922) 19.93(42.467) 
Placebo -0.26(26.770) 2.29(36.677) 
    Random 
Effects 
Variance 
    Individual 
Participant 
151 
    Residuals 1284 
Note. BED = Binge eating disorder; BN = Bulimia nervosa; ED = Eating disorder; HC = 
Healthy control. 
* p < .05 
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Table 29 
Results of the linear mixed effects analysis testing a full factorial model with fixed 
effects for eating disorder status, oxytocin, and food presentation (experiment time 
point) on attentional bias to food images 
Fixed Effects Estimate SE df t p 
Intercept -0.45 16.170 163.81 -0.03 .978 
ED Status -1.75 22.868 163.86 -0.08 .939 
Drug Condition 17.85 22.536 141.17 0.79 .430 
Experiment Time Point -0.08 10.169 142.17 -0.01 .994 
ED Status * Drug Condition -14.80 32.083 141.71 -0.46 .645 
ED Status * Experiment Time 
Point 
2.68 14.382 142.30 0.19 .853 
Drug Condition * Experiment 
Time Point 
-7.25 14.301 141.55 -0.51 .613 
ED Status * Drug Condition * 
Experiment Time Point 
14.62 20.390 141.91 0.72 .475 
Random Effects Variance     
Individual Participant 159.8     
Residuals 1263.9     
Note. ED = Eating disorder. 
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Supplementary Material 
 
Participant Inclusion and Exclusion Criteria 
Inclusion criteria for the study required participants to be female, aged between 
18 and 40 years old, display English fluency, and to be right-handed (due to an MRI scan 
which was conducted within the battery of tasks). Exclusion criteria included pregnancy, 
severe comorbidity (e.g., substance abuse, drug addiction, psychosis, diabetes), history of 
drug dependence, history of a neurological condition (e.g., epilepsy), a significant visual 
impairment not corrected by eyewear, currently suffering from a cold or flu, currently 
smoking > 5 cigarettes per day (past 6 months), consuming > 21 units of alcohol per 
week, contraindication to MRI scans (due to an MRI conducted as part of the current 
battery of tasks), and current intake of medication that might potentially interact with 
oxytocin (e.g., Prostaglandins). 
Clinical Characteristics of the Participant Sample 
Seven participants who met diagnostic criteria for BN or BED had at least one 
comorbid psychiatric disorder. Five women had comorbid depression, 4 women had 
borderline personality disorder, 4 women had comorbid generalised anxiety disorder, 1 
woman had obsessive-compulsive disorder, 1 woman had social anxiety, and 1 woman 
had an autism spectrum disorder. At the time of the study, 7 women were taking an 
antidepressant, 1 woman was taking an antipsychotic drug, and 1 woman was taking a 
mood stabiliser. 
Participants with bulimia nervosa and binge eating disorder reported an average 
binge eating frequency of 14.14 episodes over the past 28 days (SD = 9.88).  The women 
with bulimia nervosa endorsed an average frequency of self-induced vomiting equal to 
10.40 occasions over the past 28 days (SD = 13.61), an average laxative abuse frequency 
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of 5.13 occasions over the past 28 days (SD =  8.35), an average frequency of “hard 
exercise intended to control weight or shape” equal to 7.31 occasions over the past 28 
days (SD = 8.57), and one participant reported using diuretic pills on 4 occasions over the 
past 28 days. Participants with bulimia nervosa or binge eating disorder reported having 
an eating disorder for an average of 10.30 years (SD = 5.87 years), with an average age 
of onset of 15.74 years (SD = 4.76 years). 
Twenty-two of the fifty-two participants were taking hormonal contraception at 
the time of the study. Fifteen women completed the study whilst in the follicular phase 
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Supplementary Table 9 
Results of the linear mixed effects analysis testing the moderating effect of hormonal 
state on the effects of oxytocin on attentional bias to food images 
Fixed Effects Estimate SE df t p 
Intercept 12.22 10.90 108.38 1.12 .265 
Follicular Phase -5.16 4.80 107.94 -1.08 .285 
Drug Condition 3.12 13.92 135.90 0.22 .823 
Follicular Phase*Drug 
Condition 
2.82 6.11 135.51 0.46 .645 
Random Effects Variance     
Individual Participant 156.30     
Residuals 1273.20     
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Supplementary Table 10 
Results of the linear mixed effects sensitivity analysis testing the main effects of eating 
disorder status, oxytocin, and food presentation (experiment time point) on attentional 
bias to food images among healthy control and BN participants 
 
 HC (n = 27) 
Mean(SD) 







Oxytocin 10.07(37.200) 13.07(41.827) ED Status: Z = 9.39, SE = 
5.662, df = 45.64, p = .104 
Drug Condition: Z = 8.11, 
SE = 4.662, df = 141.79, p 
= .084 
Experiment Time Point: Z 
= -0.17, SE = 4.667, df = 
143.35, p = .971 




Oxytocin 2.74(31.922) 20.09(32.629) 
Placebo -0.26(26.770) 6.93(35.809) 
    Random 
Effects 
Variance 
    Individual 
Participant 
128.6 
    Residuals 1057.9 
Note. BN = Bulimia nervosa; ED = Eating disorder; HC = Healthy control. 
† Data for five participants was simulated based on the imputed mean for each drug condition 
and experiment time point among the participant group with bulimia nervosa
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Supplementary Figure 9. The effect of oxytocin on attentional bias to food images. Time point 1 occurred after the full dose of oxytocin or placebo had 
been administered, but prior to the taste test. Time point 2 occurred after the taste test. 
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Supplementary Figure 10. A box and dotplot of the attentional bias data among each diagnostic group, separated by drug condition. 
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5.3 Paper 7: The Influence of Oxytocin on Risk-Taking in the Balloon Analogue Risk Task 
Among Women with Bulimia Nervosa and Binge Eating Disorder 
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Abstract 
 Previous theoretical models of bulimia nervosa (BN) and binge eating disorder 
(BED) have implicated cross-domain risk-taking behaviour as a significant maintenance 
factor in both disorders. The current study sought to test this hypothesis by administering 
the Balloon Analogue Risk Task (BART) to 25 women with BN or BED and 27 healthy 
comparison women without history of an eating disorder. Furthermore, we tested the 
effect of a divided dose of 64IU oxytocin on risk-taking behaviour in the BART. Contrary 
to our hypothesis, women with BN or BED did not exhibit baseline differences in 
performance on the BART in the placebo condition (t = 1.42, df = 50, p = .161, d = 0.39). 
Oxytocin did not have a main effect on performance in the BART (F = 0.01, df = 1, p = 
.907, η2partial < .001); however, there was an interaction such that participants in the 
BN/BED participant group, compared to the healthy comparison group, demonstrated 
safer behaviour on the BART specifically in the oxytocin condition, but not in the placebo 
condition (F = 4.29, df = 1, p = .044, η2partial = .082). These findings cast doubt on the 
common assumption that individuals with BN and BED exhibit greater risk-taking 
behaviour in all domains and add to evidence that oxytocin plays a functional role in 
modulating behaviours which entail trade-offs between reward approach and risk in 
humans. We recommend that future dose-response studies further investigate the effect 
of oxytocin on reward approach behaviour in women with recurrent binge eating 
behaviour and the clinical significance of this effect. 
Keywords: Bulimia nervosa; binge eating disorder; oxytocin; risk-taking 
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Introduction 
Recurrent loss-of-control binge eating characterises the DSM-5 eating disorders 
bulimia nervosa (BN) and binge eating disorder (BED) 
(American Psychiatric Association, 2013). Binge eating behaviour is associated with 
significant distress, guilt, and shame (American Psychiatric Association, 2013; Haedt-
Matt & Keel, 2011; R. I. Stein et al., 2007), and detracts from the overall quality of life 
of affected individuals (Ágh, Kovács, et al., 2016). 
Furthermore, populations with recurrent binge eating behaviour, including those 
with BN and BED, have been found to exhibit heightened levels of risk-taking behaviour, 
as evidenced by the high comorbidity of BN and BED with substance abuse disorders and 
self-harm behaviour (Gómez-Expósito et al., 2016; Hudson et al., 2007). The role of 
impulsivity in binge eating behaviour has been well-studied, and has been proposed to 
account for higher levels of risk-taking behaviour in populations with recurrent binge 
eating (Giel, Teufel, et al., 2017). However, there is evidence to suggest that both 
generalised reward approach processes and impulsivity contribute to trans diagnostic risk-
taking behaviour, and that each set of processes is both conceptually and functionally 
distinct. 
In the domain of adolescent risk-taking behaviour, for example, it has been 
observed that adolescents exhibit heightened levels of risk-taking in a virtual driving task 
when observed by peers versus when completing the task alone (Chein, Albert, O’Brien, 
Uckert, & Steinberg, 2011). These increases in risk-taking behaviour were found to be 
associated with heightened BOLD responses in the ventral striatum and orbitofrontal 
cortex, two regions strongly associated with reward processing (O’Doherty, 2004). No 
difference in BOLD response was observed in prefrontal “cognitive control circuits” 
between conditions (Chein et al., 2011). Whilst care must be taken when making 
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inferences from neuroimaging data to the structure of cognitive architecture, these data 
are at least compatible with the hypothesis that risk-taking is driven by a dual process 
incorporating the conflicting tendencies for both reward approach and danger avoidance. 
The separability of reward-seeking and disinhibition in driving risk-taking 
behaviour is also supported by previous literature finding that levels of impulsivity and 
generalised reward-seeking follow separate development curves throughout adolescence 
and early adulthood (Steinberg, 2010). Indeed, it has been proposed that the convergence 
of high levels of reward-seeking with high levels of impulsivity account for the greater 
vulnerability to risk-taking behaviour observed in adolescents (Steinberg, 2010). 
However, the role of reward-seeking, versus impulsivity, in driving risk-taking 
behaviour has received relatively less attention in empirical literature pertaining to adults 
with recurrent binge eating behaviour. Nonetheless, both conceptual and empirical 
formulations of risk-taking suggest that reduced reward-seeking should have the 
consequent effect of also reducing risk-taking behaviour (Rutledge et al., 2016).  
 One laboratory task measuring risk-taking behaviour is the Balloon Analogue 
Risk Task (BART) (Lejuez et al., 2002). In the BART, participants aim to maximise a 
virtual "reward" in a game-like task that entails gambling earnings made within each trial 
as participants continue to seek greater overall reward. Therefore, the risk posed by 
continued responding taps into the ratio of participants’ tendency for reward approach 
versus punishment sensitivity (Dissabandara et al., 2014; Gray, 1970). Studies recruiting 
large community samples have found greater risk-taking behaviour on the BART among 
disinhibited, as opposed to restrained, eaters (Leitch, Morgan, & Yeomans, 2013; 
Yeomans & Brace, 2015), although this effect appears to be moderated by prior food 
consumption (Leitch et al., 2013) and exposure to food images (Yeomans & Brace, 2015).  
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Studies administering the BART in clinical eating disorder populations, however, 
have not yielded a clear pattern of results. Manasse et al. (2015), for example, found no 
differences on the BART between obese individuals with and without BED. Neveu et al. 
(2016) found that individuals with BN tend to exhibit less risky behaviour in the BART 
following exposure to food, versus neutral, images, but did not exhibit overall differences 
in behaviour compared to control participants. The study conducted by Neveu et al. 
(2016), however, was limited by low sample size, and the study conducted by Manasse 
et al. (2015) administered only 10 trials in the BART, while the BART was originally 
validated across 30 trials of balloons with the same probability of explosion. Therefore, 
limiting the task to 10 trials also limited power to detect differences between individuals 
with and without binge eating behaviour.  
On the whole, however, the general pattern of responding on the BART in samples 
with subclinical binge eating behaviour has indicated greater levels of risk-taking 
behaviour, which is in line with studies finding greater risk-taking tendencies on other 
measures in populations with clinical levels of binge eating behaviour (Giel, Teufel, et 
al., 2017). In the current study, we therefore sought to investigate whether participants 
with clinical levels of recurrent binge eating behaviour would, indeed, be found to exhibit 
greater risk-taking tendencies on the BART given the greater sample size (Neveu et al., 
2016) combined with a greater number of BART trials compared to previous 
investigations (Manasse et al., 2015). 
Subsequently, it was of interest to examine whether the hypothesised risk-taking 
tendencies in women with recurrent binge eating could be reduced via modulation of 
underlying reward-seeking. Intranasal oxytocin supplementation has emerged as a new 
investigational approach to manage hedonic and over-eating behaviour in healthy and 
overweight men (Burmester et al., 2018; Ott et al., 2013; Spetter et al., 2018; Thienel et 
al., 2016) and in BN (Y.-R. Kim, J.-S. Eom, et al., 2015). While oxytocin may partially 
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impact food intake via the integration of central and peripheral homeostatic satiety signals 
(Leslie, Silva, et al., 2018), an increasing body of evidence suggests that the effects of 
oxytocin on feeding are also mediated by the modulation of reward processes (Burmester 
et al., 2018; Ott et al., 2013; Spetter et al., 2018). For example, the fact that oxytocin has 
been found to significantly curb eating of palatable food in sated healthy normal-weight 
men, but not homeostatic eating in fasted conditions, suggests that exogenous oxytocin 
administration has a stronger effect on reward-driven, as opposed to homeostatic eating 
(Burmester et al., 2018; Ott et al., 2013; Thienel et al., 2016). 
With regards to the mechanism of effect of oxytocin on reward processing, it may 
be the case that exogenous oxytocin administration modulates dopaminergic functioning 
in mesolimbic regions. This hypothesis is supported by a range of pre-clinical studies, 
which have indicated that oxytocin directly stimulates dopamine release within the 
striatum, and reduces the likelihood of conditioned place preference to morphine in 
opioid-tolerant rats after a period of withdrawal (Georgiou et al., 2015). A recent review 
of the myriad direct and indirect effects of oxytocin in modulating opioid seeking and 
withdrawal effects has further highlighted the role of oxytocin in modulating reward-
related central functions of noradrenaline, methamphetamine, serotonin, and glutamate 
(Zanos et al., 2018). 
In humans, 24IU intranasal oxytocin administration has been found to increase 
blood-oxygenated-level dependent (BOLD) response to images of high, versus low, 
calorie foods within the ventromedial prefrontal cortex, supplementary motor area, 
ventrolateral prefrontal cortex, and anterior cingulate cortex of healthy men (Spetter et 
al., 2018). Of functional significance, the oxytocin-induced enhanced BOLD response in 
the right ventrolateral prefrontal cortex when viewing high- versus low-calorie food 
images was inversely correlated with the consumption of sweet ingredients in a breakfast 
meal.  While hypotheses stemming from these findings are still speculative, it may be the 
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case that oxytocin enhances cognitive control over hedonic eating behaviour. In a similar 
study conducted in healthy adult women, the authors found a trend-level effect of 24IU 
oxytocin administration in successfully supporting the intentional reduction of food 
craving in response to food images (Striepens et al., 2016). On the whole, previous 
preliminary evidence has therefore supported a role for oxytocin in modulating reward 
processing. However, it is not yet clear to what extent oxytocin modulates eating 
behaviour or general reward approach behaviours in the context of risk-taking tendencies 
in women with recurrent loss-of-control binge eating (Y.-R. Kim, J.-S. Eom, et al., 2015; 
Leslie, Leppanen, et al., 2018).  
In the current study, we sought to compare the performance of women with 
clinical levels of recurrent binge eating on the BART to that of control women without 
previous history of an eating disorder. Furthermore, we also aimed to investigate the 
differential effect of intranasal oxytocin on risk-taking in the BART in women with BN 
and BED compared to healthy controls. Based on theoretical models suggesting the 
existence of cross-domain risk-taking (Pearson, Wonderlich, & Smith, 2015), we 
hypothesised that women with BN and BED would demonstrate greater baseline risk-
taking behaviour on the BART in the placebo condition, relative to women without 
previous history of an eating disorder. Additionally, given previous research indicating 
that oxytocin induces a down-regulation of reward seeking in men, we hypothesised that 
a divided dose of 64IU intranasal oxytocin, versus placebo, would be associated with 
reduced risk-taking behaviour in the BART in women, and that this effect would be 
stronger in women with BN and BED due to higher trait levels of risk-taking behaviour.  
Methods 
Participants 
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 Fifty-two women participated in the current study. Given that recurrent binge 
eating behaviour was the primary trait of interest in the current study, and that populations 
with BN and BED are both characterised by recurrent loss-of-control binge eating 
behaviour, we therefore recruited a heterogeneous sample of women who met criteria for 
either disorder. Twenty-five women met DSM-5 criteria for BN or BED at the time of the 
study and twenty-seven comparison women had no history of an eating disorder and no 
current psychiatric disorder (American Psychiatric Association, 2013). Participants were 
recruited via the internal research circular at King’s College London, the website for the 
UK eating disorders charity Beat, and through flyers posted on community bulletin 
boards. By chance, an unequal number of participants with BN (n = 20) versus BED (n = 
5) volunteered to take part in the study during the recruitment period. Ethical approval 
for the current study was granted by the London – Camberwell St Giles NHS Research 
Committee (reference: 14/LO/2115). 
 Inclusion criteria for the study were as follows: age between 18 and 40 
years old, English fluency, and right-handedness (due to an MRI scan which was 
conducted within the battery of tasks). Exclusion criteria included pregnancy, severe 
psychiatric comorbidity (e.g., current or previous history of substance abuse disorder, 
psychosis), currently smoking > 5 cigarettes per day (past 6 months), consuming > 21 
units of alcohol per week,  uncompensated general medical conditions that could alter 
eating habits (e.g., diabetes, hypothyroidism), history of a neurological condition (e.g., 
epilepsy), a significant visual impairment not corrected by eyewear, currently suffering 
from a cold or flu (as this can affect nasal absorption of the oxytocin), contraindication to 
MRI scans, and current intake of medication that might potentially interact with oxytocin 
(e.g., Prostaglandins). 
 Eligibility for the current study was determined through a phone screening, which 
included an interview using the eating disorders module of the Structured Clinical 
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Interview for DSM-5 – Research Version (SCID) (American Psychiatric Association, 
2013). Phone screenings were conducted by MSc and PhD students who had received 
training in the correct use of SCID for DSM-5. 
Seven participants in the BN/BED participant group self-reported at least one 
comorbid psychiatric disorder: 5 women had comorbid depression, 4 women had 
borderline personality disorder, 4 women had comorbid generalised anxiety disorder, 1 
woman had obsessive-compulsive disorder, 1 woman had social anxiety, and 1 woman 
had an autism spectrum disorder. At the time of the study, 7 women were taking an 
antidepressant, 1 woman was taking an antipsychotic drug, and 1 woman was taking a 
mood stabiliser. Participants with BN and BED reported an average binge eating 
frequency of 14.14 episodes over the past 28 days (SD = 9.88).  The women with BN 
endorsed an average frequency of self-induced vomiting equal to 10.40 occasions over 
the past 28 days (SD = 13.61), an average laxative abuse frequency of 5.13 occasions over 
the past 28 days (SD =  8.35), an average frequency of “hard exercise intended to control 
weight or shape” equal to 7.31 occasions over the past 28 days (SD = 8.57), and one 
participant reported using diuretic pills on 4 occasions over the past 28 days.  
Participants self-reported their use of hormonal contraception or the first day of 
their most recent menstrual period and this information was used to determine menstrual 
phase at the time of the study for each participant. Twenty-two participants reported 
taking hormonal contraception at the time of the study. Fifteen women completed the 
study in the follicular phase of the menstrual cycle and thirteen women completed the 
study in the luteal phase of the menstrual cycle. Menstrual phase data were missing for 
two women. Descriptive statistics regarding the age, BMI, and education level of the 
BN/BED and comparison participant groups are presented in Table 30. 
Procedure 
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 The current study used a double-blind placebo-controlled crossover design. Each 
participant attended the laboratory for an initial orientation visit and two experimental 
visits. Each participant completed an online battery of psychological tests between the 
orientation visit and the first experimental visit. Two of the tests, the Depression, Anxiety, 
and Stress Scales and the Eating Disorders Examination – Questionnaire version, will be 
described in further detail below. During each experimental visit, participants self-
administered a divided dose of 64IU intranasal oxytocin or an equal volume of a placebo 
nasal spray. The order of oxytocin versus placebo administration was pseudo-randomised 
for each participant, such that the same number of participants received oxytocin on the 
first, versus the second, visit. Experimental study visits were held two days apart to ensure 
that each woman was in the same phase of the menstrual cycle during each visit. Perfusion 
data analysing the central effects of oxytocin suggest that carryover effects from oxytocin 
administration on the first experimental visit to the second experimental visit are highly 
unlikely (Paloyelis et al., 2016). 
 The first 40IU dose of intranasal oxytocin, or equal volume of placebo, was 
administered at approximately 5.50pm during each experimental visit. Participants 
subsequently underwent an arterial spin labelling (ASL) scan and fMRI scan, in which 
they were presented with images and flavours of water and chocolate milk. These 
neuroimaging results are not reported in the current paper. We chose to administer a 40IU 
dose of oxytocin prior to the fMRI scan in order to replicate the Y.-R. Kim, J.-S. Eom, et 
al. (2015) protocol, which found an effect of oxytocin on eating behaviour in women with 
BN at this dose. We additionally chose this dose in order to replicate the protocol of a 
previous study investigating the effects of intranasal oxytocin on cerebral blood perfusion 
in men (Martins, Mazibuko, et al., 2019). A comparison analysis with the previous ASL 
data found in men is currently in preparation for publication. 
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However, previous findings in humans have suggested that peak central effects of 
40IU intranasal oxytocin occur 39-51 minutes following administration (Paloyelis et al., 
2016), thus suggesting the need for an additional dose after this time. Therefore, following 
the conclusion of the fMRI scan, each participant self-administered the remaining 24IU 
of oxytocin or equal volume of placebo at approximately 7.10pm. Following this second 
dose of oxytocin each participant completed the Balloon Analogue Risk Task, which is 
described below. At the conclusion of the study, participants were prompted to indicate 
whether they had received oxytocin or placebo on that occasion to test the effectiveness 
of drug blinding. Drug blinding was found to be effective, as participants guessed drug 
condition correctly on 57 out of the total 104 visits (54.8% of visits), which was not 
significantly different from chance (p = .377). There was not a significant difference in 
the frequency of binge eating episodes in the 24-hr period following oxytocin 
administration, versus placebo administration, among the participants with BN and BED 
(see Supplementary Material). 
The Balloon Analogue Risk Task 
 The Balloon Analogue Risk Task (BART) is a validated measure of risk taking 
behaviour, which is presented on a computer (Lejuez et al., 2002). Each participant is 
presented with a total of 30 balloon trials. During each trial, the participant is informed 
that each additional click of the computer mouse will add one pump to the balloon, which 
is associated with an additional virtual £0.05 added to their total task bank. Once the 
participant believes they have collected enough money for that task trial, they press on a 
button reading “Collect” to collect their total earnings for that task trial and proceed to 
the next trial. However, each balloon is programmed to explode after a different random 
number of pumps. Participants do not collect any money on trials where the balloon 
explodes before the participant chooses to collect their earnings. 
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 The BART yields three measures of risk-taking tendency: the adjusted average 
pump count, total pump count, and total explosion count. The adjusted average pump 
count is sensitive to general risk-taking tendency on trials without a balloon explosion, as 
the pump count for trials in which the balloon explodes are excluded from the adjusted 
average pump count measure. A greater adjusted average pump count therefore indicates 
greater risk-taking tendency. The total number of balloon explosions captures continued 
risk-taking tendency after experiencing previous “punishment” for that risk-taking 
behaviour (in the form of prior balloon explosions). The adjusted average pump count is 
generally considered superior to the total pump count, which has an artificial ceiling on 
pumps imposed on trials in which the balloon does explode, thus potentially artificially 
suppressing variance between individuals’ performance (Lejuez et al., 2002). In line with 
standard administration of the BART, the total pump count will therefore not be 
considered in the current paper (Lejuez et al., 2002). As both adjusted average pump count 
and total number of balloon explosions both tap into general risk-taking tendency, these 
measures are positively correlated with each other (r = .91) (Lejuez et al., 2007; Lejuez 
et al., 2002). However, previous work has found interpersonal differences in responding 
to “win” versus “loss” trials, depending on whether the balloon exploded in the previous 
trial. Specifically, compared to adults, adolescents are more sensitive to the previous 
trial’s outcome, responding with more pumps after win trials and fewer pumps after loss 
trials (S. H. Mitchell, Schoel, & Stevens, 2008). Additionally, men are more likely to 
continue to respond with a greater number of pumps after loss trials (Cazzell, Li, Lin, 
Patel, & Liu, 2012). Given that the total number of balloon explosions taps into continued 
risk-taking following previous loss trials, there is evidence to suggest that total number 
of balloon explosions additionally captures risk tolerance following previous loss, which 
is not captured by the adjusted average pump count. Accordingly, we have 
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operationalised our hypotheses regarding risk-taking tendency in the BART in terms of 
both the adjusted average pump count and total number of balloon explosions. 
Psychometric Tests 
 Depression, Anxiety, and Stress Scales. The Depression, Anxiety, and Stress 
Scales, 21-item version (DASS) is a short measure of negative emotions experienced over 
the course of the past week for the individual (Lovibond & Lovibond, 1995). Each item 
is presented as a 4-point Likert scale, anchored as 0 (“Did not apply to me at all”), 1 
(“Applied to me some degree, or some of the time”), 2 (“Applied to me to a considerable 
degree or a good part of the time”), and 3 (“Applied to me very much or most of the 
time”). The total score for each subscale of the 21-item DASS is calculated by summing 
participants’ responses to the items for each subscale and multiplying this sum by two. 
Higher scores for each subscale therefore indicate greater levels of depression, anxiety, 
and stress, respectively. Each subscale of the DASS was associated with very good or 
excellent internal consistency reliability in the current study: Depression subscale α = 
0.96; Anxiety subscale α = 0.88; Stress subscale α = 0.93. The DASS-21 exhibits good 
discriminant and convergent validity, when results are compared against other 
psychometric measures of depression and anxiety (Henry & Crawford, 2005). Descriptive 
statistics associated with the DASS for each participant group are presented in Table 31. 
 Eating Disorder Examination – Questionnaire Version. The Eating Disorder 
Examination – Questionnaire Version (EDE-Q) is a self-report questionnaire measuring 
eating disorder psychopathology and the frequency of eating disorder behaviours 
(Fairburn & Beglin, 1994a). The psychopathology section of the EDE-Q contains four 
subscales presented in the form of a 7-point Likert scale: a Restraint subscale, an Eating 
Concern subscale, a Weight Concern subscale, and a Shape Concern subscale. The Likert 
scale prompts participants to report on how many days they exhibited each item of eating 
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disorder psychopathology, in which response to each item are anchored from 0 (“No 
days”) to 6 (“Every day”). Each subscale of the EDE-Q was associated with excellent 
internal consistency reliability in the current sample: Restraint subscale α = 0.92; Eating 
Concern subscale α = 0.93; Shape Concern subscale α = 0.97; Weight Concern subscale 
α = 0.94. The EDE-Q is associated with acceptable criterion validity, with significantly 
different mean scores for each subscale among individuals with, versus without, a current 
eating disorder (Mond, Hay, Rodgers, Owen, & Beumont, 2004). Descriptive statistics 
associated with the EDE-Q subscales for each participant group are reported in Table 32. 
Statistical Analyses 
 All analyses were conducted in IBM SPSS Statistics version 24. Differences in 
performance on the BART in the placebo condition between women in the BN/BED 
group and comparison women were analysed using Student’s t-test. The effects of 
oxytocin and eating disorder status on the adjusted average pump count and total balloon 
explosions in the BART were analysed with 2 x 2 mixed-design ANOVAs. The 
independent variables for each analysis were eating disorder status (healthy control versus 
BN/BED) and drug condition (placebo versus oxytocin).  
Results 
 The data were first inspected for outliers and assumptions of normality. There 
were no outliers (Z > |3.0|) in the Adjusted Pump Count or Total Explosions variables. 
Both variables were approximately normally distributed (skew < |2.0|, kurtosis < |9.0|) 
(Schmider, Ziegler, Danay, Beyer, & Bühner, 2010). Descriptive statistics for the BART 
data are presented in Table 33. Correlations between the adjusted average pump count 
variable and the total explosion variable within the healthy control group were r = .87 (p 
< .001) and r = .91 (p < .001), for the placebo and oxytocin conditions, respectively. 
Correlations between the adjusted average pump count variable and the total explosion 
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variable within the BN/BED group were r = .90 (p < .001) and r = .95 (p < .001), for the 
placebo and oxytocin conditions, respectively. Given the high correlation between the 
adjusted average pump count variable and the total explosion variable and the fact that 
there were only two main analyses, we deemed it excessively conservative to control for 
multiple comparisons using a Bonferroni correction due to the high risk of a Type II error 
(Bland & Altman, 1995). 
Adjusted Average Pump Count 
We tested baseline differences between women with BN/BED and comparison 
women on the adjusted average pump count using Student’s t-test. There was no 
significant difference between the two participant groups on the adjusted average pump 
count in the placebo condition (t = 1.11, df = 50, 95% CI [-2.95, 10.29], p = .270, d = 
0.31). We tested the influence of oxytocin and eating disorder status on the adjusted 
average pump count using a 2x2 mixed-design ANOVA. Participants without history of 
an eating disorder did not exhibit a significant difference on the average adjusted average 
pump count variable compared to participants in the BN/BED group (F = 2.99, df = 1, p 
= .090, η2partial  = .059). The main effect of drug condition on the adjusted average pump 
count was also non-significant (F = 0.02, df = 1, p = .888, η2partial < .001), as was the Drug 
Condition*Eating Disorder Status interaction (F = 0.90, df = 1, p = .348, η2partial = .018). 
A line graph depicting the adjusted average pump count for each participant group and 
drug condition is depicted in Supplementary Figure 11. 
Total Explosions 
There was no significant difference in balloon explosions between the healthy 
comparison (HC) and BN/BED participant group in the placebo condition (t = 1.42, df = 
50, 95% CI [-0.58, 3.43], p = .161, d = 0.39). We tested the influence of oxytocin and 
eating disorder status on the total number of balloon explosions using a 2x2 mixed-design 
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ANOVA. The main effect of drug condition on total number of explosions was not 
significant (F = 0.01, df = 1, p = .907, η2partial < .001).  Participants in the HC group 
exhibited a significantly greater number of balloon explosions (F = 4.06, df = 1, p = .050, 
η2partial = .078). There was a significant interaction between drug condition and eating 
disorder status: the HC group exhibited a numerically greater number of balloon 
explosions in the oxytocin condition compared to the placebo condition, while 
participants in the BN/BED group had fewer balloon explosions in the oxytocin condition 
compared to the placebo condition (F = 4.29, df = 1, p = .044, η2partial = .082). A line graph 
depicting the number of total balloon explosions for each participant group in each drug 
condition is presented in Supplementary Figure 12. 
Post hoc t-tests revealed that the difference in total balloon explosions between 
placebo and oxytocin conditions was not statistically significant when the data was 
isolated among the BN/BED participant group (t = 1.20, df = 23, 95% CI [-0.42, 1.59], p 
= .241, d = 0.30), nor among the healthy comparison participant group (t = -1.82, df = 25, 
95% CI [-1.39, 0.09], p = .081, d = 0.27). However, the difference in balloon explosions 
between the two groups did depend on drug condition. As stated previously, there was no 
significant difference in balloon explosions between the HC and BN/BED participant 
group in the placebo condition (t = 1.42, df = 50, 95% CI [-0.58, 3.43], p = .161, d = 0.39). 
However, the HC group did have significantly greater balloon explosions than the 
BN/BED group in the oxytocin condition (t = 2.50, df = 48, 95% CI [0.51, 4.71], p = .016, 
d = 0.71). As reported in Table 34, there were no significant correlations between 
depression, anxiety, stress, or eating disorder psychopathology and balloon explosions in 
the oxytocin or placebo condition among the BN/BED participant group. 
We subsequently conducted a sensitivity analysis to investigate the potential 
moderating effect of menstrual phase (follicular phase, luteal phase, or hormonal 
contraception) on the effect of oxytocin on performance in the BART with 3x2 mixed-
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design ANOVAs for the adjusted average pump count and the total number of balloon 
explosions. There was neither a significant main effect nor a significant interaction with 
oxytocin for either dependent variable. The full results of the ANOVA testing the 
influence of menstrual phase on adjusted average pump count are reported in 
Supplementary Table 11, and the results of the ANOVA testing the influence of 
menstrual phase on the total number of balloon explosions are reported in 
Supplementary Table 12. 
Discussion 
The current study aimed to test differences in risk-taking performance on the 
BART among women with and without clinical levels of recurrent binge eating, which 
includes women with both BN and BED, as compared to healthy comparison women. 
Additionally, we investigated the effect of a divided dose of 64IU intranasal oxytocin on 
risk-taking behaviours in the BART among women with BN and BED, as well as women 
without prior history of an eating disorder. We hypothesised that women with BN and 
BED would demonstrate greater risk-taking behaviour on the BART in the placebo 
condition. This hypothesis was not supported, as there were no significant differences in 
performance on the BART between the BN/BED and HC participant groups in the 
placebo condition. We also hypothesised that prior administration of intranasal oxytocin, 
versus placebo administration, would be associated with reduced risk-taking behaviour 
on the BART. Our second hypothesis was also not supported as there was no overall 
effect of oxytocin on the adjusted average pump count or total balloon explosion count in 
the BART. Our final hypothesis was that the effect of oxytocin on reducing risk-taking 
behaviour on the BART would be stronger in women with BN and BED, compared to 
women without history of an eating disorder. Our final hypothesis was partially 
supported, as oxytocin was associated with lower risk-taking tendencies among the 
BN/BED, versus healthy comparison, participant group for the total balloon explosions 
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count. However, there was no such significant moderating effect for the adjusted average 
pump count variable.  
Despite the fact that the moderation effect between participant group and drug 
condition did not reach significance for the adjusted average pump count variable, it is 
interesting to note that the direction of effect was in the same direction as for the balloon 
count variable. That is, participants in the HC group exhibited numerically greater risk-
taking tendency compared to the BN/BED participant group in the placebo condition, and 
this difference was enhanced further in the oxytocin condition. That is, the healthy control 
group displayed numerically higher risk-taking in the oxytocin versus placebo condition 
for both variables, and the BN/BED participant group displayed numerically lower risk-
taking in the oxytocin versus placebo condition for both variables. The lack of significant 
differences observed in the adjusted average pump count variable is likely a result of the 
greater variability in performance on this measure. It would therefore be interesting to 
investigate further in future studies with larger sample sizes in order to ensure adequate 
power. This replication is especially important given that we did not statistically control 
for the two analyses conducted. On the whole, however, given that the same pattern of 
effect was observed for both BART variables, these findings therefore suggest that the 
effect of oxytocin on risk-taking tendencies in the BART is moderated by baseline 
individual differences. 
The differential effect of oxytocin on risk-taking performance in the BART may 
relate to differences in oxytocin functioning among women with BN compared to healthy 
comparison women. For example, Y.-R. Kim, J.-H. Kim, et al. (2015) have found that the 
G allele of the rs53576 oxytocin receptor gene polymorphism is associated with greater 
risk for BN. Similarly, Micali, Crous-Bou, et al. (2017) found that the GG variant of the 
same gene is associated with greater binging and purging behaviour in women. Micali, 
Crous-Bou, et al. (2017) also found evidence of a gene X environment interaction, such 
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that the AG/GA variant of the rs2254298 oxytocin receptor gene polymorphism is 
associated with greater binging and purging behaviour specifically in the context of poor 
maternal care. This pattern of findings suggests that differences in oxytocinergic 
functioning play a functional role in recurrent binge-purge behaviour. Additionally, one 
can speculate that the administration of exogenous oxytocin may differentially affect risk-
taking tendencies via different patterns of central receptor binding in each participant 
group. It is possible that these differences may be related to neural circuits including the 
nucleus accumbens and ventral tegmental area, both of which contain a high density of 
oxytocin receptors and hold great significance in underpinning appetite behaviour and the 
processing of reward receipt; however, this hypothesis requires further evidence for 
corroboration (Grinevich, Knobloch-Bollmann, Eliava, Busnelli, & Chini, 2016).  
With regards to the lack of statistically significant baseline differences in risk-
taking on the BART between HC and BN/BED groups, the current results add to a mixed 
field of findings on the BART among participants with disinhibited eating. In non-clinical 
samples of participants with disinhibited eating, defined by higher scores on the 
Disinhibition scale of the Three Factor Eating Questionnaire (Stunkard & Messick, 1985), 
greater levels of risk-taking behaviour on the BART have been observed following prior 
exposure to food images and food consumption (Leitch et al., 2013; Yeomans & Brace, 
2015). The presentation of food stimuli was replicated in the current study given that 
participants viewed images and received small sips of chocolate milk during the course 
of the fMRI task conducted prior to the BART. However, we failed to observe greater 
risk-taking behaviour in the BN/BED participant group in the placebo condition. 
By contrast to previous research in sub-clinical samples of disinhibited eaters, 
previous studies recruiting clinical samples of participants with BN or BED found similar 
findings to those reported in the current study. That is, there was no difference in 
responding on the BART among obese participants with or without BED (Manasse et al., 
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2015), nor between participants with BN and healthy comparison participants (Neveu et 
al., 2016). On the whole, these findings demonstrate that individuals with BN and BED 
do not demonstrate greater risk-taking on the BART and, if anything, instead exhibit 
numerically smaller risk-taking tendency. 
With regards to limitations in interpreting the current findings, it should be noted 
that tasks such as the BART have been previously criticised for their limited utility in 
measuring the type of impulsive behaviour generally exhibited by individuals with 
clinical levels of recurrent binge eating. For example, Leitch et al. (2013) found that 
women with disinhibited eating tended to display higher levels of “Reflective 
impulsivity”, defined by a failure to compile and evaluate relevant information before 
making a decision, as compared to tendencies to perform differently on measures of 
“Impulsive actions” and “Impulsive choices”. Additionally, it is also possible that 
laboratory tasks involving virtual rewards may lack the reward value for participants 
which would elicit behaviours representative of real-world risk-taking, and more general 
reward-approach behaviours. Indeed, a similar measure of risk-taking behaviour, the 
Iowa Gambling Task, has recently been criticised for being poorly correlated with self-
reported real-life risk-taking behaviour (Schmitz, Kunina-Habenicht, Hildebrandt, 
Oberauer, & Wilhelm, 2018), leading to increased interest in the BART as an alternative  
measure of decision-making in risk-taking scenarios. Future validation studies would be 
useful in more firmly establishing the ecological validity of risk-taking tasks among 
populations with binge eating behaviour. 
Limitations of the current study also include small sample size, which limited our 
power to detect small effects. Additionally, the neural effects of oxytocin are moderated 
by dose (Cardoso et al., 2013) time and method of administration (Paloyelis et al., 2016), 
so it is possible that a different pattern of effects would have been observed using different 
doses or methods of administration. It would also be interesting to further explore 
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differences with and without prior exposure to images of food or calorie-dense drinks and 
without prior administration of the fMRI scan, which may have affected responding on 
the BART by exposing participants to an unfamiliar stressor. Given differences in 
hormonal secretion across the course of circadian cycles (Forsling, Montgomery, Halpin, 
Windle, & Treacher, 1998), which may have interacted with the effect of the 
exogenously-administered oxytocin, it should also be noted that the current results may 
not generalise to different times of day (e.g., in the morning or early afternoon). Finally, 
given the possibility for error inherent in participants self-reporting menstrual phase, 
future studies can improve accuracy in assessing the interaction between menstrual phase 
and exogenous oxytocin by testing blood concentrations of follicle stimulating hormone. 
Clinical Implications 
Previous research has described BN as being characterised by elevated levels of 
both reward and punishment sensitivity (Harrison, O'Brien, Lopez, & Treasure, 2010). 
The fact that BN is commonly comorbid with substance use disorders (O'Brien & 
Vincent, 2003) has contributed to the hypothesis that reward approach behaviours tend to 
“win out” over fear of punishment across life domains (Treasure et al., 2018; Waxman, 
2009). However, the current findings add to previous work using the BART to suggest 
that elevated risk-taking behaviour is not always evident in BN/BED. Previous work has 
suggested that elevated levels of risk-taking behaviour may exist predominantly in 
subgroup of people with BN comorbid with either  borderline personality disorder 
(O'Brien & Vincent, 2003) or attention-deficit/hyperactivity disorder (Nazar et al., 2018). 
Future research would therefore be helpful to determine whether there is differential 
responsiveness to reward, versus punishment, in women with comorbid BN and 
borderline personality disorder versus women without a comorbid personality disorder. 
Conclusion 
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To conclude, the current study aimed to replicate previous studies comparing 
performance on the BART between women with clinical levels of recurrent binge eating 
to comparison women without history of an eating disorder. We further aimed to 
investigate the influence of intranasal oxytocin on risk-taking in the BART among women 
with BN and BED and comparison women without history of an eating disorder. There 
were no significant baseline differences in performance on the BART between women 
with and without BN or BED in the placebo condition. We found evidence of a significant 
interaction for the balloon explosion variable such that a divided dose of 64IU oxytocin 
enhanced initial numerical differences in risk-taking between the participant groups: 
increasing risk-taking in the healthy control group and decreasing risk-taking in the 
BN/BED participant group. Although not reaching significance, the same trend was 
observed for the adjusted average pump count variable. Future studies with greater power 
would be useful in further clarifying whether cross-domain heightened risk-taking is 
restricted to some subgroups of people with BN. 
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Table 30 
Descriptive demographic data 
 Healthy Control (n = 27) BN/BED (n = 25) 
 Median IQR Median IQR 
Age 23.50 5.50 23.50 9.75 
BMI 22.04 1.76 23.09 3.87 
RQF Education 
Level 
6 4 4.5 3 
Note. BN = bulimia nervosa; BED = binge eating disorder; IQR = interquartile range; 




Descriptive statistics for the Depression, Anxiety, and Stress Scales (21-item version) 
 
Note. BN = bulimia nervosa; BED = binge eating disorder; EDE-Q = Eating Disorder 
Examination – Questionnaire Version. 
  
 Healthy Control  (n = 26) 
BN/BED  
(n = 25) 
    
 M SD M SD d t df p 
Depression 
Scale 1.92 3.08 21.42 11.32 
2.37 -8.31 27.53 < .001 
Anxiety Scale 1.04 1.54 12.16 9.18 1.69 -5.97 25.35 < .001 
Stress Scale 2.88 3.17 20.56 11.20 2.19 -7.59 27.81 < .001 
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Table 32 
 
Descriptive statistics for the Subscales of the Eating Disorder Examination – 
Questionnaire Version 
 
Note. BN = bulimia nervosa; BED = binge eating disorder; EDE-Q = Eating Disorder 
Examination – Questionnaire Version.
 Healthy Control (n = 26) BN/BED (n = 25)   
 Median IQR Median IQR U p 
EDE-Q Restraint 0.40 0.70 4.00 2.10 577.50 < .001 
EDE-Q Eating Concern 0.00 0.20 4.20 1.90 649.00 < .001 
EDE-Q Weight Concern 0.40 0.85 4.80 1.50 623.00 < .001 
EDE-Q Shape Concern 1.20 0.63 5.63 1.63 627.50 < .001 
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Table 33 
Descriptive statistics for performance on the Balloon Analogue Risk Task, separated by eating disorder status 
 Healthy Control (n = 27) BN/BED (n = 25) 
 Placebo Oxytocin Placebo Oxytocin 
 M SD M SD M SD M SD 
Adjusted Average Pump Count 37.62 10.656 38.43 12.033 33.95 13.061 31.95 10.926 
Total Explosions 8.70 3.760 9.19 3.950 7.28 3.422 6.58 3.387 
Note. BN = bulimia nervosa; BED = binge eating disorder. 
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Table 34 
Pearson correlations between the total balloon explosions among the BN/BED participant group and the DASS and EDE-Q scales 
 1 2 3 4 5 6 7 8 
1. Total Explosions(PL) -        
2. Total Explosions (OT) .76***        
3. DASS Stress Scale -.01 -.06       
4. DASS Depression Scale -.02 -.22 .69***      
5. DASS Anxiety Scale .22 .27 .67*** .35     
6. Restraint .05 .27 .10 -.12 .16    
7. Eating Concern .14 .31 .16 -.18 .27 .48*   
8. Shape Concern -.04 .17 .08 -.03 .17 .51* .71***  
9. Weight Concern .05 .18 .31 -.03 .33 .41* .78*** .81*** 
Note. BN = bulimia nervosa; BED = binge eating disorder; DASS = Depression, Anxiety, and Stress Scales; EDE-Q = Eating Disorder Examination – 
Questionnaire version; OT = oxytocin condition; PL = placebo condition. 
* p < .05. 
*** p < .001. 
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Supplementary Material 
Effect of oxytocin on subsequent incidence of binge eating 
 We conducted an exact binomial test to determine whether oxytocin impacted 
whether participants with bulimia nervosa or binge eating disorder had a binge eating 
episode in the 24 hours following oxytocin administration, versus placebo administration. 
Fifteen participants did not have a binge eating episode on either day. No participant had 
a binge eating episode following both respective experimental sessions. Two women 
experienced a binge eating episode in the 24 hours following oxytocin administration, 
while three women had a binge eating episode in the 24 hours following placebo 
administration. An exact binomial test revealed the frequency of binge eating following 
oxytocin administration versus placebo was not significant (p = .999). 
Supplementary Table 11 
Results of the 2x2 mixed-design ANOVA testing the moderating influence of oestrous 
phase on the effect of oxytocin on adjusted average pump count in the BART 
  F  df  p  η2partial  
Drug Condition  0.03 1 .857 .001 
Oestrous Phase 1.47 2 .242 .061 
Drug Condition*Oestrous Phase  0.44 2 .646 .019 
Note. BART = Balloon Analogue Risk Task. 
 
Supplementary Table 12 
Results of the 2x2 mixed-design ANOVA testing the moderating influence of oestrous 
phase on the effect of oxytocin on total balloon explosions in the BART 
  F  df  p  η2partial  
Drug Condition  0.15 1 .698 .003 
Oestrous Phase 0.37 2 .691 .016 
Drug Condition*Oestrous Phase  1.92 2 .158 .079 
Note. BART = Balloon Analogue Risk Task. 
  


















Supplementary Figure 11. The influence of oxytocin on the adjusted average pump 
count variable. ED = eating disorder participant group; HC = healthy control participant 
group. Error bars represent confidence intervals. 
  




















Supplementary Figure 12. The influence of oxytocin on total balloon explosions. ED = 
eating disorder participant group; HC = healthy control participant group. Error bars 
represent confidence intervals. 
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Chapter 6 
 
6 The influence of oxytocin on the neural processing of palatable taste 
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6.1 The influence of oxytocin on the neural processing of palatable taste in women with 
and without bulimia nervosa or binge eating disorder: Preliminary outcomes 
The Influence of Oxytocin on the Neural Processing of Palatable 
Taste in Women With and Without Bulimia Nervosa or Binge 
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Abstract 
Background: Bulimia nervosa and binge eating disorder are DSM-5 eating disorders 
characterized by recurrent loss-of-control binge eating episodes. Recent evidence has 
suggested that intranasal oxytocin administration can reduce food craving and increase 
cognitive control over food craving. However, previous research has not yet explored the 
effect of oxytocin on the neural processing of the receipt of palatable taste or differences 
in this effect between women with and without loss-of-control binge eating. The current 
study sought to address this gap in the literature through the use of functional magnetic 
resonance imaging (fMRI). We hypothesized: 1) That women with BN and BED would exhibit 
heightened BOLD response in the orbitofrontal cortex (OFC), ventral tegmental area (VTA)) and 
nucleus accumbens (NAcc) in response to the image of chocolate milk, versus the image of water; 
2) That women with BN and BED would exhibit lower BOLD response than healthy comparison 
women in the same regions in response to the actual receipt of chocolate taste, versus water taste; 
3) That oxytocin would suppress BOLD response in the OFC, VTA, NAcc, and hypothalamus in 
response to chocolate images, versus water images, in both groups of women; 4) That there would 
be a diagnosis x drug interaction such that oxytocin would suppress BOLD activation in the OFC, 
VTA, NAcc, and hypothalamus to a greater extent in women with BN or BED versus healthy 
comparison women in response to images of chocolate milk versus images of water. 
Methods: We recruited 25 women with bulimia nervosa or binge eating disorder and 25 
healthy comparison women. Each participant attended the lab for two experimental 
sessions, receiving 40IU intranasal oxytocin prior to the fMRI scan during one session, 
and an equal volume of placebo nasal spray during the opposite session. Both the 
participant and experimenters were blind to the order of drug allocation. During the fMRI 
scan participants viewed a series of images of a glass of water or a glass of chocolate milk 
and received the corresponding drink, water or chocolate milk, through a mouthpiece on 
a random set of trials.  
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Results: We did not observe significant differences in neural activation between women 
with BN or BED, versus healthy control women, in response to the anticipation or receipt 
of chocolate taste, versus water taste. The administration of 40IU intranasal oxytocin, 
versus placebo, did not affect the BOLD response to the anticipation or receipt of 
chocolate taste, versus water taste, in either participant group. However, the ventral 
striatum and orbitofrontal cortex were not included in the analysis presented here due to 
a technical issue, thus presenting a significant caveat to interpreting the current 
preliminary findings.  
Conclusions: As we proceed with processing the current dataset, it will be important to 
conduct region-of-interest analyses including the basal ganglia and orbitofrontal cortex 
in order to investigate potential differences in neural activation in these reward-related 
circuits between participant groups and in response to oxytocin, versus placebo, 
administration. 
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 Bulimia nervosa (BN) and binge eating disorder (BED) are DSM-5 eating disorders 
characterized by recurrent loss-of-control binge eating (American Psychiatric Association, 2013). 
Current gold standard treatments for bulimia nervosa and binge eating disorder are associated 
with only modest remission rates (Hay, 2013; Shingleton, Thompson-Brenner, Thompson, Pratt, 
& Franko, 2015). The development of more effective treatments for BN and BED is therefore a 
priority for research and has inspired the recent development of novel approaches to 
characterizing and addressing core symptomatology (Treasure et al., 2018; Turton et al., 2016). 
 Oxytocin is a neuropeptide which has been found to modulate reward processing in a 
number of domains, including the prevention of reinstated morphine-seeking in rats following a 
period of withdrawal (Georgiou et al., 2015; Zanos et al., 2014) and the reinforcement of social 
behavior (Dölen, Darvishzadeh, Huang, & Malenka, 2013). Oxytocin has recently gained further 
attention for its potential to curb overeating of rewarding palatable foods (Burmester, 2017; Ott 
et al., 2013; Thienel et al., 2016). The finding that oxytocin can specifically curb hedonic eating 
in healthy and overweight men has contributed to the hypothesis that oxytocin may also hold 
therapeutic potential for the prevention of binge eating behavior in BN and BED (Y. Kim, J. Eom, 
J. Yang, J. Kang, & J. Treasure, 2015; Leslie, Leppanen, et al., 2018; Thienel et al., 2016). 
 Currently there is mixed evidence for the effect of oxytocin on binge eating in BN. Y. 
Kim, J. Eom, et al. (2015) found that 40IU intranasal oxytocin reduces 24-hour caloric intake in 
participants with BN, but has no short-term effect on consumption of fruit juice. However, we 
recently failed to replicate the effect of intranasal oxytocin on 24-hour caloric consumption in 
women with BN and BED at a divided dose of 64IU (Leslie, Leppanen, et al., 2018). We also 
found that oxytocin did not impact the consumption of palatable foods in the lab 25 minutes after 
the conclusion of drug administration (Leslie, Leppanen, et al., 2018). However, it is of interest 
to investigate the effects of intranasal oxytocin on the neural processing of visual and gustatory 
palatable food cues in BN and BED to further elucidate any subtle effects of oxytocin on 
appetitive circuits, which may not have reached full behavioural expression at the doses and time 
points of measurement in existing studies. 
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 The neural effects of oxytocin on the processing of food cues has previously been 
investigated in healthy men and women. For example, 24IU intranasal oxytocin versus placebo 
administration is association with elevated blood oxygen level dependent (BOLD) response in the 
ventrolateral prefrontal cortex (vlPFC) in response to high versus low calorie food images in 
healthy men (Spetter et al., 2018). Given that this elevated BOLD response was inversely 
correlated with the quantity of sweet ingredients the men subsequently consumed in a breakfast 
meal, the authors have speculated that oxytocin may inhibit hedonic eating via upregulation of 
prefrontal circuits underpinning cognitive control. Additionally, a study directly testing the effect 
of oxytocin on food craving found that 24IU intranasal oxytocin, versus placebo administration, 
was associated with a trend-level effect towards reducing craving for depicted palatable foods in 
healthy women when instructed to imagine the long-term consequences of food consumption 
(Striepens et al., 2016). This oxytocin-induced reduction in craving was accompanied by elevated 
BOLD response in the precuneus, cingulate cortex and precentral gyrus, and superior temporal 
gyrus, thus leading the authors to hypothesise that these regions may mediate oxytocin-induced 
enhancements in cognitive control in healthy women (Striepens et al., 2016).  
However, the finding that oxytocin suppresses food craving and consumption was not 
replicated in another mixed sample of healthy men and women (Klaauw et al., 2017). Rather, 
24IU oxytocin was observed to suppress BOLD response to high versus low calorie foods in the 
hypothalamus, with no significant effects observed in the prefrontal cortex (Klaauw et al., 2017). 
Klaauw et al. (2017) also failed to observe any effect of oxytocin on the quantity of food 
consumed in a subsequent breakfast meal. Therefore, there is so far a mixed pattern of findings 
regarding the effects of oxytocin on the neural processing of high versus low calorie foods in 
healthy men and women. Furthermore, there is reason to believe that the central effects of 
exogenous oxytocin may differ in women with BN and BED, as compared to healthy comparison 
women, given evidence of different frequencies of oxytocin receptor gene polymorphisms in 
women with binge-purge behavior, compared to women without disordered eating (Y. Kim, J. 
Kim, C. Kim, J. Shin, & J. Treasure, 2015; Micali, Crous-Bou, et al., 2017).  
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There is a mixed pattern of evidence with regards to differential neural activation in 
response to palatable food anticipation and palatable food receipt in people with loss-of-control 
eating, versus the general population. Gearhardt et al. (2011), for example, have found that 
individuals high in food addiction exhibit heightened activation in reward-related circuits, 
including the caudate, in response to the anticipation of palatable food, and lower activation 
within the orbitofrontal cortex (OFC) in response to the actual receipt of palatable taste, when 
compared to participants low in food addiction, which the authors interpreted to correspond with 
heightened craving, versus an attenuated “liking” hedonic response, respectively. By contrast, 
however, Bohon and Stice (2011) found no significant group differences in the basal ganglia or 
OFC in response to the anticipation or receipt of chocolate milkshake in women with BN, versus 
healthy control women. Furthermore, Simon et al. (2016) rather found evidence of increased 
BOLD response in the medial OFC in response to the receipt of food reward in participants with 
BN and BED versus healthy control participants. 
 In the current preliminary outcomes report, we therefore aimed to further investigate 
differences in the neural processing of palatable food cues between women with BN or BED and 
healthy comparison women. We also sought to clarify the effects of 40IU intranasal oxytocin on 
the neural processing of palatable food cues in women with and without BN or BED. We chose 
to administer a 40IU dose of oxytocin prior to the fMRI scan in order to replicate the protocol of 
a previous study which found an effect of oxytocin on eating behaviour in women with BN at this 
dose (Y. Kim, J. Eom, et al., 2015). We additionally chose this dose given previous evidence 
demonstrating that 40IU intranasal oxytocin effectively reduces neural activation in regions of 
interest, particularly within the basal ganglia (Martins, Mazibuko, et al., 2019; Paloyelis et al., 
2016). 
We recruited women with BN or BED and comparison women without history of an 
eating disorder to take part in a functional magnetic resonance imaging (fMRI) study with a 
double-blind, placebo-controlled, crossover design. Participants self-administered 40IU 
intranasal oxytocin during the active experimental session and an equal volume of placebo spray 
during the control session. Participants were subsequently presented with images of either a glass 
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of water or glass of chocolate milk, which were accompanied by the associated taste of water or 
chocolate milk, respectively, on some trials. We hypothesized: 1) That women with BN and BED 
would exhibit heightened BOLD response in the orbitofrontal cortex (OFC), ventral tegmental 
area (VTA), and nucleus accumbens (NAcc) in response to the image of chocolate milk, versus 
the image of water; 2) That women with BN and BED would exhibit lower BOLD response than 
healthy comparison women in the same regions in response to the actual receipt of chocolate taste, 
versus water taste; 3) That oxytocin would suppress BOLD response in the OFC, VTA, NAcc, 
and hypothalamus in response to chocolate images, versus water images, in both groups of 
women; 4) That there would be a diagnosis x drug interaction such that oxytocin would suppress 
BOLD activation in the OFC, VTA, NAcc, and hypothalamus to a greater extent in women with 
BN or BED versus healthy comparison women in response to images of chocolate milk versus 
images of water. Given that we were unable to investigate most regions of interest given a 
technical issue, for the purposes of the current preliminary outcomes report, we sought to address 
the main aims of the study by conducting a whole-brain exploratory analysis to identify 
differences between the participant groups in the neural processing of palatable taste anticipation 
and delivery. We conducted a separate whole-brain exploratory analysis to identify brain  regions 
in which oxytocin impacted on BOLD response to palatable taste anticipation and receipt. 
Methods 
Participants 
 We recruited a total of 52 women for the current study: 25 women met DSM-5 criteria 
for either bulimia nervosa or binge eating disorder and 27 women had no current or prior history 
of an eating disorder. Details regarding the age, education, and body mass index (BMI) of 
participants are presented in Table 35. Participants were identified via an e-mail circular at King’s 
College London and through posters placed throughout King’s College London and local 
community noticeboards. Participants were required to be female, between 18 and 40 years old, 
proficient in English, and right-handed. Exclusion criteria included pregnancy, severe 
comorbidity (e.g., substance abuse, drug addiction, psychosis, diabetes), history of drug 
dependence, history of a neurological condition (e.g., epilepsy), a significant visual impairment, 
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which is not corrected by eyewear, currently suffering from a cold or flu, currently smoking > 5 
cigarettes per day (past 6 months), consuming > 21 units of alcohol per week, contraindication to 
MRI scans, and current intake of medication that might potentially interact with oxytocin (e.g., 
Prostaglandins).  
Participants with bulimia nervosa and binge eating disorder reported an average binge 
eating frequency of 14.14 episodes over the past 28 days (SD = 9.88).  The women with bulimia 
nervosa endorsed an average frequency of self-induced vomiting equal to 10.40 occasions over 
the past 28 days (SD = 13.61), an average laxative abuse frequency of 5.13 occasions over the 
past 28 days (SD =  8.35), an average frequency of “hard exercise intended to control weight or 
shape” equal to 7.31 occasions over the past 28 days (SD = 8.57), and one participant reported 
using diuretic pills on 4 occasions over the past 28 days.  
Of the 25 women with bulimia nervosa and binge eating disorder, 7 women had a 
comorbid psychiatric disorder. Specifically, 5 women had comorbid depression, 4 women had 
comorbid generalised anxiety disorder, 4 women had borderline personality disorder, 1 woman 
had social anxiety, 1 woman had obsessive-compulsive disorder, and 1 woman had an autism 
spectrum disorder. At the time of the study, 7 women were taking an antidepressant, 1 woman 
was taking a mood stabiliser, and one woman was taking an antipsychotic drug.  
 Ethical approval for the study was granted by the London – Camberwell St Giles 
Research Ethics Committee (Reference: 14/LO/2115). 
 Study Design 
 This proof-of-concept study was double-blind and placebo-controlled with a crossover 
design. Each participant was invited to come to the laboratory on three occasions. The first 
occasion was a preliminary screening visit in which each participant signed informed consent and 
was screened for eligibility for the study. The height and weight of each participant was also 
measured in this initial screening visit. Each participant was then given a link to an online survey 
in which they could provide basic demographic data (including age and education level) before 
the first experimental visit. 
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 Following this screening visit, each participant came to the laboratory for two 
experimental visits, held two days apart in order to ensure that each participant completed each 
of the experimental study sessions whilst in the same phase of the menstrual cycle. Each 
participant was also asked to report the first day of their last menstrual period and any hormonal 
contraception they were currently taking. Participants were asked to eat 2.5 hours prior to each 
experimental visit, and both sessions occurred at the same time of day to control for random 
variance in baseline hunger.  
 Participants presented for each experimental session at 5.00pm. At 5.50pm, each 
participant self-administered 40IU of intranasal oxytocin or identical volume of placebo spray. 
The full dose was administered over a series of 10 sprays, each administered 30 seconds apart, 
alternating nostrils each time. Spray administration was therefore complete at 5.55pm. The eight-
minute T1-weighted scan subsequently commenced at 6.00pm. The fMRI task subsequently 
commenced 24 minutes after the end of drug administration, on average (range: 6.10pm-6.27pm). 
The fMRI task and set-up are described in detail below. 
fMRI Scan Set-Up 
 Prior to the onset of the scan, each participant was instructed to lay down on the scanning 
bed. The MRI-compatible flavour-dispensing box, containing separate tanks of cold Evian water 
and cold Galaxy chocolate milk, was placed underneath the participant’s knees. A hose delivering 
the chocolate and water flavours protruded from left side of the flavour-dispensing box. This hose 
terminated in a disposable plastic mouthpiece, which the participant kept in their mouth 
throughout the duration of the scan. This mouthpiece was further secured with a plastic clamp 
attached to the participant’s head coil. The participant was provided with a button box, which had 
left and right response buttons. The fMRI scans were conducted with a field strength of 3.0 Tesla. 
fMRI Task 
 Prior to each run of the fMRI scan, the participant completed baseline ratings of the 
chocolate and water flavours. Each participant first received 0.5mL of the chocolate milk 
delivered through the mouthpiece. The participant was immediately presented with a visual 
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analogue scale (VAS) asking them to rate the hedonic aspect of the flavor on a scale anchored 
from “very unpleasant” to “very pleasant”. Other than a central demarcation, there were no other 
indicators between the two anchors at the left and right extremities of the VAS. The participant 
responded by either holding down the left button to move a central cursor towards the “very 
unpleasant” end of the VAS, or the right button to move the cursor towards the “very pleasant” 
end of the VAS. After thirty seconds this VAS was replaced with another VAS asking the 
participant to rate the intensity of the chocolate flavor. This VAS was anchored on a scale ranging 
from “not at all intense” to “very intense”. The participant responded by holding down the left 
and right buttons in the same manner as for the previous VAS. Finally, the participant was asked 
to rate their current level of anxiety on a VAS anchored from “not at all anxious” to “very 
anxious”. The participant responded using the left and right buttons as for the previous two visual 
analogue scales. The participant then received 0.5mL of the water through the mouthpiece. The 
participant then completed the same three visual analogue scales described above for the 
chocolate condition. 
 Following the baseline ratings of flavor, the first run of the fMRI task began. The 
participant was presented with a series of pictures of either a glass of chocolate milk or a glass of 
water. The participant was instructed to press the left button each time they were presented with 
a picture of chocolate milk, and to press the right button each time they were presented with a 
picture of water to ensure attention to each image. Each image was presented for 3 seconds, 
regardless of the participant’s reaction time. The image of water or chocolate milk was then 
followed by a fixation cross, which was presented for a random jitter period between 1 and 9 
seconds in duration. For “invalid” trials, the fixation cross would then remain on the screening 
for a standard period of 5 seconds, and the next trial would then commence without any further 
stimuli.  
For “valid” trials, however, the presentation of the picture of water or chocolate milk was 
followed by a squirt of the drink corresponding with the image they had just seen (i.e., if they had 
just been presented with a picture of a glass of water they would subsequently receive a squirt of 
water through the mouthpiece, and vice versa for chocolate milk). The participant was instructed 
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to hold the drink in their mouth for 3 seconds. This 3-second flavour delivery period was then 
followed by another fixation cross, which was presented for a random jitter period between 1 and 
9 seconds. At this point the participant was presented with a visual instruction to “Swallow”.  A 
fixation cross was then presented for 2 seconds prior to the onset of the next trial. 
The participant was presented with a total of 50 images for each run in a pseudo-
randomised order, such that each participant was presented with 25 images of water and 25 images 
of chocolate milk. The trials in which the participant received a squirt of water or chocolate milk 
were chosen pseudo-randomly, such that each participant received a total of 30 squirts during 
each scanning run in a random order.  Following the first valid trial the participant was presented 
with a squirt of water or chocolate milk and a VAS in which they were instructed to rate the 
hedonic aspect and intensity of the flavour they had just received. This VAS was repeated 
following each subsequent set of 10 valid trials. The participant responded to these visual 
analogue scales in the same manner to the visual analogue scales presented prior to the onset of 
the task. 
 The participant then repeated all visual analogue scales performed at baseline prior to the 
onset of the second run of the scan. The second run of the scan proceeded in an identical manner 
to the first run, except that the images and squirts of water and chocolate milk were presented in 
a different random order. 
fMRI Scanning Protocol 
 Each fMRI scanning run lasted for a total of 14 minutes and included 422 
volumes. Four dummy scans were acquired prior to each run. Dummy scans were 
subsequently discarded. Images within the fMRI scans were acquired with a slice 
thickness of 3mm and a slice gap of 0.3mm. A total of 41 slices were acquired in a top to 
bottom order. The field of view was 240mm2 with a 64 x 64 matrix size. The resulting 
voxel size was therefore 3.75mm x 3.75mm x 3mm. The scan was conducted with an 
echo time of 30ms and a repetition time of 2,000ms. The flip angle was set to 75 degrees. 
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A 3D high- spatial-resolution, Magnetisation Prepared Rapid Acquisition (3D MPRAGE) 
T1-weighted scan was also acquired. Field of view was 270mm2, TR/TE/TI = 
7.328/3.024/400ms. The final resolution of the T1-weighted image was 1.1 x 1.1 x 1.2 
mm.  
Statistical Analysis 
 All neuroimaging analyses were conducted in the Statistical Parametric Mapping 
software, version 12 (SPM). The functional images were slice-time-corrected and realigned using 
the mean functional image as a reference. Each participant’s T1-weighted scan image was then 
co-registered to the mean functional image, then segmented using unified segmentation. The 
functional images were then normalized to Montreal Neurological institute (MNI) space using the 
segmentation parameters. Finally, images were smoothed using a Gaussian kernel of full weight 
at half maximum (FHWM) 6mm. 
At the single subject level, the data were modeled using the general linear model 
framework. We constructed a design matrix with separate regressors for correct and incorrect 
chocolate anticipation, chocolate receipt, water anticipation, and water receipt. We also included 
regressors for the “Swallow” instruction and VAS completion. The six motion parameters were 
also included in the design matrix. The BOLD signal was modeled by convolving our design 
matrix with the canonical haemodynamic response function. Low frequency drift was filtered out 
using a high-pass filter set to 1/128 second. 
We estimated the following contrasts at the single-subject level: (1) chocolate 
anticipation versus water anticipation; (2) chocolate delivery versus water delivery; (3) chocolate 
anticipation versus chocolate delivery; and (4) water anticipation versus water delivery. We 
excluded trials in which participants did not correctly indicate the presence of the chocolate milk 
image versus water image to ensure that we only included trials where appropriate attention was 
paid to the water and chocolate images during anticipation and to avoid the signal noise which 
might be produced by error signaling. 
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At the group level, we conducted the following tests: (1) a one-sample F-test for the 
contrast comparing the anticipation of chocolate to the anticipation of water across all scans; (2) 
a two-sample F-test comparing the BN/BED and healthy comparison participant groups for the 
contrast comparing the anticipation of chocolate to the anticipation of water in the placebo 
condition; (3) a one-sample F-test for the contrast comparing the receipt of chocolate to the receipt 
of water across all scans; (4) a two-sample F-test comparing the BN/BED and healthy comparison 
participant groups for the contrast comparing the receipt of chocolate to the receipt of water in 
the placebo condition. We calculated difference images in which BOLD activation in the placebo 
condition was subtracted from the oxytocin condition. We the conducted the following additional 
tests: (5) one-sample F-tests investigating the effect of oxytocin on anticipation of chocolate 
versus water within each participant group; (6) a two-sample F-test comparing the effect of 
oxytocin for the chocolate anticipation, versus water anticipation, contrast between the two 
participant groups; (7) one-sample F-tests investigating the effect of oxytocin on receipt of 
chocolate versus water within each participant group; and (8) a two-sample F-test comparing the 
effect of oxytocin for the chocolate receipt, versus water receipt, contrast between the two 
participant groups. 
For all tests we conducted exploratory whole brain analyses using cluster level inference, 
reporting significant clusters at  p <.05FWE-corrected and a cluster forming threshold of p <.001 
uncorrected (or p <.001 FWE-corrected where the clusters were too big). Two participants’ data were 
excluded from the current analyses as one participant did not complete the scan in the oxytocin 
condition and the other participant did not respond correctly to confirm attention to task images 
on a minimum threshold of 70% of task trials. 
Results 
Anticipation of chocolate taste versus water taste 
 We first conducted a one-sample F-test for the contrast comparing the anticipation of 
chocolate taste versus the anticipation of water taste across participant groups (BN/BED and 
healthy control) and treatment conditions (oxytocin and placebo drug conditions). We applied a 
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cluster-forming threshold of p = .001 (uncorrected), which revealed three significant clusters. 
However, given that one cluster extended over 69,018 voxels, we therefore decided to use a more 
conservative cluster-forming threshold of p = .001FWE-corrected in order to investigate more 
anatomically specific regions of neural activation. This subsequent, more conservative, whole 
brain analysis revealed eight significant clusters. We then followed this F-test with two  one-
sample t-tests to investigate directional differences. We found significantly greater BOLD 
response to chocolate anticipation, versus water anticipation, in the bilateral visual association 
area and right extrastriate cortex. We found significantly greater BOLD response to water 
anticipation, versus chocolate anticipation in the bilateral primary visual cortex, bilateral 
extrastriate cortex, right insula, bilateral inferior parietal cortex, right primary auditory cortex, left 
inferior frontal gyrus, and left caudate. Full results of these one-sample t-tests are reported in 
Table 36. 
 We were surprised by the lack of activation in the ventral striatum given previous 
evidence finding significant contrasts in BOLD response to the presentation of visual depictions 
of sweet taste versus control images. We therefore further investigated the mask of included 
voxels for the group analysis and discovered that it did not include the ventral striatum or OFC. 
Inspection of a random sample of individual participant masks revealed that most participants’ 
masks did include voxels with signals in these regions. Therefore, the missing voxels are likely a 
result of one or more aberrant scans. While we did not have time to inspect each mask individually 
for the current preliminary outcomes report, the identification and exclusion of aberrant scans will 
form the next steps of the analysis so that we may investigate BOLD signal within the ventral 
striatum and the OFC. 
Anticipation of chocolate taste versus water taste: Between-groups comparison in the placebo 
condition 
Following the observation of significant clusters in response to the anticipation of 
chocolate taste, versus water taste, across all conditions and groups, we next sought to investigate 
group differences between participants with BN/BED and healthy comparison participants in the 
placebo condition given previous evidence of altered activation in reward-related circuits in 
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populations with loss-of-control eating (Gearhardt et al., 2011). This analysis did not reveal any 
significant clusters. 
Receipt of chocolate taste versus water taste 
We then conducted a one-sample F-test for the contrast comparing the receipt of 
chocolate taste versus the delivery of water taste across all participant groups and treatment 
conditions (including both participant groups in both oxytocin and placebo drug conditions). The 
analysis revealed five significant clusters. We therefore followed this F-test with two one-sample 
t-tests to investigate directional differences. We detected significantly greater BOLD response to 
chocolate milk receipt, versus the receipt of water, in the following regions: bilateral 
somatosensory cortex, right inferior parietal cortex, right premotor cortex, right supplementary 
motor area, the cerebellum, right putamen, right hippocampus, and right insula. We detected 
significantly greater BOLD response to the receipt of water, versus chocolate milk, in the bilateral 
primary motor cortex, right somatosensory cortex, and right dorsomedial frontal cortex. The full 
results of the whole-brain exploratory analysis for the receipt of chocolate taste versus water taste 
are presented in Table 37. 
Delivery of chocolate taste versus water taste: Between-groups comparison 
Following the observation of significant clusters in response to the delivery of chocolate 
taste, versus water taste, across all scans, we next sought to investigate group differences between 
participants with BN/BED and healthy comparison participants in the placebo condition. This 
analysis did not reveal any significant clusters. 
The effect of oxytocin on anticipation of chocolate taste versus water taste: Main effect of 
treatment condition and treatment x group interaction 
We then conducted separate whole-brain exploratory analyses within each participant 
group examining the effect of oxytocin, versus placebo, on neural activation in response to the 
anticipation of chocolate taste, versus water taste. We calculated contrast images reflecting the 
effect of treatment for each participant, by subtracting the chocolate versus water anticipation 
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contrast image in the placebo condition from the same contrast image in the oxytocin condition 
using imcalc in SPM and  conducted a one-sample F-test. We did not observe any significant 
clusters within either the BN/BED or healthy control participant groups. A two-sample F-test 
comparing the effect of oxytocin, versus placebo, on neural activation in response to the 
anticipation of chocolate taste, versus water taste, did not reveal any significant clusters 
corresponding to differences between the BN/BED versus healthy control participant groups. 
The effect of oxytocin on receipt of chocolate taste versus water taste: Main effect of 
treatment condition and treatment x group interaction 
We then conducted separate whole-brain exploratory analyses within each participant 
group examining the effect of oxytocin, versus placebo, on neural activation in response to the 
receipt of chocolate taste, versus water taste. We calculated contrast images reflecting the effect 
of treatment for each participant, by subtracting the chocolate versus water receipt contrast image 
in the placebo condition from the same contrast image in the oxytocin condition using imcalc in 
SPM and  conducted a one-sample F-test. We did not observe any significant clusters within 
either the BN/BED or healthy control participant groups. A two-sample F-test comparing the 
effect of oxytocin, versus placebo, on neural activation in response to the receipt of chocolate 
taste, versus water taste, did not reveal any significant clusters corresponding to differences 
between the BN/BED versus healthy control participant groups. 
Discussion 
The current study aimed to clarify the effects of 40IU intranasal oxytocin on the neural 
processing of palatable food cues in women with and without BN or BED. The current findings 
revealed significant differences in BOLD activation when participants observed images of 
chocolate, versus images of water, and received the taste of chocolate, versus the taste of water. 
The pattern of BOLD activation did not significantly differ between the BN/BED and healthy 
control participant groups in response to viewing or tasting chocolate, versus water. The prior 
administration of 40IU intranasal oxytocin, versus placebo, had no impact on BOLD activation 
in response to either viewing or tasting chocolate, versus water, in either the BN/BED or healthy 
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control participant groups. The effect of oxytocin on BOLD activation in response to viewing or 
tasting chocolate, versus water, also did not significantly differ between participant groups. 
Given that the presentation of a visual stimulus was constant between the chocolate 
anticipation and water anticipation conditions, we were surprised to observe that five out of the 
eight significant clusters in the one-sample F-test were in the primary visual cortex and visual 
association areas. One possible explanation is that the image of chocolate may have been more 
enticing than the image of water, thus encouraging a greater degree of visual processing. 
Additionally, the image of the glass of chocolate milk was a more complex shape, such that the 
glass had a handle and was topped with whipped cream, while the water was contained in a 
standard glass. This the processing of the more complex shape may partially account for the 
greater recruitment of visual association areas. 
We observed greater BOLD response in the premotor cortex and supplementary motor 
area, as well as regions of the parietal lobe anatomically close to the representation of the tongue 
on the somatosensory cortex in response to the anticipation of chocolate versus water, although 
separate clusters within the primary motor cortex and somatosensory cortex were associated with 
greater BOLD response to the anticipation of water, versus chocolate. These differences partially 
corroborate previous evidence showing greater BOLD activation among healthy control 
participants in the postcentral gyrus in response to tasting a milkshake, versus a tasteless solution 
(Stice, Burger, & Yokum, 2013). One can speculate that this pattern of effects may pertain to 
anticipation of the taste and viscosity of chocolate milk versus water, or the potential for 
preconscious motor planning pertaining to drink chocolate milk versus water. However, given 
that we used an encoding design, we cannot validly draw reverse inferences to this extent. 
 We did not observe significant differences between participant groups in BOLD 
activation in response to viewing or tasting chocolate milk, versus water. This current finding 
adds to an existing mixed set of findings with regards to altered neural processing of palatable 
taste anticipation and receipt in women with BN or BED. Out of two prior fMRI studies 
examining BOLD response to the sight and taste of palatable food, compared to a neutral taste, in 
people with current BN or BED, one study also failed to observe differences in the anticipation 
Monica Leslie   351 
of chocolate taste, versus a control taste, between women with BN versus healthy control women 
(Bohon & Stice, 2011). The other study, however, observed a reduced BOLD response in the 
posterior cingulate cortex in participants with BN and BED, compared to healthy control 
participants, in response to the anticipation of food reward, and heightened BOLD response in the 
medial OFC, anterior medial prefrontal cortex, and posterior cingulate cortex to the receipt of 
palatable taste. This study, in addition to a separate set of findings indicating heightened activation 
in the OFC and caudate in response to visual food cues in people high in food addiction (Gearhardt 
et al., 2011), let us to believe that we might see differences in the pattern of BOLD activation to 
the anticipation and receipt of chocolate taste, versus water taste, within reward-related circuits 
in women with BN and BED, compared to healthy control women. However, the fact that the 
OFC and basal ganglia were not included in the mask for the analyses precluded the possibility 
of detecting differences in BOLD signal in these regions in the current set of analyses. The next 
step proceeding from this preliminary outcomes report will therefore be to identify and exclude 
aberrant participant where for technical reasons their mask of inclusive voxels did not include 
signal from the anterior ventral brain regions including the ventral striaum and the OFC, beyond 
the lost that is expected due to the susceptibility artefact. The inclusion of even a single aberrant 
participant would have biased the group mask of included voxels as group analyses are based on 
the conjunction of masks of included voxels from all participants.  This will allow us to  
meaningfully investigate hypotheses pertaining to these anatomical regions. Furthermore, given 
that previous evidence gives us a priori reason to expect to see differences in the BOLD response 
to the anticipation and receipt of chocolate taste, versus water taste, in participants with BN/BED, 
versus healthy control participants, in the OFC and caudate (Gearhardt et al., 2011; Simon et al., 
2016), we will therefore also investigate these hypotheses using corresponding region-of-interest 
analyses in the next stages of the data analysis. 
 The primary limitation of the current study was our inability to investigate differences in 
BOLD signal in regions of interest for the processing of taste reward, specifically the OFC and 
ventral striatum. Additionally, previous evidence has indicated that hormonal contraception 
can suppress the effects of exogenous oxytocin on BOLD response to images of a 
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partner’s face within reward-related mesolimbic brain regions (Scheele, Plota, Stoffel-
Wagner, Maier, & Hurlemann, 2015). Going forward with the analysis of the current data, 
it will therefore be important to investigate the potential moderating effect of hormonal 
status for the influence of oxytocin on the neural processing of the anticipation and 
delivery of chocolate milk in future analyses, along with region of interest analyses, 
following the exclusion of aberrant scans. 
 In conclusion, the current study aimed to investigate differences in the neural 
processing of the anticipation and delivery of chocolate taste, versus water taste, in 
women with BN and BED versus healthy control women. We also sought to investigate 
the influence of oxytocin on the neural processing of the anticipation and receipt of 
chocolate taste, versus water taste, in women with BN/BED versus healthy control 
women. We did not observe significant differences in neural activation between women 
with BN or BED, versus healthy control women, in response to the anticipation or receipt 
of chocolate taste, versus water taste within the regions of the brain included of our 
analyses. The administration of 40IU intranasal oxytocin, versus placebo, also did not 
affect the BOLD response to the anticipation or receipt of chocolate taste, versus water 
taste, in either participant group within brain regions included in the current set of 
analyses. It will be important in the next stages of the analysis to repeat these analyses 
with the OFC and basal ganglia included in the analysis masks and to investigate relevant 
regions of interest. 
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Table 35 
Descriptive demographic data 
 Healthy Control (n = 27) BN/BED (n = 25) 
 Median IQR Median IQR 
Age 23.50 5.50 23.50 9.75 
BMI 22.04 1.76 23.09 3.87 
RQF Education 
Level 
6 4 4.5 3 
Note. BN = bulimia nervosa; BED = binge eating disorder; IQR = interquartile range; BMI = 
body mass index; RQF = Regulated Qualifications Framework. 
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Table 36 
Significant clusters identified for the anticipation of chocolate taste, versus water taste: 
One-sample t-tests conducted across participant groups and treatment conditions. 
 
A p < .001FWE-corrected cluster-forming threshold was used for the water > chocolate 
contrast due to excessively large clusters. A p < .001 uncorrected cluster-forming threshold 
was used for the chocolate > water contrast. We report significant clusters at the  
p < .05FWE-corrected threshold. 
 
 
Cluster Number Hemisphere K PFWE 
Peak Coordinates Description 
x y z  
CHOCOLATE > WATER 
Cluster 1 Left 1485 < .001 -14 -92 -8 Visual association area 
-24 -94 4 
-24 -88 -6 
Cluster 2 Right 821 < .001 24 -86 -14 Extrastriate cortex and visual 
association area 
40 -76 -12 
22 -94 2 
WATER > CHOCOLATE 
Cluster 3 Bilateral 8804 < .001 -6 -74 8 Primary visual cortex and 
extrastriate cortex 
-16 -66 -4 
16 -62 -2 
Cluster 4 Right 393 < .001 44 -64 6 Extrastriate cortex 
48 -74 18 
Cluster 5 Right 1951 < .001 36 -8 16 Insula and inferior parietal 
cortex 
54 -12 24 
58 6 18 
Cluster 8 Left 1598 < .001 -64 -48 12 Inferior parietal cortex 
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-62 -26 20 
-32 -28 10 
Cluster 9 Left 276 < .001 -40 -70 10 Extrastriate cortex 
-52 -70 12 
-36 -82 22 
Cluster 10 Right 98 < .001 48 -24 8 Primary auditory cortex 
58 -26 12 
Cluster 11 Left 32 < .001 -32 20 16 Inferior frontal gyrus 
Cluster 12 Left 173 < .001 -16 6 16 Caudate 
-16 -2 14 
-26 2 14 
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Table 37 
Significant clusters identified for the receipt of chocolate taste, versus water taste: One-
sample t-tests conducted across participant groups and treatment conditions 
 
A p < .001 uncorrected cluster-forming threshold was used for both t-contrasts. We report 
significant clusters at the p < .05FWE-corrected threshold. 
 
 
Cluster Number Hemisphere K PFWE 
Peak Coordinates Description 
x y z  
CHOCOLATE > WATER 
Cluster 1 Right 1382 < .001 58 -14 24 Inferior parietal cortex, 
somatosensory cortex, 
premotor cortex, and 
supplementary motor cortex 
60 -14 32 
56 2 32 
Cluster 2 Left 234 .035 -20 -62 -28 Cerebellum 
-26 -50 -32 
Cluster 3 Left 1024 < .001 -56 -14 20 Somatosensory cortex,  
-52 -20 28 
-58 -20 34 
Cluster 4 Right 755 < .001 26 0 -10 Putamen, hippocampus, and 
insula 
32 -12 -12 
38 16 -2 
WATER > CHOCOLATE 
Cluster 5 Bilateral 2500 < .001 -2 -26 62 Primary motor cortex 
30 -26 50 
12 -32 66 
Cluster 6 Right 247 .029 26 -10 28 Somatosensory cortex 
34 -20 20 
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26 -28 28 
Cluster 7 Right 655 < .001 30 20 34 Dorsomedial frontal cortex 
22 24 54 
12 30 50 
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7.1 Summary of Key Findings 
The current thesis proposed a novel maintenance model of recurrent binge eating: the 
addictive appetite model of bulimia nervosa and binge eating disorder. We subsequently 
tested hypotheses generated by the addictive appetite model. Figure 15 demonstrates how 
each data paper of the thesis fits within a specific hypothesis proposed by the addictive 
appetite model. The key findings of each data paper are subsequently summarised in 
Table 38. 
 
Figure 15. Summary of addictive appetite processes tested in the current thesis. 
1) The centrality of coping-focused eating in the profile of bulimia nervosa and binge eating 
disorder was tested in Paper 3; 2) The impact of oxytocin administration on subjective stress 
was tested in Paper 5; 3) The impact of oxytocin on salivary cortisol was tested in Paper 5; 4) 
The influence of oxytocin on the consumption of food was tested in a meta-analysis presented in 
Paper 4 and an original study in Paper 5; 5) The presence of preconscious attentional biases to 
palatable food in women with bulimia nervosa and binge eating disorder and the impact of 
oxytocin on these attentional biases were measured in Paper 6; 6) Differences in the neural 
processing of anticipation and receipt of palatable taste were investigated in Paper 8; 7) The 
presence of greater risk-taking in the context of reward-seeking and the influence of oxytocin on 
risk-taking tendency were investigated in paper 7. 
Note. BED = binge eating disorder; BN = bulimia nervosa; GI = glycaemic index. 
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Table 38 
Summary of key findings 
Paper Aims Findings 
Paper 3: Testing the addictive 
appetite model: The importance 
of craving, reward, and reward 
enhancement 
This original study aimed to test two maintenance 
processes proposed within The Addictive Appetite 
Model of binge eating: eating due to enhanced incentive 
salience and eating for emotion regulation. Our 
hypotheses were:  
1. People with BN and BED would show higher 
levels of craving for food than weight-matched 
controls;  
2. People with BN and BED would endorse eating 
palatable food as a method of coping with 
distress and as a means of enhancing mood;  
3. Food craving, eating for emotional coping, and 
eating for reward enhancement would 
distinguish individuals with binge-type eating 
disorders from weight-matched controls. 
Women with BN and BED endorsed significantly 
greater levels of food craving and tendencies to eat 
for purposes of coping and reward enhancement 
compared to weight-matched women without 
history of an eating disorder. These differences were 
each associated with a large effect size. 
Furthermore, a cluster analysis indicated that 
considering the variables of food craving and 
tendencies to eat for purposes of coping and reward 
enhancement were sufficient to distinguish women 
with BN or BED from the lean and 
overweight/obese healthy control women. 
Paper 4: A Systematic Review 
and Quantitative Meta-Analysis 
of the Effects of Oxytocin on 
Feeding 
This paper aimed to conduct a systematic review 
synthesising the effects of oxytocin on feeding. We used 
PRISMA guidelines to identify all original published 
and unpublished experiments testing the effects of 
exogenous oxytocin on energy intake in wild-type 
animals and in humans, where oxytocin was 
administered in the absence of other active drugs or 
Across all studies, a single dose of oxytocin was 
found to reduce subsequent eating over the 
following hour in animal studies, both when the 
oxytocin was administered centrally or peripherally. 
While some individual studies have supported the 
anorexic qualities of oxytocin in mice, rats, and 
rhesus monkeys over a two- to three-week 
administration period, the effect of chronic oxytocin 
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surgeries. We also aimed to identify relevant 
moderators of oxytocin’s effects on feeding in order to 
clarify the conditions under which these anorexigenic 
effects hold. We hypothesised that exogenous oxytocin 
administration, as compared to placebo administration, 
would reduce feeding in both humans and animals. 
on feeding was non-significant across all studies. 
The main effect of oxytocin on feeding in humans 
was not significant. However, there was a trend 
towards an inhibitory effect of oxytocin on the 
consumption of solid foods. The effect of oxytocin 
on feeding in humans was moderated by sex, weight 
status, and prior hunger. 
Paper 5: The influence of 
oxytocin on eating behaviours 
and stress in women with 
bulimia nervosa and binge 
eating disorder 
The aim of the current study was to explore the impact 
of the administration of oxytocin on both reward and 
anxiety-related processes. We hypothesised that: 
1. A divided dose of 64IU intranasal oxytocin 
administration would reduce subjective hunger, 
the immediate consumption of palatable food, 
24-hour calorie consumption, and the incidence 
of binge eating when compared to placebo. 
2. Oxytocin administration would be associated 
with lower levels of stress, and that participants 
would report lower levels of “feeling fat”.  
3. Participants would have lower salivary cortisol 
concentrations in the oxytocin, versus placebo, 
condition.  
4. Each of these effects would be moderated by 
eating disorder status, such that participants 
with BN or BED would experience greater 
reductions in food consumption and stress-
related variables than participants with no 
history of an eating disorder. 
A divided dose of 64IU intranasal oxytocin did not 
affect the immediate consumption of palatable food, 
24-hour calorie consumption, or the incidence of 
binge eating in women with and without bulimia 
nervosa or binge eating disorder. There was no 
significant effect of oxytocin on subjective stress or 
salivary cortisol in either participant group. 
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Paper 6: A Pilot Study 
Investigating the Influence of 
Oxytocin on Attentional Bias to 
Food Images in Women with 
Bulimia Nervosa and Binge 
Eating Disorder 
This study aimed to test the effect of a divided dose of 
64IU intranasal oxytocin on attentional bias to palatable 
food in women with and without bulimia nervosa and 
binge eating disorder. Our hypotheses were:  
1. Women with BN or BED would demonstrate 
greater attentional biases towards food images 
than women without history of an eating 
disorder;  
2. There would be an interaction between time 
point and participant group, such that the 
difference in attentional bias to food in the 
BN/BED, versus healthy control group, would 
be even greater following food consumption;  
3. Oxytocin administration would reduce vigilance 
towards food images in both groups of women, 
based on previous work suggesting that 
oxytocin reduces the incentive salience of 
palatable food in healthy participants (Ott et al., 
2013);  
4. Oxytocin would reduce vigilance towards food 
images to a greater degree in women with BN or 
BED, versus healthy comparison women, due to 
potential flooring effects in the healthy 
comparison group. 
There was no baseline difference in attentional bias 
to food images between women with BN or BED as 
compared to women without history of an eating 
disorder. There was a main effect of oxytocin, such 
that a 64IU divided dose of intranasal oxytocin 
increased vigilance to food images, as compared to 
placebo administration; however, this effect was 
primarily driven by the women with BED. 
Paper 7: The Influence of 
Oxytocin on Risk-Taking in the 
Balloon Analogue Risk Task 
Among Women with Bulimia 
This study aimed to compare the performance of 
women with clinical levels of recurrent binge eating on 
the BART to that of control women without previous 
history of an eating disorder. Furthermore, we also 
aimed to investigate the differential effect of intranasal 
There were no baseline differences in performance 
on the BART between women with BN or BED as 
compared to healthy control women. There was not 
a significant main effect of a divided dose of 64IU 
intranasal oxytocin on either the adjusted average 
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Nervosa and Binge Eating 
Disorder 
oxytocin on risk-taking in the BART in women with BN 
and BED compared to healthy controls. We 
hypothesised that:  
1. Women with BN and BED would demonstrate 
greater baseline risk-taking behaviour on the 
BART in the placebo condition, relative to 
women without previous history of an eating 
disorder.  
2. Given previous research indicating that 
oxytocin induces a down-regulation of reward 
seeking in men, we hypothesised that a divided 
dose of 64IU intranasal oxytocin, versus 
placebo, would be associated with reduced risk-
taking behaviour in the BART in women; 
3. We hypothesised that the effect of oxytocin in 
down-regulating reward-seeking would be 
stronger in women with bulimia nervosa and 
binge eating disorder due to higher trait levels of 
risk-taking behaviour.  
pump count or total number of balloon explosions 
in the BART. However, there was an interaction 
such that oxytocin administration reduced the total 
number of balloon explosions to a greater degree 
among the women with BN or BED, versus the 
healthy comparison women. There was no drug x 
diagnosis interaction for the adjusted average pump 
count variable. 
Paper 8: The effect of oxytocin 
on the neural processing of taste 
reward in women with and 
without binge-type eating 
disorders 
This study aimed to investigate differences in neural 
activation in response to the anticipation and receipt of 
chocolate milk, versus water, in women with BN and 
BED versus healthy comparison women. We also aimed 
to investigate the influence of 40IU intranasal oxytocin 
on the neural processing of the anticipation and receipt 
of chocolate milk, versus water.  
We conducted whole-brain exploratory analyses to 
identify regions in which women with BN and BED 
We did not observe significant differences in neural 
activation between women with BN or BED, versus 
healthy control women, in response to the 
anticipation or receipt of chocolate taste, versus 
water taste. The administration of 40IU intranasal 
oxytocin, versus placebo, did not affect the BOLD 
response to the anticipation or receipt of chocolate 
taste, versus water taste, in either participant group. 
However, the ventral striatum and orbitofrontal 
cortex were not included in the analysis masks, thus 
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exhibited different patterns of BOLD response to 
palatable taste anticipation and receipt, and regions 
where 40IU intranasal oxytocin moderated neural 
activation to palatable taste anticipation and receipt. 
presenting a significant caveat to interpreting the 
current preliminary findings. 
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7.2 Synthesis with Existing Literature 
 
7.2.1 The influence of oxytocin on eating behaviour 
While previous narrative reviews have provided comprehensive summaries of the effects 
of oxytocin on eating behaviour (Blevins & Baskin, 2015; Olszewski, Klockars, & 
Levine, 2016), the study presented in Paper 4 is the first systematic review and meta-
analysis of studies investigating the effects of oxytocin on feeding. The primary finding 
of the systematic review supports general wisdom concerning the anorexigenic effects of 
oxytocin. We found that a single dose of either centrally- or peripherally-administered 
oxytocin significantly reduces feeding over the subsequent hour of measurement in 
animals. While individual studies have indicated the potential for oxytocin to suppress 
feeding in mice, rats, and rhesus monkeys over periods of two- to three-weeks (Blevins 
et al., 2015; Blevins et al., 2016), this meta-analysis indicated that this finding is not 
significant across all animal studies measuring the effects of oxytocin on eating into the 
long-term. 
Due to the relative paucity and  wide variety of sample characteristics in studies 
investigating the influence of oxytocin on eating in humans, it is not surprising that a 
highly mixed set of findings was observed across all studies. Given that existing studies 
have been relatively internally homogeneous, the current meta-analysis contributes to 
current knowledge by indicating that sex, weight status, and hunger status are statistically 
significant moderators of the effect of oxytocin on feeding. A surprising novel finding is 
that the liquid- versus solid-state of the food also significantly moderates the effect of 
oxytocin on feeding. While the reason for this effect is not entirely clear at present, it is 
possible that oxytocin may reduce gastric motility (Flanagan, Dohanics, Verbalis, & 
Stricker, 1992; R. C. Rogers & Hermann, 1987; C. L. Wu et al., 2002; C. L. Wu et al., 
2003), with a stronger downstream effect in reducing consumption of solid food, in 
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comparison to liquid food. This finding will be interesting to explore in future studies in 
order to better understand the mechanism of the effect of oxytocin on feeding. 
While previous evidence found evidence of an inhibitory effect of intranasal oxytocin on 
24-hr caloric consumption in women with BN (Y.-R. Kim, J.-S. Eom, et al., 2015), the 
current study failed to replicate this finding. Potential reasons for this difference include 
the greater dose of intranasal oxytocin used in the current study: 64IU administered as a 
divided dose, as compared to the single dose of 40IU administered in the previous Y.-R. 
Kim, J.-S. Eom, et al. (2015) study. As mentioned previously in the current thesis, current 
evidence suggests that the dose of oxytocin may have an inverse quadratic relationship 
with the magnitude of its effect due to the rapid internalisation of oxytocin receptors at 
high doses (Cardoso et al., 2013). Furthermore, unpublished work from our laboratory 
has indicated that administration of oxytocin via conventional intranasal spray, versus a 
nebuliser, results in a different pattern of subsequent effects on cerebral blood perfusion. 
It is therefore also possible that the observed difference in findings between our study and 
the study conducted by Y.-R. Kim, J.-S. Eom, et al. (2015) are, at least partly, due to 
differences in the method of oxytocin administration. 
Additionally, we provided palatable food with a high caloric density in our taste test, 
rather than apple juice, as provided in the study conducted by Y.-R. Kim, J.-S. Eom, et 
al. (2015). Following from the predictions of the addictive appetite model, it is possible 
that dysregulation in blood sugar following consumption of the provided chocolate, 
combined with the mere suggestion of snack food, may have predisposed participants to 
consume a greater quantity of palatable foods during the 24-hour measurement period of 
caloric intake. Therefore, it is possible that these differences in protocol may have 
contributed to the failure to replicate previous research findings. Further work will be 
necessary to identify the optimal protocol, including the optimal dose and method of 
oxytocin administration, required to curb palatable food consumption in future studies 
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recruiting women with and without eating disorders. A summary of existing studies to 
have investigated the effects of oxytocin on eating behaviour and neurocognitive 
processes in populations with eating disorders is presented in Table 39.  
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Table 39 
Summary of Studies Investigating the Effects of Intranasal Oxytocin on Neurocognitive Processes and Eating Behaviour in Populations with Eating Disorders 
Author, Year Study Title Sample Dose 
Method of 
Administration 
Experimental Design Sex Summary of Findings 
Eating Behaviour in 
Binge-Type Eating 
Disorders 





Leslie et al., 2018 
The Influence of Oxytocin on 
Eating Behaviours and Stress 
in Women with Bulimia 




sample: (n = 
25) 





HC (n = 27) 
64IU Intranasal spray 
Double-blind within-subjects 
crossover design investigating the 
consumption of palatable snack 
foods in a bogus taste test, 24-hour 
caloric consumption, and binge 
episode frequency following drug 
administration 
Female 
No significant effect of oxytocin on palatable food 
consumption, 24-hr caloric consumption, or binge episode 
frequency following oxytocin, versus placebo, administration. 
There was also no evidence of a significant drug x participant 
group interaction. 
Agabio et al., 2016 
Oxytocin Nasal Spray in the 
Treatment of Binge Eating 
Disorder and Obesity: A pilot, 
Randomized, Double Blind 
Trial 







clinical trial investigating the effects 
of 4 daily doses of 24IU oxytocin, 
versus placebo, on frequency of 
binge eating episodes over a period 




Oxytocin administration, versus placebo, had no significant 
effect on number of binge eating episodes per week. 
Kim et al., 2015 
The impact of oxytocin on 
food intake and emotion 
recognition in patients with 
eating disorders: a double 
blind single dose within-
subject cross-over design 
AN (n = 35) 
BN (n = 34) 
HC (n = 33) 
40IU Nebuliser 
Double-blind within-subjects 
crossover design investigating the 
consumption of apple juice and 24-
hr caloric consumption 
Female 
Oxytocin did not impact juice consumption for any participant 
group. There was no effect of oxytocin on 24-hr caloric 
consumption for HC or AN participants. However, oxytocin, 
versus placebo, decreased 24-hr caloric consumption for 
participants with BN. 
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Eating Behaviour in 
Anorexia Nervosa 
       
Leppanen et al., 2017 
The effects of intranasal 
oxytocin on smoothie intake, 
cortisol and attentional bias in 
anorexia nervosa 
AN (n = 30) 
HC (n = 29) 
40IU Intranasal spray 
Double-blind within-subjects 
crossover design investigating 
smoothie consumption 
Female 
Oxytocin administration, versus placebo, had no effect on 
smoothie consumption in either participant group. 
Kim et al., 2015 
The impact of oxytocin on 
food intake and emotion 
recognition in patients with 
eating disorders: a double 
blind single dose within-
subject cross-over design 
AN (n = 35) 
BN (n = 34) 
HC (n = 33) 
40IU Nebuliser 
Double-blind within-subjects 
crossover design investigating the 
consumption of apple juice and 24-
hr caloric consumption 
Female 
Oxytocin did not impact juice consumption for any participant 
group. There was no effect of oxytocin on 24-hr caloric 
consumption for HC or AN participants. However, oxytocin, 
versus placebo, decreased 24-hr caloric consumption for 
participants with BN. 
Kim et al., 2014 
Intranasal oxytocin attenuates 
attentional bias for eating and 
fat shape stimuli in patients 
with anorexia nervosa 
AN (n = 31) 
HC (n = 33) 
40IU Nebuliser 
Double-blind within-subjects 
crossover design investigating the 
consumption of apple juice  
Female 
Oxytocin administration, versus placebo, had no effect on 
apple juice consumption in either participant group. 
Attentional Bias to 
Food Stimuli in Binge-
Type Eating Disorders 
   
 
   
Leslie et al. (Paper 6 of 
the current thesis)  
A pilot study investigating the 
influence of oxytocin on 
attentional bias to food 
images in women with 




sample: (n = 
25) 





HC (n = 27) 
64IU Intranasal spray 
Double-blind within-subjects 
crossover design investigating 
attentional bias to food images 
versus neutral images in a dot probe 
task 
Female 
Oxytocin increased vigilance to food images, versus neutral 
images, across all participants. Although there was not a 
significant moderating effect of participant group, the results 
of a sensitivity analysis suggest that this effect is stronger in 
women with BED. 
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Attentional Bias to 
Food Stimuli in 
Anorexia Nervosa 
   
 
   
Leppanen et al., 2017 
The effects of intranasal 
oxytocin on smoothie intake, 
cortisol and attentional bias in 
anorexia nervosa 
AN (n = 30) 
HC (n = 29) 
40IU Intranasal spray 
Double-blind within-subjects 
crossover design investigating 
attentional bias to food images 
versus neutral images in a dot probe 
task 
Female 
Participants with AN exhibited avoidance of food images 
versus neutral images, as compared to the HC group, at 
baseline. Oxytocin administration, versus placebo, reduced 
the avoidance of food images in the AN group, thus resulting 
in increased vigilance to food. 
Kim et al., 2014 
Intranasal oxytocin attenuates 
attentional bias for eating and 
fat shape stimuli in patients 
with anorexia nervosa 
AN (n = 31) 
HC (n = 33) 
40IU Nebuliser 
Double-blind within-subjects 
crossover design investigating 
attentional bias to eating and body 
weight and shape related stimuli in 
a dot probe task 
Female 
There was no difference in vigilance to eating and body-
related stimuli between the AN and HC participant groups at 
baseline. There was a significant drug x participant group 
interaction such that oxytocin reduced vigilance to eating and 
body-related stimuli only in participants with AN. 
Generalised Reward-
Seeking and Risk-
Taking Behaviour in 
Binge-Type Eating 
Disorders 
       
Leslie et al. (Paper 7 of 
the current thesis) 
The influence of oxytocin on 
risk-taking in the balloon 
analogue risk task among 
women with bulimia nervosa 
and binge eating disorder 
Binge 
eating 
sample: (n = 
25) 





HC (n = 27) 
64IU Intranasal spray 
Double-blind within-subjects 
crossover design investigating 
performance on the Balloon 
Analogue Risk Task (BART) 
Female 
There were no significant differences in performance on the 
BART between the BN/BED and HC groups in the placebo 
condition. There was no main effect of oxytocin on 
performance in the BART. There was an interaction for the 
total balloon explosion count, such that oxytocin specifically 
reduced balloon explosions in participants with BN and BED. 
However, this interaction was not found for the adjusted 
average pump count variable. 
Attentional Bias to 
Socio-Emotional 
Stimuli in Binge-Type 
Eating Disorders 
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Kim et al., 2018 
Effects of intranasal oxytocin 
on the attentional bias to 
emotional stimuli in patients 
with bulimia nervosa 
BN (n = 31) 
HC (n = 33) 
40IU Intranasal spray 
Double-blind within-subjects 
crossover design investigating 
attentional bias to happy and angry 
faces versus neutral faces in a visual 
probe detection task. 
Female 
There were no significant differences in attentional bias to 
happy or angry, versus neutral, faces between the BN and HC 
groups in the placebo condition. There was a drug x emotion 
interaction such that oxytocin reduced attentional bias to 
angry faces in both participant groups but did not affect 
attentional bias to happy faces. 
Attentional Bias to 
Socio-Emotional 
Stimuli in Anorexia 
Nervosa 
       
Kim et al., 2014 
The impact of intranasal 
oxytocin on attention to social 
emotional stimuli in patients 
with anorexia nervosa: A 
double blind within-subject 
cross-over experiment 
AN (n = 31) 
HC (n = 33) 
40IU Nebuliser 
Double-blind within-subjects 
crossover design investigating 
attentional bias to happy,  angry, 
and disgusted faces, versus neutral 
faces, in a visual probe detection 
task. 
Female 
Participants with AN exhibited avoidance of angry faces in the 
placebo condition and the HC group exhibited vigilance to 
angry faces in the placebo condition. No differences in 
vigilance to disgusted or happy faces were observed between 
the participant groups in the placebo condition. Oxytocin 
increased vigilance to angry faces only in the AN participant 
group. Oxytocin reduced vigilance to disgusted faces in both 
participant groups.  
Interpretation of 
Socio-Emotional 
Stimuli in Binge-Type 
Eating Disorders 
       
Kim et al., 2015 
The impact of oxytocin on 
food intake and emotion 
recognition in patients with 
eating disorders: a double 
blind single dose within-
subject cross-over design 
AN (n = 35) 
BN (n = 34) 
HC (n = 33) 
40IU Nebuliser 
Double-blind within-subjects 
crossover design investigating 
emotion recognition sensitivity in a 
dynamic facial morphing task. 
Female 
There were no differences in emotion recognition thresholds 
between the AN, BN, and HC participant groups in the 
placebo condition. Oxytocin improved overall emotion 
recognition sensitivity in the HC participant group and 
improved emotion recognition sensitivity for sad faces in the 
BN participant group. 
Interpretation of 
Socio-Emotional 
Stimuli in Anorexia 
Nervosa 
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Leppanen et al., 2017 
The effects of oxytocin on the 
interpretation and expression 
of emotions in anorexia 
nervosa 
AN (n = 30) 
HC (n = 29) 
40IU Intranasal spray 
Double-blind within-subjects 
crossover design investigating the 
interpretation of emotions and 
mental states using the “Reading 
the Mind in the Eyes” test 
Female 
Participants with AN were more accurate on the Reading the 
Mind in the Eyes test compared to the HC participant group. 
Oxytocin administration, versus placebo, did not affect 
accuracy in either participant group. Oxytocin led to a slower 
reaction time on the task for the AN group in session 2 and a 
faster reaction time for the HC group in session 2. 
Kim et al., 2015 
The impact of oxytocin on 
food intake and emotion 
recognition in patients with 
eating disorders: a double 
blind single dose within-
subject cross-over design 
AN (n = 35) 
BN (n = 34) 
HC (n = 33) 
40IU Nebuliser 
Double-blind within-subjects 
crossover design investigating 
emotion recognition sensitivity in a 
dynamic facial morphing task. 
Female 
There were no differences in emotion recognition thresholds 
between the AN, BN, and HC participant groups in the 
placebo condition. Oxytocin had no effect on emotion 
recognition sensitivity in the AN group. 
Note. AN = anorexia nervosa; BED = binge eating disorder; BN = bulimia nervosa. Grey rows highlight studies incorporated in the current thesis. 
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7.2.2 The influence of oxytocin on attentional bias in populations with eating disorders 
The majority of research investigating the effects of oxytocin on attentional biases in 
populations with eating disorders has so far focused primarily on anorexia nervosa, and 
no prior studies have investigated the influence of intranasal oxytocin on attentional bias 
to food stimuli in populations with either BN or BED. However, intranasal oxytocin has 
previously been found to partially normalise attentional biases in women with anorexia 
nervosa (Leppanen, Cardi, et al., 2017a), who exhibited attentional avoidance of food 
images in the placebo condition. In contrast to the study conducted by Leppanen, Cardi, 
et al. (2017a), which investigated women with anorexia nervosa, and in contrast to 
previous studies investigating attentional biases to food in populations with binge eating, 
the study reported in Paper 6 did not find a baseline difference in attentional bias to food 
between women with BN or BED and healthy comparison women in the placebo 
condition. It may be the case that attentional biases to food stimuli are specific to early 
stages in attentional processing, which were not captured in the current study. Future 
research will therefore be helpful in establishing the variation and functional significance 
of attentional biases to food stimuli across the entire span of attentional processing in 
women with BN and BED. 
 The study reported in Paper 6 also found that a divided dose of 64IU intranasal oxytocin 
significantly increased attentional bias to food images across the entire participant 
sample. This finding partially contrasts with evidence from (Leppanen, Cardi, et al., 
2017a), who reported that the effect of oxytocin in increasing vigilance to food stimuli 
was specific to participants with anorexia nervosa. That being said, it should be noted that 
the effect of oxytocin in increasing vigilance was unduly affected by the women with 
BED in our study, as sensitivity analyses excluding these five participants or imputing 
data for these participants based on the BN sample resulted in this main effect becoming 
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non-significant. Therefore, the evidence to date suggests that intranasal oxytocin may 
increase vigilance to food images across all women, though to a greater degree in women 
with anorexia nervosa or binge eating disorder. 
7.2.3 The influence of oxytocin on reward approach 
Previous evidence has tentatively supported a role for exogenous oxytocin in enhancing 
the intentional reduction of food craving in women (Striepens et al., 2016). Furthermore, 
several studies in both healthy and overweight men have found that oxytocin specifically 
reduces hedonic eating, as opposed to hunger-driven eating (Burmester et al., 2018; Ott 
et al., 2013; Thienel et al., 2016). While the mechanism for these effects is not yet clear, 
it may be the case that oxytocin reduces food approach behaviours through some 
combination of the reduction of incentive salience of food and an increase in cognitive 
control over food craving (Love, 2014; Striepens et al., 2016). Conversely, a large body 
of evidence has indicated that oxytocin rather increases the reward value of social stimuli 
(Dölen et al., 2013). However, previous evidence in humans has not investigated whether 
the effect of oxytocin generalises beyond domain-specific effects on feeding and social 
stimuli. 
The findings reported in Paper 7 suggest that oxytocin does not decrease impulsive 
reward-approach behaviours across women with and without BN or BED. However, there 
was an interaction effect such that oxytocin decreased the total number of balloon 
explosions to a significantly greater degree among women with BN or BED versus 
healthy comparison women, thus indicating a greater reduction in risk-taking, and 
particularly a reduction in persistent risk-taking following “punishment” trials. Based on 
previous evidence indicating a greater proportion of the G carriers for the OXTR gene 
among women with BN and BED (Y.-R. Kim, J.-H. Kim, et al., 2015; Micali, Crous-Bou, 
et al., 2017), we have speculated that this difference may relate to potential underlying 
differences in the functioning of the oxytocin receptor system between the two 
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populations of participants. However, further research is necessary in order to replicate 
our reported effect of oxytocin on risk-taking in a larger sample and elucidate the 
mechanism of this effect.  
7.3 Implications and future directions 
7.3.1 Implications and future directions for the addictive appetite model of recurrent binge 
eating 
The addictive appetite model proposed within the current thesis offers a novel formulation 
of the progression and maintenance of BN and BED. While other authors have previously 
highlighted the addiction-like properties of some forms of eating behaviour (Gearhardt, 
Corbin, & Brownell, 2009a; Volkow, Wang, Fowler, Tomasi, & Baler, 2011), the 
addictive appetite model makes the novel contribution of contextualising these processes 
within a comprehensive maintenance model of BN and BED. 
It should be noted that evidence for the novel components of the addictive appetite model 
is still in an early stage of development. Our first recommendation for future research 
pertains to the systematic study of tolerance effects in BN. Future longitudinal studies 
comparing participants with BN and BED against weight-matched controls would be 
invaluable in shedding light on the progression of binge size and frequency, expected 
reward value of binge eating episodes, actual reward value of binge eating episodes, 
perceived satiety, and weight. Such studies could be conducted with the use of ecological 
momentary assessments and would ideally commence from the earliest stages of the 
disorder. As capturing the progression from the earliest stages of the disorder would most 
likely require the recruitment of participants outside of treatment-seeking settings, this 
research would likely require large community samples, and may therefore be best-suited 
to a phone application to minimise required resources. 
Additionally, we would recommend that future research also investigate the development 
of food withdrawal effects through longitudinal studies administering the ProWS, a food 
withdrawal scale developed by Schulte et al. (2018). The ProWS would provide valuable 
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information on food-specific withdrawal effects, independent of trait levels of low mood. 
Furthermore, we recommend additional research investigating biological and affective 
withdrawal effects, such as those observed in substance use disorders. Withdrawal effects 
of interest to investigate include: the presence of anxiety, restlessness, sleep difficulties, 
depressed mood, and physical discomfort (Budney & Hughes, 2006). The investigation 
of these biological and affective responses to withdrawal would thus also potentially 
highlight mechanisms of behavioural withdrawal symptoms endorsed on the ProWS. 
With regards to the impact of insulin- and dopamine-mediated food craving, extensive 
work in populations with obesity and Type II diabetes have illustrated the role of insulin 
dysregulation in heightening food craving, as mediated by mesolimbic brain regions  
(Chechlacz et al., 2009; Jastreboff et al., 2013). While recent evidence has supported an 
overall reduction in insulin sensitivity across populations with BN and BED (Ilyas et al., 
2018), it is important to replicate links with food craving in people with eating disorders. 
For example, the combination of measuring fasting insulin levels and food craving within 
an fMRI design, as previously conducted by Jastreboff et al. (2013) in people with 
obesity, would help to clarify whether activity in dopaminergic brain regions also 
mediates the association between insulin resistance and food craving in people with BN 
and BED.  
Furthermore, it is also necessary to investigate the dopamine response of normal-weight 
individuals with BN to sucrose, versus sucralose, consumption against weight-matched 
controls before definitive conclusions can be drawn regarding dysregulation of dopamine 
responses to high GI foods, versus non-nutritive sweet taste, in this population. Such 
studies could employ a similar design to that previously used by Wang et al. (2014) in a 
PET study recruiting participants with obesity. 
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If further investigation ultimately corroborates key components of the addictive appetite 
model, this would carry important implications for the future treatment of BN and BED. 
One new treatment recommendation stemming from the addictive appetite model is the 
recommendation to avoid highly-processed foods during recovery from BN and BED. 
While many clinicians and current treatment models encourage continued consumption 
of high GI foods in moderation (Apple & Agras, 2004), the addictive appetite model 
argues that the addictive nature of eating in the acute phase of BN and BED entails the 
disinhibition of appetitive processes and continued food craving following the 
consumption of high GI foods. To provide an analogy to a separate eating disorder, it is 
commonly accepted that a more prescriptive clinical approach to eating is necessary in 
the early stages to recovery from anorexia nervosa before intuitive eating develops 
adequately, thus allowing for greater flexibility whilst still ensuring that basic nutritional 
needs are met (Richards, Crowton, Berrett, Smith, & Passmore, 2017). Similarly, until 
normalisation of neural circuits occurs in BN and BED, the addictive appetite model 
recommends a prescriptive avoidance of high GI foods. 
As a key tenet of the addictive appetite model pertains to the role of blood sugar flux in 
contributing to food craving and subsequent binge eating, another implication of the 
model is the importance of psychoeducation around maintaining stable blood sugar levels. 
Clinical practice currently recommends the avoidance of self-induced vomiting and 
insulin omission to prevent the health risks described in Chapter 1 of the current thesis 
(National Institute for Health and Clinical Excellence, 2017). However, 
recommendations stemming from the addictive appetite model would further highlight 
the importance of maintaining stable blood sugar levels for the additional purpose of 
contributing to remission from recurrent binge eating behaviours. 
The theoretical importance of addictive responses to food, which are highlighted within 
the addictive appetite model, also provides theoretical support for the continued 
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advancement of treatments seeking to break automated stimulus-response patterns around 
palatable food and remove binge triggers from the environment (Turton et al., 2016). Such 
research might include approach bias modification, attentional bias modification, and 
interventions informed by behavioural science, which seek to alter the environment to 
assist in shaping desired behaviour and deter binge eating (MacLeod & Clarke, 2015; 
Prinsen, de Ridder, & de Vet, 2013; Turton et al., 2018).  
7.3.2 Implications and future directions for the investigation of oxytocin in treating disordered 
eating behaviour 
It is important to note that the effect of oxytocin on eating behaviour in humans is 
influenced by several factors, including dose, sex, weight status, hunger status, and food 
type (Leslie, Silva, et al., 2018). Thus, while the current study did not find a significant 
effect of a divided dose of 64IU intranasal oxytocin on the immediate consumption of 
palatable food or 24-hr caloric consumption in women with and without BN or BED, 
these findings do not detract from the possibility that oxytocin may curb overeating 
behaviour at a different dose or method of administration.  
A perfusion study drawing from the data presented in this thesis found that 40IU 
intranasal oxytocin does not affect resting cerebral blood perfusion in women with or 
without BN or BED 18-24 minutes following drug administration, while intranasal 
oxytocin did affect resting cerebral blood flow in men at the same dose and timespan 
following administration (Martins, Leslie, et al., 2019). While these findings regarding 
cerebral blood perfusion at rest do not indicate the optimal functional dose of oxytocin 
for curbing palatable eating, this study does indicate that the architecture of oxytocin 
signalling likely differs between men and women. Therefore, the optimal dose schedule 
found for men in previous studies will not necessarily apply to women. Our primary 
recommendation for future research investigating the influence of oxytocin on eating in 
women is therefore to carry out dose-response studies to titrate the optimal dose of 
administration in women. 
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Given evidence reviewed in Paper 4 indicating that oxytocin has a greater inhibitory effect 
on eating in men, we would strongly recommend future studies to investigate the effect 
of oxytocin on hedonic eating in men with BN and BED. Men with eating disorders are 
often underserved by research; however, our knowledge to date suggests that oxytocin 
administration may be more effective in men with BN and BED versus women with BN 
and BED. Future studies investigating the differential effect of oxytocin on hedonic, 
versus hunger-driven eating, in men with BN and BED therefore presents an interesting, 
and potentially fruitful, avenue for further investigation. 
7.4 General limitations 
While each study of this thesis has served to contribute new knowledge to the 
understanding of BN and BED, these studies were also associated with several 
limitations. Study-specific limitations have been discussed within each individual paper. 
Other limitations applying across two or more papers will be discussed within the current 
thesis section. 
Papers 1 and 2 presented and defended a novel maintenance model of BN and BED: the 
addictive appetite model. The theoretical components of this model are based on evidence 
demonstrating similarities in neural functioning between people with substance 
dependence and people who score highly on measures of food addiction (Gearhardt et al., 
2011), as well as models of insulin- and dopamine-mediated food craving in animal 
models (Mebel et al., 2012) and people with Type II diabetes and obesity (Chechlacz et 
al., 2009; Jastreboff et al., 2013). However, research testing these effects in populations 
with BN and BED is currently sparse, and the addictive appetite model therefore requires 
future investigation to corroborate its central hypotheses. 
Papers 5, 6, 7, and 8 of the current thesis presented findings from a double-blind, placebo-
controlled crossover study investigating the effects of a single divided dose of 64IU 
intranasal oxytocin in women with and without BN or BED. While the sample size of 52 
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women is relatively large for a novel fMRI study, this represents a small sample size for 
the study of potentially subtle effects of oxytocin on eating behaviours, stress, attentional 
bias to food, and reward approach behaviours. We therefore cannot rule out the possibility 
that the current study may have been underpowered to detect true, but small effects on 
each of these dependent variables. Furthermore, the inclusion of a heterogeneous group 
of women with BN and BED in our clinical participant sample leaves open the possibility 
that the current study may have failed to detect some effects which are specific to one 
disorder or the other, as was indicated by our data in the context of attentional biases. We 
would therefore recommend future studies investigate BN and BED separately, and 
particularly when investigating attentional biases to palatable food. 
The choice of dose schedule in the current study was based on previous findings 
indicating that the effects of a 40IU dose of intranasal oxytocin on resting cerebral blood 
perfusion peak at 39-51 minutes following administration in men (Paloyelis et al., 2016). 
However, data drawn from the current study of oxytocin has indicated that this finding 
does not apply to women (Martins, Leslie, et al., 2019). It therefore follows from this 
finding that the dose of oxytocin chosen in the current study may not have been optimal 
to observe functional effects on eating behaviour, stress, attentional bias to food, and 
reward approach behaviours. Future dose-response studies will be needed to identify the 
best dose schedule of intranasal oxytocin administration for curbing overeating behaviour 
in women. 
Finally, in order to maximise recruitment given limited availability of the fMRI scanner, 
this proof-of-concept study did not experimentally control for menstrual phase or 
hormonal contraceptive use. Previous evidence has indicated that hormonal contraception 
can suppress the effects of exogenous oxytocin on BOLD response to images of a 
partner’s face within reward-related mesolimbic brain regions (Scheele et al., 2015). 
While we did not find a statistically significant effect of hormonal contraception on any 
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behavioural outcome in the current study, it is still plausible that including women taking 
hormonal contraception may have suppressed potential effects on eating behaviour in the 
current study. We would therefore recommend future studies experimentally control for 
menstrual phase and exclude women currently taking hormonal contraception. 
7.5 Overall conclusions 
The current thesis aimed to propose and test a new maintenance model of recurrent binge 
eating: the addictive appetite model of BN and BED. The evidence herein has supported 
the importance of food craving and eating for the purposes of coping and reward 
enhancement as distinguishing features of BN and BED. However, further evidence is 
required to support the existence of food tolerance and withdrawal in BN and BED, as 
well as the implication of glucose dysregulation in contributing to heightened food 
craving.  
Based on evidence indicating that the hormone oxytocin impacts reward processing and 
reward-driven eating, the addictive appetite model predicts that oxytocin should be 
efficacious in curbing binge-like eating behaviour. While oxytocin did curb reward 
approach behaviours to a greater degree in women with BN or BED compared to healthy 
control women, we did not find an overall effect of a divided dose of 64IU intranasal 
oxytocin on reward approach behaviours in the context of a risk-taking computerised task 
across all participants. The administration of a divided dose of 64IU intranasal oxytocin 
did not affect the immediate consumption of palatable food, 24-hr calorie consumption, 
stress, salivary cortisol, or neural response to palatable taste anticipation or receipt. 
Furthermore, a divided dose of 64IU intranasal oxytocin had the counterintuitive effect 
of increasing vigilance to palatable food images. 
Overall, the current findings therefore do not support a beneficial effect of oxytocin on 
binge-like eating behaviour in women with BN or BED at the dose used in this study. 
Based on evidence that oxytocin has a greater inhibitory effect on eating in men, we 
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recommend that future studies investigate the effects of intranasal oxytocin on binge 
eating in men with BED and BED and that future dose-response studies continue to 
investigate whether a different dose of oxytocin would enhance the beneficial effects of 
oxytocin for women with BN and BED.  
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